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P1714 Phenotypic and genotypic characterisation of
antimicrobial resistance in Egyptian Escherichia coli isolates
M.H.M. Al-Agamy, M.S-E.M. Ashour
Bonn, D; Cairo, EGY
Background: A few reports to determine bacterial resistance inclu-
ding resistance patterns in Escherchia coli isolated in Egypt were
published. No information, however, is available underlying the
resistance mechanism. Therefore, we begun our study on b-lactam
resistance and found CTX-M-18, -15 and -27 responsible for exten-
ded-spectrum b-lactam resistance, which was now extended to
resistance towards other antibiotics.
Objective: The study was undertaken to characterise phenotype
and genotype of antimicrobial resistance of CTX-M-producing
E. coli strains.
Methods: Thirty E. coli strains were isolated from two hospitals in
Cairo in 2001. MIC was determined according to NCCLS guide-
lines. PFGE was carried out. Strains were screened and mapped
by PCR methods for antimicrobial resistant genes, integrons and
gene cassettes. Genes were sequenced if necessary.
Results: The resistance Pattern of CTX-M-producing E. coli for
ampicillin, cefotaxime, ceftazidime, ciproﬂoxacin (C), tetracycline
(T), gentamicin (G), kanamycin (K), streptomycin (S), chloram-
phenicol (Ch) sulphamethoxazole (Su) and trimethoprime (T)
were 100, 100, 83, 43, 100, 90, 77, 100, 97, 100, 97%, respectively.
Ninety-seven per cent of E. coli are harboured class 1 integron.
Variable gene cassettes were obtained. A predominance of gene
cassettes that confer resistance to S and T. Sequencing of quino-
lone-resistance determining regions (QRDR) showed that strains
with a reduced susceptibility to C of MIC 1 mg/L have a single
mutation in gyrA and strains with full resistance to C of MIC
>8 mg/L have a double mutations in gyrA and single mutation in
parC. The resistance genes confers G resistance were aac(30)-IIc
(93%), aac(60)-Ib (66%) and ant(200)-1a (7%). The prevalence of
aph(3)-Ia in K resistant strains was 83%. The prevalence of Sul1
and sul2 were 90 and 100%, respectively. The prevalence of tet(A)
is higher than tet(B) in tetracycline-resistant strains. Enzymatic
(cat1 & catB) & nonenzymatic (cmlA) mechanisms of Ch resistance
were detected. The ﬂoR was not detected.
Conclusions: The CTX-M producing E. coli strains studied do not
only have a broad-spectrum b-lactam resistance phenotype due to
a different b-lactamases, they also show pronounced resistance to
other classes of antibiotics. Genotypic characterisation revealed a
high number of different resistance determinants. It is striking
that for most classes of antibiotics resistance is due to multiple
genes with similar overlapping phenotypic effects.
P1715 gyrA mutations and quinolone resistance in
Salmonella enteritidis and Salmonella typhimurium
N. Delgado Ronda, J.L. Mun˜oz Bellido, M.I. Garcı´a Garcı´a,
S. Mun˜oz Criado, M.C. Sa´enz Gonza´lez, J.A. Garcı´a Rodrı´guez
Salamanca, E
Objectives: To know the relation between gyrA mutations and
resistance to nalidixic acid (NAL) and ﬂuorinated quinolones in
Salmonella enteritidis and Salmonella typhimurium.
Methods: The in vitro activity of ciproﬂoxacin (CFX) against 29
NAL-resistant S. enteritidis and 15 NAL-resistant S. typhimurium
clinical isolates was determined by the agar dilution method. gyrA
QRDR was PCR ampliﬁed and sequenced in the 44 isolates.
Results: All 29 NAL-resistant Salmonella enteritidis isolates
(MIC > 128 mg/L) were susceptible to CFX, while the 15 NAL-
resistant S. typhimurium isolates had reduced susceptibility to CFX
(MIC 0.1–0.2 mg/L). Only ﬁve S. enteritidis isolates had gyrA
mutations clearly related to quinolone resistance (Asp87Tyr). 13
isolates had no mutations, and nine isolates had mutations whose
involvement in quinolone resistance in unclear (seven Val143Gly
and two Glu139Asp). 14 of 15 S. typhimurium isolates had a Asp87
mutation to Tyr (11 isolates) or Asn (three isolates).
Conclusions: NAL-resistant S. typhimurium have usually reduced
susceptibility to CFX, and correlate with a Asp87 mutation, which
seems to be the ﬁrst quinolone-resistance mutation to emerge.
NAL-resistant S. enteritidis are usually CFX-susceptible and in one
half of the isolates have no gyrA mutations. Further studies are
needed to elucidate if NAL-resistance justify CFX use restrictions
in S. enteritidis.
P1716 First report of a TEM-26 b-lactamase with mutations
conferring resistance to piperacillin/tazobactam
T. Collyns, F. M’Zali, C. Nice, D. Roberts, M. Wilcox
Leeds, UK
Background: Extended-spectrum b-lactams are commonly included
in empirical antibiotic regimens for the treatment of Gram-negat-
ive infections. The emergence of extended spectrum b-lactamase
(ESBL)-producing bacteria poses a serious threat to the continued
use of this family of antibiotics. Since ESBLs have previously been
uniformly susceptible to b-lactamase inhibitors (e.g. tazobactam or
clavulanic acid), inhibitor/b-lactam combinations (e.g. piperacil-
lin/tazobactam) have been advocated as potential therapeutically
effective agents.
Methods: In June 2003, a clinical isolate of Escherichia coli was
recovered from a 82-year-old woman nursed on the high depend-
ency surgical ward in St James’s University Hospital Leeds, UK.
The patient had received courses of ceftazidime and piperacillin/
tazobactam (Pip/Taz). The organism was isolated from a urine
specimen. Speciation was conﬁrmed biochemically with API 20E
system. The organism was resistant to ceftazidime, cefotaxime,
aztreonam, Pip/Taz and amoxicillin/clavulanic acid and was sus-
ceptible to meropenem, imipenem and cefoxitin using a disk dif-
fusion method. ESBL production was sought using the disc
synergy and the MAST ID tests. PCR using speciﬁc primers was
used to screen for the presence of blaSHV and blaTEM. Nucleo-
tide sequence analysis was used to determine the identity of the
resistance determinants.
Results: ESBL production was demonstrated with both the disc
synergy and the MAST ID tests. PCR showed the organism to
harbour a blaTEM. Nucleotide sequence analysis identiﬁed the
resistant determinant as a TEM-26 b-lactamase with an additional
mutation at amino-acid position 69 with the replacement of methi-
onine by valine. This mutation has previously been shown to con-
fer resistance to beta-lactamase inhibitors.
Conclusions: To our knowledge this is the ﬁrst report of a TEM
extended-spectrum b-lactamase also conferring resistance to Pip/
Taz. This highlights the continuing global emergence and mutabil-
ity of this clinically important family of enzymes. It emphasises
the importance for vigilance in identifying novel resistance mech-
anisms and the need for prudent use of antimicrobials to preserve
their clinical efﬁcacy.
P1717 New isolation of an integron-located VEB-1
extended-spectrum b-lactamase in a Proteus mirabilis
clinical strain
N. Camino, B. Rode´s, T. Alarco´n, C. Toro, A. Morente,
M. Martı´nez-Padial, V. Soriano, M. Baquero
Madrid, E
Objectives: The aim of this study was to investigate the molecular
basis of resistance observed in a Proteus mirabilis strain isolated
from an adopted Indian child.
Methods: The susceptibility proﬁle was determined using an auto-
mated microdilution MicroScan method and production of ESBL
activity was identiﬁed by a double-disc synergy test with two
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cephalosporins: ceftazidime and cefotaxime. b-lactamases were
extracted by ultrasonication. Supernatants containing crude
enzyme extracts were analysed by isoelectric focusing on ampho-
line polyacrylamide gels (pH 3.5–9.5) using a Multiphor II electro-
phoresis System (Pharmacia Biotech) and b-lactamases were
visualised with an overlay of nitroceﬁn. Previously described
primers VEBcasB and VEBcasF were used for detection of the
blaVEB-1 gene. Automated DNA sequencing was performed in
the ampliﬁed product. The 50 and 30-CS primers were used in
combination with VEB-INV1 and VEB-INV2, respectively, in order
to determine the size of the variable region of the integron. A
newly design primer PVEB was used to demonstrate the colineari-
ty of the integrase with blaVEB-1.
Results: The P. mirabilis strain was isolated from an urine sample
and showed resistance to all extended-spectrum cephalosporins,
aminoglycosides, trimethoprim–sulphamethoxazole and phospho-
mycin. An unusual synergy was observed between cefoxitin and
cefotaxime and cefuroxime using double-disc synergy. Isoelectric
focusing analysis revealed the presence of a b-lactamase with a pI
of 7.6. DNA sequencing analysis revealed the presence of a blaV-
EB-1 gene, which showed 98% identity with the blaVEB-1 gene
found in P. mirabilis Lil-1. This gene cassette was located within a
class 1 integron of approximately 3 kb. On both sides of the blaV-
EB-1 gene there were two unsequenced regions of around 600 bp
each, ﬂanked by the integrase gene upstream and the 3’conserved
segment (3’CS) downstream.
Conclusions: These data indicate that the blaVEB-1 gene is part of
a genetic environment comprised in a class 1 integron. However,
the variable regions of the integron are different in size than pre-
viously described integrons containing blaVEB-1 gene in P. mira-
bilis, E. coli or P. aeruginosa. Further studies are needed to evaluate
which gene cassettes are codiﬁed by these variable regions.
P1718 Ceftazidim-resistant Escherichia coli and Klebsiella
pneumoniae isolates from four Turkish hospitals: identiﬁcation
of TEM-, SHV-, and GES-type b-lactamases
S. Gu¨ndes, F. Kolayli, K. Demirdag, M. Gu¨naydin, M. Altindis,
R. Caylan, S. Hosoglu, H. Vahaboglu
Kocaeli, Elazig, Samsun, Afyon, Trabzon, Diyarbakir, TR
Objectives: To study the prevalence of TEM-, SHV-, and GES- type
b-lactamases among Escherchia coli and Klebsiealla pneumoniae
strains those having ceftazidime MICs higher than 2 lg/L.
Material and methods: A total of 61 E. coli and 43 K. pneumoniae iso-
lated from four different university hospitals were studied for the
existence of TEM-, SHV-, and GES- type b-lactamases. Susceptibil-
ity tests were done according to the criteria of National Commit-
tee for Clinical Laboratory Standards (NCCLS). MICs were
obtained by agar dilution method. Existence of extended-spectrum
b-lactamases were assessed by double-disc synergy test. Existence
of the above mentioned b-lactamase genes were studied by PCR
with speciﬁc oligonucleotide primers and further conﬁrmed by
isoelectric focusing the bacterial extracts.
Results: None of the isolates were carbapenem resistant. Double-
disc synergy tests were positive in 40 (66%) and 35 (81%) of E.
coli and K. pneumoniae, respectively. TEM gene was detected in 40
(65%) and 20 (47%) while SHV gene in 12 (20%) and 17 (40%) of
E. coli and K. pneumoniae strains, respectively. GES gene was not
detected.
Conclusions: TEM and SHV genes are highly prevalent among
ESBL producing E. coli and K. pneumoniae. GES type ESBLs are
not responsible in the ceftazidime resistance in the region.
P1719 Third generation cephalosporin-resistant Escherichia
coli from a paediatric hospital in Iasi, Romania
R. Filip, V. Miriagou, S. Vourli, G. Coman, E. Tzelepi
Iasi, RO; Athens, GR
Objectives: Third generation cephalosporin resistant (3GC-R)
E. coli strains are frequently involved in urinary-tract infections in
the paediatric hospital from Iasi, Romania since 1994. This prelim-
inary study was undertaken in order to obtain information on the
epidemiology of these strains and the mechanism of 3GC resist-
ance.
Methods: A random sample of eight E. coli strains isolated in the
period 2000–2001 were examined. Susceptibility status to various
antimicrobial agents was assessed using the Mini Api System (Bio
Merieux). Detection of extended spectrum b-lactamases (ESBL)
was performed with the Etest method using strips containing ceft-
azidime plus clavulanic acid. The isoelectric points of b-lactamas-
es produced by each strain were determined by isoelectric
focusing (IEF) of crude cell extracts. Typing of the strains was car-
ried out by a PCR-based method using the ERIC2 oligonucleotide
primer.
Results: All strains showed resistance to amoxicillin, amoxicillin/
clavulanic acid, ceftazidime, cefoxitin. In seven cefoxitin-resistant
strains the ESBL detection test was negative. Upon IEF these
strains were found to produce b-lactamases with highly basic iso-
electric points. It was therefore presumed that these strains pro-
duced acquired AmpC enzymes. In the remaining isolate
ceftazidime MIC was signiﬁcantly reduced in the presence of cla-
vulanic acid. The strain expressed a b-lactamase that focused at
8.2 (probably an SHV-5 enzyme). ERIC2 PCR typing showed at
least four different banding patterns suggesting a widespread of
3GC resistance mechanism to distinct strains.
Conclusions: The frequent isolation of 3GC-R E. coli in the paediat-
ric hospital of Iasi is dues to the dissemination of epidemiological-
ly distinct strains. Resistance can be attributed to production of
various b-lactamase types including AmpC (cephalosporinas-
es)and extended-spectrum enzymes. Reduction of the use of 3 GC
and enforcement of infection control measures must be applied.
P1720 Characterisation of two novels 6’-N-aminoglycoside
acetyltransferase genes, aac(6’)-30 and aac(6’)-31, found in
blaIMP-16 and blaIMP-1 Pseudomonas aeruginosa strains
carrying integron
R.E. Mendes, M.A. Toleman, R.N. Jones, T.R. Walsh
Bristol, UK; North Liberty, USA
Objectives: Two clinically unrelated Pseudomonas aeruginosa strains,
101-4704 and 48-696, were isolated from hospitalised patients in
Brasilia and Sao Paulo, respectively. Both isolated expressed class
B carbapenem-hydrolysing metallo-b-lactamase (MBL) IMP-16
(101-4704) and IMP-1 (48-696). These genes were found embedded
in class 1 integrons that also encoded aminoglycoside-modifying
enzymes. The aim of this study was further characterize the two
novels aminoglycoside resistant genes (ARG).
Methods: Primers targeting the 50CS and 30CS regions of class 1 in-
tegron were used to amplify the blaIMP-16 and blaIMP-1 contain-
ing integron. These primers yielded PCR products, which were
sequenced on both strands using DuPont Automated systems.
After integrons sequence analysis, the ARG were ampliﬁed by
PCR and cloned into the expression vector pPCRScriptCam SK.
The recombinant plasmids were transferred into Escherichia coli
DH5alfa and their respective aminoglycoside resistance proﬁle
evaluated against gentamicin, amikacin, kanamycin, neomycin,
netilmicin, sisomicin, isepamicin and tobramycin. Nucleotides
sequences and their deduced protein products, alignments and
phylogenetic relationships were determined using the Lasergene
software package.
Results: Sequence analysis revealed the presence of two novel
aminoglycoside genes just downstream of the blaIMP-16 and bla-
IMP-1, namely aacA(6’)-30 and aacA(6’)-31, respectively. The
aacA(6’)-30 was fused with the following gene, aacA(6’)-Ib’, which
formed an open reading frame of 984 bp and potentially encodes
a protein of 36.7 kDa. The AAC(6’)-30 possessed most similarity
(52.7%) to the previously described AAC(6’)-29b. The aacA(6’)-31
was 555-bp long, encoded a putative protein of 20.5 kDa and was
most similar (82.1%) to the aacA(6’)-Ib’ found in the blaIMP-16
carrying integron strain. E. coli strains harbouring the fused form
aac(6’)-30/aac(6’)-Ib’ and aacA(6’)-31 showed MICs three to ﬁve-
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fold-higher than the recipient E. coli DH5alfa strain, including to
gentamicin and amikacin. The MICs remained unaltered to isep-
amicin.
Conclusions: The fused form AAC(6’)-30/AAC(6’)-Ib’ is likely to
be a bifunctional protein rather than the expression of both
AAC(6’)-30 and AAC(6’)-Ib’. The AAC(6’)-30/AAC(6’)-Ib’ and
AAC(6’)-31 conferred a resistance proﬁle called AAC(6’)-IV phe-
notype. The association of mobile MBL genes with ARG presents
an immense concern since both enzymes cannot be neutralised by
clinically available inhibitors.
P1721 Biological cost of fusidic acid resistance in
Staphylococcus aureus
S. Besier, A. Ludwig, V. Brade, T.A. Wichelhaus
Frankfurt/ Main, D
Objectives: Antibiotic resistance due to chromosomal mutations
causing structural modiﬁcations in the cellular target of the drug
is often associated with a ﬁtness burden for the resistant bacteria.
This loss of biological ﬁtness, however, can be overcome in some
cases by the acquisition of compensatory mutations. As shown
recently, certain amino acid exchanges in elongation factor G (EF-
G) of Staphylococcus aureus, such as H457Y, cause resistance to fus-
idic acid. Interestingly, fusidic acid-resistant clinical S. aureus iso-
lates carrying the exchange H457Y frequently harbour additional
amino acid substitutions within EF-G (e.g. S416F) which do not
contribute to resistance. The aim of the present study was (i) to
analyse the biological costs of the mutation H457Y and (ii) to
investigate whether the mutation S416F is able to compensate for
this ﬁtness burden.
Methods: The inﬂuence of amino acid exchanges within EF-G on
the biological ﬁtness of S. aureus was analysed by measuring
growth kinetics and by means of ﬁtness assays and plasmaco-
agulase activity assays, using isogenic recombinant S. aureus
strains carrying either the wild-type EF-G gene (fusA) or a
mutant fusA derivative (H457Y, H457Y/S416F or S416F) on a
multicopy plasmid. All assays started with a deﬁned cell num-
ber of bacteria and were repeated three times to ensure repro-
ducibility.
Results: The assays showed that the fusidic acid resistance-medi-
ating mutation H457Y causes a marked impairment of biological
ﬁtness. The amino acid exchange S416F, however, did not inﬂu-
ence the fusidic acid susceptibility and impaired the biological ﬁt-
ness of the bacteria only slightly when present individually. The
strain expressing the EF-G derivative with the double mutation
H457Y/S416F, however, grew signiﬁcantly faster, showed
enhanced ﬁtness in competition with the wild-type and exhibited
a higher plasmacoagulase activity than the strain harbouring the
single exchange H457Y.
Conclusions: The presented data provide evidence that the amino
acid exchange S416F in EF-G functions as a ﬁtness-compensating
mutation in fusidic acid-resistant S. aureus harbouring the EF-G
mutation H457Y, thereby demonstrating that the biological cost of
fusidic acid resistance in S. aureus can be considerably reduced by
secondary mutations within the bacterial genome.
P1722 Characterisation of In77, a class 1 plasmid-located
integron carrying the novel metallo-b-latamase gene blaGIM-1
M. Castanheira, M.A. Toleman, R.E. Mendes, R.N. Jones,
T.R. Walsh
Bristol, UK; North Liberty, USA
Objective: GIM-1 was recently described as the fourth type of
mobile MBL. Primary studies showed that blaGIM-1 was embed-
ded in a class 1 integron with unusual size and structure. The aim
of this study was to characterise the genetic environment of bla-
GIM-1.
Methods: The integron structure was revealed with a walking
sequencing strategy, using custome primers. Sequencing of the
fragments was performed in both strands using DuPont Automa-
ted systems and the results analysed using DNAstar. The plasmid
obtained from the isolate harbouring blaGIM-1 was electroporated
into Escherichia coli DH5alfa and a rifampin-resistant mutant of
Pseudomonas aeruginosa pA01 (RifR). Selection was performed in
nutrient agar plates containing 4 lg/mL of ceftazidime. Restric-
tion proﬁles of the plasmid were carried out with different restric-
tion enzymes, to obtain the plasmid size.
Results: In77 is a 6-kb integron showing all the key genetic compo-
nents commonly found in a class 1 integron (the intI1 integrase
gene with its own promoter regions, an attI1 recombination site
and in the 3’-CS, the fused structure qacEdelta1/sul1). This integ-
ron harbour in the ﬁrst position the recently described blaGIM-1.
Downstream of the MBL gene was found an aacA4, followed by
an aadA1. However, this second aminoglycoside resistance gene
was interrupted by the insertion sequence, IS1394, previously des-
cribed in a Pseudomonas alcaligenes isolate. This integron also car-
ried an ESBL gene, blaOXA-2 in the last position. Two frame
shifts were found in this integron, one in the integrase gene and
the second in the IS1394. Further characterisation of the In77, rev-
ealded that this integron is likely to be located in a nontrasferable
22-kb plasmid.
Conclusions: This work describes a novel integron, In77, carrying
the lately mobile MBL gene described, blaGIM-1. Distinct fea-
tures, such as the addA1 interrupted by the IS1394 and the
frame shifts that make the integrase and the insertion sequence
stationary.
P1723 The effect of large inocula on in vitro activities of
penicillin-inhibitor combinations and cefoperazone–sulbactam
against ESBL-producing Escherichia coli and Klebsiella
pneumoniae strains
M. Edelstein, I. Edelstein, D. Semchenkova, L. Stratchounski
Smolensk, RUS
Objectives: Currently, there is little consensus about the clinical
effectiveness of b-lactam–b-lactamase inhibitor combinations in
treatment of infections caused by ESBL-producing organisms. It
has been argued that signiﬁcant decrease in activity of antimicro-
bial agents in testing with high inocula may be predictive of a
possible therapeutic failure in cases of severe infections. The aim
of our study was to determine the effect of large inocula on in vi-
tro activities of amoxicillin–clavulanic acid (AMC), piperacillin–
tazobactam (PTZ) and cefoperazone–sulbactam (CPS) against
Escherichia coli and Klebsiella pneumoniae strains producing various
types of ESBLs.
Methods: Twenty laboratory strains producing the knows ESBLs,
TEM-3–TEM-7, TEM-9–TEM-12, TEM-26, TEM-47, SHV-2–SHV-6,
CTX-M-3, CTX-M-5, CTX-M-9 and CTX-M-15 and 198 ESBL-pro-
ducing clinical isolates of E. coli (n ¼ 46) and K. pneumoniae
(n ¼ 152) collected in 21 Russian hospitals were included in this
study. ESBL production was detected by a double-disc synergy
test. Activities of AMC (2:1), PTZ (4 mg/L – ﬁxed tazobactam
concentration) and CPS (1:1) were determined by broth micro-
dilution tests using standard (5  105 CFU/mL) and 100-fold
higher inocula. Results were interpreted according to the current
NCCLS guidelines. The susceptibility to CPS was determined on
the basis of cefoperazone MIC breakpoints.
Results: In testing with standard inocula, the rates of resistance
to AMC, PTZ, and CPS were 10.6, 36.2 and 5.5%, respectively.
The data on the MICs of each drug tested with different inoc-
ula are summarised in the table. The inoculum effect, deﬁned
as an eightfold of greater MIC increase on testing with the
higher inoculum, was commonly observed with PTZ (84.4%)
and less-frequently detected with AMC (28.0%) and CPS
(25.7%). The extent of the inoculum effects with these drugs
was largely independent of the type of ESBL produced. In
high-inoculum tests, all but two (0.9%) strains appeared resist-
ant to FEP and PTZ, whereas 5 and 25.5% of strains remained
susceptible to AMC and CPS, respectively.
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Conclusions: A strong inoculum effect detected with PTZ is prob-
ably predictive of a high risk of failure if this drug is used for
treatment of serious infections caused by ESBL-producing organ-
isms. Based on the lowest resistance rate and the least pro-
nounced inoculum effect, CPS may be considered as the most
effective b-lactam–b-lactamase inhibitor combination.
P1724 Tn501-like transposons carrying novel blaVIM-4
metallo-b-lactamase (MBL) gene cassettes in Poland and GIM-1
in Germany: report from the SENTRY antimicrobial surveillance
programme
M. Toleman, R. Mendes, M. Castanheira, J. Patzer, R. Jones,
T. Walsh
Bristol, UK
Objective: Analysis of the genetic context of MBL containing integ-
rons in carbapenem resistant Pseudomonas aeruginosa strains from
Poland and Germany.
Methods: Carbapenem resistant strains were analysed by ribotyping
and pulsed-ﬁeld gel electrophoresis. The MBL-containing integrons
from these strains were ampliﬁed using primers designed to class 1
integron speciﬁc 50 and 30 conserved sequences (CS). Upstream
sequences were ampliﬁed by PCR by a novel degenerate primer
approach using one primer anchored to the 50 and 30 CS sequences
and degenerate primers designed to randomly hybridise to
upstream and downstream sequences. Sequencing was performed
on both strands by the dideoxy-chain termination method.
Results: The 11 Polish isolates all contained an identical class 1 in-
tegron containing a novel VIM-4 cassette which contained a 5’
direct repeat of 169 bp of the 3’ portion of the blaVIM-4 gene. The 11
strains represented four different PFGE types. In all of these isolates
the class 1 integron was inserted into the tnpA gene of a Tn501 type
transposon, the tnpA gene having 100% identity to the tnpA gene of
Tn501. The German isolates were all of an identical ribotype and
contained a class 1 integron harbouring the GIM-1 MBL. Interest-
ingly this class 1 integron was also inserted into the tnpA gene of a
Tn501-like transposon but at a different site.
Conclusions: The Polish integrons harbour an unusual blaVIM-4
gene cassette that has a 3’ duplication, which can be explained by
a mechanism involving deletion of a segment of an ancestral tan-
dem repeat of blaVIM-4 via slipped strand replication, mediated
by a combination of polymerase and integrase. Interestingly both
the Polish and German MBL containing isolates contain class 1 in-
tegrons that are harboured by Tn501-like transposons. In all cases
the integrons are inserted into the tnpA gene of the transposon.
This is the ﬁrst time that MBL gene cassettes have been associated
with Tn501-like transposons and this observation adds another
level of mobility to these gene cassettes.
P1725 Quinolone-resistance mechanisms of
Stenotrophomonas maltophilia strains from Greek hospitals
C. Masgala, I. Galani, M. Souli, Z. Chryssouli, H. Giamarellou
Athens, GR
Objectives: Stenotrophomonas maltophilia is an important emerging
pathogen causing a variety of nosocomial infections. Being inher-
ently resistant to many antibiotics, this species poses a therapeutic
challenge to the clinician. Fluoroquinolone (FQ) resistance in
Gram-negatives has been attributed to amino acid substitutions in
the quinolone resistance-determining regions (QRDR) of DNA gy-
rase (gyrA and gyrB) and topoisomerase IV (parC and parE). The
aim of this study therefore was to determine the sequence of the
QRDRs of gyrA, gyrB, and parC genes in nonclonal S. maltophilia
clinical isolates, resistant to quinolones.
Methods: Six nosocomial isolates from ﬁve Greek hospitals, collec-
ted during the period April 1998 to May 1999 were studied. Sus-
ceptibility testing was performed by the agar diffusion (Kirby-
Bauer) test and Etest, according to NCCLS guidelines. Epidemio-
logic relatedness between the isolates was assessed by pulse-ﬁeld
gel electrophoresis (PFGE) of SpeI-restricted genomic DNA. The
QRDR regions of gyrA, gyrB, and parC of all strains were ampli-
ﬁed by polymerase chain reaction (PCR) using speciﬁc primers
and sequenced. Active efﬂux of ciproﬂoxacin (CIP), cefepime, me-
ropenem, chloramphenicol, carbenicillin, aztreonam and tetracyc-
line was examined by determining the MICs with broth
microdilution method in the presence and absence of CCCP.
Results: Ciproﬂoxacin MICs ranged from 4 to 32 mg/L. A substi-
tution at position 47 (Arg) of gyrA particle was present in all six
strains studied. A strain with MIC of 4 mg/L harboured two more
aminoacid changes at positions 127 (Met) and 137 (Asp). GyrB
presented an 11-aminoacid gap in all strains, while no aminoacid
substitutions were found in ParC, even in the single strain with a
CIP MIC of 32 mg/L. All six isolates showed a fourfold decrease
in MICs of the above-mentioned antimicrobials in the presence of
CCCP, suggesting the presence of an active efﬂux system.
SmeABC and SmeDEF efﬂux pumps should be overexpressed in
all strains tested, except one in which only SmeDEF pump was
overexpressed.
Conclusions: No clear correlation appears between MIC of ciproﬂ-
oxacin, mutations in QRDRs of gyrA, gyrB, and parC, and active
efﬂux. The resistance of S. maltophilia to ﬂuoroquinolones seems
to be complicated and further work is required to clarify the
mechanisms behind the wide phenotypic variations observed.
P1726 Survey of extended-spectrum b-lactamase in clinical
isolates of Pseudomonas and Acinetobacter species
S. Gu¨nde, H. U¨c¸karde, A. Karadenizli, M. Ru¨zgar, F. O¨zkan,
A. Willke
Kocaeli TR
Objectives: The incidence of resistance to ESBL antibiotics is
increasing in Turkey. In this study, in-vitro activities of 17 antimi-
crobial agents against 601 Pseudomonas and 318 acinetobacter spe-
cies isolated between 01 January 2000 and 31 August 2003 were
studied for the production of ESBLs.
Methods: Identiﬁcation and susceptibility tests were done using
VITEC 2 system. Conventional methods and BBL Crystal (Bio-
Merieux, Fr) were studied additionally when necessary. Minimum
inhibitory concentration (MIC) of panresistant strains were deter-
mined by agar dilution method.
Results: A total of 177 (87%) of isolated Acinetobacter spp was
from inpatient clinics, 41 (12.8%) were from outpatient specimens.
Intensive care unit was accounted for 36.7% of positive cultures
in hospitalised patients. Among Acinetobacter species 317 were Ac-
inetobacter spp.; saccharolytic, nonhaemolytic, one was Acinetobact-
er spp., asaccharolytic, nonhaemolytic. Acinetobacter isolates were
generally more resistant than Pseudomonas isolates. Fifty-seven per
cent of all acinetobacter strains were ESBL-positive. Panresistance
rate was 8.4%. Of the antimicrobials tested, imipenem and b-lac-
tams with b-lactamase activity were found most active with sus-
ceptibility rates 50–60%. Rates of susceptibility against amikacin,
ampicillin, cefazoline, cefotetan, ciproﬂoxacin, oﬂoxacin, gentami-
cin, piperacillin, tobramycin were lower than 40%. Eighty-seven
per cent (524) of Pseudomonas isolates were P. aeruginosa, 1.16% (7)
were P. ﬂuorescence. One-third of all isolates were from intensive
care units. Fifty-six per cent of Pseudomonas isolates were ESBL-
positive. Imipenem (70%) and piperacillin/tazobactam (83%)
have the highest activity against Pseudomonas spp. Ciproﬂoxacin
Drug
% of isolates with n-fold MIC increase MIC 50; 90% mg/L*
n ¼ 1 n ¼ 2 n ¼ 4 n ¼ 8 n ¼ 16 n 32 105CFU/mL 107CFU/mL
AMC 7.8 34.4 29.8 13.3 7.3 7.3 16; 16 32; 128
PTZ 0.9 7.3 7.3 8.3 9.2 67.0 16; 1024 4096; 4096
CPS 7.8 32.6 33.9 11.0 7.8 6.9 16; 32 32; 128
*Concentration of a beta-lactam component
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resistance was 51%. Among aminoglycosides, amikacin was most
active with 73% susceptibility rate, followed by tobramycin (56%)
and gentamycin (43%).
Conclusion: Imipenem and b-lactam inhibitors are still the ﬁrst line
drugs in nonfermentative bacteria infections in our region.
P1727 Biochemical characterisation of VIM-7, a new VIM
variant produced by a Pseudomomas aeruginosa clinical isolate
from Texas
M. Castanheira, T.A. Murphy, M.A. Toleman, R.N. Jones,
T.R. Walsh
Bristol, UK; North Liberty, USA
Objectives: blaVIM-7 was the ﬁrst mobile metallo-b-lactamase des-
cribed in North America. This plasmid-encoded gene was found
in the Pseudomonas aeruginosa isolate 07-406, submitted to the
CANCER Programme in 2001. The enzyme produced is very
divergent from the other member of the VIM-family enzymes.
VIM-7 has 77% amino acid identity to VIM-1, whereas VIM-1 to
VIM-6 has 89 to 99% identity. The aim of this study was deter-
mine the kinetic parameters to VIM-7.
Methods: blaVIM-7 was ampliﬁed and aggregated with Nde I and
Bam HI restriction sites by PCR and primarily cloned in PCR
Script Cam+. The gene was subcloned in pET-9a expression vector
and overexpressed in in Escherichia coli DH5a. The VIM-7 protein
was puriﬁed using a periplasmic preparation by fast performance
liquid chromatography (FPLC). The integrity of the enzyme was
conﬁrmed using mass spectroscopy and N-terminal sequencing.
Kinetic properties were determined with several b-lactam sub-
strates measuring hydrolysis rates under initial rate conditions.
Results: VIM-7 varies from VIM-1 by 31% amino acid residues at
the level of the mature protein, being the most divergent VIM
variant so far identiﬁed. Semi-puriﬁed VIM-7 actively hydrolyses
imipenem (IMI), meropenem (MER), penicillins and cephalospo-
rins, where the penicilins and IMI appears to be the preferential
substrates. The Km (micro molar) values obtained with semi-puri-
ﬁed enzyme were 17 to ampicillin, 35 to IMI and 126 to MER.
VIM-7 showed no hydrolysis against aztreonan and poor rates
against the serine-b-lactamase inhibitors (clavulanic acid and tazo-
bactam). In comparison with VIM-1 and VIM-2, VIM-7 showed
remarkable differences.
Conclusions: VIM-7 is a new highly divergent VIM variant, which
demonstrates signiﬁcantly kinetic properties from those values
reported for VIM-1 and VIM-2. VIM-7s kinetic proﬁle and its pos-
sibility of dissemination in America, suggests that this enzyme
will compromise therapies in this region.
P1728 Distribution and association of mef(A/E), erm(B) and
tet(M) genes in erythromycin resistant S. pneumoniae and oral
streptococci
M. Santagati, C. Cascone, C. Fichera, T. Bertuccio, M. Mezzatesta,
G. Guardo, S. Stefani
Catania, I
Objectives: A clinical sample of 28 macrolide-resistant streptococci
collected in our laboratory from throat swab cultures, including
21 S. pneumoniae, four S. sanguinis, one S. mitis, one S. milleri and
one S. morbillorum was characterised in order to evaluate (i) the
distribution of mef(A/E), erm(B) and erm(A) genes; (ii) their associ-
ation with tet(M) and (iii) the localisation of resistance determi-
nants on the streptococcal genome.
Methods: PCR with primers speciﬁc for mef(A/E), erm(B), erm(A)
and tet(M) were used. The localisation of resistance genes was
obtained by PFGE, Southern Blot and hybridisation with speciﬁc
probes. Direct automated sequencing of PCR fragments was per-
formed.
Results: erm(B) was identiﬁed in 71.4% of MLSB strains (60.7% in
S. pneumoniae, 7.2% in S. sanguinis, 3.5% in S. morbillorum), mef(A)
gene was present in 17.8% of M strains (10.7% in S. pneumoniae;
3.6% in S. mitis; 3.5% in S. sanguinis), while erm(A) was never
found. In all MLSB strains erm(B) was always associated with
tet(M) in all species. In M-strains, tet(M) was associated in 7.1% in
mef(A)-positive strains (3.5% in S. milleri and 3.6% in S. sanguinis)
and in 3.5% in S. pneumoniae mef(E)-positive. Southern blotting
analysis indicated that erm(B) and tet(M) always hybridised in a
single band in all cases, suggesting a localisation in the same gen-
etic element; on the contrary mef(A) and tet(M) hybridised on dif-
ferent fragments, demonstrating the different localisation on the
streptococcal genome; in only one case mef(E) and tet(M) appeared
to be associated. The sequence analysis of long-PCR of two strains
with erm(B)/tet(M) and mef(E)/tet(M) showed the presence of
Tn1545 in the former and the integration of the MEGA element,
which carries mef(E), in Tn916 containing tet(M), in the latter. Fur-
thermore, the sequence of long-PCR of mef(A)/tet(M) positive
strains demonstrated the presence of Tn1207.1 and Tn916, which
were never associated with each other.
Conclusions: Our study demonstrated that (i) erm(B) gene is pre-
valent in all species; (ii) tet(M) is always associated with erm(B)
and sporadically associated with mef(A). Finally, only in mef(E)–
tet(M) strains, was the integration of MEGA into Tn916 demon-
strated, showing an example of genetic evolution of resistance.
P1729 Mechanisms of resistance in 17 unrelated
Escherichia coli strains of different origins with a multiple-
antibiotic-resistance phenotype
Y. Sa´enz, L. Brin˜as, J. Ruiz, M. Zarazaga, J. Vila, C. Torres
Logron˜o, Barcelona, E
Objective: To characterise the multiple antibiotic resistance mecha-
nisms in 17 unrelated Escherichia coli strains of different origins.
Methods: The strains were recovered from foods (four) and faecal
samples of healthy animals (eight) and humans (ﬁve). Susceptibil-
ity testing to 25 antimicrobial agents was performed by agar-dilu-
tion method (NCCLS). Mutations in the gyrA, gyrB and parC
genes, and the analysis of blaTEM, blaOXA and blaSHV genes
were determined by PCR and sequencing. The tet, aac(3), ant(2’’),
aphA, sul, aadA, cmlA and ﬂoR genes were detected by PCR,
whereas dfr genes were identiﬁed by PCR and RFLP. Chloram-
phenicol acetyl-transferase (CAT) activity was also studied. Type
1 and 2 integrons were analysed by PCR and sequencing.
Results: All strains were resistant to nalidixic acid, ampicillin, tet-
racycline, chloramphenicol and rifampicin, and most also to trim-
ethoprim (14 strains), sulphamethoxazole (16 strains) and
streptomycin (16 strains). Four and eight strains were resistant to
gentamicin and kanamycin, respectively. Ten strains (ciproﬂoxacin
MIC range 0.125–1 mg/L) showed a single amino acid change in
GyrA (S83L). The amino acid changes found in the remaining
seven strains (ciproﬂoxacin MIC range 4–64 mg/L) were (GyrA/
ParC changes): S83L+D87N/S80I: four strains; S83L + D87H/S80I:
one strain; S83L + A84P/S80I + A108V: one strain; and
S83L + D87N/S80I + E84G: one strain. The resistance genes detec-
ted were the following (no. strains): blaTEM1 (17); tetA (10), tetB
(seven); cmlA (ﬁve); aac(3)-IV (three), aac(3)-II (one); aphA1 (two),
aphA2 (six); aadA1 (12), aadA2 (ﬁve), aadA5 (two); sul1 (10), sul2
(11), sul3 (six); dfrA1 (nine), dfrA12 (ﬁve), dfrA17 (two), and a new
dfr gene was also found in one strain. None of the 17 strains had
blaOXA, blaSHV, ant (200) or ﬂoR genes. More than ﬁve different
resistance genes were found in 15 of the 17 strains and one strain
harboured 11 of the 18 genes detected. Ten strains showed more
than one gene implicated in the resistance to the same antimicro-
bial agent. CAT activity was found in six of the 17 strains. Eleven
strains harboured one or two type 1 integrons, which included
the following gene cassettes (no. strains): aadA1 (one),
dfrA1+aadA1 (six), dfrA12 + orf + aadA2 (four), dfrA17 + aadA5
(two). Type 2 integron was detected in four strains, which inclu-
ded the dfrA1 + sat + aadA1 gene cassettes.
Conclusions: The multiple-antibiotic-resistance phenotype in E. coli
strains of different origins is associated with heterogeneous resist-
ance mechanisms, some of which are located in integrons.
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P1730 Genetic analysis of ﬂuoroquinolone-resistant
Acinetobacter baumannii isolates from Korea
J.K. Lee, Y.S. Yoo, Y.S. Lee, J.I. Yoo, B.S. Kim
Seoul, KOR
Objectives: Acinetobacter baumannii has recognized as a important
opportunistic pathogen of nosocomial infections and the resistance
to ﬂuoroquinolone among Acinetobacter spp. has rapidly emerged
in Korea. The mechanism of resistance to ﬂuoroquinolone has
been associated mainly with mutations in quinolone-resistance-
determinig regions (QRDR) of the gyrA gene of DNA gyrase
and the parC gene of topoisomerase IV. The genetic analysis of
ﬂuoroquinolone resistance in A. baumannii isolates in Korea
remain to be investigated. To investigate the prevalence of muta-
tions in DNA gyrase and topoisomerase IV, we analysed the
QRDRs of the gyrA and parC genes against ciproﬂoxacin-resistant
A. baumannii isolates from Korean hospitals.
Methods: A total of 59 clinical isolates of A. baumannii were collec-
ted from nontertiary hospitals in 2002–2003. A. baumannii isolates
were identiﬁed by the API 20NE kit and recA-RFLP analysis with-
Tsp5091. MICs of ciproﬂoxacin and levoﬂoxacin were determined
according to the criteria of NCCLS. The QRDRs of gyrA and parC
genes were ampliﬁed by PCR using speciﬁc primers. To detect
mutations in the QRDRs, digestion of the PCR products with Hinf
I were analysed and sequencing was performed by the dideoxy-
chain termination method.
Results: Ciproﬂoxacin and levoﬂoxacin resistance rates of A. bau-
mannii isolates were 89.8 and 78.0%, respectively. The MIC50 and
MIC90 of ciproﬂoxacin and levoﬂoxacin of these isolates were 32
and 128 and 8 and 16 mg/L, respectively. All of 53 ciproﬂoxacin-
resistant A. baumannii had only a substitution of Ser83 with Leu in
the GyrA protein. Other mutations in the gyrA gene, Gly81Val
and Ala84;Pro, did not be detected. Among 53 A. baumannii iso-
lates with alteration in Ser83 of GyrA, mutations with substitution
of Ser80 to either Leu or Trp in the ParC were found in 41 and
one isolate, respectively. Nine isolates had a substitution of Glu84
to Lys and two isolates contained no mutation in the ParC.
Conclusions: In this study, double mutation at codons Ser83 in
GyrA and Ser80 in ParC were more frequently found among A.
baumannii isolates with a ciproﬂoxacin MIC of 16 mg/L. In ParC
protein, the novel substitution of amino acid, Ser80 to Trp, was
detected.
P1731 CTX-M-type extended-spectrum b-lactamases in
commensal Escherichia coli from healthy children living in
urban areas of Bolivia and Peru
L. Pallecchi, M. Malossi, A. Mantella, A. Bartoloni, C. Trigoso,
H. Guerra, F. Paradisi, G. Kronvall, G.M. Rossolini
Siena, Florence, I; La Paz, BOL; Lima, PE; Stockholm, S
Objectives: The CTX-M-type b-lactamases are acknowledged
among the most important secondary extended-spectrum b-lacta-
mases (ESBLs) spreading in Enterobacteriaceae. CTX-M-producers
have mostly been reported among nosocomial isolates, but
recently also from outpatients and animals, pointing to the pres-
ence of a large reservoir of these resistance genes. In this paper
we describe the detection of different CTX-M genes in commensal
Escherichia coli from healthy children living in Bolivia and Peru.
Methods: E. coli were from faecal swabs of healthy children from
four urban areas of Latin America, two in Bolivia and two in
Peru. Susceptibility testing and detection of ESBL production were
carried out as recommended by NCCLS. Characterisation of b-lac-
tamases was carried out by analytical isoelectric focusing (IEF),
and by molecular analysis of genes by PCR and sequencing. The
genetic support and transferability of the CTX-M determinants
were investigated by mating experiments, plasmid proﬁling, and
Southern blot experiments. The phylogenetic group of E. coli iso-
lates was determined by multiplex PCR.
Results: During a large screening (3208 subjects) carried out to
investigate antimicrobial resistance in commensal E. coli of healthy
children from Peru and Bolivia, ceftriaxone-resistant E. coli iso-
lates were recovered from four subjects (one from each urban
area). The four isolates tested positive for ESBL production in a
double-disc synergy test and IEF revealed multiple bands of b-lac-
tamase activity. Molecular analysis showed that three isolates
(two from Bolivia and one from Peru) produced the CTX-M-2
enzyme, while one (from Yurimaguas and Peru) produced CTX-
M-15. The CTX-M-2 determinants were carried on large conjuga-
tive multidrug resistance plasmids (of heteogeneous restriction
proﬁles in different isolates) that also encoded a TEM-1 b-lacta-
mase. Transferability could not be detected for the CTX-M-15
determinant. The isolates producing CTX-M-2 belonged in three
different phylogenetic groups (A, B2 and D), while the CTX-M-15
producer in phylogenetic group D.
Conclusions: These ﬁndings underscore the widespread distribution
of CTX-M genes, and the role that the commensal E. coli microbiota
can play as a potential reservoir of these resistance determinants.
To our best knowledge, this is the ﬁrst report on CTX-M enzymes in
Bolivia and Peru, and on CTX-M-15 in Latin America. ANTRES pro-
ject supported by EU INCO-DEV, ICA4-CT-2001-10014.
P1732 Characterisation of extended-spectrum b-lactamases
in Escherichia coli strains recovered in a Spanish hospital
L. Brin˜as, M. Lantero, I. de Diego, M. Alvarez, M. Zarazaga,
C. Torres
Logron˜o, Oviedo, E
Objective: To characterise the b-lactam resistance mechanisms in a
series of 33 Escherichia coli clinical isolates with MIC >2 mg/L of
ceftazidime or cefotaxime.
Methods: The strains were recovered from unrelated patients in a
hospital of Asturias, (Spain) during a 12-month period. Suscepti-
bility testing to 10 b-lactams was performed by the agar-dilution
method. Screening for detection of extended-b-lactamases (ESBL)
was carried out by the double-disc test. Genes of TEM, SHV,
OXA, CTX-M, CMY and FOX b-lactamases were investigated by
speciﬁc PCRs and sequencing. Mutations in the promoter region
of the chromosomal ampC gene were analysed by PCR and
sequencing. Clonal diversity was studied by pulsed-ﬁeld gel elec-
trophoresis (PFGE) by digestion with XbaI enzyme.
Results: The MIC ranges (in mg/L) were as follows: ampicillin,
128 to >256; ticarcillin, 32 to >256; amoxicillin–clavulanic acid, 2/
1–32/16; cefazolin, 16 to >256; cefoxitin, 1 to 256; ceftazidime, <0.5
to 128; cefotaxime, 0.25 to >128; ceftriaxone, 0.25 to >128; imipe-
nem, <0.125 to 0.25; and aztreonam, 1 to 256. Genes encoding
ESBL were detected in 23 of the strains (13 blaCTX-M-14, four
blaCTX-M-9, one blaCTX-M-29, two blaCMY-2, two blaTEM-52,
and one blaSHV-12). The 42 point mutation in the promoter of
ampC gene was detected (not associated with ESBL) in other eight
E. coli strains. Neither blaFOX nor blaOXA genes were detected in
the 33 strains. The blaTEM-1 gene was identiﬁed in 17 strains, in
11 cases associated with ESBL and in four cases with the mutation
at the 42 position of the ampC gene promoter. No ESBL or ampC
mutations were detected in the last two extended spectrum cepha-
losporin-resistant E. coli strains. All the 20 isolates with blaCTX-M
or blaCMY genes showed unrelated PFGE patterns.
Conclusions: blaCTX-M-14, and blaCTX-M-9, are the main ESBL
genes detected in our strains and the unusual blaCTX-M-29 gene
has also been found. The 42 point mutation in the ampC gene
promoter has not been detected in strains with ESBL genes.
P1733 Molecular characterisation of two multiresistent
clinical isolates of Chlamydia trachomatis
O. Misyurina, E. Chipitsyna, J. Finashutina, V. Lazarev,
A. Savicheva, V.M. Govorun
Moscow, RUS
Two clinical isolates of C. trachomatis resistant to azithromycin
and oﬂoxacin were obtained. The objective of the present work
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was studying them for possible mutations that are known as con-
ferring resistance to macrolides and ﬂuoroquinolones.
Methods: Patient 1 was a 25-year-old woman with exacerbation of
chronic salpingitis. Cervical specimens were tested for C. tracho-
matis by PCR and cell culture, and both PCR and cell culture
results were positive (isolate no. 1). Patient 2 was a 31-year-old
woman presented with endocervicitis on May 2000 and had a
positive cervical culture for C. trachomatis (isolate no. 2). She
reported that she had had an episode of C. trachomatis infection in
1997 and received spiramycin for it. The patient was treated with
doxycycline. Eight months later, PCR test of cervical specimen for
C. trachomatis was negative. Each strain was titered at 10-fold
dilutions and dilution producing approximately 104 inclusions
per well, which corresponds to 10–20 inclusion per ﬁeld under
microscope magniﬁcation of 400, was used in MIC and MBC
determination experiments. The inclusions were detected by direct
immunoﬂuorescence using ﬂuorescein-labelled antibodies against
major outer membrane protein.
Results and conclusions: Isolates no. 1 and 2 demonstrated resist-
ance to azithromycin (MIC and MBC were above 5.12 mg/mL,
compared with between 0.02 and 0.16 mg/mL for the reference
strain ATCC VR-885) and oﬂoxacin (above 256 mg/mL, compared
with 4 mg/mL for the reference strain). The isolates demonstrated
heterotypic kind of resistance, because only small numbers of
inclusions was observed in presence of antibiotic. Partial
sequences of genes gyrA, gyrB, parC, parE, L22, L4 and 23S rRNA
were determined. Both the isolates had mutations A2058C and
T2611C (the E. coli numbering) in the peptidyl transferase region
of the 23S rRNA gene. That mutations are associated with resist-
ance to macrolides in the clinical isolates of pathogenic bacteria.
Mutations in a nonconservative region of the L22 gene L22–
Gly52>Ser, Arg65>Cys, Val77>Ala – were found in the isolate no.
1. Such mutations have not been found in other macrolide-resist-
ant bacteria and we believe that they are not responsible for
macrolide resistance. Though bacterial FQ resistance has been
usually associated with certain point mutations QRDR of gyrA,
no mutations were observed in the quinolone resistance-determin-
ing regions (QRDR) of gyrA, gyrB, parC and parE genes.
P1734 The presence of tetracycline resistance determinants
and the susceptibility for tigecycline and minocycline
A. Fluit, A. Florijn, J. Verhoef, D. Milatovic
Utrecht, NL
Background: In Enterobacteriaceae tetA–tetE tetracycline resistance
determinants may be encountered depending on the species. In
Staphylococcus aureus the tetK and tetM determinants are com-
monly encountered. In some cases cross-resistance is observed
with other tetracyclines. Tigecycline is a new tetracycline-like anti-
biotic with broad activity.
Aim: Study the relationship between the presence of tetracycline
resistance determinants and MICs for tigecycline and minocycline
in Enterobacteriaceae and S. aureus.
Methods: Tetracycline resistant isolates were randomly chosen
from a collection of European isolates. MICs were determined
using NCCLS methodology. The presence of the tetracycline
determinants was established by speciﬁc PCRs. Escherichia coli
(n ¼ 51) were tested for the presence of tet(A)–(E), Klebsiella spp.
(n ¼ 49) for tet(A)–(D); Serratia marcescens (n ¼ 48) for tet(A)–(C),
and (E), and Enterobacter spp. (n ¼ 50) for tet(B)–(D). S. aureus
(n ¼ 101) were tested for tetK and tetM.
Results: Seven E. coli isolates contained two determinants, whereas
this was observed in only two Klebsiella and two Enterobacter iso-
lates. None of the tested determinants was present in 30 Enterob-
acter and 45 Serratia marcescens isolates, suggesting that other
resistance mechanisms are responsible for the tetracycline resist-
ance. For any combination of resistance determinants among the
Enterobacteriaceae the MICs for minocycline were higher than for
tigecycline. No clear correlation between any combination of
resistance determinants and the MICs for tigecycline and minocy-
cline was observed. S. aureus isolates carrying the tetM determin-
ant showed signiﬁcantly higher MICs for minocycline than for
tigecycline. When tetK alone was present the minocycline and
tigecycline MIC distribution was comparable ranging from 0.12–
2 mg/L for tigecycline and from 0.06–8 mg/L for minocycline.
In tetM-positive isolate the ranges were 0.25–0.5 mg/L and
4–32 mg/L, resp.
Conclusions: No clear relation between the presence of tetracycline
resistance determinants and the MICs for tigecycline were
observed for Enterobacteriaceae and S. aureus, whereas such a
relation was present for minocycline MICs and tetM and tetK.
P1735 Correlation of the mutation potential of
Acinetobacter baumannii clinical isolates with alterations in the
mutS gene
S.E. Davies, S. Brown, S.G.B. Amyes
Edinburgh, UK
Objectives: To analyse the amino acid (aa) sequences of the mis-
match-repair (MMR) component mutS in sensitive and resistant
clinical isolates of Acinetobacter baumannii (Ab) and to investigate
whether variations in mutS correspond with the mutation poten-
tial of the isolates in response to challenge with ciproﬂoxacin
(CIP).
Methods: A total of 12 representative Ab isolates were selected
according to sensitivities. mutS was PCR-ampliﬁed with degener-
ate primers and sequences analysed by alignment using hierar-
chical clustering. First and second step mutants were generated
with 2  MIC of CIP and mutation frequencies were calculated
as the ratio of mutant to viable cells. The gyrA (and where
appropriate parC) quinolone-resistance-determining regions
(QRDR) of parents and mutants were PCR ampliﬁed, with HinfI
restriction and sequencing indicating the presence of target site
mutations.
Results: Within a 210 base pair section of mutS spanning the mis-
match-binding domain, the majority of clinical isolates differed
from the control strains at 16 aa positions. The aa sequences of all
resistant isolates were identical whereas sensitive isolates varied.
Two sensitive isolates (E21 and E33) matched neither the controls
nor the other clinical isolates at 17 aa positions. Another sensitive
isolate (U51) had an aa sequence identical to the resistant isolates
and a higher mutation frequency (2.8  106) compared with
other sensitive isolates (6–60  108). Successive generations of
U51 exhibited a greater increase in MICs of CIP (parent to sec-
ond-step, 0.5 to 4–32 mg/L) than other sensitive isolates, their
MICs remaining low. One U51 second-step mutant (MIC ¼
32 mg/L) developed a target site mutation of gyrA Ser83 to Leu.
No parC target site mutation was found, despite the high-level
CIP resistance. Six identical aa substitutions were found in the
gyrA QRDR of both the parents and mutants of E21 and E33. No
target site mutations were found.
Conclusions: Mutants generated from a sensitive isolate that dis-
played an identical aa MutS pattern to resistant strains developed
higher levels of resistance to CIP compared with other sensitive
strains. This correlated with a higher mutation frequency and a
gyrA mutation at Ser83 in contrast to mutants of the other sensi-
tive isolates in which no corresponding mutations were seen.
P1736 Examination of the carbapenem resistance gene
activation mechanisms of imipenem-resistant Bacteroides
fragilis isolates from the UK
J. Soki, J.S. Brazier, E. Fodor, M. Gal, E. Urban, E. Nagy,
B.I. Duerden
Szeged, HUN; Cardiff, UK
Objectives: To examine the resistance mechanism, the presence of
the cﬁA resistance gene and especially the activating insertion
sequence (IS) elements of imipenem-resistant Bacteroides strains
in the culture collection of the Anaerobe Reference Laboratory,
Cardiff, UK.
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Methods: Susceptibility measurements using Etests for amoxicil-
lin/clavulanate, cefoxitine, clindamycin, imipenem and metroni-
dazole, PCR and PCR-mapping to detect the cﬁA genes and IS
elements, nucleotide sequencing and imipenemase production
assays were applied.
Results: Seven imipenem-resistant B. fragilis strains were detected
that all produced imipenemase and were cﬁA-positive. The resist-
ance genes were shown to be preceded by IS elements that were
already described (IS942, IS1186) in two strains or that were
recently detected among isolates from the USA or Nottingham,
UK in ﬁve strains. Obtaining the the full nucleotide sequence of
IS element (IS614B and IS614C) representatives of this latter
strains showed that they resemble to IS612 and IS614 detected in
imipenem-resistant B. fragilis strains in Japan but may be hybrid
or mosaic forms of these elements from Japan.
Conclusions: Our results conﬁrm that imipenem resistance is due
to cﬁA genes activated by insertion sequence elements among B.
fragilis strains and highlight, compared with earlier results, the
presence of IS614B and IS614C among isolates from the UK and
the USA as the possibly most prevalent ones at least in these
countries. (This study was supported by a Royal Society – Hun-
garian Academy of Sciences exchange fellowship and a Hungar-
ian National Research Fundation grant T037475 to Jozsef Soki.)
P1737 Evaluation of the Salmonella typhimurium proteome
by semi-automated two dimensional HPLC-mass spectrometry;
detection of proteins implicated in multiple antibiotic resistance
N. Coldham, M.J. Woodward
Surrey, UK
Objective: The proteome of Salmonella enterica serovar typhimurium
was characterised by two-dimensional HPLC mass spectrometry
to provide a platform for subsequent proteomic investigations of
low level multiple antibiotic resistance (MAR).
Methods: Cells (2.15  0.23  1010 CFU; mean  SD) were harves-
ted from liquid culture and proteins differentially fractionated, on
the basis of solubility, into preparations representative of the cyto-
sol, cell envelope and outer-membrane proteins (omps). These
preparations were digested by treatment with trypsin and pep-
tides separated into fractions (n ¼ 20) by strong cation exchange
chromatography (SCX). Tryptic peptides in each SCX fraction
were further separated by reverse phase chromatography and
detected by ion-trap mass spectrometry. Peptides were assigned
to proteins and consensus rank listings compiled using SEQUEST.
Results: A total of 816  11 individual proteins were identiﬁed
which included 371  33, 565  15 and 262  5 from the cytoso-
lic, cell envelope and omp preparations, respectively. A signiﬁcant
correlation was observed (r2 ¼ 0.62  0.10; P < 0.0001) between
consensus rank position for duplicate cell preparations and an
average of 74  5% of proteins were common to both duplicates.
A total of 35 outer membrane proteins were detected, 20 of these
from the omp preparation. A range of proteins (n ¼ 20) previ-
ously associated with MAR in E. coli were detected including the
key effectors AcrA, AcrB, TolC and OmpF.
Conclusions: Characterisation of the Salmonella typhimurium prote-
ome will provide information for the discovery of protein bio-
markers for multiple antibiotic resistance, enable the production
of speciﬁc tests and thereby, evaluation of control strategies.
P1738 Characterisation of the mechanism of resistance to
several antimicrobial agents in Salmonella clinical isolates
causing traveller’s diarrhoea
R. Cabrera, J. Ruiz, F. Marco, M. Arroyo, A. Aladuen˜a, M. Usera,
M. de Jime´nez Anta, J. Gasco´n, J. Vila
Barcelona, Madrid, E
Objectives: Analyse the antimicrobial resistance in Salmonella iso-
lates causing Traveller’s diarrhoea (TD), and characterise the
mechanisms of resistance to several antimicrobial agents.
Methods: Sixty-two Salmonella strains isolated from patients affec-
ted with TD were analysed. The antimicrobial susceptibility to 12
antibiotics: ampicillin (AMP), amoxicillin/clavulanic acid, nali-
dixic acid (NAL), tetracycline (TET), trimethoprim/sulphamet-
oxazole (SXT), chloramphenicol (CHL), gentamicin, amikacin,
imipenem, norﬂoxacin, ciproﬂoxacin, ceftazidime, were performed
using the agar dilution method. The molecular mechanisms of
resistance to several antimicrobial agents was detected by PCR
and the chloramphenicol acetyl transferase activity by a colorimet-
ric assay.
Results: Twenty different serovar were identiﬁed, being Salmonella
enteritidis the most prevalent [20 isolates (32.3%) of 62], followed
by S. typhimurium [with six isolates (9.7%)]. The remaining iso-
lates belonged to a wide variety of serovar. The highest levels of
resistance were found against TET and AMP (20.9 and 19.4%,
respectively), followed by resistance to nalidixic acid (16.1%). The
resistance to NAL was related to the presence of mutations in the
amino acid codons 83 or 87 of the gyrA gene. In the isolates resist-
ant to ampicillin different b-lactamases were found: OXA-1 (one
isolate) and TEM-like (seven isolates, in one case concomitantly
with a CARB-2). Resistance to TET, was related to tetA (ﬁve cases)
and tetB and tetG in one case each. Resistance to CHL was related
to the presence of the ﬂoR gene in one case, while CAT activity
was present in one strain. Different dihydrofolate-reductases
(dfrA14, dfrA12, dfrA17 and dfrA1) were detected in SXT-resist-
ant isolates.
Conclusions: A wide variety of serovars was found among Salmon-
ella isolates causing TD, being S. enteritidis, followed by S. typhimu-
rium the most frequently isolated. A low percentage of strains
presented multi-resistance, however the highest levels of resist-
ance were found for TET, AMP and NAL, being worthy of
remark the steadily increase of the resistance to nalidixic acid
since 2000. Surveillance for antimicrobial resistance is important
to detect any trend and therefore give a more accurate empiric
treatment.
P1739 Gene for aac(6’)-Ib, conferring resistance to
amikacin, found in four different isolates of enterobacteria
Z. Gonzalez-Lama, M. Fernandez-Burriel, P. Lupiola, A.M. Lamas,
R. Alonso
Las Palmas de Gran Canaria, E
Objectives: The study of gene cassette for aac(6’)-Ib, conferring
resistance to amikacin, found in four different clinical isolates of
enterobacteria (K. pneumoniae 31, E. cloacae 46, E. cloacae 58 and
C. freundii 69).
Methods: Conjugation was performed, using 0.1 mL of stationary
cultures from K. pneumoniae, C. freundii and E. cloacae clinical iso-
lates as donors and from E. coli 2110nal as recipient. Plasmidic
DNA from these strains, were used for dot-blot hibridisation ver-
sus probes from aac(6’)-Ia and aac(6’)-Ib. The plasmids were
digested with BamHI, and cloned into pACYC184. Transformation
with plasmidic DNA obtained from clinical isolates or transconju-
gants was performed on E. coli DH5alpha by cold calcium chlor-
ide treatment. To further characterise the amikacin resistance
plasmid it was mapped by restriction analysis, and subsequently
subcloned by partial digestion. or directed subcloning of restric-
tion fragments. To characterise the aac(6’)-Ib gene and ﬂanking
regions of our isolates we used plasmids pMFB33, pMFB331,
pMFB332 and pMFB22 for sequencing with CyDye labeled M13
direct and reverse universal sequencing primers in an ALFexpress
automatic sequencer.
Results: These four strains resistant harbouring large conjugative
plasmids ranging from 31–69 kb. Dot-blot hybridisation of plas-
midic DNA from transconjugans, showing a positive result for
aac(6’)-Ib. The transformans selected for amikacin resistance,
contained a BamHI fragment insert of 3.9 kb leading to the
plasmid pMFB2.The restriction map of pMFB2 showed a struc-
ture related to that Tn21-derived integrons. The sequence
obtained of plasmids pMFb33, pMFB331 pMFB332 and pMFB22
showed a fragment of 267 bp insert upstream of aac(6’)-Ib gene
cassette.
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Conclusions: We have found that all our isolated strains resistant
to amikacin carried a plasmid that included an integron structure
with the aac(6’)-Ib gene cassette, in this case fused in frame with
an ORF with similarietes to the protein L of plasmid CloDf13
from E. coli. As all strains carry the same integron structure this
implies a horizontal transmission. In this case the pressure due to
the use of amikacin as prophylatic in urology surgery could be
the trigger of this outbreak in our hospital.
Antimicrobial susceptibility in Gram-positive bacteria
P1740 Resistance rates and resistance mechanisms of
S. pneumoniae strains isolated from eight European countries:
ﬁnal report of the PNEUMOWORLD study
R. Reinert, S. Reinert, P. Appelbaum, M. Cil, R. Lu¨tticken,
A. Al-Lahham – Pneumoworld Study Group
Objectives: An international study named PNEUMOWORLD star-
ted in 2001 to monitor the antimicrobial susceptibility and resist-
ance mechanisms of clinical isolates of S. pneumoniae collected
from adults over 16 years of age from 32 centers of eight Euro-
pean countries (Spain, France, Germany, Austria, Portugal, Swit-
zerland, Italy and Belgium).
Methods: Serotyping was performed with the Quellung method.
Microdilution method was done for all strains according to
NCCLS with the following antibiotics: Penicillin G, amoxicillin,
cefotaxime, cefuroxime, cefpodoxime, clarithromycin, clindamy-
cin, gatiﬂoxacin, levoﬂoxacin, cotimoxazole, tetracycline, chloram-
phenicol and telithromycin. Macrolide-resistant phenotypes was
checked with double disc-diffusion test according to standard
methods. Macrolide resistance mechanisms (ermB and mefA) were
done with the RT-PCR. Strains showing no products of ermB and
mefA were checked further for 23S rRNA mutations in four alleles
and changes on the ribosomal proteins L4 and L22. Fluoroquino-
lone resistance (FQ-R) mechanisms were detected by sequencing
gyrase A (gyrA) and B (gyrB) genes and topoisomerase C (parC)
and E (parE) genes.
Results: A total of 2285 clinical isolates of S. pneumoniae from ster-
ile body cultures were collected between 2001 and 2003. Patient
ages ranged between 17 and 100 years. Resistance rates were vari-
able among the eight European countries. Penicillin resistance
(intermediate, resistant) was detected in 566 strains and was high-
est in Spain (37.8 and 25.4%) and lowest in Austria (4.4, and 0%).
The predominant serotypes of penicillin-resistant isolates were
serotype 23F (16.8%) and 14 (16.4%). macrolide resistance was
detected in 618 strains and was highest in France (45.8%). Pre-
dominant serotypes of macrolide resistant strains were 14 (20.4%)
and 6B (17%). 81.7% of macrolide resistant strains were cMLSB
phenotypes, 3.6% were inducible and 14.7% with an efﬂux mech-
anism of resistance. Six macrolide resistant isolates were neither
ermB nor mefA and possessed mutations on 23S rRNA and L4.
FQ-R (Gatiﬂoxacin >1 mg/L) was found in 15 strains with amino
acid alterations mainly on parC at positions 79, 83, 91 and 137.
and on gyrA at positions 81, 85 and 114.
Conclusions: High rates of macrolide and penicillin resistance were
detected in Spain, France and Italy and lower rates were found in
Switzerland, Austria and Germany.
P1741 European surveillance study on antibiotic sensitivity
of Propionibacterium acnes strains
C.E. Nord, C. Oprica – ESCMID Study Group on Antimicrobial
Resistance in Anaerobic Bacteria (ESGARAB)
Objectives: Propionibacterium acnes strains are recovered from infec-
tions linked to operative procedures, foreign bodies and septicae-
mia. The aim of this study was to investigate the antibiotic
sensitivity patterns of P. acnes strains isolated from different infec-
tions.
Methods: A total of 304 P. acnes strains from 13 laboratories in 13
European countries were studied. The strains were isolated from
septicemia (105), skin and soft tissue infections (77), intraabdomi-
nal infections (22), head and neck infections (19), bone infections
(15), meningitis (14), endocarditis (13), eye infections (13), pros-
thetic devices (10), lung infections (6), and other infections (10).
The organisms were identiﬁed using biochemical tests, gas-chro-
matographic analysis and PCR. Pulsed-ﬁeld gel electrophoresis
was used for further characterisation. The size of chromosomal
fragments was 40–400 kb. Mutanolysin mixed with lysozyme was
used for inducing lysis. The restriction enzyme for DNA digestion
was Spe1. The minimum inhibitory concentrations of four antimi-
crobial agents (clindamycin, erythromycin, linezolid, and tetracyc-
line) against the P. acnes strains were determined by the agar-
dilution method according to NCCLS and EUCAST. Brucella
base-sheep blood agar with 100 000 CFU of inoculum per spot
was used. The agar plates were incubated in anaerobic jars for
48 h at 37C. The MIC was deﬁned as the lowest concentration of
antimicrobial agent resulting in a marked change in the appear-
ance of growth when compared with the control plates.
Results: A total of 18 clusters and 78 banding patterns were identi-
ﬁed among the isolates of P. acnes. The similarity between major
PFGE types ranged from 54 to 100%. The minimum inhibitory
concentration values were: for clindamycin, MIC50 0.032 mg/L,
MIC90 0.25 mg/L, range 0.032–64.0 mg/L; erythromycin, MIC50
0.25 mg/L, MIC90 0.5 mg/L, range 0.032–256 mg/L; linezolid,
MIC50 0.5 mg/L, MIC90 1.0 mg/L, range 0.25–2.0 mg/L; tetracyc-
line, MIC50 0.5 mg/L, MIC90 1.0 mg/L, range 0.032–32.0 mg/L.
No strains were resistant to linezolid, 3% of the strains to tetra-
cycline, 15% of the strains were resistant to clindamycin and 17%
of the strains to erythromycin. The most resistant strains to clinda-
mycin and erythromycin were found in Croatia and Slovenia and
the most susceptible strains in the Netherlands. The blood isolates
were dominating among the resistant strains.
Conclusions: Antibiotic resistance among P. acnes strains is increas-
ing in Europe.
P1742 Increasing erythromycin MICs within Canadian
Streptococcus pneumoniae isolates with the M phenotype
J. Powis, S. Pong-Porter, J. Fuller, D. Low – Canadian Bacterial
Surveillance Network1
Objectives: Erythromycin resistance is increasing among clinical
isolates of Streptococcus pneumoniae (SPN) in Canada. We examine
the longitudinal trend in the proportion of erm and mef espres-
sion (M or MLSB phenotype, respectively) within Canada, and the
distribution of erythromycin MICs for each phenotype.
Methods: SPN isolates were collected by the Canadian Bacterial
Surveillance Network, which is comprised of private and hospi-
tal-afﬁliated laboratories from across Canada. Laboratories were
asked to collect a deﬁned number of consecutive clinical isolates
followed by all sterile site isolates of SPN. In-vitro susceptibility
testing was performed by broth microdilution using NCCLS
guidelines. Erythromycin-resistant isolates were classiﬁed as
either M or MLSB phenotype based on clindamycin resistance,
corresponding to mef and erm genes respectively.
Results: There were a total of 13 177 isolates, including all patient
age groups, were obtained from across Canada between 1997 and
2003. Erythromycin resistance has increased over that time from
6.8% in 1997 to 16.2% in 2003. The percentage of isolates with a
M vs. MLSB phenotype has remained constant over that time at
54 and 46%, respectively. The distribution of erythromycin MICs
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in MLSB phenotype isolates is unchanged comparing 1997 to
2002, with the majority of isolates having high level resistance
(MIC > 32lg/mL). The MIC50 and MIC90 to erythromcyin for M
phenotype isolates has increased from 1997 to 2002 (MIC50 2 lg/
mL vs. 4 lg/mL, MIC90 16–32 lg/mL).
Conclusions: The proportion of M compared with MLSB pheno-
types is consistent over a 10-year period within SPN in Canada.
There is a signiﬁcant shift toward higher erythromycin MICs
among M phenotype isolates. This likely indicates either a more
efﬁcient efﬂux pump or increased expression of the mef gene.
Despite the increase in erythromycin MICs amongst isolates with
the M phenotype there has been no change in the MIC90 of tel-
ithromcyin for these isolates since testing began in 1999.
P1743 Comparison of daptomycin and vancomycin MIC
results by NCCLS, SFM, DIN and SRGA methods
L. Koeth, R. Leclercq, A. Rodloff, R. Smyth
Westlake, USA; Caen, F; Leipzig, D; Vaxjo, S
Objectives: We determined if daptomycin and vancomycin MIC
results obtained with DIN (Deutsches Institut fu¨r Normung), SFM
(Societe Francaise de Microbiologie), and SRGA (Swedish Refer-
ence Group for Antibiotics) are similar to NCCLS (National
Committee for Clinical Laboratory Standards) for selective Gram-
positive organisms.
Methods: Approximately 250 enterococci, staphylococci and strep-
tococci organisms were tested at three different European laborat-
ories. Both clinical and common stock isolates were tested using
media supplemented to 50 lg/mL calcium. Test-speciﬁc media
were as follows: NCCLS, Mueller–Hinton Broth; SRGA, PDM
agar; DIN, Isosensitest broth and SFM, Mueller–Hinton agar.
Quality control strains Staphylococcus aureus (ATCC 29213) and
Enterococcus faecalis (ATCC 29212) were tested on each day.
Results: Essential Agreement Rates (% EA  1-doubling dilution)
compared with NCCLS MICs were:
DIN and SFM daptomycin MICs were within 1 dilution of
NCCLS MICs for all species except S. pyogenes (DIN EA% ¼ 96.3,
SFM EA ¼ 93.1). SRGA daptomycin MICs were within 1 dilu-
tion for 95% of strains except E. faecalis (EA% ¼ 82.1) and E. fae-
cium (EA% ¼ 75.9).
Conclusions: There was excellent correlation of daptomycin and
vancomycin NCCLS MICs compared with DIN and SFM MICs.
There was good correlation of NCCLS and SRGA MICs, with
the exception of enterococcal MICs, which will require further
study.
P1744 Application of the mutant prevention concentration
for Streptococcus pneumoniae against azithromycin,
clarithromycin and erythromycin
J. Blondeau, K. Metzler, S. Borsos
Saskatoon, CAN
Objectives: The emergence of macrolide-resistant SP is a growing
concern since macrolides are commonly used to treat Streptococcus
pneumoniae (SP) infections. Two important mechanisms of resist-
ance include ER ribosomal methylase (erm) genes and macrolide
efﬂux (mef) genes. The mutant prevention concentration (MPC) is
a novel approach for determining the likelihood of an antibiotic to
select ﬁrst-step resistant mutants in a large population of cells.
We determined MPC values for penicillin-sensitive (PSSP) and
penicillin-intermediate (PISP) isolates against macrolide/azalide
agents.
Method: Minimal inhibitory concentrations (MIC) were determined
by microbroth dilution following NCCLS guidelines. MPC testing
was done by plating 10 (10) cells onto agar plates containing
drug and incubated in CO2 at 35–37C for 24 and 48 h. The lowest
concentration preventing growth was the MPC. polymerase chain
reaction (PCR) was performed on selected organisms (MPCs
0.5 mg/L) for presence or absence of macrolide-resistant genes.
Results: To date, 59 clinical isolates (49 PSSP and 10 PISP) of SP have
been tested. For azithromycin (AZ), clarithromycin (CL), erythro-
mycin (ER), MIC50/90 (lg/mL), MPC50/90 lg/mL) and mode
MIC/MPC were as follows respectively against PSSP: 0.125/0.25,
4/8, 0.125/8; 0.031/1, 0.25/4, 0.031/0.25; 0.063/8, 0.5/4,
0.063/0.5. MIC values were elevated against PSIP. PCR analysis of
16 organisms (MPCs  0.5 mg/L; MICs  0.125 mg/L) showed six
had acquired macrolide-resistance (two ermB, four mefA), however,
their susceptible parents did not have the macrolide-resistant genes.
Mutants were selected from AZ, ER & CL plates.
Conclusions: Macrolide-resistant SP sub-populations were selected
on MPC plates from large heterogeneous bacterial populations.
MPC may, therefore, be an accurate measurement for determining
appropriate dosing strategies to prevent resistance. The rank order
of potency based on MPC was ER ¼ CL>AZ. This represents the
ﬁrst report of the MPC concept applied to macrolides.
P1745 Activity of daptomycin against clinical and
environmental enterococci from Portugal
C. Novais, J.C. Sousa, T.M. Coque, L. Peixe and the Portuguese
Resistance Study Group2
Objectives: To study the activity of the new antibiotic daptomycin
against clinical and environmental enterococcal isolates with dif-
ferent antibiotic susceptibilities.
Methods: Enterococci were isolated from the following sources: (i)
251 clinical isolates from patients located at three hospitals (HP)
in Central and North Portugal (1996–2003); (ii) 32 sewage water
(SW) samples from four hospitals in Porto city collected just
before (upstream samples, n ¼ 13) and just after leaving (down-
stream samples, n ¼ 19) the hospital setting (2001–2002). SW sam-
ples were plated on Slanetz–Bartley agar with and without
antibiotics. One isolate/morphology and resistance phenotype
was selected. Antibiotic susceptibility was determined using the
agar dilution method in Mueller–Hinton media (NCCLS).
Results: From the 464 (251 HP and 213 SW) isolates studied, 246
were identiﬁed as E. faecium (119 from HP and 127 from SW), 179
as E. faecalis (132 from HP and 47 from SW) and 39 as Enterococcus
spp. (SW). Resistance to different antibiotics was observed in iso-
lates from both sources (HP, SW): vancomycin: 54, 17%; teicopla-
nin: 51, 12%; tetracycline: 82, 39%; erythromycin: 79, 64%;
ciproﬂoxacin: 81, 72%; chloramphenicol: 20, 14%; gentamicin: 45,
33%; streptomycin: 32, 39%; kanamycin: 67, 58%; and nitrofurant-
oin: 4, 11%. Multi-resistance was observed in isolates from HP
and SW. Daptomycin showed good activity against all enterococci
studied, including the multi-resistant isolates. The MIC50/MIC90
values for E. faecium were both 4 mg/L and for E. faecalis were 2
and 4 mg/L. Differences in the antibiotic activity were not
observed in isolates of distinct sources.
Conclusions: The good activity demonstrated by daptomycin
against all enterococcal isolates studied makes this compound a
good choice to treat the infections caused by resistant enterococci
from Portugal.
MIC
Method
Daptomycin Vancomycin
n % EA n % EA
DIN 266 99.6 260 100
SFM 259 99.2 253 99.6
SRGA 244 93.0 239 99.6
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P1746 Antimicrobial susceptibility patterns and macrolide
resistance genes of b-haemolytic streptococci in Korea
Y. Uh, I.H. Jang, G.Y. Hwang, M.K. Lee, K.J. Yoon, H.Y. Kim
Wonju, KOR
Objectives: This study evaluated the antimicrobial susceptibilities
and macrolide resistance mechanisms of clinical isolates of b-hae-
molytic streptococci in Korea.
Methods: The minimal inhibitory concentrations of seven anti-
microbials were determined for 540 clinical isolates of aˆ-haemolyt-
ic streptococci between January 1990 and December 2000.
Resistance mechanisms of erythromycin-resistant isolates were
studied by the double-disc test and the PCR.
Results: Of the isolates, the overall rates of nonsusceptibility to tet-
racycline, chloramphenicol, erythromycin and clindamycin were
80.0, 22.8, 20.2 and 19.1%, respectively. Among the b-haemolytic
streptococci tested, Streptococcus agalactiae had the highest nonsus-
ceptible rates to tetracycline (95.8%), erythromycin (25.3%) and
clindamycin (28.2%). Of 109 erythromycin nonsusceptible isolates,
69 isolates (63.3%) had the cMLSB phenotype [constitutive resist-
ance to macrolide-lincosamide-streptogramin B (MLSB)], 26 iso-
lates (23.9%) had the M phenotype and 14 (12.8%) isolates had
the iMLSB phenotype (inducible resistance to MLSB). The
proportion of the three MLS resistance phenotypes of S. pyogenes
was nearly equal. About three-quarters (74.4%) of
S. agalactiae had the cMLSB phenotype, whereas two-thirds
(66.7%) of group G streptococci had the M phenotype. With the
exception of two isolates, all MLSB resistant strains carried the
erm(B) genes in cMLSB phenotype, erm(TR) genes in iMLSB phe-
notype, and mef(A) genes in M phenotype, respectively.
Conclusions: Of erythromycin-resistant isolates, the cMLSB pheno-
type with the erm(B) gene was dominant in Korea. Mechanisms
and phenotype proportions of MLSB resistance were different by
serogroup in b-haemolytic streptococci. It is possible that MLSB
resistance genes have transferred among b-haemolytic streptococci
because the erythromycin resistance genes are the same in b-hae-
molytic streptococci.
P1747 In vitro activity of daptomycin against a range of
Staphylococcus aureus and Enterococcus isolates: ﬁrst results
from Turkey
H. Arslan, O¨. Kurt Azap, F. Ergin, S. Karaman, E. Oruc¸
Ankara, TR
Objectives: The recent increase in infections caused by resistant
Gram-positive pathogens, particularly nosocomial infections, have
prompted a search for new antimicrobials that can counter these
organisms. The cyclic lipopeptide daptomycin acts by inhibiting
cell wall synthesis and has a unique chemical structure and a
novel mode of action that enables it to target organisms that are
resistant to other classes of agents. Currently, this drug is being
investigated in a phase III clinical trial as treatment for serious
Gram-positive infections in hospitalised patients. To date, there
has been no investigation of the efﬁcacy of daptomycin in Turkey.
The aim of this study was to evaluate the in-vitro activity of this
drug against S. aureus and Enterococcus strains isolated from infec-
tions at a Turkish health centre.
Materials and methods: The organisms tested were 108 Staphylococ-
cus and 183 Enterococcus strains isolated from infected patients at
Baskent University Hospital. minimum inhibitory concentrations
(MICs) were determined by Etest on Iso-Sensitest agar medium.
Results: MIC results for daptomycin activity against the 108
S. aureus and 183 Enterococcus isolates are summarised in the
Table. The daptomycin MIC50 values for the MRSA and MSSA
strains were the same (0.38 mg/L), and the MIC90 values for
the MRSA and MSSA were similar (1.5 and 1 mg/L, respect-
ively). The daptomycin MIC values for the vancomycin-resistant
and vancomycin-sensitive enterococcal strains were also similar
(Table).
Conclusions: Daptomycin showed potent activity against all the
S. aureus and Enterococcus spp. that we tested, regardless of resist-
ance to methicillin or vancomycin. Our ﬁndings for in-vitro activ-
ity of daptomycin against S. aureus and Enterococcus strains in
Turkey are the ﬁrst such results from our country. Clinical trials
will provide more data on the efﬁcacy of daptomycin in such
cases.
P1748 Time-kill evaluation of the in-vitro activity of
ertapenem against S. pneumoniae
A. Marchese, L. Gualco, G. Schito
Genoa, I
Objectives: (i) To evaluate dynamic bactericidal activity of ertape-
nem and its effects at sub-MIC level in combination with other
drugs against S. pneumoniae strains displaying different antibiotic
resistance phenotypes and (ii) to explore physiological perturba-
tions (morphological changes) induced by this new carbapenems
at sub-MIC concentrations.
Methods: Three S. pneumoniae strains for each of the following
phenotypes have been studied: penicillin-susceptible (Pen-S),
penicillin-intermediate (Pen-I), penicillin-resistant (Pen-R), eryth-
romycin-resistant (Ery-R) and multi-resistant (Multi-R: Pen-Ery-
SXT-Ch-R). Bactericidal activity of ertapenem (4  MIC) was eval-
uated by time-kill curves following NCCLS suggestions (M26-A).
Interactions of ertapenem in combination with clarithromycin
(Cla), levoﬂoxacin (Lev), rifampin (Rif) and vancomycin (Van)
were studied by the time-kill method. In order to explore the mor-
phological changes induced by ertapenem, cells were exposed to
0.5  MIC and microscopic observations were performed after 2,
6 and 24 h of incubation.
Results: Ertapenem showed remarkable bactericidal activity
against all S. pneumoniae tested irrespectively of their antibiotypes,
causing >99.9% reduction of the initial inocula within 24 h of
exposure for all strains. Results of drugs interactions are depicted
in the Table.
Synergism was the prevalent outcome, antagonism was never
found. After 2,6 and 24 h of exposure to ertapenem sub-MICs
morphological alterations were observed and these were mainly
represented by abnormal elongation of cells.
Table. The minimum inhibitory concentrations (MICs) of dapto-
mycin against the Staphylococcus and Enterococcus strains tested.
Species (No. of isolates tested)
MIC (mg/L)
Range MIC50 MIC90
MRSA (58) 0.047–2 0.38 1.5
MSSA (50) 0.094–1.5 0.38 1
E. faecalis (106) 0.047–4 0.38 1.5
E. faecium (53) 0.047–8 1 2
Other Enterococcus spp.* (10) 0.047–2 0.19 1
VRE** (14) 0.094–4 1 1.5
*4 E. casseliﬂavus, 4 E. avium, 2 Enterococcus spp.
**11 E. faecium, 2 E. avium, 1 E. faecalis.
Microorganism (n)
Cla Lev Rif Ven
SYN IND SYN IND SYN IND SYN IND
S. pneumoniae Pen-S(3) 3 0 3 0 3 0 3 0
S. pneumoniae Pen-I(3) 3 0 3 0 3 0 3 0
S. pneumoniae Pen-R(3) 3 0 3 0 3 0 3 0
S. pneumoniae Ery-R(3) 2 1 3 0 3 0 3 0
S. pneumoniae Multi-R(3) 3 0 3 0 3 0 3 0
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Conclusions: Ertapenem possesses potent bactericidal activity
against S. pneumoniae strains irrespectively of their resistance to
other molecules and is able to interfere with bacterial physiology
at sub-MIC levels. Because of these characteristics and of its sy-
nergistic behaviour when combined with other anti-pneumococcal
drugs, ertapenem is indicated in the treatment of infections
caused by this pathogen.
P1749 Activity of ertapenem and 19 other antimicrobials
against Streptococcus pneumoniae and Haemophilus inﬂuenzae
isolated from the respiratory tract showing resistance
mechanisms to betalactam antibiotics
J.L. Go`mez-Garce´s, A. Alhambra Mosquera, J.-I. Alo´s Corte´s
Madrid, E
Objectives: The purpose of this study was to examine the suscepti-
bility to ertapenem and 19 other antimicrobials of 191 S. pneumoni-
ae strains resitant or with intermediate resistance to penicillin G
and 100 H. inﬂuenzae strains resistant to ampicillin due to b-lacta-
mase productions.
Methods: All microorganisms had been isolated from clinical res-
piratory samples collected between 2000 and 2001 in the 21 parti-
cipating microbiology laboratories geographically distributed in
13 Spanish Autonomous Comunnities. The following antimicrobi-
als were tested: penicillin G, amoxicillin, amoxicillin/clavulanate,
cefaclor, cefuroxime, cefpodoxime, ceftibuten, ceﬁxime, cefotaxi-
me, ertapenem, imipenem, erythromycin, clarithromycin, azithro-
mycin, clindamycin, tetracycline, chloramphenicol, ciproﬂoxacin,
levoﬂoxacin and moxiﬂoxacin. Susceptibility to antimicrobials was
tested using an agar dilution method based on the guideliness of
the NCCLS.
Results: S. pneumoniae strains with intermediate resistance to pen-
cillin were highly susceptible to carbapenems, with MIC90 of 0.25
and 0.5 mg/L for imipenem and ertapenem, respectively. Among
the penicillin-resistant strains the MIC90 values for imipenem and
ertapenem were 1 and 2 mg/L, respectively. Eight isolated in our
global series (9.3%) would be classiﬁed as resistant to imipenem,
while for ertapenem only four strains (4.7%) would be considered
resistance. Therefore, and although imipenem in general lines is
one dilution more active than ertapenem, other pharmacological
considerations and additional clinical data would allow for cate-
gorising a greater number of organisms as susceptible to ertape-
nem comparec to imipenem. Carbapenems were extraordinarily
active against the whole group of H. inﬂuenzae strains, particularly
ertapenem, which inhibited 90% of the series at a concentrations
of 0.12 mg/L.
Conclusions: Ertapenem is a powerful agent against the most com-
mon respiratory bacterial pathogens, including those which have
gradually incorporated effective resistance mechanims. Concentra-
tions of 4 mg/L inhibited all except one of the total 291 organisms
considered. Ertapenem is at least comparable to imipenem, cefo-
taxime or the newer ﬂuorquinolones, all of which are known to
be very effective against these microorganisms. Such performance,
and its favourable pharmacokinetic characteristics, make ertape-
nem an interesting option for the treatment of respiratory tract
infections.
P1750 Daptomycin in-vitro activity tested against 2221
Gram-positive strains collected from European hospitals, 2002
H. Sader, J. Streit, T. Fritsche, R. Jones
North Liberty, USA
Background: Daptomycin (DAP) is a cyclic lipopeptide recently
approved by the US FDA for the treatment of complicated skin
and skin structure infections. We evaluated the contemporary
in vitro activity of DAP against a collection of Gram-positive (GP)
strains collected in European medical centers in 2002.
Methods: A total of 2221 clinical GP strains were collected from 29
centres. The collection included S. aureus [763 strains; 31% oxacil-
lin (OXA)-resistant (R)]; coagulase-negative staphylococci (CoNS;
281 strains; 79% OXA-R), enterococci [260; 4% vancomycin
(VAN)-R], streptococci (904) and other GP species (13). The strains
were tested by NCCLS broth microdilution in Mueller–Hinton
broth with 50 mg/L Ca++ against DAP. More than 20 compara-
tors were also tested.
Results: DAP inhibited all tested strains at 4 mg/L and only the
enterococcal isolates showed DAP MIC of 4 mg/L (14 strains;
5.4%). All staphylococcal and streptococcal isolates were inhibited
at 1 mg/L of DAP. The activities of DAP, VAN, teicoplanin
(TEI), quinupristin/dalfopristin (Q/D) and linezolid (LZD) are
shown in the table:
Conclusions: VAN-R and Q/D-R did not inﬂuence DAP activity
against enterococci, and PEN-R did not affect DAP activity on
SPN. DAP showed a signiﬁcant potency and spectrum against all
GP including multi-drug resistant strains and may represent a
therapeutic option for infections caused by these pathogens.
P1751 Activity of telithromycin against erythromycin
susceptible and resistant Streptococcus pneumoniae isolates from
adults with invasive infections
M. Ortega, F. Marco, M. Almela, J. Puig de la Bellacasa,
A. Soriano, J. Mensa
Barcelona, E
Objectives: To know the activity of different TT concentrations
against clinical isolates of S. pneumoniae susceptible and resistant
to erythromycin, that caused invasive infections in adults in our
setting.
Materials and methods: A total of 120 clinically signiﬁcant S. pneu-
moniae isolates recovered from adults admitted in our institution
at the current year (2003) were used in the study. MICs were
determined with a microdilution method using cation adjusted
Mueller–Hinton broth supplemented with 5% lysed horse blood.
Time-kill curves were performed using Todd–Hewitt broth plus
0.5% of yeast extract as culture medium. Antibiotic concentrations
were as follows: 2, 1, 0.5, 0.25 and 0.125 lg/mL for TT and 1 lg/
mL for erythromycin. ppropriate dilutions were performed at 0, 2,
4, 6 and 24 h in order to know the number of viable bacteria
(CFU/mL).
Results: A total of 60 strains were erythromycin susceptible
(MIC < 0.06 lg/mL), and the other 60 were erythromycin resist-
ant (MIC > 64 lg/mL). TT had low MICs for erythromycin sus-
ceptible (MIC 0.008–0.016 lg/mL) and for erythromycin-resistant
strains (MIC 0.125–0.25 lg/mL). TT was uniformly bactericidal
(irrespective of the strain’s erythromycin susceptibility). In case of
erythromycin susceptible strains, TT showed 99.9 % killing of all
strains at 6 h of study and in case of erythromycin-resistant
strains this descent was achieved at 18–24 h of incubation. The TT
bactericidal effect was concentration-dependent against erythro-
mycin resistant strains and was achieved with concentrations one
dilution higher than MIC.
Organism
(no. tested)
MIC90(mg/L)/% susceptible
DAP VAN TEI Q/D LZD
S. aureus (763) 0.5/100 1/100 1/100 0.5/100 2/100
CoNS (281) 0.5/– 2/100 4/98 0.5/99 1/100
S. pnemoniae
(SPN;746)
0.25/– 0.5/100 0.5/– 0.5/100 1/100
b-haemolytic
streptococci (75)
 0:12/– 0.5/100  0:12/– 0.5/100 1/100
viridans group
streptococci (77)
0.25/– 1/100  0:12/– 1/100 1/100
E. faecalis (EF;192) 2/100 2/97 1/97 >8/1 2/100
E. faecium (EFM;57) 4/– 2/91 2/93 2/79 2/100
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Conclusions: Time-kill results conﬁrmed the excellent antipneumo-
coccal activity of TT, irrespective of the susceptibility of strains to
erythromycin. Even for strains for which macrolide MICs were
>64.0 lg/mL, TT was uniformly bactericidal after 24 h at 0.25 lg/
mL.
P1752 In-vitro activities of linezolid, moxiﬂoxacin,
quinupristin/dalfopristin and tigecycline against recent clinical
isolates of Staphylococcus spp. in Spain
O. Cuevas, E. Cercenado, J.V. Guinea, M.E. Escobar, A. Bla´zquez,
E. Bouza – Staphylococcus Study Group3
Objectives: In a recent point prevalence study in Spain, we demon-
strated high percentages of resistance of S. aureus (SA) and coagu-
lase-negative staphylococci (CoNS) to many antimicrobial agents
as follows: oxacillin (SA/CoNS): 30/63; erythromycin: 33/64; gen-
tamicin: 18/35 and ciproﬂoxacin: 37/50 (13th ECCMID. Glasgow
2003). These high rates of resistance prompted us to evaluate the
in vitro activity of new antimicrobial agents against these isolates.
Methods: In 2002 we carried out a point prevalence study in 143
Spanish hospitals collecting all Staphylococcus isolated in a single
day. A total of 439 S. aureus (137 oxacillin-resistant) and 370 CoNS
(227 oxacillin-resistant) were studied. Identiﬁcation and antimicro-
bial susceptibility testing of all microorganisms was performed at
the same laboratory. MICs of linezolid (LIN), moxiﬂoxacin
(MOX), quinupristin/dalfopristin (Q/D) and tigecycline (TIG)
were determined by the microdilution method using Mueller-Hin-
ton broth (NCCLS recommendations). S. aureus ATCC 29213 and
E. faecalis ATCC 29212 were used as control strains.
Results: The MIC values (mg/L) and ranges of activity of the dif-
ferent antimicrobial agents against Staphylococcus spp. are summa-
rised in the table.
Conclusions: All isolates tested were uniformly susceptible to li-
nezolid, quinupristin/dalfopristin and tigecycline. Moxiﬂoxacin
was the less active of the antimicrobials tested. In general, the
good activity of the new antimicrobial agents tested shows prom-
ise for the treatment of infections due to multiresistant staphylo-
cocci. (This study was ﬁnanced by the Spanish Network for the
Research in Infectious Pathology).
P1753 Comparison of four commercially available systems
for antimicrobial susceptibility testing (AST) of Streptococcus
pneumoniae
R. Rennie, C. Brosnikoff, L. Turnbull, S. Shokoples, M. Lovgren,
J. Galbraith, C. Brown, L. Kipke, N. Hart
Edmonton, CAN
Objective: The objective of this study was to evaluate four com-
mercially available systems for AST of a challenge set of Strepto-
coccus pneumoniae (SPN) of known serotypes and antimicrobial
resistance patterns.
Methods: A total of 108 clinical strains of SPN were included in
this study. All strains were tested using two manually read dried
panel systems, the Sensititre Haemophilus inﬂuenzae/S. pneumoniae
(TREK Diagnostics Systems, Cleveland, OH) and Microscan
MICroSTREP plus 1 (Dade Behring, Mississauga, ON), and two
fully automated systems: Vitek 2 AST-P506 card (bioMe´rieux, St
Laurent, Quebec) and Phoenix SMIC (BD Diagnostics, Sparks,
MD). Testing was performed according to the manufacturers
guidelines and all required quality control tests were included.
SPN ATCC 49619 was included as a common quality control
strain in all systems. Reference broth micro-dilution testing (MIC)
was performed by the National Centre for Streptococcus, Edmon-
ton AB on all strains according to NCCLS recommendations and
was considered the gold standard.
Results: There were 36 different serotypes included in this set.
By reference MIC, 57% were penicillin-S, 24% were penicillin-I
and 19% were penicillin-R; 36% were erythromycin-R; seven
strains (6.4 %) were ceftriaxone-R (meningitis breakpoints) and
seven strains (6 %) were oﬂoxacin-R. The antimicrobials tested
were not identical for all systems. For penicillin, there was 90%
agreement within interpretive categories for all systems with one
major error for Sensititre and Microscan, and the remainder
were minor errors (4–10%). For erythromycin, there were ﬁve
major errors (three-Phoenix, one-Microscan, one-Sensititre) and
the remaining were minor errors (1–7%). For ceftriaxone there
was one very major error (Vitek 2), 1 major error (Microscan)
and the remaining were minor errors (7.4–12%). For quinolones,
oﬂoxacin (MIC and Vitek 2) and levoﬂoxacin (Microscan, Sensiti-
tre and Phoenix) were tested. Results for these agents showed
that there were only minor errors for all systems (5.5–7.4%)
compared with reference MIC.
Conclusions: All systems performed favourably when compared
with the reference MIC method. The isolates grew equally well in
the dried panels and the automated systems. For those agents
commonly used to treat SPN infections, these commercial systems
are easy to set up, read and provide equivalent results. The auto-
mated systems also provide expert interpretation of AST accord-
ing to NCCLS guidelines.
P1754 Comparison of the Etest and the agar dilution
method for glycopeptide susceptibility testing of staphylococci
M. Maniati, Z. Bersos, F. Kontos, I. Spiliopoulou, L. Spaliara,
D. Mylona-Petropoulou, E. Malamou-Lada, C. Koutsia-Carouzou,
E. Petinaki, A. Maniatis
Larissa, Patras, Athens, GR
Objectives: To validate the Etest for detecting glycopeptide-resist-
ant staphylococci.
Methods: A total of 450 staphylococcal isolates (150 Staphylococcus
aureus, 300 coagulase-negative staphylococci) isolated from clinical
specimens in four Greek hospitals have been examined from gly-
copeptide susceptibility by Etest using two inoculum densities, 0.5
and 2.0 Mc Farland. Results obtained were compared with those
by reference agar dilution method.
Results: All S. aureus isolates expressed susceptibility to vanco-
mycin and teicoplanin according NCCLS breakpoints. Using ino-
culum 0.5 and 2.0 Mc Farland the Etest vancomycin gave 15 and
20 false-positive results (speciﬁcity 90% and 86.6%, respectively).
In contrast, no discrepancies have been found between the Etest
teicoplanin and the agar dilution method. Among CoNS, 30 iso-
lates expressed resistance to teicoplanin but remained susceptible
to vancomycin according the reference method. Etest teicoplanin
(0.5 and 2.0 Mc Farland) identiﬁed correctly all these isolates
(sensitivity 100%). On the other hand, 20 and 40 isolates were
falsely characterised as teicoplanin-resistant by Etest with 0.5
and 2.0 Mc Farland inoculum (speciﬁcity 92.6% and 85%,
respectively). Population analysis revealed that all false-positive
isolates were not hetero-resistant and didn’t express resistance at
a low frequency.
Conclusions: This study indicates that he use of the Etest with an
inoculum of 0.5 Mc Farland provides a reliable and sensitive
method for the detection of teicoplanin-resistant staphylococci,
without incurring too many false-positives.
LIN MOX Q/D TIG
OXA-R OXA-S OXA-R OXA-S OXA-R OXA-S OXA-R OXA-S
S. aureus
Range  0.25–2  0.25–2 0.06–16 0.06–4 0.06–0.5 0.06–0.5 0.03–0.5 0.03–0.5
MIC50 1 1 1 0.06 0.12 0.06 0.25 0.25
MIC90 2 2 4 0.06 0.25 0.12 0.5 0.5
CoNS
Range 0.25–2 0.25–2 0.06–64 0.06–8 0.06–0.5 0.06–0.5 0.032–2 0.03–0.5
MIC50 0.5 0.5 0.5 0.06 0.06 0.06 0.12 0.12
MIC90 1 1 2 0.5 0.12 0.12 0.5 0.25
OXA: Oxacillin; R: resistant; S: susceptible.
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P1755 Antibiotic resistance of enterococci isolated from
blood and urine cultures during 2002–2003
H. Konstadakopoulou-Papadaki, S. Botsari, A. Koutoumanis,
M. Tsimoraga, G. Kouppari
Athens, GR
Objectives: To study the resistance of Enterococci from blood and
urine cultures during 2002–2003.
Methods: A total of 136 strains of enterococci were isolated in
blood and urine cultures. The identiﬁcation of the isolated bac-
teria was performed by standard methods and the API-strep sys-
tems(bioMerieux). The susceptibility testing was carried out by
disc-diffusion method and by Etest.
Results: Enterococci were the third cause of urinary-tract infec-
tions and bacteraemia in order of apperance. Totally 139 strains
were isolated:118 strains of enterococci were isolated from 1383
urinary-tract infections and 21 strains from 172 bacteraemias. In
three patients the same strain was isolated both in blood and in
urine cultures. Of 136 strains of enterococci were isolated 114
strains of E. faecalis, 16 E. faecium, two E. durans, two E. gallinarum,
one E. casseliﬂavus, one E. hirae. A total of 23 strains were found
resistant to ampicillin (16.9%), 62 to high level gentamycin
(45.6%), 82 to high level streptomycin (60.3%), 91 to ciproﬂoxacin
(66.9%) and three to vancomycin and teicoplanin (2.2%).None of
them was able to produce b-lactamase. Of 16 strains of E. faecium
15 were resistant to ampicillin.The determination of vancomycin
and teicoplanin MICs in strains of VRE (two E. faecium, one E. fae-
calis) were tested highly resistant to vancomycin and teicoplanin
suggesting the presence of VanA phenotype. Two strains of VRE
(E. faecium) were isolated in urine cultures and one strain of VRE
(E. faecalis) were isolated in blood culture.
Conclusions: The high resistance of Enterococcus spp. to high level
aminoglycosides and the identiﬁcation of VRE strains is critical
for infections control purposes in the hospital environment.
P1756 Resistance to b-lactams, macrolides, ketolides and
newer ﬂuoroquinolones in nasopharyngeal pneumococci with
reduced susceptibility to ciproﬂoxacin
J.L. Mun˜oz Bellido, R. Marı´n Jime´nez, S. Herna´ndez Iglesias,
J.A. Garcı´a-Rodrı´guez
Salamanca, E
Objectives: To study the susceptibility of pharyngeal pneumococci
with MICs of ciproﬂoxacin >4 lg/mL to b lactams, macrolides,
ketolides and newer ﬂuoroquinolones.
Methods: We studied the in-vitro activity of penicillin, cefazolin,
cefuroxime, cefotaxime, telithromycin, erythromycin, clindamycin,
ciproﬂoxacin, levoﬂoxacin and moxiﬂoxacin, by the agar-dilution
method according NCCLS guidelines, against 49 S. pneumoniae
strains with MICs of ciproﬂoxacin >4 lg/mL isolated from outpa-
tients throat.
Results: The MIC range of ciproﬂoxacin was 4–8 lg/mL. MIC50
and MIC90 of levoﬂoxacin were respectively, 1 and 2 lg/mL, and
MIC50 and MIC90 of moxiﬂoxacin were 0.2 lg/mL. No strains
resistant to these ﬂuoroquinolones were found. 69.5% of strains
were penicillin-susceptible (mode MIC ¼ 0.01 lg/mL). 22% of
strains were penicillin intermediate (MIC 0.1–1 lg/mL), and 8.5%
were penicillin-resistant (MIC > 1 lg/mL). All the penicillin-
resistant or intermediate isolates were resistant to cefuroxime.
45.7% were resistant to cefuroxime (MIC 50 ¼ 1 lg/mL;
MIC90  32 lg/mL) and 8.5% cefotaxime-resistant (CIM > 2 lg/
mL) (MIC50 ¼ 0.2 lg/mL; MIC90 ¼ 2 lg/mL). 40.7% of strains
were erytrhomycin-resistant (MIC50 ¼ 0.2 lg/mL; MIC90
 32 lg/mL). All of them showed constitutive MLSB phenotype.
No telithromycin-resistant strains were found.
Conclusions: Pneumococci with MICs of ciproﬂoxacin >4 lg/mL
have been shown to harbor topoisomerases mutations in at least
22% of cases. Nevertheless, these strains remain, in this study,
susceptible to newer ﬂuoroquinolones. Both high level and inter-
mediate resistance to penicillins are moderately lower than in pre-
vious studies in Spain.
P1757 Susceptibility of Streptococcus anginosus group
isolates from dental abscesses and abscesses of fascial spaces of
the face and neck
G. Bancescu, A. Bancescu, C. Defta, M. Pana, D. Ionescu, S. Alecu,
S. Dumitriu
Bucharest, RO
Objectives: Streptococci belonging to anginosus group are the
main facultatively anaerobic bacteria involved in oral and maxillo-
facial infections. The aim of the present study was to investigate
the antimicrobial susceptibility of 59 streptococcal strains of angi-
nosus group isolated (as single microbial agents or in association
with other bacteria) from pus samples collected from dental
abscesses and abscesses of fascial spaces of the face and neck in
Romanian patients.
Methods: The isolates were speciated using the Rapid ID 32
STREP system (Bio-Merieux, France). Antimicrobial susceptibility
testing against: penicillin G (PG), erythromycin (EM), clindamycin
(CM), chloramphenicol (CL) and tetracycline (TC) was performed
by Etest (AB Biodisk, Sweden). In addition, the phenotype of EM
resistance was identiﬁed by the double disc diffusion test.
Results: The isolates were identiﬁed as: S. anginosus (53 strains),
S. constellatus (ﬁve strains) and S. intermedius (one strain). The
MICs (mg/L) ranges were: PG 0.002–0.125, EM 0.016–3, CM 0.016–
0.047, CL 0.016–3 and TC 0.125–256. All isolates were susceptible
to PG, CM and CL. Only three strains of S. anginosus were found
resistant to EM and they showed the M phenotype. Intermediate
susceptibility (8.5% of all strains) and resistance (40.7% of all
strains) to TC were found among isolates of all three species.
Conclusions: (i) PG still remains the drug of choice for the treat-
ment of infections caused by these bacteria, but in mixed infec-
tions with b-lactamase producers, amoxicillin/clavulanic acid
(Augmentin) or ampicillin/sulbactam (Unasyn) are indicated to
be used; (ii) the frequency of EM resistance was low (5%) com-
pared with other reports; (iii) on the basis of these in-vitro results,
CM might be an alternative to b-lactam antibiotics in patients
allergic to penicillin or in mixed infections with penicillin-resistant
microorganisms.
P1758 Comparative in-vitro activity of telithromycin
against viridans group streptococci
C.-J. Soussy, C. Lascols, C. Dib, N. Moniot-Ville
Cre´teil, Paris, F
Objective: The objective of this study was to evaluate the in vitro
activity of telithromycin (TEL) comparatively to other antibiotics
against viridans group streptococci (VGS) isolates collected in
2002 from clinical specimen in France.
Methods: In total, 123 isolates of VGS were tested including 49 iso-
lates of Streptococcus mitis, 49 of S. oralis, 13 of S. sanguis, eight of
S. salivarius, three of S. parasanguis and one isolate of S. gordonii.
MICs of TEL, penicillin (PEN), amoxicillin (AMX), cefuroxime
(CFM), erythromycin (ERY), clarithromycin (CLA), and azithromy-
cin (AZI) were determined by agar dilution according to the 2003
recommendations of the Comite´ de l’Antibiogramme de la Societe´
Franc¸aise de Microbiologie (CA-SFM). Quality control was per-
formed with the three following strains of S. pneumoniae (SP):
ATCC49619 (wild strain), Drug 4428 (mefA) and Drug 3031 (ermB).
Susceptibility rate to TEL was calculated according to European
breakpoints determined by EMEA: 0.5 to >2.
Results: MIC50/90 (mg/L) and the percentage of susceptibility
(%) against VGS strains are presented below:
Overall VGS (n ¼ 123): TEL: 0.06/0.12; 99.2, PEN: 0.12/2; 44.7,
AMX: 0.06/4; 74, CFM: 0.5/8; 63.4, ERY: 0.25/4; 85.4, CLA: 0.25/
2; 85.4, AZI: 0.25/16; 85.4.
S. mitis (n ¼ 49): TEL: 0.06/0.12; 98, PEN: 0.12/4; 49, AMX: 0.12/16;
71.4, CFM: 0.25/16; 65.3%, ERY: 0.25/2; 89.8, CLA: 0.25/1; 89.8,
AZI: 0.25/16; 89.8.
S. oralis (n ¼ 49): TEL: 0.03/0.12; 100, PEN: 0.12/2; 46.9, AMX: 0.12/
4; 75.5, CFM: 0.5/8; 57.1, ERY: 0.12/>128; 85.7, CLA: 0.12/16; 85.7,
AZI: 0.12/64; 85.7.
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Other VGS (n ¼ 25): TEL: 0.06/0.06; 100, PEN: 0.12/1; 32, AMX:
0.25/2; 72, CFM: 0.12/2; 72, ERY: 0.5/>128; 76, CLA: 0.25/32; 76,
AZI: 1/32; 76. So, 55.3% of the 123 VGS isolates showed
decreased susceptibility to PEN, 41.5% were intermediately resist-
ant and 13.8% highly resistant. 26% were intermediately resistant
to AMX. In total, 36.6 and14.6% of the overall VGS showed
decreased susceptibility to CFM and macrolides respectively.
Conclusions: These results demonstrated that telithromycin has
good in vitro activity against viridans group streptococci inclu-
ding strains with reduced susceptibility to PEN, AMX, CFM and
macrolides.
P1759 In vitro susceptibility of Streptococcus pneumoniae
to ertapenem and other antibiotics
Z. Samra, O. Oﬁr, I. Shalit
Petach -Tiqua, IL
Objectives: Infections caused by Streptococcus pneumoniae continue
to be frequent worldwide and are associated with signiﬁcant mor-
bidity and mortality. The emergence of S. pneumoniae strains
resistant to penicillin and other antibiotics has complicated the
treatment of such infections. The aim of the study was to evaluate
the in vitro susceptibility of S. pneumoniae to ertapenem, a new
carbapenem, in comparison to other antibiotics.
Methods: A total of 80 clinical isolates of S. pneumoniae were tested
by the Etest method on Muller–Hinton agar supplemented with
5% deﬁbrinated sheep blood. 60 isolates were penicillin resistant
(33 intermediate, MIC 0.1–1 lg/mL, and 27 resistant MIC > 1 lg/
mL) and 20 were penicillin sensitive. The MIC50 and MIC90 were
determined for penicillin (PEN), vancomycin (VAN), erythromy-
cin (ERY), ciproﬂoxacin (CIP), levoﬂoxacin (LEV), ceftriaxone
(CEF) and ertapenem (ERT).
Results: The results of the 60 penicillin resistant isolates are given
in the following table:
The highest MIC value of 256 lg/mL was found for ERY in
25% of the resistant isolates. In the 20 penicillin sensitive isolates,
antimicrobial resistance was found only for CIP (5%). The
MIC50, MIC90 for VAN was 0.38 and 0.5 lg/mL, and for ERT
0.008 and 0.16 lg/mL, respectively.
Conclusions: ERT was the most active agent against both penicillin
resistance and sensitive isolates. Although all isolates were sensi-
tive to VAN and ERT, the MIC of ERT was always lower in all 80
isolates, a ﬁnding that may be meaningful from a pharmacody-
namic viewpoint. Ertapenem may be an important, potent agent
for the treatment of invasive pneumococcal infections.
P1760 Trend of Streptococcus pyogenes antimicrobial
resistance in Reggio Emilia, Italy
L. Ricci, A. Polese, G. Bertoldi, L. Vecchia
Reggio Emilia, I
Objectives: The recognition of the prevalence of antimicrobial
resistance in streptococci has implications for the choice of antibi-
otic therapy in clinical practice. We evaluated the antimicrobial
resistance of S. pyogenes (SGA) isolates among patients with upper
respiratory tract infections in Reggio Emilia (Italy) and the data
were included in the ARES project (Antimicrobial Resistance Evi-
dence Survey).
Methods: The study was conducted over a 12-months period and
included patients with symptoms of acute pharyngotonsillitis. The
471 Streptococcus pyogenes isolates were identiﬁed according to
standard laboratory techniques. Catalase-negative and b-emolitic
colonies isolated from 5% sheep blood agar were identiﬁed using
latex agglutination test and Api 20 S system. Sensitivity testing
was done with disc diffusion according to the National Commit-
tee for Clinical Laboratory Standards (NCCLS). Antimicrobial sen-
sitivity to penicillin, erytromycin, tetracycline, clindamycin,
rokitamicin and amoxicillin/clavulanate was determined.
Results: All the 471 isolates were uniformly susceptible to penicil-
lin. Overall 69/468 isolates (14.74%) showed resistance to erytro-
mycin and 33/463 (7.13%) were also resistant to clindamycin
(constitutive resistance). Erytromycin resistance trend in our area
is variable (30% in 1999, 24.63 in 2000, 12.43 in 2001 and 14.74%
in 2003). The prevalence of rokitamicine-resistant isolates is 5.23%
in Reggio, Emilia (24/459isolates)and 5.60% (216/3715 isolates) in
the National area.
Conclusions: Streptococci may be the most virulent organism, caus-
ing septic and nonseptic complications. Failure to eradicate strep-
tococci from patients can occasionally lead to rheumatic fever and
rarely to glomerulonephritis. With the emergence of increased
treatment failures, it has been necessary to consider alternative
therapies for patients who cannot tolerate penicillin. Our date
suggest the importance of testing the sensitivity of Streptococcus
pyogenes to macrolides, particularly 16-atoms suchas Rokitamicin.
P1761 In vitro activity and synergism studies of linezolid
alone or in combination with several antimicrobial agents
against Nocardia spp.
M.-F. Tripodi, R. Fortunato, C. Farina, G. Ruggiero, R. Utili
Naples, Milan, I
Pulmonary nocardiosis is a severe complication in heart-trans-
plant (HT) patients. No standardised treatment has been estab-
lished. Recent data seem to indicate a good clinical efﬁcacy of
Linezolid (LZD) against Nocardia spp.
Objectives: To evaluate the in vitro susceptibility of Nocardia spp.
to LZD and several other antibiotics and the efﬁcacy of antibiotic
combinations including LZD.
Methods: Six strains of Nocardia (N. asteroides, two; N. brasiliensis,
two; N. farcinica, one; N. spp., one) were isolated from ﬁne-needle
biopsy of pulmonary lesions from HT patients with clinical signs
and symptoms of pulmonary nocardiosis. Growth was obtained
on conventional bacterial media, incubated at 37C in 5% CO2 for
24–72 h. Antimicrobial susceptibility studies were performed by
Kirby–Bauer method and MIC determination by a microdilution
method in Mueller–Hinton broth II. Synergism studies were per-
formed by disc technique on Mueller–Hinton II agar using the fol-
lowing antibiotics: LZD, piperacillin–tazobactam (TZP), imipenem
(IMP) and trimethoprim–sulphametoxazole (TMP-SMX) alone or
in combination with each other and with ciproﬂoxacin (CIP), levo-
ﬂoxacin (LVX), oﬂoxacin (OFX) moxiﬂoxacin (MFX), amikacin
(AN), netimicin (NET), tobramycin (NN), gentamicin (GM) and
streptomicin (ST). Susceptibility tests were read at 24 and 72 h;
for synergism studies, plates were observed up to 144 h.
Results: By Kirby–Bauer method, all strains were susceptible to
LZD, IMP and AN; ﬁve to doxycycline, cefotaxime (CTX), ceftriax-
one (CRO), cefepime; four to TMP-SMX; three to cefamandole and
MFX, two to TZP and azithromicin. One strain was susceptible to
ampicillin (AM), ampicillin-sulbactam (SAM), CIP and rifampin.
The MIC 90 (mg/L) were minor or equal to the following: LZD
eight; IMP two; AN one; AM 62; AMS 32; TZP 256/32; CTX four;
CRO four; CIP 32; MFX 8; TMP-SMX 8/152. Synergism studies: at
72 h, most of the combinations were indifferent. Synergism was
observed for: LZD with AN, GM, NN in one strain; IMP with
AN, CIP in three, with GM, NN, TZP, LZD in two,with LVX,
MFX, SXT in one; TZP with NET in three, with AN, GM, NN in
one; with OFX, LVX, MFX in one; TMP-SMX with NN in three,
MIC50 MIC90 Range % Resistance
PEN 0.5 2 0.125–8 100
VAN 0.5 0.75 0.25–1 0
ERY 0.094 256 0.023–256 50
CIP 0.5 0.75 0.25–8 0.7
LEV 0.5 0.75 0.38–24 3.3
CEF 0.25 0.5 0.0324 5
ERT 0.19 0.5 0.006–0.75 0
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with AN in two, with ST in one. Antagonism was observed for
LZD with AN in ﬁve cases, with TMP-SMX and CIP in three.
Conclusions: LZD shows a good in vitro activity. Based on these
preliminary data, the combination of IMP and AN appears suit-
able as initial treatment of invasive nocardiosis, while LZD may
represent a good choice for sequential oral therapy.
P1762 Effect of pH, media and inoculum size on
telavancin (TD-6424) in vitro activity
K. Kaniga, K. Krause, D. Johnston, C. Lane, L. White, T. Wu,
D.V. Debabov, J.L. Pace, D.L. Higgins
South San Francisco, USA
Objectives: Telavancin (TD-6424), a rapidly bactericidal agent with
multiple mechanisms of action, is in phase 2 clinical trials for seri-
ous Gram-positive infections. Telavancin (TLV) has potent activity
against Gram-positive bacteria and exhibits concentration-depend-
ent behaviour. We studied the effect of pH, media and inoculum
size on the in vitro activity of TLV in comparison with that of
vancomycin (VAN).
Methods: The effect of pH (6–8) and inoculum size (105–108 CFU/
mL) on MIC was determined against Enterococcus faecalis, Staphylo-
coccus aureus and Streptococcus pneumoniae according to the NCCLS
method. The effect of inoculum size (106–108 CFU/mL) and
media consisting of cation-adjusted Mueller–Hinton broth (MHB)
and brain–heart infusion broth (BHI) on bactericidal activity was
determined for TLV and VAN against S. aureus strain MRSA
33591 by time-kill kinetics.
Results: Although an increase in inoculum from 105–106 CFU/mL
had no effect on the MIC of TLV, higher inocula (107 and
108 CFU/mL) resulted in a two to eightfold increase in MIC. pH
variation of 1 U from the normal value had little effect on TLV
MIC against staphylococci and enterococci but negatively affected
MIC against S. pneumoniae (four dilution increase). The bacteri-
cidal activity of TLV and VAN was unchanged in either MHB or
BHI. Increasing the inoculum size increased the time required to
produce 3 or 5 log10 of killing.
Conclusions: High inoculum had little impact on telavancin inhibi-
tory and bactericidal activity against S. aureus. Unlike vancomy-
cin, telavancin was able to decrease an inoculum of 108 CFU/mL
to undetectable levels at a clinically achievable concentration. This
suggests possible advantages in treating infections associated with
large inocula of organisms.
Mycology
P1763 Pneumocystis jiroveci: a new human saprophyte?
F.J. Medrano, N. Respaldiza, J.M. Varela, A. Gasch,
M.A. Montes-Cano, M.J. Pe`rez-Lozano, C. de la Horra,
R. Valencia, M. Conde, E. Caldero´n
Seville, E
Recently, it has been shown that patients with chronic lung dis-
ease have a high rate of colonization by Pneumocystis jiroveci (for-
merly known as P. carinii) and also that acute infection, usually
asymptomatic, is common during the ﬁrst years of life. However,
so far it has not been established whether the pathogen can colo-
nise the immunocompetent adult host in a subclinical way.
Objectives: To evaluate the possibility of subclinical infection by
P. jiroveci (Pc) in the general adult population.
Methods: (i) Population: Prospective study (February–July 2003)
in which were included the ﬁrst 50 patients evaluated in the
Unit of Work Health of our hospital, not exposed to hospital
environment during the previous year and not meeting the
exclusion criteria (conﬁrmed diagnosis or suspicion of chronic
lung disease, neoplasm or immunosuppression of any aetiology).
Every patient was presented with a clinical-epidemiological sur-
vey and oropharingeal washes (OW) samples were obtained by
gargling with 10 cc of sterile 0.9% physiological serum for analy-
sis. (ii) Method: The presence of fragments of the mtLSU-rRNA
region of Pc was analysed in OW by means of nested polym-
erase chain reaction (PCR) using the primers AZ1002-E/-H and
pAZ102-X/-Y.
Results: The mean age of individuals was 33.9  9.45 years old. 19
of them (31.6%) were male. 28 (56%) were newly employed med-
ical residents, 13 (26%) common services staff and nine (18%)
administrative staff. Pneumocystis infection was observed in 13
(26%) of the 50 individuals. All positive subjects were asympto-
matic at the time of their enrolement in the study and only one of
them had taken steroids for a brief period of time in the 6 months
prior to the study. No relationship was established between the
presence of Pc infection and age, sex, professional standing or a
previous history as smokers.
Conclusions: For the ﬁrst time a high prevalence of subclinical
infection by Pneumocystis has been established in the general pop-
ulation. This fact supports the theory claiming the saprophytic
nature of the pathogen in humans. Though further studies are
necessary to determine the feasibility and transmission of the
infection in immunocompetent individuals, our results suggest
that the general population might play an important role as a res-
ervoir and source of infection from the microorganism to the im-
munocompromised host. (Research Project 32/02. Ministry of
Health- Junta de Andalucı´a) and (Eurocarinii Project QLK2-CT-
2000-01 369).
P1764 Genetic diversity of Pneumocystis jiroveci isolates
obtained in the area of Seville, Spain
F.J. Medrano, M.A. Montes-Cano, J.M Varela, N. Respaldiza,
C. de la Horra, J. Martı´n-Juan, R. Torronteras, I. Mateos,
E. Caldero´n
Seville, E
Pneumocystis jiroveci (Pc) is one of the most important opportunis-
tic infections affecting immunocompromised individuals but our
knowledge about its epidemiological characteristics is still very
limited. Molecular techniques have made it possible to identify
different Pc genotypes, which could be associated with the viru-
lence and clinical manifestations of the infection. In Spain there
are not available data about the distribution of these genotypes.
Objectives: The aim of our study was to provide with some infor-
mation in this respect.
Methods: We analysed 32 bronchoalveolar lavage samples from 11
individuals with HIV infection and Pc Pneumonia and from 21
individuals with chronic lung diseases colonised by Pc. In all
Time (hr) to  3 log10 ( 5 log10) reduction of
inoculum
105 CFU/mL 107 CFU/mL 108 CFU/mL
TLV (16 ug/mL) 8 (24) 24 (24) 24 (48)
TLV (32 ug/mL) 4 (4) 8 (24) 24 (24)
VAN (16 ug/mL) 8 (24) 24 (>48) 24 (>48)
VAN (32 ug/mL) 8 (24) 24 (>48) 24 (>48)
TLV, but not VAN, reduced the inocula to undetectable levels within 24 and
48 hours at 107 and 108 CFU/mL.
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cases the diagnosis was obtained by means of nested-PCR (prim-
ers pAZ102-E and –H and pAZ102-X and –Y). The genotypic char-
acterisation was performed by sequencing a fragment of 360-bp of
the locus mtLSU-rRNA of Pc, which enables the identiﬁcation of
four genotypes according to the mutations observed in positions
85 and 248.
Results: See Table.
Conclusions: In our region there are a predominance of genotype 1.
The similar distribution of genotypes in individuals with and
without HIV infection suggests a common source of infection for
both populations or either the transmission of the pathogene from
one population to another. Supported by Eurocarinii Project
QLK2-CT-2000-01 369 & SAF 2003-06061.
P1765 Pneumocystis jiroveci colonisation in lung
transplantation receptors with cystic ﬁbrosis
F.J. Medrano, F.J. Dapena, M.A. Montes-Cano, J.M. Varela,
N. Respaldiza, C. de la Horra, D. Gonza´lez-Jime´nez, E. Caldero´n
Seville, E
Background: Bronchopulmonary infections are the most serious
complication for patients with cystic ﬁbrosis (CF) and very often
lung transplantation (LT) becomes the only therapeutic alternative
to improve the survival rate of these patients. The prognosis of
LT depends on such factors as the rejection of the graft and the
occurrence of opportunistic infections. Recently, the presence of
asymptomatic Pneumocystis jiroveci carriers has been observed
among patients suffering from CF, but their role in the natural
history of the disease has yet to be established.
Objectives: To determine the occurrence of P. jiroveci colonisation
in individuals with CF who have become immunocompromised
as a result of LT.
Methods: Prospective study in a cohort of patients with CF, inclu-
ding a group of LT receptors. Every patient ﬁlled in an epidemio-
logical survey and sputum and/or oropharingeal lavage samples
were obtained. The diagnosis of P. jiroveci colonisation was
reached by means of nested-PCR.
Results: A total of 52 sputum samples and 47 oropharingeal
lavage samples from 98 patients with CF were analysed. All trans-
planted patients received prophylaxis with cotrimoxazole and
none of them developed P. pneumonia during the follow-up period
of 1 year (see Table).
Conclusions: Prophylaxis with cotrimoxazole does not prevent col-
onization by P. jiroveci in individuals with CF who have received
LT. As a result the development of strains resistant to this drug
poses a risk of P. pneumonia infection and the possibility of their
presence should be monitored in these patients.
(Research Project 11/01. Consejerı´a de Salud Ministry of
Health-Junta de Andalucı´a) and (Eurocarinii Project QLK2-CT-
2000-01 369).
P1766 Genotypic resistance to sulpha drugs in patients
with Pneumocystis pneumonia in southern Spain
F.J. Medrano, C. de la Horra, M.A. Montes-Cano, N. Respaldiza,
J.M. Varela, I. Mateos, J. Martı´n-Juan, R. Torronteras,
R. Garcı´a-Contreras, E. Caldero´n
Seville, E
The lack of techniques to obtain Pneumocystis jiroveci (Pc) cultures
has made it necessary to develop molecular techniques to detect
its resistance to different drugs. Punctual mutations 55Thr!Ala
and 57Pro!Ser in the DHPS gene are associated with the failure
of treatment with sulpha drugs and with the worsening of the
prognosis of Pc pneumonia. Nevertheless, the importance the dis-
covery of these mutations may have in the clinical ﬁeld has still
to be established. The aim of our study was to ascertain the occur-
rence of strains with DHPS mutations in our milieu and its clin-
ical implications.
Methods: We included in our study all patients diagnosed for a
period of 2 years in our hospital of whom bronchoalveolar lavage
samples and/or sputum were available. The diagnosis was per-
formed by means of nested PCR. Primers DHPS-3/-4 were used
to identify the resistant mutations by means of restriction
enzymes.
Results: DHPS gene could be ampliﬁed in nine of the 12 identiﬁed
cases (75%) (see Table):
Conclusions: We observed in our area an elevated occurrence of
pneumonias provoked by strains of P. jiroveci with mutations
associated with resistance to sulpha drugs. Supported by Eurocar-
inii Project QLK2-CT-2000-01 369 & Research Project 55/03 - Con-
sejeria de Salud - Junta de Andalucia.
P1767 Quantitative real-time PCR TaqMan assay for
detection of Pneumocystis jiroveci
F. Brancart, H. Rodriguez-Villalobos, P.A. Fonteyne, D. Peres Bota,
D. Swinne, N. Nolard, C. Liesnard
Brussels, B
Objective: Pneumocystosis remains difﬁcult to diagnose by current
microbiology methods in particular in non-HIV immunodeﬁcient
patients and rapid diagnostic tools are necessary. We describe a
rapid and reproducible real time PCR method for detection and
quantiﬁcation of the tubuline P. jiroveci (PJ) gene in bronchoalveo-
lar lavage (BAL) samples.
Method: A quantitative real time PCR was developed for detection
and quantiﬁcation of PJ. Speciﬁc PJ primers and ﬂuorogenic probe
were chosen in the tubuline gene sequence. A plasmid containing
the target sequences was used to construct a standard curve for
quantiﬁcation. DNA extraction was performed with Qiagen Kit
according to the manufacturer’s recommendations. Different con-
trol samples including human DNA, virus, bacterial and fungal
species were also tested to investigate the assay speciﬁcity. All
samples and controls were tested in duplicate. Fifty-three BAL
samples sent to the laboratory for diagnosis of pneumocystosis
Genotypes
(Cases)
Pneumonia
Patients with
HIV infection +
Pc (n¼11)
Patients with
chronic lung disease +
colonized by Pc (n¼21) P
G-1(19) 7(63.6%) 12(57.1%) 0.98
G-2(3) 1(9.1%) 2(9.5%) 0.54
G-3(10) 3(27.3%) 7(33.4%) 0.95
G-4(0) 0(0%) 0(0%) –
Cohort
Lung
Transplantation
Non Lung
Transplantation
N (Male/Female) 98(44/54) 10 88
Average age 
SD(years)
16 6.8 20.9 6.5 15.5 6.7
P. jiroveci(+) 23 pt(23.5%) 3 pt(30%) 20 pt(22.7%)
Case Risk factor Age
Exposure to
sulfa drugs Genotype CD4
Response to
treatment
1 HIV 41 No Wt 20 Unfavourable
2 HIV 51 No Wt and 55 25 Favourable
3 HIV 42 Yes Wt 212 Favourable
4 HIV 28 No 55/57 406 Favourable
5 HIV 52 No Wt 35 Unfavourable
6 Renal trans-
plantation
44 No Wt NA Favourable
7 HIV 38 No Wt 1 Favourable
8 HIV 38 Yes Wt 105 Favourable*
9 HIV 41 Yes Wt/57 14 Unfavourable*
Wt: wild strain; 55: mutation in codon 55; 57: mutation in codon 57; 55/
57: double mutation; NA: not available; *: pentamidine theraphy
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were prospectively investigated by real time PCR and direct
microscopic examinations (DME) using Giemsa stain and direct
immunoﬂuorescence.
Results: The PCR assay showed a limit of detection of 50 gene
copies per millilitre. A linear signal over a range of 4 log10 of
magnitude was obtained. The assay was reproducible as indicated
by the intra-assay CV values obtained with the plasmid standard
(0.09–1.17%). The PCR assay proved to be highly speciﬁc, reacting
only with the tubuline PJ gene but with none of the other species
tested. All PCR-negative samples were DME-negative. Twenty-
four (45%) BAL were PJ-positive by PCR assay. Among these,
eight were positive by DME (35 %). The range of PJ DNA gene
copies per millilitre were 9.190 to 1.467.628 and 8 to 10.470 for the
PCR+/DME+ and PCR+/DME- samples, respectively.
Conclusions: We developed a rapid, sensitive and speciﬁc real time
PCR for the diagnosis and quantiﬁcation of PJ in BAL samples.
Correlation of our results with clinical data should now be inves-
tigated in order to establish clinical predictive values of our
method.
P1768 Susceptibility proﬁle of medically relevant
Basidiomycota species other than Cryptococcus neoformans
M. Cuenca-Estrella, A. Gomez-Lopez, E. Mellado, V. Parra,
J.L. Rodriguez-Tudela
Majadahonda, E
Objectives: We have analysed the susceptibility of several fungal
species with clinical relevance belonging to the division Basidiomy-
cota apart from Cryptococcus neoformans. As with other opportunis-
tic fungi, the number of infections due to these species has
increased steeply during the past two decades, however, little is
known about their susceptibility proﬁle.
Methods: A collection of 130 clinical isolates was tested. All
strains were recovered during a period of 9 years (1995–2003)
from 45 Spanish hospitals. Each clinical isolate represented an
unique isolate from a patient. The susceptibility testing followed
strictly the EUCAST-AFST recommendations for testing Candida
spp. (EUCAST discussion document 7.1), but included minor
modiﬁcations. Brieﬂy, all microplates were wrapped with ﬁlm
sealer to prevent the medium from evaporating, attached to an
electrically driven wheel inside the incubator, agitated at
350 rpm and incubated at 30C for 48 h. C. parapsilosis
ATCC22019 and C. krusei ATCC6258 were used as quality con-
trol strains.
Results: Table displays ranges and geometric means (GMs) of
MICs of antifungal agents in mg/L, classiﬁed per Basidiomycota
species:
Conclusions: (i) Resistance in vitro to amphotericin B among Basidi-
omycota species is not common with the exception of T. asahii and
T. ovoides. (ii) Cryptococcus spp. and Pseudozyma spp. exhibit high
MICs of ﬂucytosine and ﬂuconazole (iii) R. mucilaginosa is resist-
ant in vitro to azole agents (iv) These ﬁndings reinforced the need
of continued surveillance programs that analyse species distribu-
tion and antifungal susceptibility proﬁles of medically important
fungal isolates.
P1769 Investigation of Pal’s agar to detect in vitro
phenoloxidase activity of Cryptococcus neoformans strains and
to differentiate C. neoformans from Candida albicans
A.S. Kantarcioglu, A. Yucel, V. Vidotto
Istanbul, TR; Turin, I
Objectives: Cryptococcus neoformans can be isolated on most routine
mycologic or bacteriologic media. However its growth from the
sputum and urine samples of particularly HIV-infected patients
may be confused and/or obscured by Candida albicans on conven-
tional media. This is due to the fact that both C. neoformans and C.
albicans produce white colonies on the ﬁrst days of isolation.
Brown colonies of C. neoformans due to melanin formation on
media containing phenolic compounds such as caffeic acid con-
taining Staib’s (Guizotia abyssinica) agar (SA) is typical marker
for the presumptive identiﬁcation of C. neoformans.We assessed
another medium Pal’s agar (PA) containing caffeic acid from He-
liantus annus to detect phenoloxidase activity in C. neoformans
strains and to differ C. neoformans colonies from those of C. albi-
cans.
Methods: A total of 57 C. neoformans strains were used: 49 were
human isolates (47 HIV+) and eight were environmental isolates.
C. neoformans ATCC90112 and eight C. albicans refference strains
were used for control. To detect phenoloxidase activity the strains
were streaked on PA and SA plates and incubated at 30C for
2–5 days. Colony colour was examined visually every 24 h for up
to 5 days. In order to investigate the differentiation ability of PA
between C. neoformans and C. albicans as a primary culture med-
ium randomly selected 10 C. neoformans strains were used
together with the reference C. albicans strains in dual combina-
tions. SA and SDA were used along with PA in each test. Plates
were inoculated by streaking preadjusted inoculum of mixed sus-
pensions and incubated at 30C for 2–5 days. Colony colour and
count was read visually every 24 h for up to 5 days.
Results: All yeast isolates tested grew well on PA. All C. neofor-
mans isolates grew typical brown colored colonies and selectively
detected on both PA and SA plates after 48–96 h of incubation.
Indistinguishable white colonies growth from mixed suspensions
on SDA. Colony count has no signiﬁcant meaning on differenti-
ation suggesting that both PA and SA do not selectively stimulate
C. neoformans growth but only differ the colony colour
Conclusions: PA is an excellent primary, differential medium to
evidentiate C. neoformans isolates, easy and inexpensive to prepare
from readily available seeds. Its routine use in microbiology labor-
atories could be very useful for easy and rapid diagnosis of
C. neoformans infection from a wide range of patient populations
including particularly HIV + individuals and HIV- at risk patients
P1770 Cryptococcosis in non-HIV infected patients: a
report of 29 cases
S. Kiertiburanakul, S. Wirojtananugoon, R. Pracharktam,
S. Sungkanuparph
Bangkok, TH
Objectives: To determine the patients characteristics, clinical fea-
tures, and outcomes of cryptococcosis in non-HIV-infected
patients.
Methods: We retrospectively reviewed the medical records of non-
HIV-infected patients who had positive culture for Cryptococcus neo-
formans in Ramathibodi Hospital from 1987 to 2003.
Species n
Ranges/ GMs
Amphotericin B Flucytosine Fluconazole Itraconazole Voriconazole
Cryptococcus
laurentii
7 0.03–0.5/0.12 1.0–128/35.3 4.0–64.0/11.9 0.06–8.0/0.37 0.06–8.0/0.39
Cryptococcus
albidus
6 0.06–2.0/0.50 0.25–128/12.7 4.0–64.0/17.9 0.12–1.0/0.39 0.12–4.0/0.44
Cryptococcus
humicola
3 0.03–0.50/0.20 8.0–64.0/20.1 2.0–64.0/12.7 0.06–1.0/0.31 0.01–0.25/0.01
Cryptococcus
curvatus
1 0.25 1.0 8.0 1.0 0.25
Rhodotorula
mucilaginosa
28 0.06–8.0/0.29 0.06–128/0.47 8.0–256/78.0 0.06–16.0/2.56 0.5–8.0/3.05
Rhodotorula
glutinis
4 0.03–1.0/0.09 0.25–1.0/0.42 64.0–128/90.5 0.12–16.0/1.0 0.25–2.0/0.63
Rhodotorula
aurantiaca
1 0.50 128.0 8.0 0.06 0.12
Trichosporon
mucoides
28 0.03–16.0/0.33 0.50–256/26.2 1.0–64.0/7.24 0.03–8.0/0.40 0.01–8.0/0.25
Trichosporon
asahii
20 0.12–16.0/4.0 2.0–128/12.9 1.0–64.0/6.5 0.03–8.0/0.57 0.03–8.0/0.23
Trichosporon
inkin
18 0.03–1.0/0.19 0.25–128/24.4 0.5–32.0/2.42 0.03–2.0/0.21 0.03–2.0/0.13
Trichosporon
cutaneum
9 0.03–16.0/0.31 4.0–128/20.1 0.25–64.0/2.51 0.01–8.0/0.13 0.01–8.0/0.05
Trichosporon
ovoides
3 0.5–16.0/3.17 8.0–128/40.3 1.0–6.4/8.0 0.12–1.0/0.25 0.03–0.25/0.06
Pseudozyma
spp.
2 0.12–0.25/0.19 0.50–128/3.0 16.0–64.0/32.0 0.06–0.25/0.12 0.12–0.25/0.19
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Results: During 17 years, 33 non-HIV-infected patients with cryp-
tococcosis were identiﬁed. Of these, 29 patients had available
medical records for the study. The mean age was 46 years (range,
18–72 years) and 76% were female. Twenty patients (69%) had at
least one associated underlying medical condition. The three most
common underlying conditions included systemic lupus erythe-
matosus (36%), diabetes mellitus (21%) and malignancies (16%).
C. neoformans was recovered from cerebrospinal ﬂuid (CSF) (41%),
sputum/bronchoalveolar lavage ﬂuid (39%) and blood (18%).
Other sites of cryptococcal infection were gastrointestinal tract,
bone and joints, lymph nodes, and skin and soft tissue. Eight
patients (28%) had disseminated cryptococcosis. who presented
as meningitis and abnormal chest radiography. Serum cryptococ-
cal antigen was tested in 20 patients and yielded positive titres,
ranging from 1:4 to more than 1:1024, in 12 patients (60%). CSF
cryptococcal antigen was tested in 18 patients and yielded posit-
ive titres, ranging from 1:4 to more than 1:1024, in 15 patients.
Most of patients were treated with amphotericin B and subse-
quent ﬂuconazole. Two patients were initially misdiagnosed and
treated as tuberculosis. Two patients were lost to follow-up. The
overall mortality rate was 17%.
Conclusions: Cryptococcosis is not uncommon in non-HIV-infected
patients. Cryptococcosis should be recognised as a possible cause
of meningitis and pulmonary infection especially in patients with
underlying immunocompromised condition(s). Cryptococcal anti-
gen may be helpful but culture is needed for the diagnosis. Early
recognition of cryptococcosis and appropriate antifungal therapy
in these patients may improve clinical outcomes.
P1771 In vivo interaction of ﬂucytosine in combination
with amphotericin B against ﬂucytosine-resistant and
ﬂucytosine-susceptible Cryptococcus neoformans
clinical isolates
P. Schwarz, F. Dromer, O. Lortholary, E. Dannaoui
Paris, F
Objectives: To evaluate the in vivo interaction of ﬂucytosine com-
bined with amphotericin B against one ﬂucytosine-resistant
(MIC ¼ 64 lg/mL) and one ﬂucytosine-susceptible (MIC ¼ 4 lg/
mL) clinical isolate of Cryptococcus neoformans using fungal burden
as endpoint.
Methods: Mice were infected with an inoculum size of
5  106 CFU per mouse. Treatment was started 24 h postinfection
and was continued for 5 days. Mice were treated with the drugs
alone or in combination. Amphotericin B was given intraperitone-
ally (IP) at 0.25 or 0.5 mg/kg/day and ﬂucytosine was given per
os (PO) at 100 or 250 mg/kg/d. The four possible combinations
were tested. Control groups receiving either water PO or glucose
5% IP were included. Each group contained ﬁve mice. On day 6
mice were sacriﬁced and quantitative cultures of brain, lungs and
spleen were done.
Results: For the ﬂucytosine-susceptible isolate a decrease of
approximately 1 to 2 log 10 CFU/g was observed in all three
organs for ﬂucytosine monotherapy and only in the lungs and
spleen for amphotericin B monotherapy. Combination of ﬂucyto-
sine at 250 mg/kg/day and amphotericin B at 0.5 mg/kg/day
signiﬁcantly decreased the fungal burden in all three organs com-
pared with each drug alone, with the highest efﬁcacy in the lungs.
Antifungal interactions were considered to be synergistic. Against
the ﬂucytosine-resistant isolate, ﬂucytosine alone at both concen-
trations was ineffective in all three organs and amphotericin B
alone was ineffective in brain, poorly active in spleen (decrease of
approximately 0.5 log 10 CFU/g) and active in the lungs
(decrease of approximately 1.5 log 10 CFU/g). Combination of
ﬂucytosine at 250 mg/kg/day and amphotericin B at 0.5 mg/kg/
day was considered to be synergistic with a signiﬁcant decrease
of the fungal burden in the brain and in the spleen, but not in the
lungs.
Conclusions: Synergistic interaction was observed in vivo between
amphotericin B and ﬂucytosine, even in the brain, in both ﬂucyto-
sine-susceptible and -resistant isolates.
P1772 In vitro interaction of ﬂucytosine in combination
with amphotericin B against ﬂucytosine-resistant Cryptococcus
neoformans clinical isolates
P. Schwarz, F. Dromer, O. Lortholary, E. Dannaoui
Paris, F
Objectives: To determine in vitro if the addition of ﬂucytosine to
amphotericin B will modify the activity of amphotericin B against
ﬂucytosine-resistant clinical isolates of Cryptococcus neoformans
with three different techniques.
Methods: Ten ﬂucytosine-resistant (MIC  32 lg/mL) clinical iso-
lates of C. neoformans were used. Checkerboard studies were per-
formed in accordance with NCCLS M-27 A2 document modiﬁed
to assess antifungal interactions. Microplates were read spectro-
photometrically after 72 h of incubation and interactions were
interpreted by FIC indices. Time-kill studies were done in RPMI
pH 7 with a starting inoculum of 1.0  105 CFU/mL. Flucytosine
alone and in combination was tested at a concentration of 64 lg/
mL and amphotericin B at 0.125, 0.25 and 0.5 lg/mL. Interactions
were evaluated after 72 h of incubation. Susceptibility by Etest
was tested on RPMI-agar (pH 7) and MICs of the antifungals
were determined after 72 h of incubation.
Results: MICs of the drugs alone determined by NCCLS methodo-
logy ranged from 32 to 128 lg/mL (geometric mean MIC of
120 lg/mL) for ﬂucytosine and ranged from 0.5 to 1 lg/mL for
amphotericin B. By checkerboard studies synergy was observed
for 70% and additivity for 30% of the tested isolates. Antagonism
was not observed. Antifungal interactions observed by time-kill
studies were synergistic for four isolates, additive for one and
indifferent for four isolates. It was not possible to detect synergy
for any of the strains by Etest with the chosen technical condi-
tions.
Conclusions: Synergy between amphotericin B and ﬂucytosine can
be detected in vitro on ﬂucytosine-resistant isolates of C. neofor-
mans. Studies on the different mechanisms of resistance to ﬂucyto-
sine are warranted to determine whether it inﬂuences the type of
interaction of this drug with amphotericin B.
P1773 First isolation of Sporopachydermia cereana in
humans
P.-M. Rath, A. Haas, B. Grabein, H. Dermoumi
Essen, Munich, D
Objectives: Yeasts with identical, but unknown biochemical proﬁle
(ID 32 C, Bio Me´rieux, France) were isolated from ﬁve hospital-
ised patients in a university hospital (blood culture, n ¼ 1, tra-
cheal secretion, n ¼ 4) between 2001 and 2002.
Methods: The isolates were identiﬁed by sequencing the ITS-
regions. Phenotypically, the SDS-PAGE patterns and the suscepti-
bility to antimycotic agents were investigated, genotypically a
PFGE- and RAPD-analysis was performed.
Results: Sequence analysis of the ITS 1 and ITS 2 region of the ﬁve
patient’s isolates revealed a homology of 93–100 % (ITS 1) and
88–95% (ITS 2) to the cactophilic species Sporopachydermia cereana.
The identiﬁcation was conﬁrmed by the CBS, the Netherlands. In
the SDS-PAGE the patient’s isolates and two reference strains
(CBS 6644, 6645) showed identical protein patterns. The two refer-
ence strains differed in their PFGE patterns (three and ﬁve bands,
respectively, in the range of 0.9–2.5 Mb) from the patient’s iso-
lates, which showed nearly identical patterns with six bands. Ana-
lysis of the isolates in the RAPD-PCR with primers previously
used to type aspergilli revealed identity of the patient’s isolates,
whereas the reference strains were different. All seven isolates
were susceptible to amphotericin B, 5-ﬂuorocytosine, ﬂuconazole,
itraconazole, and voriconazole, as determined by a microdilution
assay and Etest.
Conclusions: This is the ﬁrst description of Sporopachydermia cereana
in humans. The source of the strains remains unknown, since no
epidemiological link was found between the patients.
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P1774 Outcome of fungal peritonitis in patients on
continuous ambulatory peritoneal dialysis: analysis of an
11-year experience in a single centre
C.P.K. Subudhi, T. Ledson, K.S. Raman, S. Waldek,
P.R. Chadwick
Salford, UK
Objective: Fungal peritonitis is a serious complication in patients
on continuous ambulatory peritoneal dialysis (CAPD) and is asso-
ciated with high rates of morbidity and mortality. We retrospec-
tively reviewed 35 episodes of fungal peritonitis in our hospital
over an 11-year period (1992–2002) in an attempt to identify risk
factors and determine the clinical outcome of these patients.
Methods: Patients on CAPD with fungal peritonitis were identiﬁed
from our computerised mycology laboratory database. An audit
template was designed and used to collect relevant information of
these patients from their medical records.
Results: There were 43 episodes of fungal peritonitis in 41 patients
during this period. There were 35 episodes of fungal peritonitis in
34 patients whose medical notes could be reviewed. C. albicans
and C. parapsilosis were the two predominant species isolated
from peritoneal efﬂuent in this study. 76.4% of the patients had
received antibiotics in 2 months prior to the episode of fungal
peritonitis. 55.8% of patients had intraperitoneal antibiotics for
management of bacterial peritonitis. The attributable mortality
from fungal peritonitis was 26.4% despite therapy that included
early removal of the peritoneal dialysis catheter and prolonged
antifungal therapy. Peritoneal dialysis catheter was removed in
82% of the patients.
Conclusions: Fungal peritonitis is a relatively uncommon complica-
tion in patients on CAPD, but it is associated with signiﬁcant
morbidity and mortality. Prior antibiotic use and recent bacterial
peritonitis were found to be risk factors in developing fungal peri-
tonitis. Treatment requires the administration of antifungal agents
and the early removal of the peritoneal catheter. The prompt diag-
nosis of fungal peritonitis and the early institution of therapy are
essential for better outcome in the management of fungal perito-
nitis in patients on CAPD.
P1775 Fusarium fungaemia in four Danish haematological
patients
T.G. Jensen, B. Gahrn-Hansen, M. Arendrup, B. Bruun
Odense, Copenhagen, Hillerød, DK
Objective: Fusarium species, the majority of which are soil sapro-
phytes or plant pathogens, cause severe disseminated infections
in immunocompromised patients with granulocytopenia, often
despite antimycotic treatment. We describe four cases of
F. fungaemia, in three of which the microorganism was not initially
recognised as Fusarium, due to lack of familiarity with the organ-
ism.
Methods and results: During a 3-year period, we diagnosed four
cases of fungaemia with Fusarium species in Danish haematologi-
cal patients. All four patients had clinical sepsis, three of four had
pneumonia. Characteristically, three of the four patients presented
with painful localised erythromatous cutaneous papular lesions
mimicking pyoderma gangraenosum. Despite intensive antifungal
treatment, three of the four patients died. Results of in vitro sus-
ceptibility test of relevant amtimycotic drugs using a modiﬁed
NCCLS microdilution method and the E-test method showed
some discrepancies especially for amphotericin B. Voriconazole
seems to be a promising new agent.
Conclusions: The majority of cases of disseminated Fusarium infec-
tions has been reported from warm climate zones. From the Nor-
dic countries only a single case has up till now been published.
As both macroscopic and microscopic appearance of Fusarium
species is rather characteristic and as Fusarium is resistant to most
available antimycotic agents, we ﬁnd it relevant to increase micro-
biologists awareness of the occurrence of disseminated fusariosis
also in colder climates in severely immunocompromised patients.
P1776 The aetiologic agents of onychomycosis in Latvia
E. Lavrinovica, I. Jakobsone, I. Briede, J. Kroica
Riga, LV
Objectives: Onychomycosis is a global problem. From 5 to 20% of
inhabitants suffer from fungal nail infections. The causative agents
are classiﬁed in different groups – dermatophytes, moulds and
yeasts. The dystrophic nails harbour a large amount of bacteria
and secondary invading yeasts and moulds. The role of moulds
and yeasts in aetiology of onychomycosis or aggravation of the
condition is quite questionable. The aim of this study was to
establish the main causative agents of fungal nail infection in Lat-
via. Before this there was no research about onychomycosis in
Latvia – about the main causative agents, optimal diagnostic
methods, susceptibility to the clinically used antifungal prepara-
tions.
Methods: The present research work was done at the laboratory of
The State Centre of Skin and sexually transmitted diseases within
last 3 years. In the research were involved 671 patients with clin-
ically changed nails and suspicion to onychomycosis. Microscopy
and cultivation methods were used (Mycoline, bioMerieux) with
further identiﬁcation of Candida spp. by Fungi fast/twin (Arbor
medical).
Results: The presence of pathogenic fungi was conﬁrmed for 511
patients (76.15%). The most often causative agent was Trichophy-
ton rubrum (64%) as being the only causative agent of monoinfec-
tion and T. rubrum in mixed infection with C. spp., Penicillium
spp.and Aspergillus spp. (5.65%). Other dermatophytes (Epidermo-
phyton ﬂoccosum) and different species of Trichophyton (T. mentagr-
ophytes, T. tonsurans) were detected (2.72%). Totally the
dermatophytes as the causative agents of onychomycosis were
isolated in 72.37%. The second largest group of causative agents
was Candida spp. (17%). The moulds were isolated in the remain-
ing 10.63%.
Conclusions: Tinea unguis most often is caused by dermatophytes
– T. rubrum and T. mentagrophytes. C. albicans and C. parapsilosis
are the main causative agents from yeasts. From nondermato-
phytes the most often isolated was Scopulariopsis brevicaulis.
P1777 Rapid identiﬁcation of opportunistic fungi with
generic PCR and pyrosequencing
V. Fernandez, M. Krabbe, E. Jakobsson, P. Hagblom
Solna, Uppsala, S
Background and objectives: The incidence of life-threatening fungal
infections is rising in proportion to the increasing number of sub-
jects at risk, including AIDS, transplant, cancer and elderly
patients and premature infants. At present, identiﬁcation of the
most frequently encountered fungal pathogens is based on an
array of different laboratory methods and often requires up to
several days. Simple and rapid diagnosis of fungal infections war-
ranting timely and efﬁcient therapy remains a goal sought after.
In this study we have used the internal transcribed spacer (ITS)
regions within the ribosomal DNA gene complex as molecular tar-
gets in a generic assay for the identiﬁcation of pathogenic fungi.
Methods: DNA of cultured yeast and ﬁlamentous fungi was
extracted or released for subsequent ampliﬁcation of the polymor-
phic ITS2 spacer using oligonucleotides priming at regions of ri-
bosomal genes 5.8 S and 28 S which are universally conserved
throughout the fungal kingdom. Short amplicon fragments were
sequenced using pyrosequencing analysis. For species determin-
ation, direct local BLAST against our fungal ITS database was
performed.
Results: Over 300 isolates and laboratory strains comprising the
clinically most signiﬁcant opportunistic yeast and mould patho-
gens were analysed. A 40-m long ITS2 sequence signature showed
to provide enough discriminatory power for unambiguous identi-
ﬁcation of all species included in the study. Highly signiﬁcant
E-values were obtained in all BLAST searches against local and
public GenBank databases. In contrast to conventional fungal
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identiﬁcation methods, the species identiﬁcation time was the
same for all organisms, nearly 6 h.
Conclusions: Rapid analysis of short ITS sequence signatures of
fungi by generic PCR ampliﬁcation and pyrosequencing shows
considerable potential for the diagnosis of invasive fungal infec-
tions.
P1778 Cyclic peptides and depsipeptides: markers of
fungal infections
A. Jegorov, M. Sulc, A. Ulrych, P. Navratil, V. Curn, B. Kratochvil,
V. Havlicek
Ceske Budejovice, Prague, Hradec Kralove, CZ
Objectives: Fungi produce cyclic peptides and depsipeptides by
multifunctional synthetases. The nonribosomal biosynthesis is not
speciﬁc with respect to possible amino-, hydroxy-, fatty-acids, etc.
used as substrates, and so very often one can meet ‘weird’ resi-
dues forming the cyclopeptide molecules. Speciﬁcity of fungal
synthetases thus makes it possible to use cyclic peptides as very
selective markers of fungal infections useful both in human or
veterinary medicinal diagnostics and even in agriculture and
safety food proﬁling. Most of clinically important fungi strains
have been described as ‘small’ cyclopeptide or peptide producers.
These secondary metabolites can be found both in strains respon-
sible for cutaneous infections (some Trichophyton species produce
ferrichrome) and more importantly in systemic fungal infections
(e.g. some aspergilli and Candida generate gliotoxin, etc.).
Methods and results: We have cultivated a series of fungal patho-
gens, e.g. of the genera Aspergillus, Fusarium, Paecilomyces, Beauve-
ria, Metarhizium, Alternaria, Emericella, Trichothecium and
Pseudallescheria. Particular attention has been dedicated to the
isolation of pure spores. Crude extracts were puriﬁed by LC and
HPLC. Results of this part are represented by series of novel cyc-
lic peptides from genera: Trichothecium, Metarhizium, Beauveria and
Paecilomyces. We have also described a new series of cyclic pep-
tides from true in vivo isolated pathogen Pseudallescheria. In addi-
tion, we have developed several mass spectrometric protocols for
cyclic peptide sequencing. Their application in HPLC/MS conﬁ-
guration can be used for sensitive detection and unambiguous
cyclic peptide identiﬁcation even in complex biological ﬂuids.
Conclusions: We suggest to use cyclic peptides and depsipeptides
as an extremely speciﬁc marker family for fungal infection diag-
nosing. Cyclic peptides have been described so far in fungi (also
basidiomycetes like Amanita phalloides), some bacteria (e.g. Micro-
cystis and Nodularia), plants and few marine animals only. Thus,
any molecule of this category found in mammal clinical sample
should indicate the corresponding infection.
Acknowledgement: Czech Science Foundation (203/02/1417 and
203/04/0799).
P1779 Identiﬁcation and characterisation of clinical isolates
of Trichosporon species from Kuwait
S. Ahmad, M. Al-Mahmeed, Za. Khan, Zi. Khan
Safat, KWT
Objective: Disseminated trichosporonosis is an emerging disease
in immunocompromised patients particularly those with persist-
ent granulocytopenia. This study was carried out to identify local
clinical isolates of Trichosporon species by biochemical and
molecular methods. Molecular typing was also performed for in-
traspecies diversity.
Methods: Twenty-nine isolates of Trichosporon species recovered
from clinical specimens from Kuwait were ﬁrst speciated by VITEK
2 yeast identiﬁcation system. PCR ampliﬁcation assays based on
sequences within internally transcribed spacer (ITS)-1 and ITS-2 of
rDNA were developed for speciﬁc detection of three Trichosporon
spp. viz. T. asahii, T. mucoides and T. jirovecii. The methodology
established with reference strains was then applied for species-spe-
ciﬁc ampliﬁcation of genomic DNA from the clinical isolates. The
results were conﬁrmed and extended by direct DNA sequencing of
ITS-1 and ITS-2 of rDNA. The typing of the isolates for intraspecies
diversity was performed by randomly ampliﬁed polymorphic DNA
(RAPD) analysis using two different primers.
Results: The VITEK 2 yeast identiﬁcation system identiﬁed all 29
clinical isolates from Kuwait as T. asahii. However, using T. asahii-
speciﬁc primers, genomic DNA of only 25 of 29 isolates was
ampliﬁed, while no ampliﬁcation was obtained for the remaining
four isolates. The identity of T. asahii isolates was further con-
ﬁrmed by direct DNA sequencing of ITS regions of rDNA of three
randomly selected isolates. The identity of the remaining four
non- T. asahii isolates as T. asteroids was established by ampliﬁca-
tion of rDNA, with panfungal primers followed by sequencing of
ITS-1 and ITS-2. The RAPD patterns for T. asahii isolates exhibited
little intraspecies diversity. However, the typing patterns for the
four T. asteroids isolates were different from the patterns obtained
from the T. asahii isolates.
Conclusions: The currently available VITEK 2 yeast identiﬁcation
system does not adequately discriminate between different Tricho-
sporon species. Molecular methods based on rDNA ampliﬁcation
and sequencing may also be needed for species-speciﬁc identiﬁca-
tion of Trichosporon species. Supported by Research Admn. pro-
jects grants MY 02/02 and the college of Graduate Studies,
Kuwait University.
P1780 Phylogenetic positions of clinical isolates within the
ﬁlamentous fungal genus Trichoderma
L. Kredics, Z. Antal, A. Szekeres, M. La´day, I. Do´czi, J. Varga,
L. Manczinger, E. Nagy
Szeged Budapest HUN
Objectives: The imperfect ﬁlamentous fungal genus Trichoderma is
already on the growing list of opportunistic fungal pathogens.
Most of the Trichoderma infections are reported from patients
undergoing peritoneal dialysis and from immunocompromised
transplant recipients. As the rapid and accurate identiﬁcation of
opportunistic fungi is crucial for the choice of adequate therapeu-
tic interventions, we studied the taxonomic positions of 12 clinical
Trichoderma strains including 10 human pathogenic and two nasal
mucus isolates.
Methods: The examined clinical isolates were originally identiﬁed
based on their morphology. As the identiﬁcation of Trichoderma
strains is difﬁcult if only morphological characters are considered,
we used molecular techniques to conﬁrm the identity of the exam-
ined clinical Trichoderma isolates and to study their phylogenetic
positions within the genus. Sequence analysis of the internal
transcribed spacer region was carried out with primers ITS1
(50-TCCGTAGGTGAACCTGCGG-30) and ITS4 (50-TCCTCCGCTT-
ATTGATATGC-30). Random ampliﬁed polymorphic DNA analysis
was carried out using the OPA random primer kit of Qiagen. Iso-
enzyme analysis of glucose-6-phosphate-dehydrogenase, glucose-
6-phosphate-isomerase, peptidase B, phosphoglucomutase and 6-
phosphogluconate-dehydrogenase enzymes was performed by cel-
lulose acetate electrophoresis.
Results: The applied molecular techniques revealed that certain
Trichoderma strains involved in the study should be reidentiﬁed.
ITS-data conﬁrmed the identities of nine isolates, while three
strains, originally described as T. pseudokoningii (IP 2110.92),
T. citrinoviride (UAMH 9573) and T. koningii (CM 382) proved to
be T. longibrachiatum. This was supported by data from isoenzyme
analysis.
Conclusions: Our results support the hypothesis that most of the
clinical Trichoderma isolates are restricted to section Longibrachia-
tum of the genus, and that previous reports about the isolation of
other Trichoderma species from immunocompromised and periton-
eally dialised patients may not have been correct. However, the
identitity of the T. harzianum isolate involved in the study could
be conﬁrmed with molecular techniques, suggesting that strains
belonging to other species of the genus may also cause infections
in humans, but with a lower frequency than T. longibrachiatum
strains. This work was ﬁnancially supported by grant F037663 of
the Hungarian Scientiﬁc Research Fund.
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P1781 Growth of Aspergillus fumigatus is inhibited by
Candida species on sealed Sabouraud agar plates, but not on
sealed Columbia agar plates
A. Becker, N. Akkad, D.H. Forster, E. Kniehl
Karlsruhe, D
Objectives: Randhawa et al. (1) reported that some Candida species
inhibit growth of Aspergillus fumigatus when cocultured on pep-
ton-glucose agar (PGA), especially on sealed agar plates. C. glab-
rata and C. albicans proved to be the major inhibitors in this study.
The authors speculate that colonisation by Candida species may
delay a deﬁnite diagnosis of aspergillosis from sputum or other
clinical specimens. To assess the possible impact of these ﬁnd-
ings for clinical diagnostics of A. fumigatus, we questioned the role
of used media.
Methods: The experiments of Randhawa et al. (1) were repeated
with Sabouraud dextrose agar (SDA), Candida-II agar (C-II),
Columbia agar (CA) and CLED agar on sealed and unsealed agar
plates for cocultivation of A. fumigatus with C. albicans (six
strains), C. glabrata (one strain), C. krusei (three strains) and
C. tropicalis (three strains).
Results: On SDA, growth of A. fumigatus was strongly inhibited by
Candida species, especially on sealed plates. On unsealed plates,
C. glabrata and C. albicans were strong inhibitors as well, whereas
C. tropicalis and C. krusei were only weak inhibitors. After coculti-
vation with strong inhibitors for 48 to 72 h, no visible growth of
A. fumigatus was obtained. These results were in concordance
with those reported for PGA (1). There was no difference in
growth inhibition between SDA and C-II. In contrast, on CA, all
tested Candida species were weak inhibitors on sealed plates. On
unsealed plates, a relevant inhibition was registered for C. tropical-
is and C. albicans, whereas C. glabrata and C. krusei were only
weak inhibitors. After 48 to 72 h of cocultivation, visible growth
of A. fumigatus was obtained, regardless of the tested Candida
strain. Growth inhibition on CLED was comparable with that on
CA.
Conclusions: To avoid contamination, sealed agar plates are often
used for isolation of A. fumigatus in clinical laboratories. When
specimens that might be heavily contaminated by Candida species
are cultured on SDA, delayed growth or growth inhibition of As-
pergillus might be a concern. Our results suggest that this problem
might be overcome by simultaneous inoculation on a glucose-poor
medium, e.g. CA plates, and prolonged incubation of these plates
for more than 48 h.
Reference:
1. Randhawa HS et al. (2002). In vitro inhibition of Aspergillus fumigatus by
Candida species, especially C. albicans and C. glabrata. Current Science 82,
860–865.
P1782 Phenotyping by Fourier-transform infrared
spectroscopy versus restriction- and ampliﬁcation-based
genotyping of Candida tropicalis isolates: a comparison
A.S. Al Masri, F. Kipp, H.C. Gugnani, W. Fegeler, K. Becker
Munster, D; Delhi, IND
Invasive candidiasis has increased dramatically over the past dec-
ades. The contribution of non-albicans Candida spp. including
C. tropicalis to invasive infections is rising, yet little is known of
their molecular epidemiology. Therefore, effective typing systems
are required for tracing epidemiological distribution patterns. In
addition to restriction endonuclease analysis of genomic DNA
(REAG) followed by pulsed-ﬁeld gel electrophoresis (PFGE), dif-
ferent ampliﬁcation-based methods were studied: Arbitrarily
primed (AP)-PCR under low-stringency conditions with a set of
38 different 10mer arbitrary oligonucleotides (G + C content: 30–
90%), interrepeat (IR)-PCR based on micro- and minisatellite
sequences and eucaryotic telomeric motifs using eight different
primers. These results were compared with those obtained by
phenotyping the isolates with Fourier-transform infrared spectros-
copy (FTIR). For ﬁngerprinting, 60 C. tropicalis reference strains
and clinical isolates from different European and Asian centers
were included into the study. The rank order of discriminatory
ability among the genotyping methods was as follows: REAG
using BssH II >> AP-PCR > IR-PCR. In contrast to other restric-
tion enzymes used, BssH II revealed a series of distinct bands in
the region from 100–300 bp to approximately 2–3 kb. Regarding
AP-PCR ﬁngerprinting, random primers with a G + C content of
50% showed the best discriminatory power if prolonged ramp
times (5 min) were applied. In contrast, IR-PCR was shown to be
not suitable for genotyping C. tropicalis isolates. Using the ‘Ward’
algorithm and the ﬁrst derivates of the spectra, FTIR showed a
main branching into two groups, which was further divided in
several subgroups depending on the heterogeneity level selected.
In general, FTIR was less discriminatory than REAG, but easier to
perform. The classiﬁcations derived from REAG and FTIR were
not completely congruent. Strains representing the same major
proﬁle but being epidemiologically unrelated appeared to be
widespread in several centres included. These ﬁndings indicate
that REAG followed by PFGE is the most useful molecular
method for the investigation of inter-strain variation within the
species C. tropicalis. Dependent upon primer design, AP-PCR may
offer a fairly well alternative molecular ﬁngerprinting method. In
addition, the whole-organism ﬁngerprinting by FTIR provides a
tool with sufﬁcient resolving power to distinguish isolates of this
Candida species.
P1783 Development of a lovastatin resistance-based
transformation system for Rhizomucor miehei
C. Vagvolgyi, G. Lukacs, I. Nyilasi, T. Papp
Szeged, HUN
Objectives: Various members of the class Zygomycetes are known
as agents of opportunistic infections in men and animals. The
thermophilic organism, Rhizomucor miehei, is a practically and the-
oretically signiﬁcant member of this fungal group. The aims of
the present study were to clone and characterise the 3-hydroxy-3-
methylglutharyl coenzyme A reductase (HMG-CoA reductase)
gene (hmg) of R. miehei, and to elaborate a direct selection method
for the transformants based on lovastatin resistance,which does
not require the usage of auxotrophic markers.
Methods: Genomic DNA library and genomic DNA used as tem-
plates in PCR reactions were derived from the wild-type R. miehei
ATCC 46344. The genomic library screening, subcloning, extrac-
tion of DNA, sequencing and construction of plasmids were per-
formed using the standard techniques. PEG mediated protoplast
transformation was used to introduce the expression vectors into
R. miehei. 8 lg/mL lovastatin was used as selecting agent. The
transformants were analysed by PCR and Southern hybridisation.
Results: A genomic library was constructed from the chromosomal
DNA of R. miehei and it was screened using a probe ampliﬁed by
PCR with degenerated primers designed for the most conserved
regions of the hmg. As a result of this analysis, a genomic insert
of about 8000 bp containing the entire hmg gene was cloned into
pBluescript vector and it was used for sequencing. As a result,
the complete nucleotide sequence was determined and analysed.
The putative protein sequence proved to be 1020 aa in length.
R. miehei was transformed with plasmids containing the hmg
gene. Transformants could be selected for lovastatin resitance.
Analysis of transformants and optimisation of transformation
were also done.
Conclusions: Lovastatin is a competitive inhibitor of HMG-CoA
reductase and wild-type R. miehei cannot form colonies on plates
containing 4–16 lg/mL lovastatin. We have cloned and character-
ized the hmg gene from R. miehei. This gene catalyses the conver-
sion of HMG-CoA to mevalonate: this is the rate-limiting step of
the acetate/mevalonate pathway leading to sterol and isoprene bio-
synthesis. Transformantions with hmg harbouring vectors resulted
transformants resistant to lovastatin, because they contained hmg
in high copy number. We elaborate a transformation method based
on hmg gene, which could open the way for further molecular
studies, such as analyses of possible virulence factors.
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P1784 Identiﬁcation of Rhizomucor species by means of
biochemical and molecular methods
T. Papp, G. Lukacs, M. Vastag, C. Vagvolgyi, E. Nagy
Szeged, HUN
Objectives: Expanding set of data demonstrate the opportunistic
pathogenic role of the Rhizomucor species. The genus involves two
species: R. pusillus and R. miehei. Their thermophhilic nature and
characteristic morphological features clearly distinct them from
other members of the Mucorales. Identiﬁcation of Rhizomucor iso-
lates at species level seems to be more problematic frequently
resulting misidentiﬁcations or species names remained to be
determined. The purpose of the present study was to broaden the
basis of knowledge affording a methodically simple, quick and
more unambiguous identiﬁcation of the two Rhizomucor species.
Methods: Carbon source utilisation analysis of 17 Rhizomucor iso-
lates using 87 different compounds. Isoenzyme analysis of 18 iso-
lates testing ﬁve enzyme system. Random ampliﬁed polymorphic
DNA (RAPD) analysis of 23 isolates with 7–10 bp oligonucleotide
primers. Lovastatin inhibition tests of 30 isolates.
Results: Four carbon compounds were identiﬁed whose utilisation
showed a clear difference between the R. miehei and R. pusillus
isolates. These were sucrose, glycine, phenylalanine and alanine.
Staining patterns of three enzyme system also showed two differ-
ent electromorphs correlating perfectly with the two investigated
Rhizomucor species. RAPD analysis revealed higher genetic variab-
ility. However the genetic variability was found to differ in R.
pusillus and R. miehei: the latter revealed less-intraspeciﬁc poly-
morphism. As the results of highly different ampliﬁcation patterns
of the two Rhizomucor species, RAPD bands characteristic of
R. miehei or R. pusillus isolates could be identiﬁed. The susceptibility
of R. miehei and R. pusillus to lovastatin under different culturing
conditions was investigated also. R. pusillus proved to be signiﬁ-
cantly more sensitive to lovastatin than R. miehei. Malt extract agar
(pH 3.5) supplemented with 10 lg/mL lovastatin inhibit the
growth of R. pusillus but allows the vigorous growth of R. miehei.
Conclusions: Besides determining easily countable characters for
the identiﬁcation of Rhizomucor isolates, the experimental data
provide information concerning the genetic variability of these
species. The extent of genetic polymorphism is different in the
two Rhizomucor species: while substantial polymorphism was
found among the R. pusillus strains, the investigated R. miehei
strains proved to be almost homogenous. We elaborate a simple
and very reliable method for species level differentiation.
P1785 In vitro antifungal activity, cytotoxicity and cellular
accumulation of new water-soluble amphotericin B (AMB) –
polyvinylpyrrolidone (PVP) formulations
E. Charvalos, M.N. Tzatzarakis, F. Van Bambeke, P.M. Tulkens,
A.M.Tsatsakis, M.-P. Mingeot-Leclercq
Athens, Crete, GR; Brussels, B
Objectives: Amphotericin B, the drug of choice for the treatment of
systemic fungal infections, is characterised by (i) a negligible solu-
bility in water and therefore a poor bioavailability for host cells
and (ii) a cellular toxicity. Liposomal or colloidal formulations
have been developed to palliate these drawbacks. Conjugation of
the aqueous-insoluble drug to water-soluble biodegradable poly-
meric carriers also constitutes an attractive approach for improv-
ing AMB bioavailability. In the present work, we have
investigated the in vitro antifungal activities of new water-soluble
AMB-PVP complexes, and their accumulation in macrophages, in
relation with their cytotoxicity.
Methods: Two new AMB–PVP complexes were synthesised as des-
cribed earlier (Patent Certiﬁcate: 1003871, Greek Industrial Prop-
erty Organization), namely AC2 (MW ¼ 24 kDa), and AC5
(MW ¼ 90 kDa). MICs and MFCs of Candida spp. and Aspergillus
spp. were determined according to NCCLS guidelines. Killing activ-
ity at 2  MIC against Candida was also determined. Cytotoxicity
was evaluated by haemolysis of sheep red blood cells and release of
LDH from macrophages. Cellular accumulation in J774 macrophag-
es was determined after measuring AMB concentration by HPLC.
Results: MIC of AMB-PVP complexes were up to 20 times lower
as compared with AMB, (with AC2 showing the lowest MICs and
MFCs) against Candida spp. and slighty lower to equal against As-
pergillus spp. Killing activity after 2 h exposure of C. albicans to
AMB and AMB-PVP complexes at 2  MIC, reached 2 log for
complexes as compared with 1 log for AMB. Uptake in J774
macrophages after 24 h was three times lower for complexes than
for AMB. Haemolytic activity and LDH release were approxi-
mately three times lower for complexes than for AMB.
Conclusions: AMB-PVP complexes showed improved antifungal
activity when compared with AMB against Candida spp. and As-
pergillus spp. They accumulate to lower levels than AMB in eu-
caryotic cells, which may explain their lower toxicity. These data
demonstrate the potential beneﬁts of these new formulations and
suggest future applications.
P1786 Two cases of severe phototoxic reactions related to
long-term outpatient voriconazole treatment
S.J. Vandecasteele, E. Van Wijngaerden, W.E. Peetermans
Leuven, B
Introduction: Voriconazole is an alternative for amphotericin B in the
treatment of invasive aspergillosis. Voriconazole has a high oral bio-
availability and is therefore promising for outpatient treatment. It is
well tolerated, but one noncomparative study reported (mild) cuta-
neous side-effects in 8.6% of the patients. Case 1, a man (24 years)
with chronic granulomatous disease was diagnosed with probable
invasive pulmonary aspergillosis according to the EORTC/MSG
deﬁnitions. Outpatient treatment with oral voriconazole (200 mg
BID) was started and the patient improved. After 8 weeks, he devel-
oped profound erythema in sun-exposed areas (face, hands). Voric-
onazole was stopped and the erythema resolved within 2 weeks. Six
weeks later the patient relapsed. Voriconazole was reinstituted.
Despite protective measures, he redeveloped profound skin ery-
thema and friability in sun-exposed areas after 4 weeks. After
6 weeks, lesions evolved to desquamation and small ulcers at the
hands. After 8 weeks, the patient had large areas with bulla, desqua-
mation and superﬁcial ulcerations on lips, face and hands. Voricon-
azole was switched to itraconazole oral solution and all lesions
healed within 1 week. Case 2 (man, 52 years, diabetes mellitus)
underwent aortobifemoral vascular grafting. He was reoperated for
thrombotic problems. Multiple cultures of the explanted graft
yielded Aspergillus fumigatus. The vascular graft infection was com-
plicated with acro-ileiitis and arthritis of the right knee and ankle.
Amphotericin B was given for 1 month. Thereafter the patient was
discharged with oral voriconazole (200 mg BID). After 2 months,
asymptomatic hyperpigmentation in sun-exposed areas was
noticed. After 20 weeks small vesicles appeared in sun exposed
areas (face, neck, arms and legs). The vesicles evolved to bulla
(diameter 1–2 cm) and ruptured after a few days. Crustae were
formed and the lesions healed in 2 weeks. New lesions continued to
appear while old lesions were healing. Voriconazole was switched
to itraconazole oral solution and all lesions resolved within 2 weeks.
Discussion: Skin reactions, mainly rash, pruritus and phototoxic
induced erythema, are known but mostly mild side-effects of vor-
iconazole. More severe facial erythema and cheilitis were reported
in ﬁve patients. We reported severe late-onset phototoxic skin
reactions in two patients. Further postmarketing surveillance on
the incidence and impact of these late-onset cutaneous side-effects
is warranted.
P1787 Outcome and aqueous drug levels of voriconazole
in four patients with fungal keratitis treated with voriconazole
A. Zinkernagel, M. Scherrer, J. Burhenne, W.E. Haefeli, M. Thiel
Zurich, CH; Heidelberg, D
Objectives: To report on outcome and antifungal concentrations in
aqueous humor and plasma of four patients with fungal keratitis
treated with topical and/or oral voriconazole.
Methods and results: Voriconazole eye drops were prepared by sup-
plementing the voriconazole lyophilisate for the i.v. administration
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by 0.9% sodium chloride, yielding a 1% solution. An ophthalmic
nurse administered the voriconazole eye drops daily one drop
hourly. Aqueous humor of the affected eye and plasma samples
were collected concurrently 1 h after the last eye drop and 12 h after
oral voriconazole administration in order to obtain trough concen-
trations of both routes of application in both compartments. Sam-
ples were immediately frozen at 20 C until analysis with HPLC/
UV (plasma) and LC/MS (aqueous humor). Three patients with
Candida albicans keratitis and one patient with Aspergillus fumigatus
keratitis were treated with systemic (800 mg b.i.d. p.o) and topical
(one drop of 1% i.v. solution hourly) voriconazole. After 2 days of
systemical and topical administration the voriconazole concentra-
tions in aqueous humor were 2.5–3.6 and 3.2–4.2 lg/mL in plasma.
Clinical improvement was seen in all patients. After switching to
topical administration of voriconazole, the concentrations in aque-
ous humor fell to values of 0.08–0.9lg/mL after 2–14 days and the
voriconazole concentrations were undetectable in plasma (<0.2 lg/
mL). Recurrence of fungal keratitis occured within 14 days in the
patient suffering form keratitis due to A. fumigatus. After switching
back to systemic voriconazole clinical improvement was again
observed in this patient. The other three patients remained well
with topical voriconazole.
Conclusions: Treatment with systemic voriconazole resulted in
aqueous humor concentrations well above MIC for Aspergillus and
Candida species, which was associated with a good response in all
patients. Systemically applied voriconalzole is a good alternative
with excellent response rates for fungal keratitis whereas topical
voriconazole resulted in lower intraocular concentrations, and in
one patient, recurrence of clinical symptoms.
P1788 Voriconazole for the treatment of drug-resistant
fungal infections: experience from a Compassionate-Use
Programme in Spain
J.M. Aguado, J.M. Cisneros on behalf of the Spanish Group of
Voriconazole Study4
Objective: To describe the safety and efﬁcacy of voriconazole in
patients treated within the compassionate-use programme.
Methods: Retrospective study of patients (pts) received voriconaz-
ole through a compassionate-use programme in Spain for treat-
ment of an invasive fungal infection if they were refractory to or
intolerant of approved antifungal therapy. Depending on tolerab-
ility voriconazole was administered either intravenously or orally.
I.v. voriconazole was administered as a loading dose of 6 mg/kg/
12 h on day 1 followed by 4 mg/kg/12 h thereafter. Oral voricon-
azole was administered as a loading dose of 200 or 400 mg/12 h
on day 1 followed by 100 or 200 mg twice a day per patients
weighing <40 or >40 kg, respectively. When feasible the route of
administration of voriconazole was changed from i.v. to oral. Out-
come was assessed by investigators at the end of therapy or at the
last visit as success (complete or partial response), stable infection,
or failure, based on protocol-deﬁned criteria.
Results: During the period of April 2003 through November 2003,
59 patients (35 males/24 females) were reviewed. The age of the
patients ranged from 15–79 years. The most common underlying
disease was leukaemia (22%). Nineteen patients (19%) presented
neutropenia. The most common fungus isolated was Aspergillus
spp. (47%), followed by Candida spp. (20%). A total of 17 fungal iso-
lates were recovered from tissues, followed by blood and broncho-
alveolar lavage. Prior to voriconazole, 60 patients received
amphotericin B, 19 itraconazole, 16 ﬂuconazole and four caspofun-
gin. The reason for using voriconazole was failure of other antifun-
gal drugs (69%), intolerance (11%), and both failure and
intolerance (20%). The advert events reported were generally mild
to moderate in severity, transient in nature, and reversible. Twenty-
nine patients (78%) responded to voriconazole therapy, in four
cases (4%) infection progressed.
Conclusion: Voriconazole provided high rated of cure with very
good overall tolerance. These data conﬁrmed the efﬁcacy of voric-
onazole in the treatment of invasive fungal infections specially
invasive aspergillosis even in patients who are intolerant of or
refractory to conventional antifungal therapy.
P1789 Lack of hepatic effect of anidulafungin
D. Krause, J Schranz, W. Birmingham
King of Prussia, USA
Introduction: There is a need for safe and effective antifungals.
ANID is a novel echinocandin antifungal agent with demonstra-
ted efﬁcacy in mucosal and invasive infections due to Candida
spp., and is currently under regulatory review. Hepatic toxicity is
a common reason for failure of new drugs, and rules have been
proposed to detect and evaluate the hepatic safety of new agents
via monitoring hepatobiliary parameters for potential signals of
toxicity.
Objectives: To evaluate the hepatic safety of ANID.
Methods: Patients (pts) with conﬁrmed oesophageal candidiasis
were enrolled in a multinational, randomised, controlled, double
blind, double-dummy, phase 3 clinical trial. After obtaining
informed consent, pts were randomised to receive i.v. ANID
50 mg or oral ﬂuconazole (FLU) 100 mg, plus corresponding pla-
cebo. Pts returned daily for 14–21 days of therapy, and at follow-
up (FU), 2 weeks after end-of-therapy (EOT). Hepatobiliary
parameters (ALT, AST, ALP, Bili) were obtained at baseline, days
3, 7, 14, EOT (if EOT was not day 14) and FU. Thresholds for clin-
ically signiﬁcant (CS) increases from baseline were prospectively
speciﬁed prior to unblinding, as were various signiﬁcant combina-
tions of changes, such as ALT >3 the upper limit of normal
(ULN) plus bili >1.5 ULN.
Results: A total of 601 pts, most with AIDS, were enrolled. Most
(98%) took one or more nonantifungal medication concomitantly.
The number and percentage of pts with CS increases are shown
in the table for ALT. Similar results were obtained for the other
hepatic values noted above.
There was also no difference between the arms when various
prospectively deﬁned combinations of values were considered.
Conclusions: In this immunocompromised population of pts on
multiple medications, no signal of hepatic effects of anidulafungin
was apparent.
P1790 Ex vivo combined activity of posaconazole and
granulocyte-macrophage colony-stimulating factor-treated
neutrophils against Scedosporium proliﬁcans
M. Simitsopoulou, C. Gil-Lamaignere, L. Kourounaki,
D. Loebenberg, E. Roilides
Thessalonica, GR; Kenilworth, USA
Objectives: Scedosporium proliﬁcans causes therapy-refractory inva-
sive infections with high mortality in immunocompromised
patients. We tested the combined effect of posaconazole (POS), an
investigational antifungal triazole, and granulocyte-macrophage
colony-stimulating factor (GM-CSF) on ex vivo activity of neu-
trophils (PMNs) against S. proliﬁcans.
Methods: Balb/c mice were treated with 50–250 ng of murine GM-
CSF or saline sc daily for 4 days. PMNs, isolated from GM-CSF-
or saline-treated mice, were incubated with POS (1lg/mL) and
hyphae at effector cell: target ratio 5:1. Per cent damage of S. pro-
liﬁcans hyphae was assessed by XTT metabolic assay. ANOVA with
Tukey test were used for multiple comparisons.
Table: Patients with CS* ALT increases from baseline
ALT ANID n/N (%) FLU n/N (%)
Day 3 1/265 (0.4) 0/268
Day 7 2/258 (0.8) 3/260 (1.2)
Day 14 2/237 (0.8) 8/243 (3.3)
EOT 0/43 1/37 (2.7)
FU 2/240 (0.8) 5/240 (2.1)
*CS ¼ 3 fold increase from baseline, and at least 3 ULN
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Results: PMNs from GM-CSF (100 ng)-treated mice did not induce
signiﬁcantly increased damage of S. proliﬁcans hyphae ex vivo
compared with untreated controls (n ¼ 8, P ¼ 0.15). POS (eight
studies) had synergistic effects when combined ex vivo with either
untreated (P < 0.01) or GM-CSF-treated PMNs (P < 0.01) on per
cent hyphal damage.
Conclusions: POS exerts synergistic activity in combination with
PMNs, especially from GM-CSF-treated mice, against S. proliﬁcans
hyphae. Combined activity of POS and phagocytes may play an
important role in the management of invasive S. proliﬁcans infec-
tion.
P1791 Posaconazole as salvage therapy for Pseudallescheria
infections: a case series
R. Hachem, J.R. Graybill, R. Negroni, K. Presberg, G. Schiller,
P. Zakowski, L. Pedicone
Houston, San Antonio, USA; Buenos Aires, AR; Milwaukee,
Los Angeles, Kenilworth, USA
Objectives: Pseudallescheria boydii (Scedosporium apiospermum) is a
virulent fungal pathogen capable of infecting immunocompro-
mised and immunocompetent patients. Immunocompetent per-
sons typically acquire this disease after penetrating trauma or
near-drowning in polluted water. Pseudallescheria infections are
challenging to manage since the organism is relatively resistant to
amphotericin B. In some reports, mortality associated with dis-
seminated or central nervous system disease approaches 100%.
Posaconazole (POS) is an investigational, broad-spectrum agent
for the treatment of invasive fungal infections. We report the suc-
cess of POS salvage therapy in the treatment of Pseudallescheria
infections.
Methods: POS activity was evaluated in a large open-label, multi-
centre clinical trial conducted in patients intolerant of or with dis-
ease refractory to other antifungal therapy, of whom seven had
Pseudallescheria infections. Patients received POS 800 mg/day in
divided doses. Complete or partial response was considered a
success; stable or persistent disease was considered a failure.
Results: Six patients had underlying disease, including haemato-
logic malignancy (three), HIV infection (one), diabetes (two), solid
organ or bone marrow transplantation (two) and graft vs.host dis-
ease (one); One patient had no identiﬁable underlying disease.
POS therapy produced successful outcomes in three of seven
(42%) patients. Sites of infection included lung, brain, bone, sinus,
joints and skin. Cumulative duration of prior therapy with itrac-
onazole, ketoconazole, or amphotericin B ranged from 1 month to
3 years. POS treatment duration ranged from 7 days to >1 year
and was well tolerated. Importantly, POS demonstrated activity in
bone and in the central nervous system. Additionally, two
patients who were considered treatment failures had stable dis-
ease; one of these two patients responded after a second course of
therapy.
Conclusions: POS resulted in successful outcomes in three of seven
patients in whom other antifungal therapies had failed. POS was
well-tolerated without any signiﬁcant adverse events even with
prolonged administration (>1 year). These cases suggest that POS
is useful for the treatment of Pseudallescheria infections, for which
there are few therapeutic options.
Progress in pharmacokinetics and pharmacodynamics - II
P1792 Serum protein binding of erythromycin as measured
by ultraﬁltration, dialysis ﬁltration and ultracentrifugation
A. Sandberg, H.U. Nielsen, O. Cars, M. Christiansen,
N. Frimodt-Møller
Copenhagen, DK; Uppsala, S
Objectives: The protein-free, unbound fraction of antibiotic concen-
tration is used for PK/PD calculations. Reliable and easy meas-
urements of protein binding are therefore needed. Three methods
are usually recommended: ultraﬁtration (F), dialysis (D) or ultra-
centrifugation (C), but we have not seen the methods compared
simultaneously for any antibiotic. We studied the three methods
for estimation of serum protein binding of erythromycin.
Methods: The same portion of pooled human serum was used for
all experiments. Three concentrations of erythromycin (3, 1.5 and
1 mg/L, respectively), were subjected to the three protein binding
methods. Erythromycin concentrations of serum or ﬁltrate/dialy-
sate/supernatant were measured by bioassay, with serum or PBS
for standards. Protein binding was calculated from the formula
(erythromycin concentrations): Serum–ﬁltrate (dialysate, superna-
tant)/Serum, in per cent, corrected for binding of serum-free con-
trols.
F: Amicon UF-vials, YM30 ﬁlter, were added one ml serum and
centrifuged in a ﬁxed-angle rotor Sorval RC-50 centrifuge at
3000 g for 8 min. This resulted in approx. 0.2 mL ultraﬁltrate. D:
Dialysis tubes (Spectra/por, MWCO 10.000) in pieces of 20 cm,
were tied in both ends after adding 2 mL serum. With tubings
placed in U-form in plastic tubes, these were centrifuged in a free
angle rotor centrifuge at 339 g for 5 min, excess water was
removed, and tubes centrifuged again at 339 g for 40 min. This
resulted in approximately 0.12 mL dialysate. C: A Beckman ultra-
centrifuge type L-80, type 80 Ti rotor, was used. Beckman Ultra-
Clear Centrifuge Tubes were ﬁlled with 13.4 mL serum samples
and centrifuged at 175.000 g for 8 h at 30C. The 0.5 mL superna-
tant was removed with a pipette.
Results: For the three samples with 3, 1.5 and 1 mg/L erythromy-
cin the following serum protein binding was found (in %): F: 63,
65 and 65. D: 58, 70 and 72. C: 54, 58 and 60, respectively.
Conclusions: Within the variation of the methods we found slight
concentration related binding, but little differences between meth-
ods. The results are comparable with published data of 41–74%.
The ultraﬁltration method was by far the easiest and least time
consuming.
P1793 Pharmacokinetics of moxiﬂoxacin in patients
undergoing continuous ambulatory peritoneal dialysis
C. Skalioti, T. Tsaganos, M. Raftogiannis, D. Plachouras,
H.Giamarellou, E.J. Giamarellos-Bourboulis
Athens, GR
Objectives: Moxiﬂoxacin is a novel 8-methoxy-ﬂuoroquinolone
with high oral availability and considerable in vitro activity on
Gram-positive cocci. The impact of end-stage chronic renal failure
on pharmacokinetics of moxiﬂoxacin was evaluated in four anuric
patients on continuous ambulatory peritoneal dialysis (CAPD).
This group of individuals is at high risk of presenting with infec-
tions by Gram-positive cocci, especially spontaneous bacterial
peritonitis.
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Methods: A single 400 mg dose was administered orally followed
by blood and peritoneal ﬂuid sampling in 0.5, 1, 2, 3, 4, 6, 12, 18
and 24 hours afterwards. Concentrations of moxiﬂoxacin were
estimated by a microbiological assay. Vital signs were observed
and laboratory tests and ECG were performed every 24 h.
Results: Mean  SD of moxiﬂoxacin in serum 0.5, 1, 2, 3, 4, 6, 12,
18 and 24 h after oral intake were 2.48  3.01, 4.91  0.71,
4.11  0.81, 3.80  1.29, 3.05  1.05, 2.44  0.66, 1.52  0.39,
1.12  0.54 and 0.90  0.28 lg/mL, respectively. Mean  SD of
moxiﬂoxacin in peritoneal ﬂuid 6, 12, 18 and 24 h after oral intake
were 2.30  0.60, 1.09  0.44, 0.93  0.33 and 0.78  0.08 lg/mL,
respectively. No adverse reactions were observed.
Conclusions: Oral intake of moxiﬂoxacin in anuric patients on
CAPD is accompanied by adequate penetration in the peritoneal
cavity for 12 h after intake so as to be a promising agent for the
therapy of spontaneous peritonitis.
P1794 An oral regimen to achieve steady serum levels of
levoﬂoxacin in patients undergoing haemoﬁltration
P. Kouki, T. Tsaganos, M. Raftogiannis, P. Digenis,
H. Giamarellou, E.J. Giamarellos-Bourboulis
Athens, GR
Objectives: To evaluate the pharmacokinetics of levoﬂoxacin in an-
uric patients undergoing chronic haemoﬁltration and to establish
an oral regimen delivering therapeutic trough serum levels.
Methods: In the ﬁrst phase of the study, 10 anuric patients were
given a single oral dose of 500 mg of levoﬂoxacin. Patients under-
went haemoﬁltration after 2 h. In the second phase after 21 days,
the same patients received 500 mg daily for 3 days consecutively.
In that phase, haemoﬁltration was performed on days 1, 3 and 5.
In both phases blood was sampled at regular time intervals. Con-
centrations of levoﬂoxacin were estimated by a microbiological
assay.
Results: In the ﬁrst phase, estimated mean (SE) concentrations
were 0.97  0.45, 2.67  1.09, 3.37  0.95, 4.22  1.14, 7.41  1.72,
4.25  1.65 and 3.10  2.23 mg/L at 0.25, 0.5, 0.75, 1.5, 24 and
48 h after intake, respectively. In that phase, estimated mean
(SE) respective concentrations at the arterial and the venous end
of the ﬁstula were 5.54  1.18 and 3.08  0.26 mg/L (P ¼ 0.014)
on the ﬁrst hour of haemoﬁltration; 4.17  0.87 and
2.50  0.33 mg/L (P: NS) on the second hour of haemoﬁltration;
and 3.90  0.62 and 2.10  0.29 mg/L (P ¼ 0.018) on the fourth
hour of haemoﬁltration. In the second phase, estimated mean
(SE) concentrations on day 1 after haemoﬁltration, on day 2, on
day 3 before haemoﬁltration, on day 3 after haemoﬁltration, on
day 4, on day 5 before haemoﬁltration and on day 5 after haemo-
ﬁltration were 3.18  0.34, 2.55  0.34, 6.54  0.73, 7.30  0.95,
6.84  0.86, 5.77  0.76 and 2.97  0.65 mg/L, respectively.
Conclusions: Levoﬂoxacin is rapidly eliminated during haemoﬁl-
tration. Oral administration at the proposed regimen of 500 mg
daily for 3 days results in adequate therapeutic though serum lev-
els for 5 days allowing its application in case of infections by
Gram-positive cocci.
P1795 Multiple-dose pharmacokinetics of linezolid during
continuous venovenous haemoﬁltration
B. Meyer, G. Kornek, M. Nikfardjam, G. Delle Karth, G. Heinz,
G. Locker,W. Jaeger, F. Thalhammer
Vienna, A
Objectives: Linezolid is a potent antimicrobial agent with a broad
spectrum of activity against Gram-positive pathogens including
methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-
resistant enterococcus (VRE) and penicillin-resistant Streptococcus
pneumoniae. The aim of this study was to determine the pharmaco-
kinetic characteristics of linezolid in critically ill patients undergo-
ing continuous venovenous haemoﬁltration (CVVH).
Methods: A total of 20 patients was included. All patients received
600 mg linezolid intravenously every 12 h. CVVH was performed
using highly permeable polysulphone membranes (PSHF 1200,
Baxter, Germany and AV 400, Fresenius, Germany). Mean blood
ﬂow rate and ultraﬁltration rate were 182  15 mL/min and
40  8 mL/min, respectively. Postdilution was performed. Li-
nezolid concentrations in serum and ultraﬁltrate were determined
by high-performance liquid chromatography (HPLC).
Results: The mean linezolid serum concentration peak (Cmax)
was 15.32  3.98 lg/mL, the mean trough level (Cmin) was
1.87  1.70 lg/mL. The elimination half-life (T1/2) was
4.30  1.74 h. The total clearance (CLtot), haemoﬁltration clear-
ance (CLhf) and volume of distribution (Vd) were 9.31  3.48 L/
h, 31.25  12.77 mL/min and 51.30  12.30 L, respectively.
Conclusions: Our results show that patients with severe Gram-pos-
itive infections undergoing CVVH can be treated effectively with
a dosis of 600 mg linezolid every 12 h.
P1796 The breakpoint index – a new pharmacodynamic
parameter for assessing antibiotic combinations
I.M. Gould, K. Milne, F.M. MacKenzie
Aberdeen, UK
Objectives: The standard method of assessing antibiotic combina-
tions is the measurement of fractional inhibitory concentration
indices (FICIs). The FIC however, gives no indication of the break-
points (BPs) of the antibiotics. With the well established role of
the MIC and BP in determining outcome of antibiotic therapy, we
have developed a new measurement of antibiotic combinations,
the breakpoint index (BPI), which takes into account both the
minimum inhibitory concentrations (MICs) and BPs of antibiotics
in combination.
Methods: FICIs for antibiotic combinations against Gram-negative
isolates from cystic ﬁbrosis patients, as measured by Etest, were
compared against the MICs alone and in combination, expressed
as a ratio to the relevant antibiotic BPs. The BPI ¼ [(BP antibiotic
1/combination MIC of antibiotic 1) + (BP antibiotic 2/combination
MIC of antibiotic 2)].
Results: A total of 120 strains of Pseudomonas aeruginosa (PA) were
tested against 38 different antibiotic combinations, 69 strains of
Burkholderia cepacia (BC) against 60 combinations and 27 strains of
Stenotrophomonas maltophilia (SM) against 37 combinations. The
number of organism/antibiotic combinations tested for PA was
740, for BC was 462 and for SM was 172. The BPI bore no rela-
tionship to the FICI (r2 ¼ 6.9 to 0.4). High BPIs were present in
combination with low FICIs (synergistic combinations) and those
with high FICIs (antagonistic combinations). The mean BPIs
(SD) for the synergistic combinations (FICI  0.5) for PA, BC
and SM were 55.3 (102), 25.5 (55) and 29.1 (41.1), respect-
ively. The mean BPIs (SD) for the additive combinations
(FICI > 0.5 and 1.0) for PA, BC and SM were 8.7 (132), 17.9
(25.1) and 44.5 (43.6) respectively. The mean BPIs (SD) for
the indifferent combinations (FICI 1.0 and 2.0) for PA, BC and
SM were 68.1 (112), 25.1 (38.2) and 67.1 (69.4), respectively.
The mean BPIs for the antagonistic combinations of PA, BC and
SM were 20 (20.6), 15.5 (22.1) and 53.5 (60.2), respectively.
Conclusions: The higher the BPI the greater the difference between
the tissue levels and the MIC ensuring maximum clinical effect. It
is apparent that the FICI can give quite misleading data, underes-
timating the pharmacodynamic beneﬁts of additive and indiffer-
ent antibiotic combinations.
P1797 Inﬂuence of protein binding on the activity of
b-lactam antibiotics on Haemophilus inﬂuenzae
C. Fuhst, A. Barger, B. Wiedemann
Bonn, D
Objectives: Antibiotics are known to bind to plasma proteins,
mainly to albumin. This leads to a change in the PK of the antibi-
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otic and thus to a change in its pharmacology. It is supposed that
protein binding (PB) only has to be taken into consideration if it
exceeds 80% and that only the free fraction of an antibiotic is act-
ive. To examine these hypotheses, we performed kill kinetics of
H. inﬂuenzae with four b-lactam antibiotics with diverse PB (me-
ropenem (M) PB 2%, cefotaxim (CF) PB 40%, cefoxitin (CX) PB
70% and faropenem (F) PB 94%).
Methods: Kill kinetics of H. inﬂuenzae (MIC M: 0.06, CF: 0.06, CX:
4 and F: 0.5 mg/L) were carried out in batch cultures over 6 h
with constant concentrations starting with 0.5 up to 128 times the
MIC. Three types of kill kinetics were performed (i) without
human albumin, (ii) with the addition of 40 g/L albumin and (iii)
a dose resembling the free fraction. Kill kinetics of H. inﬂuenzae
were performed in in vitro models over 24 h (M: 500 mg i.v., CF/
CX: 2 g i.v., F: 300 mg p.o.). Again, albumin was added in differ-
ent ways [s.a.(i) to (iii)]. The AAC values (area above the curve,
as an indicator for the effect) were calculated. E-max and EC50
values were determined with the computer program GraFit.
Results: Results derived from the batch cultures show that for M,
CF and CX (PB <80%) the addition of albumin does not change
the activity of the drugs. This is also seen in similar EC50 values.
For CF and CX the simulation of only the free fraction slightly
reduces the effect of the antibiotic at lower concentrations. For F
the addition of albumin leads to a reduced effect and therefore to
a higher EC50 value. However, this reduction is not as pro-
nounced as in the experiment when only the free concentration is
simulated (table). Above a concentration of 32-fold MIC, when E-
max is obtained, the protein binding does not effect the activity of
F at all.
Data derived from the in vitro models show for M, CF and CX
that the addition of albumin does not cause a reduction of anti-
bacterial activity. When adding albumin to F a marked reduction
of the effect is observed. Moreover, the simulation of the free frac-
tion of CX and F leads to a (further) reduced effect.
Conclusion: PB inﬂuences the activity of an antibiotic only in a
narrow concentration range between no effect and the maximal
effect. For drugs bound below 80%, an inﬂuence could not be
observed. However, the hypothesis that only the free fraction is
active could not be conﬁrmed.
P1798 PK/ PD indices: good predictors for highly protein
bound drugs?
C. Fuhst, A. Barger, B. Wiedemann
Bonn, D
Objectives: Many authors use PK/PD indices to predict the efﬁc-
acy of antibiotics. According to the International Society of Anti-
infective Pharmacology (ISAP) these indices should be referred to
the nonprotein bound fraction of the drug, as only the free frac-
tion is active. This hypothesis was examined, as it is possible that
not just the free fraction is active. Therefore, we performed kill
kinetics with three different strains with faropenem, a highly pro-
tein bound antibiotic (94% protein binding).
Methods: Kill kinetics of S. aureus (MIC 0.125 mg/L), H. inﬂuenzae
(MIC 0.5 mg/L) and S. pneumoniae (0.25 mg/L) were performed
in a pharmacological in vitro model with faropenem (F). Three
dosing schemes were simulated:
(i) 300 mg dose without human serum albumin (Cmax: 11.8 mg/L;
AUC12: 28.125 mg h/L);
(ii) 300 mg dose with 40 g/L albumin(free Cmax: 0.708 mg/L, free
AUC12: 1.7 mg h/L);
(iii) a dosing scheme resembling the free fraction (6% of 300 mg;
Cmax: 0.708 mg/L, AUC12: 1.7 mg h/L). The PK/PD indices
Cmax/MIC, AUC/MIC and T > MIC and the PD parameter AAC
(area above the curve, as an indicator for the effect of F) were cal-
culated.
Results: The table shows the calculated PK/PD indices based on
the free fraction and the AAC values. If just the free fraction
would be active, there should not be any difference between the
AAC values of simulation (ii) and (iii). However, for S. pneumoniae
and S. aureus the effects of (i) and (ii) are similar, whereas the
effect of (iii) is much lower. For H. inﬂuenzae, whose MIC is in the
range of the free Cmax, there is a difference between the effect of
(i) and (ii). Again, the effect of (iii) is lower. These differences
are not reﬂected in the PK/ PD indices, as they are the same for
(ii) and (iii).
Conclusion: Not only the free fraction of F is active, the addition
of albumin leads to a higher effect. Calculating the indices AUC/
MIC, Cmax/MIC and T>MIC based on the free fraction does not
reﬂect the actual conditions.
P1799 A new pharmacokinetic/pharmacodynamic model to
characterise the antibacterial effect of antibiotics against
Escherichia coli
A. Barger, C. Fuhst, B. Wiedemann, W. Alt, J. Kreft
Bonn, D
Objectives: The aim of the study was to develop a PK/PD model
for the prediction of the effect of antibiotics on Escherichia coli.
Therefore the long-term effect of constant ciproﬂoxacin (CIP) con-
centrations against E. coli was examined. Based on these experi-
mental data, the model was developed and applied for the
calculation of the effect of moxiﬂoxacin (MOX), tobramycin (TOB)
and ampicillin (AMP) on E. coli.
Methods: The efﬁcacy of various constant CIP, MOX, TOB and
AMP (0.5- to 32-fold MIC) concentrations against E. coli [MICCIP:
0.03125 mg/L, MICMOX: 0.0625 mg/L, MICTOB: 1 mg/L, MI-
CAMP: 2 mg/L] was studied in batch cultures over 24 h. The
experimental kill curves were used to develop the PK/PD model.
The simulation and ﬁtting of the model was performed with the
computer program MatLab.
Results: The antibacterial activity of CIP against E. coli showed an
increasing effect of CIP up to 16-fold MIC. This or higher concen-
trations could not effect a total killing of the cultures as some bac-
teria persisted despite the presence of CIP. These data were ﬁtted
Table: EC50 and Emax values for faropenem against H. inﬂuenza
in batch culture for the three different types of simulation
Type of simulation EC50 Emax
(i) without albumin 1.06 17.07
(ii) with 4% albumin 9.88 17.56
(iii) free fraction (6%) 20.89 17.74
Table: PD parameters and PK/PD indices for faropenem and
S. aureus, S. pneumoniae and H. inﬂuenzae
Tested
strain:
Simulated
dosing
scheme of
faropenem:
Pharmacodynamic
(PD) parameters
PK/PD indices
MIC
(mg/L)
Effect
(AAC12)
(Delta
cfuh)
AUC12/
MIC (h)
Cmax/
MIC
T>MIC
(h)
S. aureus (i) 300 mg
without
albumin
0,125 12,81 225 94,4 8
(ii) 300 mg with
4% albumin
13,98 13,6 5,7 4
(iii) 6% of 300 mg
(free fraction)
3,65 13,6 5,7 4
S. pneumoniae (i) 300 mg
without
albumin
0,25 26,33 112,5 47,2 7,5
(ii) 300 mg with
4% albumin
20,95 6,8 2,8 2,5
(iii) 6% of 300 mg
(free fraction)
0,83 6,8 2,8 2,5
H. inﬂuenzae (i) 300 mg
without
albumin
0,5 11,29 56,25 23,6 6,5
(ii) 300 mg with
4% albumin
6,11 3,4 1,4 0
(iii) 6% of 300 mg
(free fraction)
13,93 3,4 1,4 0
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to the following PK/PD model: The model assumes that the bac-
terial population (Ntotal) is heterogenous, consting of the subpop-
ulations N1 and N2. N2 are persisting cells that cannot be killed
by the antibiotic. The kill rate of N1 depends on the antibiotic
concentration C and incorporates the Emax model. With time, N1
adapts to the antibiotic according to e-h	t. The growth rates of
both N1 and N2 depend on the antibiotic concentration. The
growth of the bacterial culture cannot exceed Nmax, the maximal
density of bacteria in the culture (¼logistic growth). Fitting the
effect of CIP on E. coli resulted in a set of parameters, which
allowed kill curve ﬁtting of E. coli after the inﬂuence of MOX,
TOB and AMP.
Conclusions: Based on the experimentally determined kill curves
the model allows excellent curve ﬁts of the activity of CIP. Fur-
thermore, the variation of the parameters in the model enables the
prediction of the antibacterial activity of MOX, TOB and AMP on
E. coli. Thus, the new PK/PD model enables the prediction of the
antibacterial effect of constant concentrations of various antibiotics
on E. coli.
dN1
dt
¼ lmax 1 	 ea1 	C 	 1
Ntotal
Nmax
 
 Emax 	 C 	 e
h	t
EC50 þ C 	 eh	t
  
	N1
dN2
dt
¼ lmax2 	 ea2 	C 	 1
Ntotal
Nmax
  
	N2
Ntotal ¼ N1 þN2
P1800 Interaction of bacterial inoculum, strain mic and
drug formulation on the antibacterial effect of co-amoxiclav on
penicillin-resistant S. pneumoniae
K. Bowker, A. Noel, A. MacGowan, C. Rogers
Bristol, UK
Objectives: Previous data has shown using S. pneumoniae (SP)
strains with raised Co-a MICs that bacterial inoculum and strain
MIC may impact signiﬁcantly on the antibacterial effect meas-
ures (ABE). However, none of these data had been analysed col-
lectively. The aim of this study was to perform ANOVA on the
combined dataset to establish which of these factors were signiﬁ-
cant in determining the ABE for SP strains with raised Co-a
MICs
Methods: An in vitro pharmacokinetic model was used to simulate
pharmacokinetically enhanced (PE) [2000 mg amoxicillin (AMOX);
125 mg clavulanate] and standard formulation (SF) (875 mg
AMOX:125 clav) co-amoxiclav (Co-a), against six SP strains with
raised Co-a MICs (3–8 mg/L). The T > MIC for PE Co-a was 39–
60% and SF 20–41%. All simulations were performed in triplicate
using Brain Heart Infusion broth for 24 h. The initial bacterial ino-
culum was either 106 or 108 CFU/mL. ANOVA was used to exploit
the factorial structure of the data to analyse the effect of MIC,
drug formulation and initial bacterial inoculum on the ABE meas-
ure – the area under the bacterial kill curve (AUBKC).
Results: All three factors (inoculum, MIC and formulation) affec-
ted ABE as measured by ln AUBKC24. Signiﬁcant interactions
were noted between formulation and inoculum and formulation
and MIC suggesting, formulation and MIC had different effects
on ln (AUBKC24). For both inocula the ln AUBKC24 increased
with increasing MIC, however the mean ln AUBKC24 increase for
the standard formulation was greater than for PE Co-a. There was
no interaction between inoculum and MIC.
Conclusions: PE Co-a is more likely to have a T > MIC of >40%
against resistant SP than SF especially for strains with Co-a MIC
>4 mg/L. These data conﬁrm that MIC impacts upon on Co-a
ABE and that drug formulations that have the greatest T>MIC are
more effective.
P1801 High frequency of adverse effects to antibiotics in
cystic ﬁbrosis patients and fast protocol of intravenous
desensitization
S. Farina, G. Taccetti, T. Repetto, E. Novembre, R. Bernardini,
S. Campana, F. Festini, N. Ravenni, G. Mergni, M. de Martino
Florence, I
Objective: Cystic ﬁbrosis (CF) is a multisystem disease due to a defective
gene on chromosome 7 which codiﬁes for an altered cystic ﬁbrosis trans-
membrane regulator protein. Median survival is improved thanks to
aggressive treatments which include higher doses of antibiotics infused
for 14–21 days. CF patients experience adverse effects (AE) from antibiot-
ics more frequently than does the general population. We describe AE
patterns in patients attending our CF Centre and the protocol for rapid
intravenous (IV) antibiotic desensitisation employed when no alternative
treatment is available.
Methods: Between January 1 1993 and December 31 2000, 71 of 145
patients (48.9%) were treated with IV antibiotic (cephalosporins, carb-
apenems, glycopeptides, ﬂuoroquinolones in association with amino-
glycosides). The CF patients’ airways were colonised by: Staphylococcus
aureus (n: 99, 68.2%), Pseudomonas aeruginosa (n 60, 41.3%), Alcaligenes
xylosoxidans (n: 8, 5.5%), methicillin-resistant S. aureus (n: 8, 5.5%),
Burkolderia cepacia (n: 6, 4.1%), S. maltophilia, (n: 2, 1.3%). Since some
patients were colonised by more than one bacteria, the absolute num-
ber is higher than 71 and the overall proportion is over 100%. In
patients with AE and no alternative antibiotic treatment, prick and in-
tradermal skin tests with the native drug were carried out. Desensitisa-
tion begins by administering IV a 10-fold lower concentration of
antibiotic than the concentration negative to the intradermal test. The
doses are subsequently infused using a 10-min washout between doses.
Each dose is increased from 2 up to 10 times until the therapeutic dose
is reached and it takes about 4–5 h.
Results: Sixteen of 71 (22.5%) presented AE: 9 (56.2%) to ceftazidime,
two to carbapenems, three to vancomycin, one to aztreonam, one to ci-
proﬂoxacin (Table 1). Eleven patients experienced AE after more than
two courses with the same antibiotic. Desensitisation was carried out
in nine patients in whom no alternative antibiotics therapy was avail-
able and was well tolerated in seven cases (Table 2).
Table 1. Adverse effects occuring in CF patients after intravenous antibiotic administration
Pt adverse
effect
i.v.
antibiotic
occur AE after
antibiotic courses (n)
prick tests intradermal
tests
desensitization
1 urticaria imipenem 2 negative negative no reaction
(25 mg/ml) (1 mg/ml)
2 urticaria ceftadizime 11 negative negative mild hand rash
(50 mg/ml) (1 mg/ml)
3 angioedema meropenem 1 ¼ ¼ ¼
4 urticaria aztreonam 2 ¼ ¼ ¼
5 urticaria ceftazidime 1 negative negative no reaction
(50 mg/ml) (1 mg/ml)
6 angioedema ceftadizime 6 ¼ ¼ ¼
7 urticaria ceftazidime 4 negative negative no reaction
(200 mg/ml) (1 mg/ml)
8 red men vancomycin 1 negative negative mild urticaria
syndrome (100 mg/ml) (0.1 mg/ml)
9 urticaria ceftazidime ¼ ¼ ¼
10 urticaria vancomycin 2 ¼ negative no reaction
(0.1 mg/ml)
11 urticaria vancomycin 2 positive positive no reaction
(50 mg/ml) (0.1 mg/ml)
12 urticaria ceftazidime 6 negative positive no reaction
(250 mg/ml) (1 mg/ml)
urticaria ceftazidime 6 negative negative no reaction
13 angioedema (350 mg/ml) (35 mg/ml)
14 anaphylaxis ceftazidime 3 negative positive ¼
(250 mg/ml) (1 mg/ml)
15 urticaria ceftazidime 2 ¼ ¼ ¼
16 urticaria ciproﬂoxacin 1 ¼ ¼ ¼
Table 2. Ceftazidime desensitization schedule for CF patients
step
antibiotic concentration
(mg/mL)
dose infused (mg) time/vol infuse (min/mL
sodium chloride 0.9%)
cumulative
dose (mg)
1 0.0001 0.005 20/50 0.005
2 0.001 0.05 20/50 0.055
3 0.01 0.5 20/50 0.555
4 0.1 5 20/50 5.555
5 1 50 20/50 55.555
6 5 250 20/50 305.555
7 10 500 20/50 805.555
8 20 1000 20/50 1805.555
9 22.5 2250 40/100 4055.555
*According to intradermal test
513Clinical Microbiology and Infection, Volume 10, Supplement 3, 2004
Conclusion: High dosage, long treatments, frequent infusions, and
possibly altered pharmacokinetics could explain the high fre-
quency of AE to antibiotics in CF patients. When no alternative
treatment strategy is possible, desensitisation is helpful. This regi-
men is fast and allows the large majority of patients to tolerate
essential antibiotic treatment.
P1802 Pharmacokinetics of gentacoll investigated by
in vivo microdialysis
L. Stolle, M. Arpi, P. Holmberg-Jorgensen, J. Keller,
P. Riegels-Nielsen
Aarhus, Esbjerg, DK
Objectives: Antimicrobial agents exert their effect inside the inter-
stitial space, which is the site of many infections. Recently, micro-
dialysis was applied to cortical and cancellous bone for the
evaluation of gentamicin. The principle of microdialysis is to
introduce a semipermeable membrane into bone and perfuse it
with liquid, thus enabling dynamic measurements to be
made. The aim of this investigation was to measure pharmacoki-
netics of a Gentacoll sponge in bone tissue by the technique of
microdialysis.
Methods: Nine pigs were randomised to either wet or dry applica-
tion of a Gentacoll sponge (10  10 cm) into the bone marrow of
tibia. Two catheters were inserted into cancellous bone tissue, one
1 cm (MD1 cm) and one 2 cm (MD2cm) apart from the aimed
location of the sponge. Then, the Gentacoll sponge was implanted.
Wet application was deﬁned as; the sponge was wetted in 2 mL.
blood. Dry application was deﬁned as usual surgical procedure.
Concentrations of gentamicin were measured in serum and micro-
dialysates on an Abbott Drug Analyser. Data presented are med-
ian (range). A rank sum test was performed for statistical
analysis. A P-value below 0.05 was considered signiﬁcant. The
pharmacokinetic measure presented is the area under the curve
(AUC6h) and peak concentration (C peak).
Results: The AUC6h, serum wet was 92 (72–129) and AUC 6 h,
serum dry was 196 (142–626) mg min/L (P ¼ 0.02). The AUC6h,
wet-group was12.631 mg min/L (5.155–152.855) and AUC6h, dry-
group was 19.869 mg min/L (11.336–87.209) (P ¼ 0.45). The
Cpeak, wet-group was 120 mg/L (33–585) and Cpeak, dry-group
178 mg/L(59–1294), (P ¼ 0.31). The overall (n ¼ 9) AUCMD1 cm
was 24431 mg min/L (5.155–152.855) and similar the AUCMD
2 cm 13759 mg min/L (6.351–74.573) (P ¼ 0.25). The Cpeak, MD
1 cm was 209 (33–1294) and Cpeak, MD 2 cm was 106 (41–354)
(P ¼ 0.21).
Conclusions: This is the ﬁrst study applying microdialysis for
pharmacokinetic measurements of local implants. The distribution
of local applied antibiotics into bone tissue is difﬁcult to measure.
The small sample size precludes a detailed analysis, but it is note-
worthy that previous found variation on the distribution of gen-
tamicin from a Gentacoll sponge is reproduced in this work. It
seems that neither application nor distance had signiﬁcant impact
on the initial pharmacokinetic of Gentacoll in bone tissue.
P1803 Pharmacodynamics of levoﬂoxacin (usual and high
dose) and moxiﬂoxacin vs. Streptococcus pneumoniae from the
SENTRY antimicrobial surveillance programme (2002–2003) in
elderly patients using Monte Carlo Analysis and population
pharmacokinetics
R.C. Owens Jr., R. Jones
Portland, North Liberty, USA
Objectives: Streptococcus pneumoniae (SP) is a leading cause of com-
munity-acquired infections worldwide. Decreased susceptibility to
ﬂuoroquinolones (FQ) has increased in parallel with FQ utility
since 1997 and is more common in elderly vs. younger patients
(Chen7 , 1999). Recent studies have correlated microbiologic out-
comes with FQ pharmacokinetic-pharmacodynamic (PK-PD) tar-
get attainments (fAUC:MIC (0–24) 30) against SP (Ambrose8 ,
2001). Monte Carlo (MC) analyses comparing FQ target attainment
rates vs. SP have generally been conducted in the general popula-
tion; however, none have focused on the group at highest risk for
FQ SP resistance, the elderly. To evaluate and compare PK-PD tar-
get attainment rates for intravenous (IV) levoﬂoxacin(L), including
the high dose formulation (L750), and for IV moxiﬂoxacin (M)
against clinical isolates from elderly patients from the SENTRY
Program in North America (2002–2003).
Methods: Mean parameter estimates and measures of dispersion
derived from patient population PK models that included elderly
patients were used to perform a 5000 patient MC simulation to
determine the probability of PK-PD target attainment (based on
free drug) for fAUC: MIC(0–24) ratios 30 for the three regimens.
MIC distributions were obtained from clinical isolates from
patients 65 years of age. AUC(0–24) values from population PK
models for L500, L750, and M were mean (SD): L500, 50.8 (35.8);
L750, 76.2 (53.7); M, 15.1 (5.53) mg/mL  h. MIC data were char-
acterised as follows: (L, MIC50/90: 1.0/1.0, range 0.03 to >4); M,
MIC50/90: 0.125/0.25, range 0.03–4).
Results: The probabilities (mean %) of achieving a fAUC:MIC(0–
24) ratio 30 against SP isolates were as follows: L500, 74.9; L750,
90.6; and M, 98%.
Conclusions: Although previous MC simulations have shown com-
parable results between L750 and M for reaching a fAUC:MIC(0–
24) 30 in the general population, the target attainment for M is
greater than L750 in the elderly population. Because optimising PK-
PD target attainment results in a greater probability of microbiolog-
ic cure, selecting agents with the greatest PK-PD target attainment
may improve not only outcomes but also minimize SP resistance
development in speciﬁc patient populations (Bhavnani9 , 2003).
P1804 Pharmacokinetics and pharmacodynamics of
ciproﬂoxacin in relation to the mutant prevention concentration
for E. coli
S. Olofsson, D. Hughes, O. Cars
Uppsala, S
Objectives: Mutant prevention concentration (MPC) has been
deﬁned as the lowest antibiotic concentration at which resistant
mutants do not arise on antibiotic-containing agar plates in a pop-
ulation of 1010 cells at 24–48 h. However, to become a clinically
useful concept the MPC needs to be related to the pharmacokinet-
ics and pharmacodynamics (PK/PD) of the drug. Our aim was to
study, in an in vitro kinetic model, the relation between MPC
and pharmacokinetic parameters needed to prevent selection of
ciproﬂoxacin resistant mutants.
Methods: One wild-type (wt) E. coli and one gyrA mutant were
used and their MIC and MPC on agar were measured. In the
in vitro model a ﬂask was inoculated with 108 bacterial cells and
incubated for 3–4 h to obtain a total of 1010 cells. During the static
experiments different concentrations of ciproﬂoxacin were main-
tained through a continuous ﬂow of fresh antibiotic-containing
medium. When using kinetics the antibiotic in the ﬂask was dilu-
ted with a half-life of 4 h. In all experiments the number of
remaining living cells, and their MIC values, were determined at
intervals during 24 h. In addition the population was analysed on
ciproﬂoxacin-containing agar plates.
Results: The MIC was 0.008 and 0.094 mg/L for the wt and
mutant, respectively. The MPC of the wt using constant conc. in
the model was 16  MIC and corresponded well to the MPC on
agar. In experiments with lower concentration resistant bacteria
arose. In the kinetic experiments T>MPC varied between 2 and
24 h. Resistance appeared when T > MPC was <8 h (an AUC24/
MIC ratio of <364 h). Population analysis revealed at least three
subpopulations with different levels of resistance. In contrast, for
the gyrA mutant the MPC was much lower (2  MIC or less) and
during the kinetic experiments no selection of further resistance
could be detected.
Conclusions: Selection of resistant mutants from the wt could be
prevented in these single dose experiments when the T > MPC
exceeded 8 h (33% of the dosing interval). For the gyrA mutant,
no further increase in resistance could be noticed. However, it is
possible that a low-level resistant subpopulation (with an increase
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of <4  MIC) was selected. This model was shown to be useful in
deﬁning the mutant preventive pharmacodynamic index, e.g.
T > MPC.
P1805 Pharmacodynamics of levoﬂoxacin-imipenem
combination against mutants of Pseudomonas aeruginosa
resistant to one or both drugs
P. Lister, D. Wolter, P. Wickman, M. Reisbig
Omaha, USA
Objectives: Previous studies demonstrated the ability of levoﬂoxa-
cin-imipenem to prevent the emergence of resistance among clin-
ical isolates of P. aeruginosa in a two-compartment in vitro
pharmacodynamic model (IVPM). This study was designed to fur-
ther analyse levoﬂoxacin-imipenem against strains of P. aeruginosa
already lacking susceptibility to one or both drugs by different
efﬂux- or OprD-associated mechanisms.
Methods: The strains used in this study included four levoﬂoxacin-
nonsusceptible strains overexpressing MexAB-OprM, MexCD-OprJ,
MexEF-OprN or MexXY, one imipenem-resistant strain lacking
OprD, and one dual-resistant strain overexpressing MexXY and
lacking OprD. Log-phase cultures (107–108 CFU/mL) were inocula-
ted into peripheral compartment of the IVPM and treated with
simulated doses of 750 mg levoﬂoxacin, 250 mg imipenem, or levo-
ﬂoxacin-imipenem. Levoﬂoxacin was dosed at 0 and 24 h, and imi-
penem at 0, 12, and 24 h. Doses were adjusted to account for
protein binding, and pharmacodynamics were evaluated over 30 h.
Results: Against the MexAB-OprM, MexCD-OprJ, and MexEF-
OprN overexpressing mutants, levoﬂoxacin-imipenem achieved a
5-log total kill of one strain and eradication of two strains . Fur-
thermore, levoﬂoxacin-imipenem prevented emergence of resist-
ance observed with each drug alone. Levoﬂoxacin-imipenem also
prevented emergence of levoﬂoxacin resistance and achieved
eradication of the strain lacking OprD. Although levoﬂoxacin-imi-
penem initially achieved 6- to 7 log kills of the two MexXY
mutants, it could not prevent the emergence of resistance.
Conclusions: These data further support levoﬂoxacin-imipenem as
an effective combination for treating P. aeruginosa and preventing
emergence of resistance during therapy. These data warrant fur-
ther evaluation of levoﬂoxacin-imipenem against P. aeruginosa.
P1806 Concentrations in plasma and urinary excretion of
ciproﬂoxacin XR (1000 mg) vs. levoﬂoxacin (500 mg) in healthy
volunteers receiving a single oral dose
F.M.E. Wagenlehner, U. Tischmeyer, M. Kinzig-Schippers,
C. Wagenlehner, F. So¨rgel, K.G. Naber
Straubing, Nuremberg-Heroldsberg, D
Objectives: The new extended release formulation of ciproﬂoxacin
(Cipro XR) was designed for once daily administration in the
treatment of urinary tract infection (UTI). The aim of the study
was to compare its plasma and urine concentrations and its phar-
macokinetic parameters with those of levoﬂoxacin (LVX).
Methods: In a randomised crossover study, 12 volunteers (six males,
six females) received a single oral dose of 1000 mg of Cipro XR or
500 mg of LVX to assess the concentrations (by high-pressure liquid
chromatography) in plasma and the urinary excretion at intervals
up to 36 h. The following pharmacokinetic parameters were stud-
ied: Cmax, tmax, t1/2, AUC, Cltot, Clren, Vdß, Vdss, maximal urin-
ary concentration (Umax), and urinary excretion (UE).
Results: Both ﬂuoroquinolones were tolerated well. The mean
pharmacokinetic parameters are shown in the table. The median
cumulative levels of renal excretion of the administered dose of
the parent drug were 43% for ciproﬂoxacin (range, 14–51%;
mean  SD, 41  10%), and 80% for levoﬂoxacin (range, 74–88%;
mean  SD, 80  5%). Cmax, AUC and UE were statistically
signiﬁcantly higher in the LVX phase, whereas the other pharma-
cokinetic indices, except t1/2, were statistically signiﬁcantly
higher in the cipro XR phase.
Conclusions: After oral administration of Cipro XR 1000 mg and
LVX 500 mg Cmax and AUC in plasma were signiﬁcantly higher
in the LVX phase. The renal excretion (in milligram) of cipro XR
1000 mg once daily, however, is equivalent to that of LVX 500 mg
and overall comparable urinary concentrations and areas under
the urinary concentrations are reached by both drugs. Therefore,
it can be assumed that the two doses investigated can be consid-
ered equivalent for the treatment of UTI.
P1807 Failure to detect emergence of resistance to
moxiﬂoxacin at AUC/MIC ratios between 9 and 216 in
Bacteroides fragilis (Bf), Clostridium perfringens (Cp) and
Gram-positive anaerobic cocci (GPAC) in an in vitro
pharmacokinetic (pK) model
K. Bowker, A. Noel, A. MacGowan
Bristol, UK
Objectives: Moxiﬂoxacin (moxi) has in vitro activity against many
anaerobes and human pK such that it may be clinically useful in
anaerobic infection. We performed a dose ranging study to assess
emergence of resistance (EoR) to moxi in Bf, Cp and GPAC strains
with typical MICs – i.e. 0.25, 0.25, 0.12 mg/L, respectively.
Methods: An in vitro, dilutional, open, single compartment model
was adapted to support anaerobic growth. N2 replaced air and
tryptone, yeast extract, dithiothreitol, cysteine HCI broth was used.
Moxi AUC/MICs from 9 to 216 were simulated with values of 72–
144 equating to 400 mg/day doses. EoR was assessed by population
analysis proﬁles before drug exposure and after 48 h (two doses) on
recovery agar containing 0, 0.5, 1, 2, 4 MIC moxi.
Results: The PAPs were (mean of three experiments) – the three
strains selected were nonheterogeneous in their moxi PAPs : no
resistant subpopulations were recovered on MIC 2 plates. The
strains were not cleared from the model but EoR did not occur at
any AUC/MIC ratio.
Indices Cmax tmax t1/2 AUC Cltot
Unit lg/mL h h lh/mL mL/min
CiproXR 3.28 1.96 8.17 19.5 927.1
LVX 6.17 1.16 6.40 47.8 174.4
Indices CIren Vdb Vdss Umax UE
Unit mL/min L L lg/mL %
CiproXR 351.3 856.4 485.9 892.5 41
LVX 142.9 97.0 95.5 498.9 80
*t-test(P<0.05)
MIC
multiple
moxi in
recovery
media
pre exposure
time
log reduction in count after 48hrs at
AUC/MIC log.cfu/ml.h
0 9 18 36 72 216
B. fragilis
0 6.9 5.1 3.2 3.4 2.6 2.7
x0.5 6.8 4.8 <2 3.3 <2 2.6
x1.0 4.1 <2 <2 <2 <2 <2
x2.0 <2 <2 <2 <2 <2 <2
C. perfringens
0 6.5 4.3 2.9 <2 2.8 2.9
x0.5 6.3 3.9 2.9 <2 2.8 ND
x1.0 5.2 2.2 <2 <2 2.8 ND
x2.0 <2 <2 <2 <2 <2 ND
GPAC
0 6.5 4.0 3.3 2.9 2.7 2.8
x0.5 6.4 3.2 3.3 2.9 3.1 2.6
x1.0 5.4 2.2 3.1 2.8 2.9 2.5
x2.0 <2 <2 <2 <2 <2 <2
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Conclusions: Bf, Cp, GPAC do not have heterogeneous PAPs to
moxi; EoR was not detected even at AUC/MIC ratios of 9–18.
P1808 Prevention of resistance development with
levoﬂoxacin in epithelial lining ﬂuid demonstrated by
simulation of the concentration time curves in an in vitro model
B. Wiedemann, M. Kresken, S. Bagel
Bonn, D
Objectives: The epithelial lining ﬂuid is the real site of infection for
pulmunory infections. The concentration of Levoﬂoxacin here is
higher than its concentration in the serum of the same patient.
Therefore these concentrations are responsible for the antibacterial
effect. With Pseudomonas aeruginosa and S. pneumoniae as test organ-
isms we wanted to test the killing activity of Levoﬂoxacin on these
organisms and the development of resistant subpopulations.
Methods: The concentration time curves of Levoﬂoxacin doses of
500 and 750 mg were simulated in an open in vitro model as they
were described by G. Mark et al (2001)10 in human volunteers.
Brain–heart infusion broth was used as nutrient. Colony counts
were done in appropriate time intervals. Concentration of Levoﬂ-
oxacin was determined by a bioassay using K. pneumoniae as test
organism. All experiments were done in triplicate.
Results: Data of the three parallel experiments matched sufﬁ-
ciently, demonstrating the reproducibility of the in vitro model
experiments. Simulating an oral dose of 750 mg Levoﬂoxacin
P. aeruginosa was reduced for ﬁve to six orders of magnitude
within 4 h. Regrowth was seen after 8–12 h. The bacterial count
after 24 h was still three orders of magnitude below the inoculum.
Resistant subpopulations were seen in the order of the mutation
rate of about 107 but were eliminated after 2 h and did not reap-
pear. The 500 mg dose gave similar results. Reduction of the cell
count was ﬁve orders of magnitude after 5 h. After 24 h the cell
count was 1/10 of the inoculum. However, resistant mutants per-
sisted and reached a cell count of ﬁve orders below the inoculum
after 24 h. For S. pneumoniae the reduction of the bacterial count
went continuously down for three orders of magnitude within
24 h. Resistant mutants did not arise. There was no real difference
for both dosing schedules.
Conclusions: Results demonstrate, that Levoﬂoxacin after sufﬁcient
dosing is able to reduce the actual bacterial count in the epithelial
lining ﬂuid for three to six orders of magnitude and to prevent
selection of resistant mutants for Gram-positive and Gram-negat-
ive bacteria. Thus this drug seems useful for the treatment of no-
socomial pneumonia.
P1809 Use of an in vitro pharmacodynamic model and
Monte Carlo simulation to characterise the pharmacokinetics
and pharmacodynamics of gatiﬂoxacin vs. Salmonella typhi
B.M. Booker, P.F. Smith, A. Forrest, J. Bullock, P. Kelchlin,
S.M. Bhavnani, P.G. Ambrose
Buffalo, USA
Background: Salmonella is an important public health concern,
especially in third world countries. Ampicillin, TMP/SMX and
chloramphenicol no longer provide reliable coverage in many
areas and there are reports of resistance emerging to older quino-
lones. To date, no studies evaluating the pharmacokinetics-phar-
macodynamics (PK-PD) of quinolones vs. Salmonella typhi have
been conducted.
Methods: An in vitro PD model (IVPM) simulating human gatiﬂoxa-
cin (GAT) PK was used to determine which PK-PD measure is most
strongly associated with drug response, and the relationship
between exposure and response for S. typhi strains (GAT MIC 0.5–
4 mg/L). Drug response was expressed as a log ratio of the 24 h
area under the bacterial kill curve (AUBKC24) for drug and growth
control (GC). Regimens (QD, BID, CI) that produced wide ranges of
free (f) %T > MIC, peak:MIC and AUC:MIC ratios of GAT were
studied. Using PK-PD targets derived from the IVPM and the cur-
rent NCCLS susceptibility breakpoint for ciproﬂoxacin (CIP) vs. S.
typhi, Monte Carlo simulation (MCS) was performed to assess the
% PK-PD target attainment for recommended doses of selected
quinolones. PK was obtained from normal healthy volunteers.
Results: Using nonlinear regression, a sigmoidal inhibitory E-max
model was ﬁt to log 10 AUCBK24 Drug/AUBKC24 GC for each
PK-PD measure (see ﬁgure). fAUC:MIC correlated best with GAT
efﬁcacy (R2 ¼ 0.96). Peak:MIC also correlated with GAT efﬁcacy
(R2 ¼ 0.93) but %T>MIC did not (R2 ¼ 0.68). Model estimates of
E-max, AUC:MIC50 and Hill’s constant were 3.58, 34.7 and 2.04,
respectively. Assuming that at least 90% of the IVPM Emax
would translate to good activity in vivo, a GAT fAUC:MIC ratio of
105 mg/L  24 h was identiﬁed as the PK-PD target. The per cent
PK-PD target attainment for GAT, levoﬂoxacin (LEV), oﬂoxacin
(OFL) and CIP, based on simulations of 10 000 healthy subjects
receiving standard dosing regimens for a range of S. typhi MICs
(mg/L), is shown in the table below.
Conclusions: A fAUC:MIC ratio of 105 mg/L  24 h was associ-
ated with optimal effect for S. typhi. These ﬁndings are consistent
with quinolone PK-PD target measures reported for other Gram-
negative enterics. MCS results suggest a low per cent PK-PD tar-
get attainment for S. typhi strains with quinolone MICs  0.5 mg/
L. Given the current NCCLS susceptibility breakpoint of 1 mg/L
for CIP vs. S. typhi, these data suggest the need to reassess this
susceptibility breakpoint.
P1810 Bactericidal activities of moxiﬂoxacin in comparison
to other substances used for the oral treatment of pulmonary
infections
S. Schubert, U. Ullmann, A. Dalhoff
Kiel, Germany, Leverkusen, D
Objective: This in vitro study investigated the bactericidal activity
of moxiﬂoxacin (MXF) when compared with amoxicillin (AM),
coamoxiclavulanate (AMC), cefuroxime (CFR), ceﬁxime (CFX) and
clarithromycin (CLA) against Streptococcus pneumoniae (Sp), Morax-
ella catarrhalis (Mc), Haemophilus inﬂuenzae (Hi), and one strain of
Staphylococcus aureus (Sa). Also, the inﬂuence of human serum on
drug activities was determined.
0.03 0.06 0.125 0.25 0.5 1 2 4
LEV, 500 mg PO QD 100 100 99.2 92.1 <0.5 0 0 0
GAT, 400 mg PO QD 100 100 99.5 61.2 <0.43 0 0 0
OFL, 400 mg PO BID 100 100 100 99.54 64.1 <0.4 0 0
CIP, 500 mg PO BID 100 99.7 96.48 5.4 <0.48 0 0 0
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Methods: Killing kinetics were performed under batch culture con-
ditions . Two strains each (ATCC strain and a recent clinical iso-
late) of Sp, Mc, Hi and one clinical isolate of Sa were used. All
strains were serum resistant and cultivated in BHI broth 50%
human serum in ambient air. The ﬁnal inoculum was approxi-
mately 10 exp.6 CFU/mL. Multiples of the MICs were added to
the cultures, drug concentrations ranging from 1 to 32 MIC.
Samples were taken at 0.5, 1, 2, 4, 6, 8, and 24 h and subcultured
quantitatively.
Results: Human serum promoted the growth of the drug-free con-
trols by approximately 1–2 log CFU/mL and reduced the bacteri-
cidal activities of all agents studied . However, when the data
were normalised by subtracting the effect of serum promoted
growth, bactericidal activities of all agents against the gram +
were enhanced in the presence of serum, irrespective of their %
protein binding. Also, MXF exhibited a concentration dependant
bactericidal effect against all pathogens and all ranges of concen-
trations studied; typically, the bactericidal effect of the b-lactams
could not be increased beyond the optimally bactericidal concen-
tration. CLA reduced the CFUs of the gram+ as well, but was
ineffective against Hi as was CFX against Sa.
Conclusions: Despite the differences in protein binding between
CLA (70%), MXF (39%), AM and CFR (30-40%), the addition of
serum affected the bactericidal activities of the agents studied
similarly. The augmented bactericidal activity in the presence of
serum indicates that other yet unknown variables must have an
impact on the bactericidal activities. Consequently, the effect of
protein binding on the bactericidal activity cannot be mathematic-
ally corrected by exposing the bacteria to the calculated free frac-
tion only. Compared with other agents widely used for the oral
treatment of pulmonary infection, MXF exhibits the most pro-
nounced bactericidal effect against all the pathogens and through-
out the whole range of concentrations studied.
P1811 Pharmacodynamic studies of amoxicillin in an
in vitro kinetic model against Streptococcus pneumoniae with
different susceptibilities to amoxicillin: a comparison of
different dosage regimens including a new pharmacokinetically
enhanced formulation
I. Odenholt, O. Cars, E. Lo¨wdin
Malmo¨, Uppsala, S
Objectives: To compare the pharmacodynamic effects of a new
pharmacokinetically enhanced formulation of amoxicillin 2000 mg
(XR), (component of Augmentin XR; amoxicillin/clavulanate
2000/125 mg) twice daily, with amoxicillin 875 mg twice daily,
875 mg three times daily and 500 mg three times daily against
Streptococcus pneumoniae with different susceptibilities to amoxicil-
lin in an in vitro kinetic model.
Methods: The strains of S. pneumoniae with MICs of 1, 2, 4 and
8 mg/L at an initial inoculum of approximately 105 CFU/mL
were exposed to amoxicillin in an in vitro kinetic model with a
concentration time-proﬁle simulating the human serum proﬁle of
XR twice daily. All isolates were also exposed to amoxicillin with
concentration time-proﬁles correlating to the human dosage of
875 mg twice, 875 mg three times daily and 500 mg three times
daily with simulated half-life of 1 h. Repeated samples were taken
regularly during 24 h and viable counts were performed.
Results: With the XR amoxicillin proﬁle, bacterial eradication was
noted for strains with a MIC of 1 and 2 mg/L and with a
T > MIC of 73 and 60%. In the experiments with XR and the
strain with a MIC of 4 mg/L (T > MIC of 47%) some regrowth
occurred at the end of the dosing interval but there was a net
reduction in bacterial counts at 24 h. The least-effective dose for
all strains were 875 mg twice daily with T > MIC of 43, 35, 26
and 10%, respectively for strains with a MIC of 1, 2, 4 and 8 mg/
L. None of the regimens were able to eradicate the strain with a
MIC of 8 mg/L, although an initial substantial kill was noted with
the enhanced XR proﬁle after both doses.
Conclusions: The enhanced XR proﬁle of amoxicillin was more
effective in comparison to the other dosing regimens in eradicat-
ing S. pneumoniae with a MIC < 2 mg/L. For the strains with a
MIC of 4 mg/L, there was a reduction of bacterial counts of
approximately 1 log 10 CFU at 24 h with the XR regimen while
all the other regimens resulted in static effect. Our in vitro system,
like others, does not include the potential synergistic effects
between the antibiotic and the immune defence system and may
thus reﬂect the situation in immunocompromised hosts rather
than in normal patients.
P1812 Strain-independent ratios of the 24-h area under the
curve (AUC) to MIC of moxiﬂoxacin (MXF) associating with the
emergence of Streptococcus pneumoniae resistance: related
changes in susceptibility and resistance frequency in an in vitro
dynamic model
S. Zinner, D. Gilbert, K. Simmons, I. Lubenko, A. Firsov
Cambridge, Providence, USA; Moscow, RUS
Objective: According to the mutant selection window (MSW)
hypothesis, resistant mutants are selected or enriched at antibi-
otic concentrations above the MIC but below the mutant pre-
vention concentration (MPC). This hypothesis has been
successfully tested in an in vitro dynamic model with MXF-
exposed S. pneumoniae ATCC 49619 over a wide range of the
AUC/MIC. The emergence of resistance was dependent on the
simulated AUC/MIC ratio with most pronounced losses in the
susceptibility and the highest resistance frequencies at AUC/
MICs of 40–60 h. To explore if the AUC/MIC relationships of
resistance are bacterial strain-independent, the development of
resistance in a less susceptible strain of S. pneumoniae was tes-
ted using the same model.
Methods: Daily administration of MXF for 3 days consecutively
was mimicked using a two-compartment dynamic model with
peripheral units containing a starting inoculum of 108 CFU/mL
of S. pneumoniae M231 (MIC 0.35 mg/L; MPC 6 mg/L). A series
of monoexponential proﬁles of MXF was simulated to provide
peak concentrations between the MIC and MPC (AUC/MIC 40–
60 h). Changes in the susceptibility of S. pneumoniae to MXF were
examined by repeated MIC determinations at 24, 48, 72 h and at
the end of treatment. To determine the resistance frequency (f),
the surviving organisms were counted by plating the specimens
on agar containing 0, 2, 4, 8  IC of MXF.
Results: MXF concentrations determined by bioassay were close to
the target values. The respective AUC/MICs varied from 40 to
58 h. Loss in the susceptibility of S. pneumoniae M231 to MXF was
reﬂected by a six to 10-fold increase in MIC determined at the
end of treatment and by an increased resistance frequency (f)
(with specimens plated on agar containing 4  MIC of MXF). The
respective ratios of the elevated MIC to the initial value and the
ratios of the ﬁnal to initial f were concordant with those reported
for S. pneumoniae ATCC 49619.
Conclusions: The present study demonstrates that S. pneumoniae
resistance expressed by susceptibility testing and by population
analysis relates to MXF AUC/MIC in a strain-independent fash-
ion.
P1813 Pharmacodynamic activity of ﬂuoroquinolones on
different genotypes of Escherichia coli
A. Carricajo, A. Texier, N. Fonsale, A.C. Vautrin, G. Aubert
Saint-Etienne, F
Objectives: The aim of the study was to assess the pharmacody-
namic proﬁle of ciproﬂoxacin (CIP) with regard to 11 strains of
E. coli and on their ﬁrst-step mutants.
Methods: We evaluated nine clinical strains of E. coli resistant to
nalidixic acid but susceptible to CIP (antibiogram) and two ref-
erence strains of E. coli susceptible to nalidixic acid (NA). The
MICs of nalidixic acid, oﬂoxacin, levoﬂoxacin and CIP were
evaluated using the Etest method. Mutant prevention concentra-
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tions (MPC) were determined by applying 1011 CFU/mL of
each organism to serially diluted antibiotic-concentration agar
plates. All plates were incubated at 37C for 2 days. The MPC
of a drug is the lowest concentration capable of inhibiting
growth of an organism. All procedures were performed in trip-
licate to ensure reproducibility. For the genotype, we sequenced
the quinolone resistance-determining region on gyrA and parC
from clinical strains and mutants. Bactericidal activity was
determined by preparing time-killing curves for CIP with
regard to three strains and the ﬁrst-step resistant mutant for
each strain.
Results: We noted three genotypes for these strains: two strains
with no mutation (MIC < 0.025 mg/L of CIP and MIC < 4 mg/L
of NA), six strains with a gyrA mutation at codon 83 or 87
(MIC ¼ 0.06–0.5 mg/L of CIP and MIC > 12 mg/L of NA) and
three strains with a gyrA mutation (codon 83) and a parC muta-
tion at codon 80 (MIC ¼ 1.5 mg/L of CIP and MIC > 12 mg/L
of NA). MPCs ranged from 0.12 to 0.5 for the ﬁrst genotype, 0.5
to 6 for the second genotype and 4–8 mg/L for the third geno-
type. For the wild strain with no mutation, concentration-depen-
dent bactericidal activity of CIP was observed. For both clinical
strains with gyrA mutation and ﬁrst-step resistant mutants, we
noted slow bactericidal activity of CIP (between 6 and 24 h).
The minimum bactericidal activity of CIP ranged from
2–8 MICs.
Conclusions: CIP is less concentration-dependent against strains
having a gyrA mutation.
P1814 Bone and serum concentrations of moxiﬂoxacin in
patients undergoing knee arthroplasty
L. Malincarne, M. Ghebregzabher, M.V. Moretti, G. Tavolieri,
D. Francisci, G. Stagni, G. Cerulli, F. Baldelli
Perugia, I
Objectives: Prosthetic joint infections represent an infrequent but
feared complication of total joint arthroplasty, leading to a sub-
stantial postoperative morbidity, prosthesis failure and, in some
cases, to death. Moxiﬂoxacin is a new ﬂuoroquinolone with a
broad antibacterial spectrum and improved activity against
gram positive microorganism and anaerobes; it shows an
enhanced potency against methicillin-susceptible and -resistant
isolates of S. aureus and S. epidermidis, if compared with the
older ﬂuoroquinolones. Penetration of moxiﬂoxacin in bone has
not still assessed. The main purpose of this study was to deter-
mine moxiﬂoxacin levels in serum and bone following oral
administration of single and multiple oral doses of 400 mg of
the drug, to evaluate its potential use in perioperative orthopae-
dic prophylaxis.
Methods: Thirty consecutive patients, undergoing routine total
knee arthroplasty were enrolled in this study. Three groups of 10
patients each were formed. Group A received moxiﬂoxacin os
400 mg 2 h 30’ preoperatively. Group B received moxiﬂoxacin
os 400 mg 4 h 30’ preoperatively. Group C received moxiﬂoxa-
cin os 400 mg 14 h preoperatively, followed by a second dose
2 h 30’ preoperatively. During surgery, at the time of bone
removal, a blood sample and aliquots of cortical-cancellous bone
were collected and moxiﬂoxacin concentrations were measured by
high performance liquid chromatography.
Results: The mean plasma, cancellous and cortical bone concentra-
tions were respectively:
Group A: 3.45, 1.89 and 1.43 lg/mL.
Group B: 3.73, 1.81 and 1.56 lg/mL.
Group C: 6.26, 2.97 and 2.54 lg/mL.
Conclusions: These data show good penetration of moxiﬂoxacin in
both cancellous and cortical bone with higher serum and bone
concentrations obtained after two doses of the drug (group C).
Therefore, moxiﬂoxacin may be considered in perioperative ortho-
paedic prophylaxis and repeated administrations should be pre-
ferred to achieve maximum antibacterial activity at the site of
surgery.
P1815 Evaluation of the antibacterial activity of
moxiﬂoxacin vs. gatiﬂoxacin vs. levoﬂoxacin in serum and target
tissues using in vitro and in silico PK/PD modelling
H. Stass, S. Schubert, L. Kieselbach, A. Dalhoff
Wuppertal, Kiel, D
Objective: Evaluation of the inﬂuence of PK-properties of moxiﬂ-
oxacin (MXF), gatiﬂoxacin (GTF) and levoﬂoxacin (LVF) in the
various target tissues on the bactericidal activity (BA) of the drugs
against causative pathogens encountered in RTIs using a PK/PD
mapping technique. This new method provides a better view on
their therapeutic use in the clinical situation than AUC/MIC or
Cmax/MIC surrogates.
Methods: Time-kill studies were performed by exposing seven
strains (3 S. pneumo, 1 K. pneumo, 3 S. aureus) with varying
susceptibilities to ﬂuctuating drug concentrations mimicking sin-
gle oral doses of MXF (400 mg), GTF (400 mg) and LVF (500 mg)
in serum and human target tissues (i.e. ELF, bronchial mucosa,
macrophages). PK/PD surrogates such as AUBKCnorm (area
under the curve normalised to the inoculum, and the bacterial
elimination rate of from the test system, h) kel (h1) were used to
map the in vitro BA as a function of the MIC of the pathogens
and the concentrations represented by the PK in the target tissues.
PK and PK/PD parameters were estimated using noncompart-
mental methods. Low AUBKCnorm <<24 h indicates high efﬁ-
cacy, while a value of 24 h indicates ‘stasis’.
Results: AUBKC24 h,norm for MXF were consistently below
10–3 h indicating a good antimicrobial activity independent from
the MIC and target tissue concentration. Similar results were
obtained for GTF with the only exception that AUBKC tended to
increase (AUBKCnorm ¼ 1 h) when MIC was high (1 mg/L) and
drug levels were low (i.e. in serum). For LVF AUBKCnorm con-
sistently increased with increasing MIC of the pathogens and was
>100-fold higher for less-susceptible bacteria when compared with
GTX and MFX. This indicates an inferior BA which can not easily
be overcome by increasing the dose. kel was in the range of 0.2–
1.5 h1 for GTF and 0.1–2.2 h1 for MXF and independent from
the tissue or the MIC, while kel tended to be higher for LVF (rate
0.5 – 6.9 h1).
Conclusions: PK/PD mapping showed good activity of the three
FQs against RTI pathogens with the broadest therapeutic window
for MXF > GTF > LVF, the latter being characterised by a shallow
relationship between PK and PD indicating its inferior BA against
pathogens with high MICs.
P1816 Population PK/PD analysis for moxiﬂoxacin 400 mg
once-daily to treat Streptococcus pneumoniae infections
H. Stass
Wuppertal, D
Objectives: For ﬂuoroquinolones AUC/MIC ratios are known to
correlate with clinical outcomes for patients suffering from respir-
atory tract infections (RTI). This paper describes the results of a
population-PK/PD analysis followed by Monte Carlo simulations
to estimate clinical outcome for a 400 mg once daily moxiﬂoxacin
(MFX)-treatment schedule.
Methods: Based on PK data from 416 subjects a noncompartmental
population-PK model was developed ﬁrst to describe the expected
exposure (AUC) distribution in humans. Height and gender were
the main population covariates with moderate inﬂuence on PK
variability. Albumin, bilirubin and creatinine clearance (as derived
from serum creatinine according to Cockroft and Gould) had a
mild effect on AUC. Residual unexplained variability of AUC was
low (13.1%). To describe the PD function the MIC distribution
pattern of more than 3000 isolates of S. pneumoniae as a represen-
tative pathogen for RTI (MIC90, range: 0.125; 0.006–4 mg/L) was
built into the population-PK/PD model. Simulations for 20000
subjects were performed to evaluate the AUC/MIC characteristics
for MXF. Target hit rates were calculated using the AUC/MIC
cut-off points for ﬂuoroquinolones published in the literature.
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Results: Overall, a target hit rate was approximately 99% when
applying an AUC/MIC threshold of >30 predictive for commu-
nity acquired pneumonia. A target hit rate of 93.6% was predic-
ted when assuming that an AUC/MIC of >125 is indicative of
clinical success (as shown for ciproﬂoxacin and severe RTIs due
to Gram-negative infections). In clinical trials success rate was
approximately 93.5%. Broken down according to MICs the data
suggest that a the overall likelihood of getting an AUC/MIC <30
at an MIC ¼ 1 mg/L is approximately 0.25% (for MIC ¼ 2 mg/L:
predicted likelihood approximately 0.5%) in case of S. pneumoniae
infections. This ﬁnding is in line with the breakpoint deﬁnition of
NCCLS for MXF.
Conclusion: The results of the investigation indicate that the non-
compartmental PK/PD model for MXF is suitable to predict clin-
ical outcomes in CAP.
P1817 Pharmacodynamics of moxiﬂoxacin in combination
with ceftazidime of P. aeruginosa
A. Dalhoff, I. Schneider, A. Bauernfeind
Wuppertal, Munich, D
Objective: Killing of ceftazidime susceptible P. aeruginosa (MIC
CAZ 1 or 4 mg/l) was 2–3 log for MIC CAZ 1 mg/L and <1 log
for MIC CAZ 4 mg/L when simulating serum pharmacokinetics
of ceftazidime. We asked the question whether the ceftazidime-
mediated killing can be affected in combination with a nonantip-
seudomonal agent (moxiﬂoxacin).
Methods: Strains enrolled were P. aeruginosa ATCC 27853 and a
nonmucoid P. aeruginosa isolate C7-2-2 from a cystic ﬁbrosis
patient. A pharmacodynamic in vitro model described previously
[Bauernfeind, (1993) JAC 31, 789–798] was used. The serum phar-
macokinetic proﬁles of moxiﬂoxacin 400 mg o.d. and ceftazidime
1 g o.d. were reproduced in bacterial cultures (Mueller–Hinton
broth). The dynamics of killing were followed by colony counts at
time intervals.
Results: For P. aeruginosa ATCC 27853 (MIC CAZ 1, MIC MOX
4 mg/l) exposure to the combination moxiﬂoxacin plus ceftazi-
dime strongly enhances killing in comparison with exposure to
moxiﬂoxacin alone by >1 log (3.5 to >4.5, sterilization) and to ceft-
azidime alone by >2.1 log (2.4 to >4.5, sterilization). Conversely
dual combinations of moxiﬂoxacin plus ceftazidime did not
enhance the killing of P. aeruginosa C 7-2-2 (MIC CAZ 4, MIC
MOX 16 mg/L) in comparison with single antibiotics signiﬁcantly
(0 log vs. moxiﬂoxacin; 0.2 log vs. ceftazidime).
Conclusions: Enhanced killing of dual combinations of moxiﬂoxa-
cin plus ceftazidime was restricted to P. aeruginosa resistant to
moxiﬂoxacin and susceptible to ceftazidime while indifferent
effects were seen against strains resistant to moxiﬂoxacin and
moderately susceptible to ceftazidime.
P1818 Comparative levoﬂoxacin and ciproﬂoxacin mutant
prevention concentrations in Pseudomonas aeruginosa
populations from cystic ﬁbrosis and ICU patients
M. Garcı´a Castillo, M.I. Morosini, M.R. Baquero, A. Oliver,
F. Baquero, R. Canto´n
Madrid, Palma de Mallorca, E
Background: Levoﬂoxacin (LEVO) has been advocated to be at
least as active as ciproﬂoxacin (CIP) against P. aeruginosa accord-
ing to pharmacokinetic/pharmacodynamic parameters. The aims
of this study were assess mutant prevention concentrations
(MPCs) of both quinolones in two different P. aeruginosa popula-
tions and compare them with pharmacokinetic parameters in the
respiratory compartment.
Methods: We studied 14 P. aeruginosa isolates recovered from res-
piratory secretions from patients with ventilator associated pneu-
monia admitted to an ICU in our hospital and 42 from cystic
ﬁbrosis (CF) patients. MPCs, deﬁned as the lowest drug concen-
tration precluding any bacterial growth at 48 h, were determined
by applying 109–1010 CFU/mL of each organism to serially dilu-
ted CIP and LEVO containing plates. MICs were determined by
the Etest.
Results: P. aeruginosa from ICU patients were both susceptible to
LEVO (MIC range 0.12–0.5 lg/mL) and CIP (MIC range 0.03–
0.12 lg/mL) whereas 69 and 76% isolates from CF patients were
susceptible to LEVO (MIC  2 lg/mL) and CIP (MIC  1 lg/
mL, respectively. In P. aeruginosa from ICU patients, LEVO-
MPCs (range 0.5–8 lg/mL; geometric mean 5.1 lg/mL) were
higher when compared with CIP-MPCs (range 0.25–8 lg/mL;
geometric mean 2.0 lg/mL). MPCs were higher in CF popula-
tions but maintaining similar differences among both antibiotics:
CIP-MPCs (range 2–64 lg/mL; geometric mean 12.9 lg/mL) and
LEVO-MPCs (range 8–128 lg/mL; geometric mean 24.6 lg/
mL).All isolates from ICU patients displayed MPCs below epi-
thelial lining ﬂuid (ELF) steady-state concentrations obtained at
4 h after once-daily dosing of LEVO-500 mg (Gotfried et al. Chest
(2001), 119, 1114–1122) whereas only 21.5% were below MPC
values of CIP concentrations with similar dosing. The corres-
ponding values with CF isolates were 9.5 and 0%, respectively.
Interestingly, the percentage of MPC values below ELF concen-
trations increased to 47.6% with once-daily dosing of LEVO-
750 mg.
Conclusions: Although higher MPC values for LEVO than CIP
were observed in both P. aeruginosa isolates from ICU and CF
patients, the risk for selection of ﬂuoroquinolone resistant
mutants may be higher with CIP monotherapy than with LEVO
monotherapy in the respiratory tract compartment. Moreover,
the risk for selection of ﬂuoroquinolone resistant P. aeruginosa
mutants may be lower with high scheduled regimens using
LEVO-750 mg.
P1819 Comparative pharmacodynamics of telithromycin
and clarithromycin against differentially susceptible
Streptococcus pneumoniae in an in vitro dynamic model
I. Alferova, I. Lubenko, S. Zinner, A. Firsov
Moscow, RUS; Cambridge, USA
Objective: To compare the anti-pneumococcal effects of telithromy-
cin (TEL) and clarithromycin (CLA), their pharmacodynamics
with differentially susceptible S. pneumoniae were studied in an
in vitro dynamic model that simulates their human pharmacoki-
netics.
Methods: Pharmacokinetic data reported in human studies with
TEL and CLA were ﬁtted by the two-compartment model with
ﬁrst-order absorption (ka, alpha and beta are 0.3; 1.9; 0.06 h1,
respectively, for TEL and 0.5; 0.8 and 0.14 h1, respectively, for
CLA). Based on this analysis, time courses of TEL and CLA con-
centrations were simulated. S. pneumoniae ATCC 49619 (MICTLR
0.001 and MICCLR 0.08 mg/L) and S. pneumoniae 1516 (MICTLR
0.01 and MICCLR 0.04 mg/L) were exposed to a single dose of
TEL (800 or 1600 mg) vs. two 12-h doses of CLA (2  500 or
2  1000 mg). To quantitatively compare the antimicrobial effects,
a 24-h area between the control curve and the time-kill curve
(ABBC) was calculated.
Results: There was a distinct dose-dependent anti-pneumococcal
effect with both TEL and CLA. In terms of the minimal number
of surviving organisms, the effect of 800 mg TEL on S. pneumoniae
ATCC 49619 was more pronounced than 2  500 mg CLA, but
these differences were not seen with S. pneumoniae 1516. Similar
results were obtained at higher doses: again, the advantages of
TEL were seen with S. pneumoniae ATCC 49619 but not S. pneumo-
niae 1516. These ﬁndings were conﬁrmed by the ABBC analysis.
For the ATCC strain, a larger area under the curve (AUC) to MIC
ratio of CLA may be needed to produce an ABBC similar to that
of the smaller AUC/MIC of TEL.
Conclusions: These data pharmacodynamically support once-daily
administration of 800 mg TEL in the treatment of infections due
to S. pneumoniae.
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P1820 Bactericidal activity and postantibiotic effects of
clarithromycin against Streptococcus pneumoniae with the efﬂux
mechanism of macrolide resistance
T. Horvat, F. Warkentine, Y. Li
Kansas City, USA
Objective: This study assessed clinical isolates of Streptococcus
pneumoniae (SPN) with the macrolide efﬂux mechanism to deter-
mine if the time kill (TK) kinetics and the postantibiotic effects
(PAE) of clarithromycin-14-OH clarithromycin (CH-14OH, 3:1)
and clarithromycin (CH) alone were comparable with macrolide
susceptible isolates.
Methods: Four SPN isolates with the macrolide efﬂux pump were
identiﬁed using PCR to detect the presence of the mefE gene. Four
SPN isolates without the mefE gene were also identiﬁed. The mini-
mum inhibitory concentration (MIC) for each antimicrobial agent
was determined using broth dilution. TK studies were performed
by exposing SPN in broth to 4 the antimicrobial concentrations
of the MIC and assessing viable bacterial colony counts after 0, 2,
4, 6, 12, and 24 h of incubation. PAE studies were perfomed by
exposing SPN isolates in broth to 4 the MIC for 2 h and remov-
ing the antimicrobial agent with washing. After suspended the
bacteria in fresh, drug free media aliquots were withdrawn at
hourly intervals for viable bacterial colonies. The PAE was calcu-
lated as T–C (where T is the time for viability counts of an experi-
mental culture to increase by 1 log 10 above bacterial counts
taken immediately after drug removal and C is the corresponding
time for the growth control).
Results: The MICs for CH in susceptible SPN ranged from 0.06 to
0.25 mg/mL and MICs in SPN with the mefE gene were 2–16 mg/
mL. TK assays of each drug showed similar kinetics between iso-
lates with and without the mefE gene. The mean PAEs of CH-
14OH, and CH with macrolide susceptible SPN were 6.1 and
7.4 h, respectively. The mean PAEs of CH-14OH, and CH with
mefE positive SPN were 9.4 and 8.9 h, respectively.
Conclusions: In vitro SPN isolates with the macrolide efﬂux pump
have MICs that are higher than the SPN isolates without the
pump. However, when measuring the kinetics of antimicrobial
activity the TK and PAE of SPN with the mefE gene are similar to
SPN isolates fully susceptible to macrolides.
Molecular bacteriology: streptococcus, meningococcus and haemophilus
P1821 Cpn60 gene based PCR identiﬁcation of
streptococcal species
A. Dmitriev, L. Tkacikova, I. Mikula
Saint-Petersburg, RUS; Kosice, SK
Objectives: Streptococcus agalactiae, S. dysgalactiae and S. uberis are
the major streptococcal causative agents of bovine mastitis. The
rapid simultaneous identiﬁcation of these species is necessary for
monitoring mastitis caused by streptococci. The 60 kDa chapero-
nin cpn60 genes were recently discovered in all S. agalactiae, S.
dysgalactiae, S. uberis strains and sequenced. The goal of the pre-
sent study was to develop the cpn60 gene based PCR approach
for simultaneous identiﬁcation of streptococcal species.
Methods: A total of 52 strains of S. agalactiae, S. dysgalactiae and
S. uberis isolated from the dairy cows were tested. Human S. aga-
lactiae strains were also analysed. Bacteria were grown in Todd-
Hewitt broth. Sequences of cpn60 genes were originally accessed
through the GenBank database. DNA samples for PCR were pre-
pared by boiling of one to two bacterial colonies for 5 min. PCR
products were sequenced using ABI Prism 377 Perkin-Elmer Se-
quencer.
Results: Comparative analysis of nucleotide sequences of S. agalac-
tiae, S. dysgalactiae and S. uberis cpn60 genes revealed the certain
differences between species. Based on these differences, three
pairs of primers were designed and each pair was suggested to
be the species-speciﬁc. After PCR analysis, ampliﬁcation frag-
ments of the expected sizes of 310, 192 and 400 bp were obtained
for S. agalactiae, S. dysgalactiae and S. uberis strains, respectively.
Both human and bovine S. agalactiae revealed PCR products of the
same size. Nucleotide sequences of S. agalactiae, S. dysgalactiae and
S. uberis ampliﬁcation fragments were determined and an expec-
ted species-speciﬁcity of the primers was demonstrated. All the
primers were used in multiplex-PCR for simultaneous identiﬁca-
tion of streptococcal species. Multiplex-PCR revealed the complete
correlation with results of conventional PCR and neither false-pos-
itive no false-negative results were received.
Conclusions: These data demonstrate that cpn60 gene based multi-
plex-PCR assay can be effectively used for simultaneous identiﬁ-
cation of S. agalactiae, S. dysgalactiae and S. uberis strains. This
novel approach can be employed for analysis of the milk products
and monitoring mastitis. This work was supported by Slovak
Grant Agency VEGA 1-8021-01, Russian Grants MK-2782.2003.04,
NSh-2206.2003.4 and RFBR 03-04-49760.
P1822 Molecular epidemiology of nasopharyngeal
penicillin-non-susceptible Streptococcus pneumoniae isolated
from children in day-care centres and orphanages in Russia
(SPARS study)
I.S. Palagin, R.S. Kozlov, A.D. Narezkina, M.V. Edelstein,
L.S. Stratchounski
Smolensk, RUS
Objectives: Streptococcus pneumoniae (SP) is one of the leading bac-
terial pathogens causing a variety of community-acquired infec-
tions among children. Pneumococcal resistance represents a
problem of high concern in many countries, including Russia. This
study describes molecular typing of penicillin-nonsusceptible SP
(MIC > 0.06 mg/L) isolated from children from day-care centres
from Asian and Russian day-care centers (DCCs) and orphanages.
Methods: Fifty two penicillin-nonsusceptible SP isolates (MIC
range 0.12–8 mg/L) from 14 Russian DCCs and orphanages situ-
ated in eight cities (Moscow, Kazan, St Petersburg, Voronezh, Ufa,
Smolensk, Yakutsk, Khabarovsk) located in the areas of Western,
Southern, Central Russia, Siberia and Far East during 2001–2002
underwent molecular typing by BOX-PCR with primer BOX-A
(ATACTCTTCGAAAATCTCTTCAAAC) and RAPD-PCR with
primer M13 (GAGGGTGGCGGTTCT). Cluster analysis of genetic
ﬁngerprints was performed by UPGMA algorithm with Pearson
coefﬁcient using the GelCompar software (AppliedMaths).
Results: The combined analysis of BOX- and RAPD-PCR patterns
revealed 21 unique genetic types of which eight major groups
comprised from three to six isolates each, and the other 13 inclu-
ded single isolates. Strains from the same orphanage in Moscow,
Ufa and Khabarovsk belonged to one major clone suggesting their
rapid transmission in closed communities. Two cases of clonal
relatedness between the isolates from geographically distinct cen-
ters (Kazan and Moscow, Saint Petersburg and Voronezh) were
also found. However, the multiplicity of genetic types indicated
that resistance to penicillin was acquired by numerous strains.
Conclusions: Combination of BOX- and RAPD-PCR had a sufﬁ-
cient discriminatory power to allow distinguishing between peni-
cillin-nonsusceptible clones. Penicillin-resistant SP isolated from
Russian DCCs and orphanages mostly represent genetically
diverse population of strains. Clonal transmission of penicillin-
resistant clones was conﬁrmed both within cities and also
between geographical distinct areas.
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P1823 Heterogeneity of PavA ﬁbronectin-binding protein
in Streptococcus pneumoniae
N. Virgincar, J. Leeming, H. Jenkinson, R. Heyderman
Bristol, UK
Objectives: Streptococcus pneumoniae is an important human patho-
gen, causing life-threatening invasive diseases, such as pneu-
monia, meningitis and bacteraemia, and less serious but highly
prevalent infections, such as otitis media and sinusitis. Fibronectin
binding is an important factor in streptococcal colonisation of host
tissue but the bacterial adhesins mediating these reactions are lar-
gely uncharacterised. Holmes et al. (Mol. Microbiol. (2001) 41,
1395–1408.) have described a novel protein PavA in invasive iso-
lates of pneumococci which binds ﬁbronectin and is associated
with pneumococcal adhesion and virulence. This is a potential
candidate for novel pan-pneumococcal vaccines. The objectives of
this study were to determine the prevalence and degree of
sequence conservation of PavA among invasive and noninvasive
isolates of S. pneumoniae.
Methods: Polymerase chain reaction (PCR) was used to determine
the presence of pavA in 34 isolates from invasive disease and 32
isolates from throat swabs. PCR amplicons were then differenti-
ated by digestion with frequent cutting endonucleases Hinf1 and
Alu1 (PCR-RFLP). The nucleotide sequence of amplicons from
four invasive and four noninvasive isolates.
Results: The presence of pavA gene was conﬁrmed in both the
invasive and noninvasive isolates. PCR-RFLP showed variation in
pavA gene. Hinf-1 and Alu-1 digestion divided noninvasive iso-
lates into ﬁve different groups and invasive isolates into 12 differ-
ent groups. Sequence analysis showed that both the N- and
C-terminal coding regions of PavA are conserved, but there were
nucleotide polymorphisms at 21 locations predicted to result in 11
amino acid substitutions in the middle portion of the pavA gene.
Conclusions: Our study shows that pavA gene sequence is not
completely conserved. The heterogeneity observed, although not
substantial, could have functional or pathogenic implications.
Since variation could potentially reduce cross-protection between
different pneumococci, further work is needed to understand the
implications of this variation on the potential of PavA as a vaccine
component.
P1824 Evaluation of a LightCycler PCR assay for detection
of group B streptococcus in pregnant women with rupture of
membranes at term
R.P. Spence, K. Levi, K.J. Towner
Nottingham, UK
Objectives: To evaluate the effectiveness of a LightCycler PCR
assay for the detection of Group B streptococcus (GBS) infection
or colonisation in pregnant women with rupture of membranes
(ROM) at term, and to compare it with conventional culture tech-
niques.
Methods: A total of 100 high vaginal swabs (HVS) from women
with ROM at 35 weeks gestation were incubated in nutrient broth.
The ﬁrst 50 HVS swabs were incubated for 5, 30, and 60 min. The
remaining 50 HVS swabs were incubated for 1 and 18 h. Follow-
ing incubation, DNA was extracted using the InstaGene matrix
DNA kit (Bio-Rad) and real-time PCR was performed using a
LightCycler instrument (Roche Diagnostics). Oligonucleotide
primers and ﬂuorescence-labelled hybridisation probes were used
for the speciﬁc ampliﬁcation and detection of a 153-bp fragment
of the cfb gene. The HVS were also examined by conventional cul-
ture by plating out onto ISLAM agar and incubating overnight at
37C aerobically with 5% CO2. The sensitivity of the assay was
examined by analysing dilutions of overnight broths of GBS,
while speciﬁcity was studied by testing different species of Strep-
tococcus with the assay.
Results: The LightCycler PCR assay was able to detect 103 GBS
CFU/mL. All non-GBS isolates examined were negative when
tested, thereby demonstrating the speciﬁcity of the assay. Of
the ﬁrst 50 HVS examined, four (8%) were positive at each
time point (5, 30 and 60 min) by both the LightCycler assay
and conventional culture. Of the second 50 HVS, eight (16%)
were positive by LightCycler and six (12%) were positive by
culture after 1 h incubation. Following 18 h incubation, 13
(26%) samples were positive by LightCycler, but only six (12%)
were culture-positive. Three of these samples were only Light-
Cycler-positive after overnight incubation. Four samples were
negative by culture, but LightCycler-positive after 1 and 18 h
incubation. Two culture-positive samples were LightCycler-posit-
ive only after 18 h incubation, indicating that these samples
contained low numbers of GBS.
Conclusions: The LightCycler PCR assay is a speciﬁc, sensitive and
rapid means of detecting GBS from HVS. The LightCycler assay
was more sensitive than conventional culture, but overnight incu-
bation increases the detection rate of GBS. However, whether this
is clinically signiﬁcant (i.e. is the woman infected or colonised)
requires further investigation.
P1825 A PCR-RFLP assay for detection of parC, and gyrA
mutations in ﬂuoroquinolone-resistant Streptococcus pyogenes
R. Alonso, M. Galimand, R. Cisterna, P. Courvalin
Vitoria-Gasteiz, E; Paris, F; Bilbao, E
Objetives: Quinolone resistance in S. pyogenes is mainly due to
mutations in the quinolone resistance-determining regions
(QRDR) of either the ParC subunit of topoisomerase-IV or the
GyrA subunit of DNA gyrase. We have developed a PCR-RFLP
assay to detect mutations in the Ser79 and Asp83 codons of parC,
and Ser81 and Glu85 of gyrA genes which lead to quinolone
resistance.
Methods: S. pyogenes CIP56.41T and 5 in vitro and in vivo-resistant
derivatives, with known mutations in the QRDR of the parC, and
gyrA genes, were used to validate the assay. Mutations within
parC were detected using restriction endonucleases HinfI (Ser79)
and LweI (Asp83), and those within gyrA by MboII (Ser81 and
Glu85).
Results: The 339-bp parC product from CIP56.41T contained two
HinfI and one LweI cutting sites generating fragments of 212, 95
and 32 bp and of 229 and 110 bp, respectively. Loss of a HinfI
site following mutations at the Ser79 codon resulted in frag-
ments of 127 and 212 bp. Mutations at the Asp83 codon sup-
pressed the LweI site and a 339-bp fragment was observed. The
203-bp gyrA product from CIP56.41T contained a natural MboII
site and an artiﬁcially created MboII site generating fragments
of 126, 45 and 32 bp. Loss of the MboII site in resistant isolates
due to mutations at the Ser81 codon led to 158 and 45 bp frag-
ments. Mutations at the Glu85 codon were associated with loss
of the artiﬁcially created MboII site leading to 126 and 77-bp
fragments. Simultaneous mutations at Ser81 and Glu85 codons
suppressed both MboII sites and a 203-bp fragment could be
observed.
P1826 Cloning and expression of group B streptococcal
gene – analogue of the streptococcal adherence related
lipoproteins
E. Vorobieva, A. Suvorov
St Petersburg, RUS
Objectives: In the genus of Streptococcaciae there exist a gene fam-
ily: papA or psaA from Streptococcus pneumoniae, ssaB from Strepto-
coccus sanguis, ﬁmA from S. parasanguis and scaA from S. gordonii.
All these genes encode for lipoproteins involved in metal trans-
port and adherence, which are considered the possible virulence
factors. We attempted cloning and expression analysis of the
group B streptococcal (GBS) analogue of this gene family.
Methods: GBS strain O9OR (derivative of Ia serotype) used for clo-
ning of the adherence genes analogue. PCR primers were designa-
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ted according to the conserved regions of the gene family under
study (scaA gene was used as a source of original sequence).
DNA fragment of GBS scaA analogue was ampliﬁed and se-
quenced. Using this fragment as a probe the entire sequence of
GBS scaA analogue was determined in the phage library. The gene
was sequenced and expressed in E. coli.
Results: The entire sequence of scaA gene analogue of the GBS
had been cloned, sequenced, and deposited into gene bank.
GBS scaA regulon was found to be similar to one in group A
streptococci where scaA gene is located in direct proximity to
ATP binding protein scaC with similar orientation and negative
regulator scaR which has an opposite orientation. The central
portion of GBS scaA had been cloned into integration vector
pT7Erm B. The resultant plasmid was used for GBS strain
O9OR transformation. GBS transformants were unable to grow
like parental strain in liquid media forming clots instead of typ-
ical chains and it expressed substantially different level of
adherence. GBS scaA gene had been cloned in E. coli system
and expressed employing pQE expression vector system. How-
ever, it was impossible to purify the entire protein using six
His residues located in the N terminus because of processing of
the recombinant streptococcal lipoprotein in the E. coli. In order
obtain the mature protein we have cloned the GBS scaA starting
from the region encoding the lipoprotein cleavage site LXXC.
Puriﬁed mature protein of 35 kDa was obtained and used for
immunisation experiments on mice and rabbits. The possible
usage of GBS ScaA protein as vaccine against GBS infection is
discussed.
Conclusions: A novel GBS gene encoding for putative metal trans-
port adherence related lipoprotein was cloned and expressed in
E. coli. The protein might be important for GBS adherence to
human epithelium.
P1827 The relationship between the modular structure of
eucaryotic-like serine/threonine protein kinase StkP of
Streptococcus pneumoniae and its function
P. Pallova, L. Prenosilova, L. Novakova, P. Branny
Prague, CZ
Objectives: The main objective of this work was to determine the
relationship between structure and function of eucaryotic-like
Ser/Thr protein kinase StkP in S. pneumoniae. In the C-terminal
part of StkP we identiﬁed four repeats with the PASTA signature
(penicillin-binding protein and serine/threonine kinase associated
domain). It has been proposed that this domain could bind
unlinked peptidoglycan and act as its sensor. Thus, StkP might be
involved in cell-wall biosynthesis through interaction of their
PASTA domains with cell wall components. The PASTA domain
is also an important antibiotic resistance determinant in the peni-
cillin-binding proteins.
Methods: To determine cellular localisation StkP we prepared epi-
tope-labelled protein kinase StkP. Both full-length and truncated
forms of StkP were constructed and corresponding mutants were
created by allelic exchange.
Results: The full-length form of StkP was detected in membrane
fraction. Deletion of the C-terminal part of StkP including puta-
tive transmembrane domain resulted in the presence of mutant
form of StkP exclusively in cytoplasmic fraction. These results
clearly showed that StkP is a membrane-associated protein. We
investigated further the inﬂuence of deletion of StkP C-terminal
module on antibiotic susceptibility. S. pneumoniae mutant strain
with cytoplasmic StkP showed increased sensitivity to penicillin
G and vancomycin, antibiotics that inhibit cell-wall synthesis. In
addition, the ability of mutant strain to develop a state of nat-
ural competence as measured by the efﬁciency of transforma-
tion was two orders of magnitude lower when compared with
wild type strain.
Conclusions: These results indicate that the C-terminal part of StkP
acts as a sensor that activates signalling pathway controlled by
StkP protein kinase activity.
P1828 Identiﬁcation of streptococci to the species level by
pyrosequencing
M. Haanpera¨, P. Huovinen, J. Jalava
Turku, FIN
Objectives: The objective of this study was to develop a molecular
method for inexpensive, reliable and simple identiﬁcation of
streptococcal species.
Methods: We developed a method for identiﬁcation of strepto-
cocci based on pyrosequencing technique using PSQ 96MA Sys-
tem (BiotageAB, Uppsala, Sweden). Two hypervariable regions
of the streptococcal 16S rDNA were analysed. These regions,
called V1 and V2, locate close to the 50 terminus of the 16S
rRNA gene. In this study, the V1 and V2 signature sequences of
60 type strains of 54 different streptococcal species were deter-
mined. The ﬁrst step in this method is to perform a PCR com-
prising both regions to be sequenced. In the PCR, heat-
inactivated streptococcal suspension may be used as a sample.
After checking the presence of the PCR products on an agarose
gel, sequencing is carried out. Sequencing reactions of the V1
and V2 regions are performed separately using primers speciﬁc
for V1 and V2 regions, respectively.
Results: By sequencing approximately 35 bases long signature
sequences of both regions, all streptococcal species with a few
exceptions can be differentiated. The two species groups that can-
not be differentiated from each other are S. salivarius, S. vestibular-
is and S. thermophilus as well as S. bovis and S. lutetiensis.
Conclusions: A simple, reliable and fast method for identiﬁcation
of vast majority of streptococcal species was developed: the
whole procedure can be completed during a single working
day.
P1829 Multi-locus sequence typing of group A streptococci
from a London hospital
K. McGregor, B. Spratt
London, UK
Objectives: Group A streptococci (GAS) were collected from a Lon-
don Hospital and characterised by multi-locus sequence typing
(MLST) to determine the identity and prevalence of clones circula-
ting in this setting. London GAS were compared with strains from
a global collection of GAS via the internet accessible MLST data-
base (http://www.mlst.net).
Methods: An MLST sequence type (ST) was assigned to each iso-
late based on sequence of internal fragments of seven housekeep-
ing loci. emm-type was deﬁned by 160-bp of sequence at the 50-
end of the central emm gene. All isolates were tested for suscepti-
bility to erythromycin and tetracycline.
Results: Between July and October 2003, 121 clinical isolates
were collected from 121 persons, including hospitalised patients
(9%) and outpatients attending emergency rooms (31%), special-
ity outpatient clinics (6%) and GPs (48%). Forty-one STs were
identiﬁed of which 20 were represented by a single isolate. The
eight most prevalent types among the 121 GAS were ST117/
emm81 (15%), ST39/emm4 (9%), ST62/emm87 (7%), ST28/
emm1 (6%), ST36/emm12 (6%), ST46/emm22 (5%), ST326/
emm82 (5%) and ST101/emm89 (4%). When compared with the
MLST database 14 (34%) of the 41 STs had not been previously
identiﬁed, although six of these differed from recognised STs at
only a single locus suggesting they were closely related. Resist-
ance to erythromycin and tetracycline was seen in 5 and 18% of
isolates, respectively, with three isolates resistant to both agents.
Resistant isolates included strains with 12 distinct STs. Of
these ﬁve STs were represented by both resistant and suscept-
ible isolates.
Conclusions: GAS strains with higher emm types (>80) accounted
for a signiﬁcant proportion of GAS isolates collected during this
study. This information may have important ramiﬁcations for
emm-directed vaccine strategies. The appearance of resistant iso-
lates was not associated with particular clones.
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P1830 Microarray-based identiﬁcation of genes and 2-D gel
analysis of proteins regulated by Ser/Thr protein kinase of
Streptococcus pneumoniae
L. Prenosilova, L. Novakova, P. Branny
Prague, CZ
Objectives: Searching in the genome sequence of S. pneumoniae
revealed the presence of a single eucaryotic-like Ser/Thr protein
kinase gene stkP, associated with a gene encoding Ser/Thr protein
phosphatase phpP. Eucaryotic-like protein kinases and phospha-
tases in procaryotes coordinate processes of differentiation and
pathogenesis. Thus, StkP and PhpP may play a role in pneumo-
coccal pathogenesis. The main objective of this work was to deter-
mine the targets of protein kinase StkP.
Methods: In order to determine the function of StkP we prepared
deletion of the corresponding gene in S. pneumoniae by PCR liga-
tion mutagenesis and allelic exchange. To identify the genes that
are controlled by StkP we analysed the transcription proﬁle of
stkP loss-of-function mutant by DNA microarray technology.
Results: Measurement of transformation efﬁciency during natural
competence development showed that deletion of stkP gene in S.
pneumoniae resulted in the loss of genetic competence. The tran-
script analysis revealed the StkP-dependent expression of many
potential target loci that were speciﬁcally and strongly up- and
downregulated in stkP mutant suggesting the important regula-
tory role of StkP in S. pneumoniae. The data obtained from tran-
scriptome mapping were further extended by proteomic studies.
Mass spectrometric sequencing was used to identify putative tar-
gets of post-translational modiﬁcation.
Conclusions: In conclusion, genes whose transcription was induced
or repressed in S. pneumoniae stkP deletion mutant were identiﬁed.
Proteomic studies and mass spectrometry were used to conﬁrm
some of the results.
P1831 Rapid identiﬁcation of Streptococcus spp. by
PyrosequencingTM analysis of the rnpB gene
A˚. Innings, B. Herrmann, J. Ta¨pp, M. Thollesson, M. Krabbe
Uppsala, S
Objective: The objective of this study was to investigate the use of
pyrosequencing analysis of a variable region within the rnpB gene
as species-speciﬁc target in identiﬁcation of bacteria within the
Streptococcus genus.
Methods: The rnpB gene is universally present in bacterial species
and encodes a subunit of the RNaseP enzyme. Comparison of
rnpB DNA sequences has been shown to be useful in phylogenetic
studies of bacterial genera (Ta¨pp et al., 2003). A short region of
this gene was used as target in pyrosequencing, which is a rapid
real-time method for sequencing-by-synthesis.
Results: The rnpB DNA sequences from 49 streptococcal species
were aligned to identify target regions for PCR and DNA sequen-
cing. The rnpB P3 region was chosen as the target, as this region
is highly variable and is ﬂanked by conserved DNA regions. The
target region was ampliﬁed in PCR using DNA prepared from
type strains as well as clinical isolates as templates. These ampli-
cons were then analysed by pyrosequencing. Obtained DNA
sequences 20–25 bases in length were found to be sufﬁciently
informative for identiﬁcation of most species in BLAST searches
against a local database and GenBank. A limited number of clo-
sely related species could not be discriminated from each other in
this analysis (e.g. S. salivarius and S. vestibularis). Most of these
pairs could be separated to correct species level by sequence ana-
lysis of a second region in the same PCR fragment, the P9 region.
Conclusions: Pyrosequencing analysis of a short, variable region
within the rnpB gene is a valuable tool in high-resolution species
identiﬁcation of streptococci.
Reference:
1. Ta¨pp J., Thollesson M., Herrmann B. (2003) Phylogenetic relationships and
genotyping of the genus Streptococcus by sequence determination of the
RNase P RNA gene, rnpB. Int J Syst Evol Microbiol 531861–531871.
P1832 Multilocus sequence typing of Neisseria
meningitidis directly from cerebrospinal ﬂuid
J. Kalmusova, P. Kriz, R. Haugvicova, J. Felsberg
Prague, CZ
Objectives: The polymerase chain reaction (PCR) for nonculture
diagnosis of invasive meningococcal disease was introduced in
the Czech Republic in 2000. The multi-locus sequence typing
(MLST) of PCR products was developed in our laboratory [Epi-
demiol Infect (2002) 128: 157] to detect sequence types (STs) and
ST-complexes from the culture-negative patients.
Methods: DNA was extracted from the cerebrospinal ﬂuid (CSF)
by the QIAamp kit (QIAGEN, Germany). MLST was carried out
as described at the MLST website (http://neisseria.mlst.net). First
ampliﬁcation of seven alleles (abcZ, adk, aroE, fumC, gdh, pdhC
and pgm) was performed in a Amplitrone II thermocycler using
Hot start. Second ampliﬁcation of the same alleles was performed
from 1 lL of ampliﬁed products followed by puriﬁcation of the
product with 20% PEG. The sequencing reactions were performed
in PCR tubes with the BigDye terminator cycle sequencing kit (PE
Biosystems) and subsequently analysed with an ABI PRISM 377
automated DNA sequencer (Perkin Elmer). The ﬁnal sequence of
each locus was determined using the LASERGENE software pack-
age (DNASTAR, Madison, WI, USA).
Results: The PCR conﬁrmation rate of meningococcal aetiology of
invasive disease increased from 2% in 2000 to 13% in 2002. In last
2 years (2002 and 2003), the PCR investigation is used simulta-
neously with culture and gives quicker results. The MLST of the
PCR products was performed only in culture-negative patients. It
was performed directly from 21 samples of CSF and revealed STs
in all PCR products mostly belonging to the hypervirulent men-
ingococcal complexes: ST-11 (eight samples), ST-32 (four samples)
and ST-18 (two samples).
Conclusions: MLST of Neisseria meningitidis directly from clinical
specimens was introduced successfully and allows identiﬁcation
of STs and ST-complexes in culture-negative patients. It improves
surveillance of invasive meningococcal disease.
Acknowledgements: This study was supported by research grants
NI/6882-3 and NI/7109-3 of the Internal Grant Agency of Minis-
try of Health of the Czech Republic and made use of the Multi
Locus Sequence Typing website (http://neisseria.mlst.net).
P1833 Clonal distribution of Czech invasive Neisseria
meningitidis isolates
M. Musilek, P. Kriz, J. Kalmusova, R. Haugvicova, J. Felsberg
Prague, CZ
Objectives: Clonal feature of 907 isolates, acquired from 70% of
cases of invasive meningococcal disease in the Czech Republic
since 1990 till 2003 (November), has been determined in order to
monitor the spread of hypervirulent clonal lineages responsible
for the most severe forms of the disease.
Methods: Multi-locus enzyme electrophoresis typing together with
whole-cell ELISA phenotyping was used for routine screening of
isolates, multi-locus sequence typing was adopted for further
characterisation of isolates representative of electrophoretic types
detected.
Results: Due to the increased disease incidence related to spread
of the hypervirulent ET-15 strain of the ST-11/ET-37 complex,
representation of serogroup C meningococci had prevailed since
1993 till 1999. In parallel to the decline of the ST-11/ET-37 com-
plex, endemic occurrence of hypervirulent serogroup B lineages of
the ST-32/ET-5 complex and the ST-18 complex of serotype 22-
related strains increased for a temporary period. At present, the
proportion of ST-11/ET-37 isolates increases again. Two other lin-
eages showing hypervirulent nature, the ST-269 complex and the
ST-23 complex/cluster A3, have been isolated to a small extent.
Isolation of strains of the ST-41/44 complex/lineage III and the
ST-8 complex/cluster A4, spread in western and southern Euro-
pean regions previously, was rare over the study period. In oppos-
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ite to serogroup C strains, phenotyping of serogroup B isolates
was frequently not reasonable for assessment of clonal relevance.
Conclusions: Partial replacement of the ST-11/ET-37 complex
within N. meningitidis population in the Czech Republic was
linked to the spread of serogroup B strains of the ST-32/ET-5 and
ST-18 complexes. The detection of hypervirulent serogroup B line-
ages, for which a comprehensive vaccine is yet not available,
underlines the need for assessment of clonal nature of clinical N.
meningitidis isolates by multilocus genotyping.
Acknowledgements: The work was supported in part by the grants
NJ/7458-3 and NI/7109-3 of the Internal Grant Agency of Minis-
try of Health of the Czech Republic and the MEN-Net project
QLK2-CZ-2001-01436 of the European Commission and made use
of the Neisseria Multi Locus Sequence Typing website (http://
pubmlst.org/neisseria/), developed by Dr M.-S. Chan and Dr K.
Jolley of the University of Oxford under funding of the Wellcome
Trust and European Union.
P1834 Correlation of the latex agglutination and the PCR
method in patients with invasive meningococcal disease
E. Bronska, V. Maresova, P. Kriz, J. Kalmusova, O. Dzupova
Prague, CZ
Objectives: Invasive meningococcal disease is still life threatening.
It is important to diagnose the infection rapidly in order to start
appropriate treatment as soon as possible or continue treatment
already initiated. Latex agglutination (LA) and PCR method are
direct, quick and nonculture methods. LA is an immunological
technique for detection of soluble antigens. The PCR method
detects the presence of the DNA of pathogen. We focused our
project on the correlation of the positive results of LA and PCR in
various clinical materials and its time development.
Methods: We assessed 29 patients hospitalised at the clinic of
infectious diseases with invasive meningococcal disease. The cere-
brospinal ﬂuid (CSF), serum and urine were collected from the
ﬁrst to the seventh day of hospitalisation. We used two kits for
LA: Slidex me´ningite kit for CSF and Pasteur meningitis kit for
other biological materials. The DNA was isolated by Qiagen kit
and PCR method was used. PCR products were detected on the
2% gel electrophoresis. We tested 31 CSF, 94 serum and 99 urine
samples.
Results: CSF: 54% of LA and 96% of PCR results were positive in
the day of admission, 19% of them after the onset of antibiotic
therapy (a.o. ATB). In 16 patients subsequent CSF testing was per-
formed, six with positive and 10 with negative result of PCR. LA
was negative in all the cases.
Serum: 31% of LA and 43% of PCR results were positive in the
day of admission, 13% of them a.o. ATB. In samples collected for
four and more days a.o. ATB the results of LA and PCR were
negative. Urine: 21% of LA results were positive in the day of
admission. In samples collected during next days the results were
positive in a lower percentage.
Conclusions: The results of both methods depend on concentration
of the pathogen in clinical material. LA is less sensitive than PCR.
LA did not bring positive results in subsequent CSF testing, while
38% of PCR results were positive. There is correlation between
the results of PCR and LA in serum.
Acknowledgement: This study was supported by research grant
NI/7109-3 of the Internal Grant Agency of the Ministry of Health
of the Czech Republic.
P1835 Design and evaluation of a CustomSeq microarray
for genotypic characterisation of Neisseria meningitidis
C. Corless, J. Prosser, R. Borrow, E. Kaczmarski, M. Guiver
Manchester, High Wycombe, UK
Objectives: CustomSeq is a resequencing microarray where up to
29.3 kbp of DNA sequence from multiple gene targets can be
interrogated on a single array in a single hybridisation reaction.
The technology is based on a 25-nucleotide probe ‘tiling’ strategy
where four probes are used to interrogate the central nucleotide.
The objectives were to design a CustomSeq microarray for the
genotypic characterisation of Neisseria meningitidis using combined
DNA sequences from four gene targets for the predication of gen-
ogroup, genotype and genosubtype.
Methods: The array was designed using the guidelines of Affyme-
trix Corporation. Genogrouping: alignments of available ctrA and
siaD gene sequences were performed and eight fragments (total
0.91 kbp) identiﬁed that could predict genogroups A, B, C, 29E,
H, W135, X, Y and Z. Genotyping is typically based on sequen-
cing of four porB gene variable regions (VR). The encoded Outer
Membrane Protein is divided into classes 2 and 3. The sequences
to be included on the microarray were based on those in Sacchi et
al. (1998). Multiple sequences for each class were aligned and new
variants identiﬁed. There were 114 sequences (total 6.180 kbp).
Genosubtyping is typically based on sequencing two porA VRs.
All porA variant sequences (available at http://www.neisse-
ria.org) within each VR were aligned and variant-deﬁning
sequences identiﬁed. There were 244 sequences (total 14.490 kbp).
Seventy-ﬁve meningococcal isolates from diverse serogroups, ser-
otypes, serosubtypes and genotypes were tested in the system.
Data analysis was performed using GeneChip DNA Analysis Soft-
ware.
Results: The CustomSeq microarray could be used to predict sero-
group, serotype, serosubtype and genosubtype. There was 100%
concordance with previous porA genosubtyping capillary-based
sequence data. All samples were newly genotyped for porB.
Conclusions: This is the ﬁrst application of CustomSeq technology
to microbial typing. It provides DNA sequence data from a single
PCR product for each target, an advantage over conventional
capillary-based sequencing of porA and porB genes, which cur-
rently require multiple sequencing reactions for each. The geno-
typing data complements the current phenotypic typing scheme,
where a proportion of isolates cannot be typed because of a lim-
ited number of monoclonal antibodies. This prototype could be
applied to other organisms where extensive sequence data is
required for typing.
P1836 Recent emergence of a virulent clone of Neisseria
meningitidis C:2b:P1.5 with decreased susceptibility to penicillin
in Italy
P. Stefanelli, C. Fazio, A. Neri, T. Soﬁa, P. Mastrantonio
Rome, I
Objectives: A great increase in cases due to Neisseria meningitidis
with the phenotype C:2b:P1.5 with decreased susceptibility to
penicillin (penI) has occurred in Italy since 2002. All the penI
meningococci were analysed by MLST and PFGE to verify whe-
ther the increase in the number of cases with this phenotype cor-
relates with the emergence of a single clone readily spreading in
the country.
Methods: A phenotypic characterisation was obtained by deﬁning
the serogroup and sero/subtype, and the penicillin susceptibility
by Etest method. The molecular analysis of the penA gene was
carried out in all the strains; in addition, the new approach by
RealTime-PCR, recently set up, was applied. PFGE was performed
by digesting chromosomal DNA with NheI and BglII and MLST
by sequencing gene fragments of housekeeping genes as described
(http://neisseria.org/nm/ typing/mlst/).
Results: Among serogroup C meningococci isolated since 2002, 30
(44.1%) belonged to phenotype C:2b:P1.5. Interestingly, the major-
ity of them (80%) showed a decreased susceptibility to penicillin
(MICs > 0.06 mcg/mL). The spread of these meningococci was
more remarkable in the ﬁrst 6 months of 2003 when twice as
many were isolated compared with the previous year. According
to MLST website data, all the C:2b:P1.5 penI meningococci were
identical and assigned to the ST8/A4 cluster. DNA macrorestric-
tion fragments generated with NheI and analysed by PFGE
showed one main pulsetype (PTA) and two subclones with some
minor differences, named PTA1 and PTA2. When BglII was used,
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all the strains showed the same PT. The most frequent PT (PTA)
seems to be identical to the ﬁngerprint pattern 2 described by Ar-
reaza et al. (J Med Microbiol 2000). It is possible to hypothesise that
our clone is imported but, differently to the Spanish one, it is able
to cause meningococcal invasive disease in all age groups.
Conclusions: All these ﬁndings unambiguosly conﬁrm that the
increase of meningitis caused in Italy by N. meningitidis C:2b:P1.5
is caused by the spreading of a single emergent clone belonging
to the hypervirulent cluster A4. Moreover, it is also important to
underline that there is a direct relationship between the increase
in serogroup C strains in Italy and the eightfold increase of penI
meningoccci as a result of spread of this single virulent clone.
P1837 Molecular characterisation by PFGE of
phenotypically indistinguishable Neisseria meningitidis stains
M.J. Simo˜es, L. Brum on behalf of the Laboratory
Meningococcal Disease Network
Lisbon, P11
Objectives: Since October 2002, Portugal has a new laboratory sur-
veillance system for Meningococcal Disease (VigLabMD) in which
our Institute receives all N. meningitidis strains from the national
hospital labs network. Between October 2002 and November
2003, the majority of cases of meningococcal disease were due to
serogroup B of N. meningitides. Also, previous serotyping and sub-
typing of N. meningitides strains showed that phenotype C:2b:P1.5
was the most frequently isolated in strains from cerebrospinal
ﬂuid (CSF) and blood. In an epidemiological propose, we used
molecular techniques to differentiate strains antigenically undis-
tinguishable. Admitting the possibility of nonexpression of sero-
subtype-speciﬁc antigenic determinants we also included in this
study strains NST (nonsero subtypable) and expressing any deter-
minant from variable region VR2 of class 1 outer-membrane pro-
tein.
Methods: Strains with the same or potentially the same antigenic
proﬁle were submitted to a molecular characterisation by pulsed-
ﬁeld gel electrophoresis (PFGE), using the enzyme Bgl I. The restric-
tion proﬁles were analysed by Bionumerics software application.
Results: We found 19 strains with the same, or potentially the
same, antigenic type, which were submitted, to PFGE.
Eleven different PFGE patterns were found, in the 19 strains
studied.
Conclusions: Considering the diversity of pulsed ﬁeld types of the
studied strains and the geographic distribution of them, we did
not identify any focus or outbreak during the period of this
study.
P1838 Application of real-time PCR to Meningococcus
detection in formalin-ﬁxed tissues
A. Ferna´ndez-Rodrı´guez, R. lvarez-Lafuente, B. Aguilera,
M.P. Sua´rez-Mier, J.A. Va´zquez, G. Vallejo, J. Go´mez
Madrid, E
Objectives: Invasive meningococcal infection is a major cause of
sudden death. Neisseria meningitidis has to be distinguished from
other bacteria that can also be involved in Waterhouse-Friderich-
sen syndrome (WF). Due to the rapid development of such infec-
tions, antemortem cultures sometimes are not taken, and
establishing the aetiology is needed. However, because of the un-
reliability of postmortem cultures a molecular diagnosis is nee-
ded. The aim of this study was to investigate the presence of
meningococcus in formalin-ﬁxed tissues from a legal sudden
death by a real-time PCR assay.
Methods: The microbiological and histopathological analyses from
a legal autopsy of an adult with a WF were performed. The possi-
bility of a malpractice was being investigated. Formalin-ﬁxed
heart, liver, lung, kidney and supra-adrenal glands were the only
available samples. DNA extraction from paraﬁn-embeded sections
of these tissues was performed with the Mini Kit Extraction Sys-
tem (QiaGen). Detection of ctrA, a gene target speciﬁc for N. men-
ingitidis, was accomplished by a real-time PCR assay using a
MGB-probe developed on the ABI 7000 Sequence Detection Sys-
tem. Posterior serogrouping was performed by ampliﬁcation of
the group speciﬁc siaD B and C genes. All real-time PCR assays
were performed twice. Sensibility and speciﬁcity studies were also
carried out to evaluate the PCR assays in postmortem samples.
Results: Positive real-time PCR results for ctrA were obtained in
heart, liver, lung and kidney. The samples Ct (cycle number to
reach the baseline threshold) values were between 34 and 39.
serogroup B was detected by the siaD PCR assay. On the contrary,
a postmortem haemoculture only yielded contaminants. The ctrA
primer set ampliﬁed DNAs from meningococcal serogroups A, B,
C, W135 and Y. There was no cross-reactivity with any of the
other bacterial DNA extracts tested.
Conclusions: A reliable microbiological identiﬁcation is particularly
important in legal sudden deaths due to meningococcus, which
has to be distinguished from other bacteria. We report the detec-
tion of meningococcus by real-time PCR in parafﬁn-embedded
formalin-ﬁxed tissues from a legal autopsy of a WF case. Meningo-
coccus real-time PCR performed in formalin-ﬁxed tissues may be
of great help in the diagnosis of fulminant deaths when no other
samples are available.
P1839 Ampliﬁcation of capsule b locus in invasive
H. inﬂuenzae strains isolated from children with Hib conjugate
vaccine failures
M. Cerquetti, R. Cardines, M. Cioﬁ degli Atti, M. Giufre`,
P. Mastrantonio, M. Slack
Rome, I; Oxford, UK
Objectives: H. inﬂuenzae type b (Hib) strains isolated from invasive
disease generally possess a duplication of the capsule (cap b)
locus. Ampliﬁcation up to ﬁve copies has been reported and has
been proposed to be a mechanism to evade host defence. To ver-
ify if ampliﬁcation of cap b locus is involved in vaccine failure we
determined the number of copies of the cap b locus in Hib iso-
lates from true vaccine failures (TVFs) and from age-matched con-
trols.
Methods: A total of 189 invasive Hib strains isolated from infants
or children in the UK and the Republic of Ireland were tested. Of
these, 95 were from patients with TVFs and 94 from age-matched
controls. The copy number of cap b locus was determined by
Southern blot analysis, using as a probe the 480 bp amplicon (cap-
sule type b-speciﬁc) obtained by PCR of the Hib strain Eagan. As
the KpnI and SmaI sites ﬂank the cap b locus, the copy number
can be estimated by the size of the restriction fragment obtained
following digestion of the chromosome with these enzymes. The
DNA fragment for a two-copy strain was expected to be approxi-
mately 45 kbp; strains with three or more copies of the locus fea-
tured fragments of increased size (63, 81 and 99 kbp).
Results: Most isolates both in the TVFs and the control group
exhibited hybridisation signals at the expected position for a two-
copy arrangement of cap b locus. However, besides the 45 kbp
band, several isolates containing the two-copy arrangement
showed strong hybridisation signals at molecular weights higher
than 50 kbp, indicating the presence of multiple copies (three,
four and ﬁve repeats) of the locus. A signiﬁcantly greater propor-
tion of isolates from patients with TVFs contained multiple copies
compared with strains from controls. In fact, 24/95 strains har-
boured three or more copies of the locus in the TVF group, vs.
Number of strains
C:2b:P1.5 11
C:2b:NST 4
C:2b:P1.2,5 3
C:2b:P1.5,15 1
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11/94 among controls (P ¼ 0.016). Interestingly, the presence of
multiple copies was signiﬁcantly associated with a greater propor-
tion of clinical presentations other than meningitis in children
belonging to both the TVFs and control groups.
Conclusions: Our results show the number of multiple copy strains
found among TVFs was signiﬁcantly higher than in the control
group. Although cases of invasive Hib disease in vaccinated chil-
dren have been generally related to clinical or immunological con-
ditions of the host or the use of less immunogenic vaccines, these
data suggest that ampliﬁcation of cap b locus may also be
involved.
P1840 Comparison of conventional culture and PCR
techniques in detection of Haemophilus inﬂuenzae in
cerebrospinal ﬂuids and middle ear effusions
I. Jbara, M. Baysallar, S. Yetiser, B. Unay, L. Doganci
Ankara, TR
Objectives: Otitis media with effusion (OME) is one of the major
causes of hearing loss in childhood, it is known that H. inﬂuenzae,
S. pneumoniae, and M. catarrhalis are considered the chief patho-
gens of OME in children. Bacterial meningitis is still a disease
with high morbidity and mortality rates despite the effective anti-
microbial therapy. H. inﬂuenzae, S. pneumoniae, and Neisseria men-
ingitidis are responsible for the most cases. These micro-organisms
in both bacterial meningitis and OME have a fastidious character-
istics in conventional culture, that have not been able to make
clear cascade for identiﬁcation, therefore, PCR has been applied to
detect the bacterial DNA in cerebrospinal ﬂuid (CSF) and middle
ear effusion (MEE) specimens, and to evaluate the signiﬁcant
diagnostic value of PCR technique compared with conventional
culture methods as ‘gold standard’.
Methods: A total of 53 CSF and 22 MEE samples were collected
from meningitis- and OME-suspected children, respectively, that
were tested by both conventional culture and PCR methods.
Results: One of 53 CSF (S. pneumoniae) and three of 22 MEE (one
H. inﬂuenzae non-b and two M. catarrhalis) samples were culture
positive. The PCR revealed genomic DNA sequences of 5 (S. pneu-
moniae) from 53 CSF samples, and eight (three H. inﬂuenzae, three
M. catarrhalis and two yielding both S. pneumoniae and M. catarrh-
alis with each others) from 22 MEE samples. The sensitivity, spe-
ciﬁcity, positive predictive value, negative predictive value, and
the correlation rate for the total study samples from both CSF and
MEE were 100, 87.3, 30.8, 100 and 88%, respectively.
Conclusions: It is concluded that PCR technique is a more sensi-
tive, more rapid and appropriate method than conventional cul-
ture for detection of the most three common micro-organisms that
lead to meningitis and OME in children.
Emerging infectious diseases
P1841 A prospective multicentre study on community-
acquired pneumonia in the postoutbreak period of SARS in
South Korea: a role of atypical pathogens including SARS-CoV
J.W. Sohn, M.J. Kim, Y.H. Choi, H.J. Lee, H. Chun, H.S. Shim,
E.J. Choi, S.C. Park
Seoul, Suwon-si, Kyunggi-do, KOR
Background: Since global threat of severe acute respiratory syn-
drome (SARS) outbreak, originally described as a severe atypical
pneumonia in the Guangdong Province of China, has successfully
been contained on early July, 2003, many countries remain vigil-
ant for resurgence of SARS. We investigated the causative roles of
SARS coronavirus (SARS-CoV) and atypical pathogens in commu-
nity-acquired pneumonia (CAP) in the post-outbreak period.
Methods: From September to November 2003, a prospective multi-
centre study was performed to determine the atypical causes of
CAP including SARS-CoV. Clinical samples collected from CAP
patients between February and May, 2003 were also examined. To
detect SARS-CoV, RT-PCR and Indirect IFA and rapid antibody
tests were performed for respiratory specimens and paired sera,
respectively. Tests for Mycoplasma pneumoniae, Chlamydia pneumo-
niae, Legionella species, and respiratory viruses (inﬂuenza virus A
and B, adenovirus, parainﬂuenza virus, respiratory syncytial
virus) included PCR, urinary antigen test, indirect IFAs and virus
culture.
Results: A total of 134 patients were enrolled in this study (103
patients prospectively and 29 patients retrospectively). SARS-CoV
was not detected in any patients. Based on seroconversion, high
antibody titre together with the presence of bacterial DNA in res-
piratory secretions (M. pneumoniae, C. pneumoniae, and L. pneumo-
phila) or bacterial antigen in urine (L. pneumophila), M. pneumoniae,
C. pneumoniae, and L. pneumophila were responsible for 12.2, 10.7
and 13.9% of cases, respectively. Respiratory viruses were not
detected except for adenovirus in one patient.
Conclusions: Although SARS-CoV was not detected in this post-
outbreak surveillance, we must remain vigilant for reemergence
of SARS. Atypical bacterial pathogens appeared more prevalent
than the previous reports in South Korea.
P1842 Detection of SARS-CoV by oligochromatography of
RT-PCR amplicons
P. Mertens, L. Vijgen, C. Olungu, S. Degallaix, I. Renuart,
M. Van Ranst, T. Leclipteux
Gembloux, Leuven, B
The severe acute respiratory syndrome (SARS) is a new respirat-
ory infection that has been reported in several countries around
the world. It is recognised as a new type of atypical pneumonia
that infects the lungs, caused by a new strain of coronavirus,
SARS-CoV. SARS has killed at least 770 people and infected more
than 8500 worldwide since the outbreak in China’s Guangdong
province late 2001. Molecular ampliﬁcation has emerged as a
powerful technology for the speciﬁc and sensitive detection of
such a virus. However, the use of this new technology in routine
laboratories requires a rapid, easy-to-perform and affordable
detection method. Analysis on agarose gel is time-consuming and
cannot exclude false-positive products while alternate speciﬁc
detection methods are time and labour-consuming (ELISA) or
require very expensive equipment (real-time ampliﬁcation). In
order to perform an easy and speciﬁc detection of ampliﬁed gene
products, we set up and tested a new detection technology: oligo-
chromatography. An internal probe to the nucleic acid sequence
to be detected is conjugated to collodal gold particles. A conjugate
pad containing this dried conjugate is placed overlapping the
membrane of a chromatographic stick where anti-hapten antibod-
ies are coated. Ampliﬁcation is carried out with hapten-labelled
primer(s). Detection is performed by dipping an oligochromato-
graphic stick in the ampliﬁed solution. While migrating in the
stick, amplicons react with the colloidal gold-conjuguated probe.
The probe-amplicon complexes accumulate on the line where the
anti-hapten antibody is coated, giving rise to a visible red line in
<5 min. A highly sensitive RT-PCR for the detection of SARS-CoV
was developed. It contains an internal control allowing to test for
the absence of PCR inhibitors in the ampliﬁed material. Detect-
ability of this RT-PCR coupled to oligochromatographic detection
was compared with agarose gel electrophoresis with ethidium
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bromide staining. Oligochromatography shall probably become
the best way to speciﬁcally detect nucleic acid sequences after a
molecular ampliﬁcation process. It is rapid, speciﬁc, easy to han-
dle, and does not require any speciﬁc equipment.
P1843 Experience in PCR diagnosis of SARS coronavirus
in Taiwan
J.J. Lu, C.L. Perng, T.S. Chiueh
Taipei, TW
Objectives: An outbreak of the severe acute respiratory syndrome
(SARS) occurred in Taiwan in April, 2003, therefore we urgently
established a nested RT-PCR and a real time RT-PCR to detect the
SARS coronavirus.
Methods and Materials: From May 5th to August 31st, we examined
2585 specimens from 814 patients or medical workers. Viral RNA
was extracted with the Blue Extract solution or the Qiagen viral
kit from various clinical specimens. Each sample was tested in
duplicate by both PCR methods.
Results: Eighty-eight of the 257 specimens from patients suspected
to have SARS were positive for both PCR assays. These specimens
included sputum (65%, 26/40), throat swabs (52%, 16/31), gar-
gles (13%, 4/32), stool (35%, 17/48), urine (18%, 9/49), and blood
(32%, 18/57).
Conclusions: Sputum and throat swabs were found to be the best
sample types for the PCR assays, whereas gargle and urine sam-
ples were the least satisfactory. The ﬁrst serum samples from 10
of the 30 SARS-probable patients were PCR positive, suggesting
that serum samples can be used for early diagnosis of SARS.
P1844 Study of Q-fever on the territory of the Republic of
Moldova
I. Uspenskaia, A. Movila, V. Chicu, A. Gutsu, J. Konovalov,
V. Melnic, E. Kulibacnaia
Kishinev, MD
Objective: Study of epidemiological and epizoological situations of
Q-rickettsiosis, for determination the criteria of Q fever natural
focus on the territory of the Republic of Moldova.
Methods: The research was carried out in the period 1997–2002.
During the work were used standard zoological, parasitologic and
bacteriologic methods. The caught small animals, gathered Ixodid
ticks, people and farming animals blood serum were investigated
in the laboratory of Extremely Dangerous Infection of the National
Scientiﬁc-Practical Center of Preventive Medicine of the Republic
of Moldova.
Results: During the investigation period the positive results of
Q-rickettsiosis, from different carriers, were found in 30 areas. -
Out of 3946 investigated persons suspected of Q fever, seroposit-
ive results were found at 2.46%. The cases of fever illnesses were
registered since December till July in Southern and Central district
of Moldova. It was established that most of the patients were rela-
ted to farming animals‘ care or to processing of animal breeding
products. The research into spontaneous contamination of Coxiella
burneti, the dominant species of ticks in the republic (Dermacentor
reticulatus, D. marginatus, Haemaphysalis punctata, Ixodes ricinus),
gave the positive result in 62.19% of 6986 specimens. The study
of epizoological situations among the feeders of all stages of ticks
showed their presence in central and southern districts of the
Republic of Moldova: among small animals were found antibodies
of C. burneti at 0.17% of 2803 investigated specimens; in the blood
of cattle at 1.9% of 207 and at 5% of sheep of 458 investigated
animals.
Conclusions: Analysis of received materials allowed establishing
the criteria of Q fever natural focus on the territory of the Repub-
lic of Moldova: (1) territorial coincidence at detection of Q-rickett-
siosis signs at different natural objects, for example at farming
animals and people; (2) presence of natural factors, especially in
the foci of ticks increased number, among what it is a high per-
centage of C. burneti infection. According to these materials there
were emphasised and described the most likely natural foci of Q-
rickettsiosis on the territory of Moldova.
P1845 Human granulocytic Ehrlichiosis in Austria:
epidemiological, clinical and laboratory ﬁndings in four
patients
G. Walder, R. Hartl, B. Falkensammer, M.P. Dierich, R. Wu¨rzner
Innsbruck, A
Objective: The aim of our study was to determine, if Anaplasma
phagocytophilum causes febrile illnesses after tick-bites in Western
Austria.
Methods: Between May 2003 and October 2003, 167 patients with a
nonspeciﬁc febrile illness, recent tick exposure and nonrevealing
physical examination were tested for infection with A. phagocyto-
philum by a commercially available immunoﬂourescence assay
and a real-time PCR targeting the groEL-gene.
Results: Four patients fulﬁlled the WHO-criteria for conﬁrmed
infection with A. phagocytophilum (human granulocytic Ehrlichio-
sis), i.e. PCR yielded a positive result with subsequent seroconver-
sion (1 case) or they seroconverted against A. phagocytophilum
with an at least fourfold titre rise within 2–4 weeks after onset of
symptoms (three cases). All infections were acquired in the Inn
valley between June and August 2003, three of four patients deﬁn-
itely recalled a tick-bite 1–2 weeks prior to onset of symptoms.
Three patients required hospitalisation, one patient was treated as
an outpatient. During the acute stage of illness laboratory ﬁnd-
ings included thrombocytopenia (100%), elevated CRP (100%),
elevated neopterine (100%), elevated LDH (75%). Leucopenia, ele-
vation of liver enzymes and elevated procalcitonin were less com-
monly observed. All patients were treated with tetracyclines,
which lead to prompt improvement of clincal conditions.
Conclusions: Our ﬁndings demonstrate the presence of human
granulocytic Ehrlichiosis in western Austria. It should be included
in differential diagnosis of febrile illnesses after previous tick-
exposure.
P1846 Bartonella infections in the British Isles: review of
7 years of diagnostic testing
N. Doshi, H. Ford, T. Stocki, J. Duncan, N. Fry, T.G. Harrison
London, UK
Objectives: To review microbiological data and basic demograph-
ics of Bartonella infections in the British Isles obtained during
7 years of routine laboratory testing.
Methods: Since January 1997, to aid the clinical diagnosis of Barto-
nella infections in the British Isles, RSIL has offered a service for
the estimation of Bartonella antibodies using the Focus Bartonella
IFA IgM and IgG kits. Serological data were reviewed for all
patients from whom samples had been submitted during the
7 years to November 2003. All sera were examined in the indirect
immunoﬂuorescent antibody test according to the manufacturers’
instructions: patient’s age and sex were also recorded. Referral
forms were reviewed for the ﬁrst 1000 consecutive patients with
positive serology and from the clinical details each was classiﬁed
as a case of: Cat Scratch Disease (evidence of lymph node involve-
ment and/or histological evidence), Bacillary Angiomatosis/pelio-
sis, Bartonella endocarditis, PUO, other recognised manifestation
(e.g. ophthalmic bartonellosis) or insufﬁcient details. Serological
results were interpreted as ‘no evidence of recent infection’, ‘evi-
dence of current/recent infection’, ‘suggestive of infection at an
undetermined time’ or ‘evidence of past infection’ as indicated by
the manufacturers. Where available, biopsy samples from seropos-
itive patients were examined by PCR to detect Bartonella DNA.
Results: Samples were received from 10507 patients. Overall 1759
(16.7%) patients had evidence of infection: 947 (9.0%) recent/
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current infection, 740 (7.0%) infection at an undetermined time
and 72 (0.7%) past infection. Analysis by age showed that rates of
infection were highest in the decades 0–9 years (20.1%) and 10–
19 years (18.7%), but they fell only a little in the next three (20–
29: 17.2%, 30–39: 16.8%, 40–49: 14.9%). Of the ﬁrst 1000 seroposit-
ive patients 449 had reported clinical features of CSD, 56 Bartonel-
la endocarditis, 19 PUO, 3 BA, 40 other manifestations and 433
insufﬁcient details. PCR analysis of excised heart valves from
some of the endocarditis patients conﬁrmed B. henselae, B. quintana
and B. vinsonii as causative agents.
Conclusions: Bartonella spp. are a major cause of zoonotic infection
in the British Isles in all age groups but particularly in children.
Bartonella infection should always be considered as a possible aeti-
ology in patients with endocarditis. Serology is an excellent and
cost effective approach to the diagnosis of these infections.
P1847 Weil’s disease in Northern Greece. Correlations
between clinicoepidemiological aspects and laboratory
parameters in 88 patients
E. Vasileiadou, M. Soubourou, M. Sidiropoulou, D. Chrysagis,
F. Kamaria, P. Mamasi, D. Kolokotroni, A. Papachristou
Thessalonica, GR
Objectives and aims: Leptospirosis has been described as a zoonosis
of protean manifestations. This study was elaborated to search for
associations between the multiform clinical course of the disease,
on one hand, and selected epidemiological, clinical and laboratory
parameters on the other.
Material and methods: During the period 1981–2000, 88 patients
with Weil’s disease, 85 males and three females (mean age
41.7  14.2 years) were admitted to our hospital. Diagnosis was
based on the clinical manifestations of the disease, and was subse-
quently conﬁrmed serologically by ELISA method. All the clinical
and laboratory data were assessed and multivariate analysis was
performed.
Results: (a) Older patients (41–74 years, n ¼ 44), compared with
younger (16–40 yrs, n ¼ 44) had: (1) longer duration of the disease
(20.4 vs. 16.8 days, P < 0.05) and of antibiotic administration (9.1
vs. 6.7 days, P ¼ 0.007), (2) twofold elevation of CPK levels (983
vs. 451.1 U/L, P ¼ 0.02), (3) higher values of BUN (163.5 vs.
110 mg/dL, P ¼ 0.005), total BIL (19.8 vs. 13.9 mg/dL, P ¼ 0.05),
as well as WBC (13.55 vs. 9.46  103/mL, P < 0.0001). (B) Patients
with azotemia (BUN  90 mg/dL, n ¼ 48), compared with those
without azotemia (n ¼ 40): (1) were older (44.6 vs. 38.3 years,
P < 0.05), (2) had higher values of total BIL (22 vs. 10.5 mg/dL,
P < 0.0001), (3) lower values of PLT (86.1 vs. 115  103/mL,
P ¼ 0.04) and Hb (10.8 vs. 12 g/dL, P ¼ 0.035), (4) was the only
patient group with complications (acute renal failure, myocarditis,
pericarditis). (C) Patients with jaundice (total BIL > 3 mg/dL,
n ¼ 69), compared with those without jaundice (n ¼ 19): (1) were
older (43.1 vs. 34.4 years, P < 0.05), (2) had shorter symptomatic
preadmission period (6.5 vs. 9.9 days, P < 0.007), (3) were admi-
nistered antibiotics for longer time (8.8 vs. 5.4 days, P < 0.02), (4)
had lower Hb levels (10.9 vs. 12.2 g/dL, P < 0.003), and higher
WBC count (11.7  103/mL vs. 8.72  103/mL, P < 0.01).
Conclusions: The course of Weil’s disease is more severe in older
patients with azotemia and/or jaundice. Complications are related
to the patients with azotemia.
P1848 Tick-borne pathogens in Danish roe deer
S. Skarphedinsson, B. Lyholm, P.M. Jensen, K. Kristiansen
Odense, Copenhagen, Ro¨nne, DK
Objectives: Roe deer-associated tick-borne infections form a large
portion of emerging infections in Denmark. The aim of this study
was to describe the seroprevalence of Anaplasma phagocyophilium,
Borrelia burgdorferi s.l. and tick-borne encephalitis virus (TBE) in
Danish roe deer (Capreolus capreolus) and at the same time to
evaluate Anaplasma spp. infection by PCR.
Methods: Blood samples from 237 roe deer were collected during
the hunting season (15/5–15/7 2002 and 1/10–15/1 2003). Sam-
ples were from 22 of 25 Danish State Forest districts. An indirect
immunoﬂuorescence assay was used to identify sera reactive
against A. phagocytophilium and B. burgdorferi. For TBE serology
haemagglutination inhibition (HI) test was used and positive sam-
ples were veriﬁed using neutralisation assay. Blood samples were
tested for A. phagocytophilium genogroup 16S rRNA sequences by
PCR. Positive samples were sequenced.
Results: Anaplasma seroprevalence was 87% with some variation
between the two hunting periods (83%–91%). Overall a mean of
47% roe deer were found Anaplasma positive in PCR. Marked sea-
sonal variation in PCR positive roe deer was found between the
two hunting periods (71% vs. 26%). Sequencing revealed besides
A. phagocytophilium, A. platy in two roe deer and a co-infection
with an uncultured eubacterium (AJ 292457) Borrelia seropreva-
lence was 36% with even distribution between the two periods
and no regional variation. TBE seroprevalence was 9% and posit-
ive animals were found in 10 forest districts.
Conclusion: These ﬁndings conﬁrm that roe deer in Denmark are
commonly infected with Anaplasma and provide evidence that roe
deer are a major reservoir of Anaplasma. Borrelia seroprevalence in
Denmark has not increased or changed in distribution over the
last decade, whereas TBE distribution has increased and is now
not only limited to the island of Bornholm.
P1849 Rapid PCR-based method for detection of
orthopoxviruses and of other viruses important for differential
diagnosis of smallpox
F. Carletti, A. Di Caro, A. Grolla, M. Czub, N. Petrosillo,
G. Ippolito, M.R. Capobianchi
Rome, I; Winnipeg, CAN
Objective: Variola virus, belonging to Orthopoxviridae family, is
one of the most dangerous biological agents that could be used as
biological weapon. Problems associated with such an event are
mainly due to high morbidity and mortality, absence of herd
immunity in young population, and difﬁculty in the clinical diag-
nosis, due to the similarity with other exantematous diseases.
Laboratory diagnosis is crucial to increase global preparedness to
such an event. As culture-based methods are only applicable
under maximum biosafety level, molecular methods are preferred
for wide application, as they can be used in laboratories were
BSL-3 or higher facilities are not available. To this aim, we estab-
lished a rapid PCR-based protocol for the contemporary detection
of Orthopoxviruses, VZV and HSV, that are relevant for differen-
tial diagnosis.
Methods: The target for detection of orthopoxvirus DNA is a region
of the crmB gene, which is common to variola virus and to other
old world orthopoxviruses pathogenic for humans. The VZV and
HSV targets are ORF 29 and DNA polymerase, respectively. Suit-
ability of the ampliﬁed fragments to RFLP or sequencing analysis
was also tested, to recognise the involved viral species.
Results: Three primer set, for the three viruses, were selected,
showing high sensitivity and speciﬁcity, and compatibility with
common ampliﬁcation conditions. The test conditions selected
were validated by using biological samples from patients showing
herpesviral infections, and, for orthopoxviruses, laboratory strains
including vaccinia, camelpox, cawpox, monkeypox viruses. The
results indicate that, by this method, it is possible to obtain rapid
differentiation of herpesviral from orthopoxviral infections using
a common ampliﬁcation run. Furthermore, the amplicons obtained
in this phase are suitable for further molecular analysis, allowing
virus identiﬁcation and deﬁnitive laboratory diagnosis.
Discussion: The PCR-based protocol here established for differen-
tial diagnosis of orthopoxvirus and herpesviral infections is rapid
and speciﬁc. The ampliﬁcation products are suitable for further
molecular analysis, leading to deﬁnitive laboratory diagnosis
under easily achievable laboratory conditions, without biological
hazard for laboratory personnel. This method can be used also to
detect orthopoxviral infections due to imported viruses, such as
monkeypox. Work supported by grant by RF 2001-01.102.
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P1850 Prevalance and impact of human meta pneumo
virus among children and immunocompromised patients
M. Raza, A. Chawla, E. Hainsworth, M. Potter, W. Labbett,
P. Grifﬁths, M. Zambon, A. Geretti
London, UK
Objective: To determine the prevalence of Human Metapneumovi-
rus (HMPV) infection among children and immunocompromised
patients presenting with respiratory symptoms in the season
November 2002 to March 2003.
Methods: Nasopharyngeal aspirates (NPAs) were collected from
55 patients and tested by direct immunoﬂuorescence and virus
culture for the presence of common respiratory viruses (CRVs)
including respiratory syncytial virus (RSV), inﬂuenza viruses A
and B, parainﬂuenza viruses (PIV), adenoviruses, enteroviruses
and rhinoviruses. Specimens that tested negative for CRVs were
submitted to a central laboratory and retrospectively tested for the
presence of HMPV by PCR.
Results: The study included two groups. Group A, 29 children (M
12, F 17; mean age: 6 months, range 9 days–2 years) requiring
hospitalisation for bronchiolitis, pneumonia or respiratory dis-
tress. Of these, 14 (48%) tested CRV positive (RSV 11, PIV-3 1, En-
terovirus 1, Flu B 1) and 4 HPMV positive. The latter presented
with disease ranging from mild-moderate wheeze, to pneumonia
and respiratory failure. All four patients made a full recovery
with supportive therapy. Group B, 26 patients (M 18, F 8; mean
age: 39.1 years, range 2–80 years) who had either received stem
cell transplantation (SCT, n ¼ 16) or were receiving myelotoxic
chemotherapy for haematological (n ¼ 15) or other (n ¼ 1) malig-
nancies. Of these, 8 (31%) tested CRV positive (Flu A 2, RSV 6).
One recipient of allogeneic STC was HMPV positive. The 32 year
old patient was admitted on day 28+ after Sibling HLA-Identical
T-cell depleted BMT with fever and bilateral lung shadowing. A
bronchoalveolar lavage (BAL) was negative for fungal and bacter-
ial pathogens. Both a NPA and the BAL were negative for viral
pathogens. He received therapy with broad spectrum antibiotics
and antifungals, but progressed to respiratory failure and died at
day 57+. The diagnosis of HMPV pneumonia was obtained retro-
spectively.
Conclusions: These data are minimal estimates of the prevalence of
HMPV, as dual CRV HMPV infections were not excluded. HMPV
was common among children hospitalised with RSV-like disease,
accounting for 14% of such presentations (RSV 38%). Although
HMPV was less common among immunocompromised patients
than RSV (4% vs. 23%), it was associated with fatal pneumonia in
the post-SCT setting. These data highlight the potential for signiﬁ-
cant morbidity and mortality associated with HMPV infection.
P1851 Isolation and characterisation of spotted fever group
rickettsiae in Taiwan
D.-D. Ji, P.-Y. Tsui, Y.-T. Liu, M.-H. Weng, J.-C. Lien, P.-R. Lin,
M.-F. Shaio
Sanhsia, Taipei, Taichung, TW
Objective: Spotted fever group (SFG) rickettsioses have been recog-
nised as important emerging vector-borne human diseases world-
wide. Several distinct SFG rickettsiae had been reported just near
by Taiwan, such as Rickettsia sibirica (in China), R. australia (in
Australia) and R. japonica (in Japan). This study therefore sought
to isolate and characterise the SFG rickettsiae from arthropods in
Taiwan.
Methods: All arthropods were collected from rodents captured in
Kinmen, Matsu and Taiwan main-island. The citrate synthase
(gltA) and 17 kDa protein genes were partially or completely
ampliﬁed and sequenced for determining the phylogenetic rela-
tionship between Taiwan strains and other SFG rickettsiae.
Results: After BLAST comparison, three SFG rickettsia strains
named TwKM01, TwKM02 and TwKM03 were identiﬁed and
were most similar to R. rhipicephalis, R. australisi and Rickettsia
spp. California, respectively. Sera from TwKM01, TwKM02 and
TwKM03 infected rodents were positive to R. rickettsii by indirect
immunoﬂuorescent assay indicated that SFG rickettsia might
widely distributed in wild rodents of Taiwan. TwKm01 and
TwKm02 were ﬁrst detected from Rhipicephalus haemophysaloides
tick and Leptrombidial chiggers. A recombinant 17 kDa protein
had been expressed and puriﬁed by the His-tagged afﬁnity col-
umn, in order to further evaluate the prevalence of SFG rickettsial
infection in humans and wild rodents.
Conclusions: Although the infectivity and pathogenicity of these
three SFG rickettsia for vertebrates are unknown, this ﬁnding rai-
ses the possibility that bacteria other than Orientia tsutsugamushi,
Coxiella burnetii and R. typhus may be involved in rickettsial dis-
eases in Taiwan.
P1852 Fluoroquinolones vs. macrolides in the treatment of
Legionnaires’ disease
M.L. Pedro-Botet, J. Gomez, J. Roig, Z. Vilaseca, N. Sopena,
O. Sarroca, A. Garcı´a Cruz, S. Ragull, M. Garcı´a Nu´n˜ez,
C. Rey-Joly, M. Sabria`
Badalona, Murcia, E; Escaldes, AND
Objectives: Erythromycin has been the treatment of choice for
Legionnaires’ disease (LD). However, new drugs such as ﬂuoro-
quinolones are currently under evaluation. In a comparative study
in 2001 we found ﬂuoroquinolones to be as effective as erythro-
mycin in LD treatment and time to apyrexia and hospital stay ten-
ded to be shorter in patients on quinolones, although the small
number of patients included did not allow signiﬁcant differences
to be found. We have now included cases of LD from 2 other cen-
tres in Spain, which use both of these antibiotics. The present
study compares the evolution of patients with LD treated with
macrolides or ﬂuoroquinolones.
Methods: We performed a prospective observational study in 130
patients diagnosed by Legionella urinary antigen. Patients receiving
any antibiotic more than 36 h before starting the study therapy
were excluded. The patients were divided into two groups: 76 in
group 1 receiving macrolides (erythromycin/clarithromycin) and
54 in group 2 receiving ﬂuoroquinolones (oﬂoxacin/levoﬂoxacin).
Results: No signiﬁcant differences were seen between the two
groups regarding age, sex, smoking, alcohol intake, underlying
diseases or community/hospital acquisition. Time from onset of
LD symptoms until starting antibiotic treatment was 78.5 and
92.7 h in groups 1 and 2, respectively (P ¼ 0.1). Time to apyrexia
was signiﬁcantly longer in the macrolide group (77.1 vs. 48 h for
groups 1 and 2, respectively) (P ¼ 0.000). There were no differ-
ences in radiologic, clinical complications or mortality. However,
a trend to longer hospital stay was observed in Group 1 (9.9 vs.
7.6 days in Groups 1 and 2, respectively) (P ¼ 0.09).
Conclusions: Fluoroquinolones were found to be as effective as
erythromycin in the treatment of LD. Time to apyrexia was signi-
ﬁcantly shorter and hospital stay tended to be shorter in patients
on ﬂuoroquinolones.
P1853 The characteristics of Crimean Congo haemorrhagic
fever in a recent outbreak in Turkey and the impact of oral
ribavirin therapy
O. Ergonul, A. Celikbas, B. Dokuzoguz, S. Eren, N. Baykam,
H. Esener
Ankara, TR
Objective: The epidemiological, clinical, and laboratory ﬁndings of
the patients diagnosed as Crimean-Congo haemorrhagic fever
(CCHF), and the role of ribavirin therapy were described.
Methods: The patients infected with CCHF virus in 2002 and 2003,
and hospitalised in Ankara Numune Education and Research
Hospital were studied. All the patients had positive results of
IgM, and/or IgG, and/or PCR results for CCHF virus in blood or
tissue. The patients were grouped as mild-moderate or severe.
The severity was deﬁned as having thrombocytopenia <20 000,
active bleeding, and somnolence.
529Clinical Microbiology and Infection, Volume 10, Supplement 3, 2004
Results: Thirty-ﬁve cases were eligible, and all were from the
northeastern Anatolia and the southern parts of Black sea region;
all of them were dealing with husbandry. The mean age was
43.4 (+17.3). Fifty-three per cent of the cases had the history of
tick bite. The clinical status of 31% of the cases was deﬁned as
severe. The age, geographic residency, history of tick bite, mean
number of days before hospitalisation, the complaints were not
different between mild to moderate cases and severe cases
(P > 0.05). The mean length of stay was longer among severe
cases (P ¼ 0.040). Females were more severely affected than
males (RR, 1.8; CI, 0.2–1.5, P ¼ 0.146). The decrease in haemoglo-
bin level (p ¼ 0.042), elevated AST (P ¼ 0.002), ALT (P ¼ 0.007),
LDH (P ¼ 0.042), and AST/ALT ratio (P ¼ 0.044) were more
common among severe cases. Five out of 11 severe cases were
given ribavirin therapy according to WHO recommendations,
and all survived. Six of the severe cases did not receive ribavirin
therapy, one of them died. The overall case fatality rate (CFR)
was 2.8%, which was the lowest rate in the literature. The CFR
was increased to 17% among severe cases, who did not receive
ribavirin. The cost-effectiveness assessment was limited to the
severe cases, which includes the drug, laboratory, and hospital
expenses. The cost of the infection in ribavirin group was 3661
per patient after excluding the outlier, whereas it was 4860 per
patient among nonribavirin group.
Conclusions: CCHF was not reported before in Turkey, although
epidemics were reported from the neighbouring countries. In con-
clusion, oral ribavirin should be administered to the severe cases,
which have been suspected of having CCHF virus infection.
P1854 Phenotypic characters of S. aureus strains associated
with 79 cases of toxic shock syndrome in the Czech Republic
P. Petras
Prague, CZ
Objectives: The Czech reference laboratory for staphylococci has
been paying attention to the Toxic Shock Syndrome (TSS) since
1983 when the disease emerged. Seventy-nine cases with required
clinical records and diagnosis conﬁrmed by toxinogenicity screen-
ing of S. aureus isolates have been documented in our laboratory
to date. The aim of this study was to investigate relevant charac-
teristics of strains.
Methods: The production of TSST-1 and enterotoxins A, B, C, D
and E was detected by microslide-gel diffusion test, using Berg-
doll’s antisera until 1997. The RPLA method (Denka Seiken kit for
types A, B, C, and D) has been used since 1998. The production
of alpha, beta, and delta-haemolysin was detected based on either
synergy or antagonism with beta-haemolysin of the S. intermedius
standard strain on blood agar plates in mixed atmosphere. Phage
typing was performed by the standard method using the interna-
tional set of phages (PHLS London). Resistance to 12 antibiotics
was tested by the disk diffusion method (Oxoid).
Results: The aetiological agents of eight cases of the menstrual
form of TSS were S. aureus strains with TSST-1 production, mostly
with parallel enterotoxin A toxigenicity. All of the patients sur-
vived. Other 71 cases of TSS were complications of the following
staphylococcal infections: infected injury wounds (13 cases), post-
operative hospital infections (11), and infected scaldings and
burns (9). Fatal outcomes were reported in 17 cases, i.e. in three
patients aged over 75 years, two patients with TSS-like complica-
tion of staphylococcal endocarditis and 12 other patients account-
ing for a signiﬁcant lethality rate of 17%. As many as 43 (60%)
strains produced TSST-1 and 34 of them in combination with en-
terotoxin of any type. The other 28 (40%) strains produced con-
siderable amounts of the following enterotoxins: A (5 strains), B
(9), C (10), D (2), and two strains produced types A + C or B + C.
Conclusions: TSS morbidity in the Czech Republic is evidently
under-reported. TSS should be taken into account in differential
diagnosis. Two of our patients with misdiagnosed streptococcal
infection unresponsive to treatment with penicillin recovered
when given oxacillin. TSS is a life-threatening illness. The work
was partially supported by grant GACR 301/02/1505 from Grant
Agency of the Czech Republic.
P1855 The recognition of two tentative novel species
among haemolytic Acinetobacter strains
A. Nemec, L. Dijkshoorn, T.J.K. van der Reijden, T. De Baere,
P.J. van den Broek, M. Vaneechoutte
Prague, CZ; Leiden, NL; Ghent, B
Objectives: The genus Acinetobacter currently consists of 32
(genomic) species and a number of as yet unclassiﬁed strains. The
aim of the present study was to classify haemolytic Acinetobacter
strains of unknown taxonomic status isolated mostly from human
clinical specimens.
Methods: Twenty-eight haemolytic strains that could not be identi-
ﬁed as belonging to any known (genomic) species were studied
by phenotypic analysis, ampliﬁed rDNA restriction analysis
(ARDRA), AFLP ﬁngerprinting and 16S rDNA comparative
sequence analysis. Type or reference strains of all known Acinetob-
acter (genomic) species were included.
Results: Using a polyphasic approach, the investigated strains
were classiﬁed into two well-separated phenetic groups, termed
phenon 3 (n ¼ 8) and phenon 7 (n ¼ 15), ﬁve isolates remaining
ungrouped. Each of the two phenons contained nonglucose-acidi-
fying strains that showed identical or highly similar phenotypic
properties and ARDRA proﬁles, and formed distinct AFLP clus-
ters at a similarity level of >50% which is generally the species
delineation level. In addition, 16S rDNA sequence analysis of
three and two strains of phenons 3 and 7, respectively, indicated
that these groups formed two separate lineages within the genus
Acinetobacter. The phenons could be distinguished phenotypically
from each other and from all known (genomic) species. The
strains of phenon 3 were isolated exclusively from human clinical
specimens whereas the phenon 7 strains originated from human
(n ¼ 8) and equine (n ¼ 2) clinical specimens, hospital environ-
ment and staff (n ¼ 2), or from soil (n ¼ 2). The human clinical
specimens were mostly represented by tracheal aspirate of hospi-
talised patients.
Conclusions: This study has shown that most of the unclassiﬁed
haemolytic strains belong to two phenons distinct from all des-
cribed (genomic) species of the genus Acinetobacter. These phenons
probably represent two novel species as indicated by the presen-
ted results and by partial DNA-DNA reassociation data available
from the previous taxonomic studies. The available epidemiologi-
cal and clinical data suggest that the strains of both phenons may
play a role in infections of hospitalised patients.
P1856 First Austrian case of a severe infection with a
sorbitol-fermenting, Shiga toxin-producing E. coli O157 and ﬁrst
case of a documented transmission of such a strain by animal
contact
D. Orth, K. Grif, M. Dierich, R. Wu¨rzner
Innsbruck, A
Objectives: Vero or shiga toxin (Stx)-producing Escherichia coli
(VTEC) O157:H7 is a major cause of haemorrhagic colitis and
haemolytic-uraemic syndrome (HUS) worldwide. Human infec-
tions with VTEC serotype O157 have been linked to transmis-
sion from animals. Cattle act as domestic animal reservoir for
VTEC O157. The aim of this study was to investigate an out-
break of sorbitol-fermenting (SF) VTEC O157 infection affecting
a farmer family during June 2003 in the Austrian province Salz-
burg.
Methods and results: The investigations started when a 10-month-
old boy was admitted to the Childrens’ Hospital in Salzburg on
07 June 2003 because of gastroenteritis accompanied by fever
and jaundice. In the hospital the child developed a HUS. A
stool specimen yielded SF VTEC O157. Isolate identiﬁcation was
conﬁrmed by conventional biochemical tests and serotyping by
latex test (Murex). Production of toxins by the isolates was
assayed by EIA (Premier EHEC; Meridian, Milano, Italy) and
presence of stx, eaeA and hlyA genes were conﬁrmed by PCR. b-
Glucuronidase activity and motility were also tested. As a part
530 Abstracts
of the case–control study conducted at the ARLV faecal speci-
mens of the rest of the farmer family and their cattle were col-
lected. An investigation was initiated to identify a source and
contributing factors and to determine the extent of the outbreak.
A stool specimen of the 2-year-old brother of the patient and
two faecal samples of two cattle (one calf and one bull) also
identiﬁed SF STEC O157. All four STEC isolates carried the
virulence genes stx 2, eaeA and hlyA, and were characterised by
automated ribotyping (using EcoRI as restriction enzyme) and
pulsed-ﬁeld gel electrophoresis (PFGE; with XbaI as restriction
enzyme). The patterns of all four strains were indistinguishable
from each other by both typing methods. SF VTEC O157 strains
have been previously discovered in Germany and the Czech
Republic.
Conclusions: This is the genuine Austrian case of a VTEC O157
and furthermore resembles the ﬁrst case of such a strain with
documented transmission by animal contact. It illustrates the
hazards associated with animal contact and underlines the
importance of microbiological diagnostic approaches designed to
detect SF VTEC O157. These strains are normally missed by
methods solely relying on sorbitol–Mac Conkey agar plates.
Thus, stool specimens not only from patients with HUS but also
from young children should at least be tested for the presence
of Shiga toxins.
P1857 The molecular epidemiology of selected food-borne
pathogens recovered from paediatric patients, indigenous
peoples, and food animals in northern Thailand
R. Hanson, J. Kaneene, P. Padungtod, K. Van Maele, K. Lewiston,
R. Batizy
East Lansing, USA; Chiang Mai, TH
Objectives: Prospective epidemiological studies were conducted
to determine the molecular relatedness of Campylobacter and
Salmonella isolates from paediatric patients, indigenous peoples
(farm and nonfarm workers), and food animals in northern
Thailand.
Methods: Faecal samples were collected from food animals at
farms, farm workers and their nonfarming neighbours (con-
trols), animals and workers at slaughterhouses from 2000 to
2002, and from paediatric patients from three hospitals in Thai-
land in 2003. Multiplex polymerase chain reaction (M-PCR)
assay of various genes was used to determine the species of
Campylobacter. Single-stranded conformation polymorphism
(SSCP) was used to determine the molecular proﬁle of ﬂaA
gene of Campylobacter.
Results: A total of 369 Campylobacter and 221 isolates of Salmonella
were processed during 2000–2002 from farm workers, nonfarm
workers and food animals. Samples were also collected from three
paediatric hospitals yielding 36 Campylobacter and 136 Salmonella
isolates from 205 children <5 years of age with acute diarrhoea.
The risk factors for Campylobacter infections in children age <5-
year-old include consumption of pork (OR 2.86), of chicken (OR
5.27) and of milk products (OR 1.05). Comparison of SSCP proﬁle
showed that all Campylobacter isolated from paediatric diarrhoea
cases shared similar molecular proﬁles with isolates from food
animals at the farm. Ninety-four and 98% of Campylobacter isola-
ted from the market and slaughterhouse share similar proﬁle with
Campylobacter isolated at the farm. Ninety per cent of Salmonella
isolated from the paediatric diarrhoea patients had similar proﬁles
with the Salmonella isolated at the farms, slaughterhouse or mar-
ket.
Conclusions: Analysis of risk factors for acute diarrhoea showed a
positive association with the consumption of pork and milk, but
the association was not statistically signiﬁcant, except for chicken
(OR 5.27, P ¼ 0.043) in relation to the Campylobacter infections in
children <5 years old. There were also positive associations
between the consumption of chicken and pork with Salmonella
infection, but the association was not statistically signiﬁcant.
Campylobacter and Salmonella from food animals at the farm may
be transmitted through the food chain and cause diarrhoea in
children in Northern Thailand.
P1858 Chlamydia pneumoniae infection in carotid artery
disease (CAD) patients and its clinical impact
J. Niedzwiadek, E. Mazur, M.A. Wolski, M. Koziol-Montewka
Lublin, PL
Objectives: The aim of our study was to assess the presence of Chl-
amydia pneumoniae infection in CAD patients and to evaluate its
association with clinical symptoms.
Material and methods: Twenty-eight patients operated for CAD
(eight females, 20 males; mean age 64.5 years) and 20 healthy con-
trols took part in our study. Microimmunoﬂuorescence method
was applied to evaluate the level of anti-C. pneumoniae IgG, IgA
and IgM. C. pneumoniae micro-IF test (Labsystem) was used. PCR
method was applied for C. pneumoniae DNA detection in athero-
sclerotic plaques, obtained during carotid endartherectomy.
Results: Serological markers of chronic C. pneumoniae infection
were detected in 22 of 28 (78.6%) patients and in six of 20 (30%)
healthy controls. In 36.4% (eight of 22) of patients with serological
markers of chronic C. pneumoniae infection high titres of speciﬁc
IgG and IgA were noted. Interestingly, all patients in high serol-
ogy group proved to have transient ischaemic attacks (TIA).
C. pneumoniae DNA was present in carotid atherosclerotic plaques
obtained from 17 (60.7%) patients.
Conclusions: Serological signs of chronic C. pneumoniae infection
occur statistically more frequent in CAD patients in comparison
with healthy controls. High titres of IgG and IgA against C. pneu-
moniae are associated with TIA symptoms.
P1859 Extraintestinal salmonellosis
M. Jovanovic, S. Pavic, G. Kovacevic, V. Vasiljevic, G. Lazarevic
Belgrade, Uzice, CS
Objectives: To explore the proﬁle and frequency of nontyphoid
extraintestinal salmonellosis at the regional General Hospital
Uzice.
Methods: We retrospectively surveyed (1972–2001) microbiology
records of 360 patients, with primary nontyphoid Salmonella infec-
tions. Our strains were obtained from blood, cerebro-spinal ﬂuid,
burns, wounds, urines and sputa. We compared the number of
these isolates with the total number of Salmonella isolates.
Results: Although we found 26 serotypes of all Salmonella isolates,
only 16 serotypes and 360 strains were recovered from nonfaecal
material. S. wien was the most prevalent isolate (77.30%), then
S. abony (9.72%) and S. enteritidis (5.67%). In our hospital, the
number of Salmonella isolates per year persists (average 93.8,
range 35–261), but the number of extraintestinal isolates decreases,
so in the last 10 years their total number was 10 and no one speci-
men yielded S. wien. Children and neonates were 46.21% of stud-
ied populaton.
Conclusions: Our ﬁndings strongly support the fact that S. wien is
known to have a propensity for causing extraintestinal infections.
But, nowadays it’s rare in faecal and nonfaecal isolates and S. en-
teritidis prevails. As S. enteritidis is moderately invasive serovar,
the total number of extraintestinal isolates is decreasing.
P1860 Extended-spectrum beta-lactamase producing
Salmonella isangi, an emerging pathogen in South Africa
M.A. du Toit, S. Mehtar, N. Cameron, K. Keddy
Tygerberg, Johannesburg, ZA
Salmonella isangi (group C1) is a poorly known enteric pathogen
peculiar to Africa. Since the national surveillance was introduced
in 1999, isolates have been identiﬁed in South Africa. It is unusual
in its presentation as it predominantly affects extreme ages, has a
propensity to invade the blood stream and most importantly its
multiple-antibiotic resistant which poses serious problems for
management.
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Objective: To determine the size of the problem in children less
than 5 years of age with diarrhoea admitted to Tygerberg Hospi-
tal (Cape Town).
Method: The study covered the period from 01 October 2002 to 31
May 2003 where all cases of diarrhoea under the age of 5 years
had a stool sample sent for bacteriological examination for S. isan-
gi. Antibiotic sensitivity was performed on all isolates. Demogra-
phic data, which included age, sex, location and HIV status,
where available, was collected on conﬁrmed cases below the age
of 5 years admitted to hospital with diarrhoea.
Results: There were 21 cases of ESBL producing S. isangi identiﬁed
from stool culture (and blood culture). Sixteen (76.2%) of the 21
cases were nalidixic acid resistant. Three children died two of
whom were HIV+. The median hospital stay (excluding the
deceased) was 31.5 days. The ESBL producing S. isangi was com-
munity-acquired bacterium but was highly resistant to other anti-
biotics including nalidixic acid.
Conclusions: ESBL producing S. isangi, which is also nalidixic acid
resistant, affects mostly the very young children from poor socio-
economic conditions. Further surveillance is warranted into rea-
sons for the development of multiply-antibiotic resistance devel-
oping in this species.
P1861 Meningococcal carriage in an urban population in
Burkina Faso in 2003
J.E. Mueller, S. Yaro, L. Sangare´, Z. Tarnagda, A. Drabo,
Y. Traore´, B. Lafourcade, B. Gessner
Paris, F; Bobo-Dioulasso, Ouagadougou, BF
Objectives: Recurrent epidemics of meningitis in Burkina Faso
usually are caused by serogroup A meningococci, but a large
W135 epidemic occurred in 2002. In order to deﬁne an appropri-
ate future vaccination strategy, the propagation of this new epi-
demic strain in the population needs to be better known. This
longitudinal study describes meningococcal carriage in an urban
population of Burkina Faso during the 2003 meningitis season.
Methods: In a representative sample of residents between 4 and
29 years of age in Bobo-Dioulasso, Burkina Faso, oro-pharyngeal
swabs were taken from each participant at ﬁve study visits
between February and June 2003. The swabs were analysed by
culture and all isolated N. meningitidis were serogrouped by PCR
[A, B, C, W135, Y; nonserogroupable (ns)].
Results: Of 491 participants included, 407 came to all ﬁve visits
without use of any relevant antibiotic treatment during the
4 weeks before the visits. The 5-months carriage prevalence was
7% (95% conﬁdence interval 5, 11) for serogroup W135, 0.3%
(0.03, 2) for A, 0.7% (0.2, 4) for Y, 14% (11, 18) for ns, and 14%
(10, 17) for N. lactamica. No serogroup B or C was found in car-
riage. A signiﬁcant difference between the age strata was found
only for carriage of N. lactamica: 21% in 4–14 years vs. 6% in 15–
29 years (P ¼ 0.002). Recent meningococcal vaccination status did
not have any impact on carriage. During the observation time,
only ns meningococci demonstrated an increase in the point car-
riage prevalence (from 1 to 7%, P < 0.001); for serogroup W135,
the point prevalence at each visit was approximately 2%. Antibio-
tical resistance was found against oxacillin (36% of N. meningitid-
is. strains) and cotrimoxazole (11%), but not for chloramphenicol,
ciproﬂoxacine, ceftriaxone, or penicillin (resistance in <1% of
strains). ns meningococci are currently being analysed by immun-
sera.
Conclusions: Concurrent meningitis surveillance during the study
season in Bobo-Dioulasso found that W135 and A caused an
approximately equal number of meningitis cases. Nevertheless,
we found that W135 was the most commonly identiﬁed N. menin-
gitidis. Serogroup among healthy carriers with a 5-month preval-
ence over 20-fold higher than serogroup A. Combined, these
ﬁndings suggest that serogroup W135 may require a substantial
carriage burden for the propagation of epidemic disease while
serogroup A may have a higher virulence.
ESBL and metallo-beta-lactamases - II
P1862 Evaluation of extended-spectrum beta-lactamase
(ESBL) among K. pneumoniae and its susceptibility pattern
among infection isolates from a university hospital in So Paulo,
Brazil
F. Rossi, M.N. Burattini, R. Arruda, D. Andreazzi, C. Bento,
S. Freitas, G. Almeida
So Paulo, BR
K. pneumoniae (Kp) ESBL are also a growing concern in our Uni-
versity Hospital in So Paulo, Brazil. When producing ESBLs those
strains become highly efﬁcient at inactivating third and fourth-
generation cephalosporins and in addition may frequently be
resistant to other classes of antibiotics, resulting in difﬁculties-
to-choose adequate empiric therapy before antibiogram results
become available.
Objective: Evaluation of ESBL prevalence among Kp from blood
and urine nosocomial isolates during 2002 and analysis of its spe-
ciﬁc antimicrobial susceptibility pattern.
Methods: The 624 Kp strains (no duplicates) were tested for ESBL
by three-disc-combination methodology (ceftazidime, ceftriaxone
and cefpodoxime with and without clavulanic acid; Oxoid). Sus-
ceptibility tests were performed by the Vitek System (GNS-650
and GNS-204) and interpretations were made according to current
NCCLS recommendations. QC strains achieved properly results.
Data analyses were performed before any report susceptibility
change due to ESBL detection.
Results: 57% from 189 blood isolates were ESBL positive and 55%
from 455 urine isolates.
Susceptible patterns were as follow from blood and urine
respectively: See Table below.
Conclusion: Kp ESBL susceptibility data from both clinical sources
were similar. Amikacin was the most active agent after imipenem
witch narrows therapeutical choices. Cefotaxime was more affec-
Antimicrobial agent Blood Urine
Amikacin 67% 59%
Gentamicin 49% 44%
Aztreonam 4% 7%
Cefepime 27% 30%
Ceftazidime 58% 38%
Cefotaxime 11% 21%
Cefoxitin 98% 87%
Cephalothin 3% 2%
Ciproﬂoxacin 43% 37%
Imipenem 100% 100%
Piperacillin/taz 43% 42%
Trimethoprim-sulfa 20% 15%
Nalidixic acid NA 31%
Nitrofurantoin NA 27%
Norﬂoxacin NA 40%
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ted than ceftazidime and this resistance phenotype can be consid-
ered an important preliminary indicator of CTX-M producing
strains, even though a genotyping conﬁrmation of this enzyme is
essential in this study. Epidemiological and molecular studies will
be conducted to establish the relationship between ESBL produ-
cing isolates and to characterise the different types of ESBL in our
hospital.
P1863 Risk factors for acquisition of carbapenem-resistant
Klebsiella pneumoniae among hospitalised patients
I.-G. Bae, Y.G. Kwak, E.J. Choo, S. Choi, J. Chung, Y.S. Kim,
N.J. Kim, J. Ryu
Jinju, Seoul, KOR
Objectives: Carbapenem has been therapeutically used for patients
infected with organisms that are resistant to multiple classes of
antibiotics, including third-generation cephalosporins. The use of
carbapenem has resulted in the emergence of carbapenem-resist-
ant mutants and K. pneumoniae has been included in the class of
bacterial species that are likely to be resistant to carbapanem since
1997. This study aimed to identify risk factors for the nosocomial
isolation of carbapenem-resistant K. pneumoniae from clinical spec-
imens.
Methods: A case–control study was conducted for the intended
objective. Case patients were deﬁned as patients from whom carb-
apenem-resistant K. pneumoniae was isolated in clinical cultures.
Control patients were randomly selected by the ratio of 4:1 from
the same medical or surgical services that hospitalised case
patients at the time of isolating carbapenem-resistant K. pneumoni-
ae. Risk factors that were investigated included antimicrobial drug
exposures, demographic variables, comorbid conditions, and vari-
ables related to hospitalisation.
Results: Carbapenem-resistant K. pneumoniae was isolated from
30 patients during the period of January 1997 to August 2003.
93.3% of carbapenem-resistant K. pneumoniae was analysed as
ESBL(extended-spectrum beta-lactamase)-producing organisms.
Carbapenem-resistant K. pneumoniae was recovered from bile
(36.7%), most frequently. The rest was recovered from clinical cul-
ture of wound specimens (23.4%), ascitic ﬂuid (16.7%), and blood
(13.3%). Logistic regression analysis demonstrated the previous
use of carbapenem (odds ratio 28.68; P < 0.001) and cephalosporin
(odds ratio 4.10; P ¼ 0.013) as signiﬁcant risk factors for the acqui-
sition of carbapenem-resistant K. pneumoniae. The use of quinolone
appeared to be protective (odds ratio 0.26; P ¼ 0.045).
Conclusions: Carbapenem resistance in K. pneumoniae is a partic-
ularly disturbing development in the world of antibiotic resist-
ance. This study identiﬁed carbapenem and cephalosporin as risk
factors. The protective effect of quinolone against isolation of carb-
apenem-resistant K. pneumoniae is issue for further investigation.
P1864 Incidence rate and detection of Klebsiella
pneumoniae producing extended-spectrum beta-lactamase in a
department of anaesthesiology and resuscitation, Ceske
Budejovice
M. Hornikova, M. Balejova, M. Hynkova, P. Kucerova
Ceske Budejovice, CZ
Introduction: Klebsiella pneumoniae is the ﬁrst pathogen to be found
producing extended-spectrum beta-lactamases (ESBLs), mainly
due to TEM and SHV enzymes gene mutation. The mutation
development is facilitated by frequent empiric use of third genera-
tion cephalosporins in the ICU setting.
Methods: To detect the presence of ESBL, we use Double Disc Syn-
ergy Test, utilising the following discs: amoxicillin/clavulanic acid
(AMC)-disc contents 20/10 lg, ceftazidime (CTZ) – 30 lg, cefpo-
doxime (CPD) – 10 lg, aztreonam (AZT) – 30 lg. The test is based
upon the susceptibility of extended spectrum beta-lactamases to
clavulanic acid. A positive result is manifested by characteristic
extension of inhibition zone between the discs with AMC and a
third generation cephalosporin (or AZT). The test is performed in
K. pneumoniae strains that show intermediate susceptibility or
resistance to second and third generation cephalosporins.
Results: From 2000 till 2003, the number of patients who tested
positive for ESBL producing strains of K. pneumoniae dropped
from 80 (17%) down to 2 (0.4%). Concurrently, the use of third
generation cephalosporins (ceftazidime, cefotaxime, ceftriaxone,
cefoperazone) was reduced from 3.5 g down to 2 g per one hospi-
talised patient. A certain contribution should also be attributed to
a more strict adherence to hygienic guidelines (patient isolation,
handwashing, single-use devices, etc.).
Summary: The incidence rate of multiresistant, ESBL-producing
strains of K. pneumoniae may be mitigated by controlled broad-
spectrum antibiotic use and a stricter adherence to hygienic
guidelines.
P1865 Extended-spectrum beta-lactamases in Klebsiella
pneumoniae isolates from a Madrid hospital: an updated
complex situation (2001–2003)
A. Valverde, T.M. Coque, N. Nattell, A. Novais, A. Rolla´n,
F. Baquero, R. Canto´n
Madrid, E
Background: Although ESBL producing Escherichia coli isolates
have rising to prominence during the last years, K. pneumoniae
(Kp) is maintained as an important reservoir of these enzymes.
The aim of this study was to analyse ESBL producing Kp isolates
recovered in our institution January 2001 to June 2003 and
compare current situation with that previously found (1988–2000)
(Coque et al. (2002) AAC 46, 500–510).
Methods: All Kp isolates recovered during the studied period
were screened for ESBL production. One isolate per patient was
selected for clonal typing (XbaI-PFGE) and ESBL characterisation
(IEF, PCR, and sequencing).
Results: A total of 56 ESBL producing Kp (3.7%) isolates recov-
ered from 35 patients (43%, surgical wards; 23%. ICU; 14%, med-
ical wards; 20%, outpatients) were identiﬁed. The proportion of
outpatients with ESBL-Kp isolates signiﬁcantly increased
(P < 0.01) during the studied period. Population analysis revealed
a complex situation with the absence of outbreaks and the pre-
sence of a polyclonal structure. Moreover, the variety of different
ESBL signiﬁcantly increased, with persistence of previously identi-
ﬁed ESBL types (TEM-4, SHV-2, CTX-M-9, CTX-M-10) and the
emergence of new ESBL (SHV-11, SHV-12, CTX-M-14). Co-resis-
tance analysis revealed an increment of resistance to nalidixic acid
(30%), ciproﬂoxacin (30%), trimethoprim (48%), and sulphona-
mide (62%), most of these antibiotics widely used in the commu-
nity. Changes in the prevalence of different ESBLs may justify
associated changes in the frequency of gentamicin and tobramycin
resistance that were reduced to 23 and 37%, respectively.
Conclusions: Although epidemics involving ESBL-Kp were not
observed in our institution during 2001–2003, this organism act-
ively participates in global dissemination and maintenance of ES-
BLs. Moreover, the signiﬁcant increase in the entrance of ESBL-Kp
from the community to the hospital setting represent a new con-
cern for nosocomial infections.
P1866 The occurrence and relatedness of extended-
spectrum beta-lactamases (ESBLs) among Enterobacter spp.
isolates in Tel Aviv
J. Schlesinger, S. Navon-Venezia, I. Chelminitzki,
O. Hammer-Muntz, M. Schwaber, Y. Carmeli
Tel Aviv, IL
Background: Enterobacter are leading nosocomial pathogens. ESBL-
producing phenotype (PP) was found among 22% of Enterobacter
clinical isolates in our institution. We examined the clonal related-
ness, and characterised the ESBL enzymes of these strains.
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Methods: Seventeen Enterobacter spp. with ESBL PP were studied.
Clonal relatedness determined by PFGE. Enzymes were character-
ised using Isoelectric focusing (IEF) staining with nitroceﬁn  cla-
vulanate. Transconjugation experiments were performed with E.
coli HB101 selected on ceftazidime and streptomycin. ESBL gene
families were screened by colony hybridisation. PCR for TEM,
SHV, CTX-M genes was performed and products were sequenced.
Results: Seventeen Enterobacter isolates [E. cloacae (13), E. aerogenes
(3), and not identiﬁed (1)] belonged to 15 distinct PFGE types. All
isolates had at least one IEF band that hydrolysed nitrocephin and
whose activity was inhibited by clavulanate (range 1–5 bands); pI
ranged between 5.4 and 7.8. All 17 strains had a beta-lactamase
with a pI of 5.4, and 11 strains had a beta-lactamase with pI of
7.8. Colony hybridisation identiﬁed in 16 isolates at least one
family of beta-lactamase gene: two harboured only a TEM gene,
four CTX-M only, seven TEM and SHV, two SHV and CTX-M, and
one Enterobacter isolate harboured all three. PCR screening for
TEM and SHV yielded similar results. Seven isolates were labelled
with the CTX-M speciﬁc probe, but only one was positive accord-
ing to PCR. One isolate not labelled with the CTX-M probe gave a
CTX-M gene PCR product. Sequence analysis of PCR products
identiﬁed all the TEM genes as TEM-1 (11 isolates), all the SHV
genes as SHV-12 (seven isolates), except one identiﬁed as SHV-1.
CTX-M PCR product sequencing identiﬁed one of the two CTX-M
genes as similar to CTX-M-2, and the second as similar to CTX-M-
26. In trans-conjugation experiment with four isolates harbouring
TEM-1 and SHV-12, both genes were simultaneously transferred to
E. coli HB101 recipient; trans-conjugants exhibited ESBL PP, had
two distinct IEF bands (pI 5.4 and 7.8) similar to their parental
Enterobacter isolates, and PCR and sequencing, conﬁrmed that all
carried the same beta-lactamases as their parental strains.
Conclusions: The widespread of ESBL among Enterobacter isolates
in Tel Aviv is not due to clonal spread but rather by multiple
clones carrying various and multiple enzyme families, some of
which are transferred simultaneously. The dominant identiﬁed
ESBL was SHV-12.
P1867 Outbreaks of SHV and CTX-M co-producing
Enterobacter cloacae in the intensive care unit of a Belgian
hospital
J. Frankard, R. Li, R. De Mendonc¸a, H. Rodriguez-Villalobos,
A. Deplano, B. Byl, J.-L. Vincent, M. Struelens
Brussels, B
Objectives: The rapid increase of extended-spectrum beta-lacta-
mases (ESBLs) producing Enterobacteriaceae has become a serious
problem in European hospitals. The purpose of this study was to
assess the molecular epidemiology of two successive outbreaks of
E. cloacae (EC) resistant to third generation cephalosporins (CIII-
R), which occurred during periods from June 2000 to March 2001
and July 2001 to December 2002, respectively.
Methods: A total of 75 CIII-R E. cloacae clinical isolates from
patients admitted in ICU were included. ESBL screening was per-
formed by double disk (DD) synergy test using cefepime, ceftazi-
dime and amoxicillin–clavulanate. A multiplex PCR was used to
detect blaTEM, blaSHV and blaCTX-M gene families. Genotyping
was performed by pulsed ﬁeld gel electrophoresis (PFGE) with
XbaI restriction.
Results: From the 75 CIII-R E. cloacae strains, ESBL was detected
in 58 (77%) by DD synergy test. Co-resistance to sulphamethoxaz-
ole was also found in 81%, to ciproﬂoxacin in 18%, to gentamicin
in 48%, amikacin in 1%, to cefepime in 18% and to meropenem
in 1%. PFGE analysis of ESBL producing strains revealed 20 dif-
ferent clonal types including three major ones: A (n ¼ 28), L
(n ¼ 14) and K (n ¼ 6). During the ﬁrst outbreak, clone A was
recovered in 22 of 30 strains, while the second outbreak was char-
acterised by 14 of 45 strains from clone L, six of 45 from clone K
and six of 45 from clone A. The three epidemic clones and 10
sporadic isolates harboured both SHV and CTX-M ESBL, repre-
senting 83% of ESBL-producing EC. Among 11 ESBL environmen-
tal isolates, seven also carried both SHV and CTX-M genes.
ESBL-carrying Enterobacteriaceae strains of four species other
than EC were co-isolated during this period in 15 patients, of
which 8 had both SHV and CTX-M genes (two E. coli, one E. aero-
genes, four K. pneumoniae, one M. morganii). DNA sequencing of
representative strains revealed SHV-12 ESBL. CTX-M identiﬁca-
tion and plasmid proﬁle analysis are still under investigation.
Conclusions: These successive polyclonal ICU outbreaks of CIII-R
E. cloacae are highly suggestive of horizontal co-transfer of SHV
and CTX-M ESBL-carrying plasmid. However, further investiga-
tion is necessary to determine if SHV and CTX-M genes are car-
ried by the same plasmid. Our study demonstrates that ESBL-
producing EC is an emerging threat causing nosocomial outbreaks
and underlines its probable role as a reservoir of ESBL gene inter-
species transmission.
P1868 The ﬁrst identiﬁcation of VIM-1 in an Enterobacter
cloacae isolate from a university hospital in Greece
I. Galani, M. Souli, Z. Chryssouli, K. Orlandou, H. Giamarellou
Chaidari, GR
Objectives: Carbapenem resistance in E. cloacae is unusual and has
been described in strains with porin alterations combined with
hyperproduction of chromosomal cephalosporinase, in strains pro-
ducing class A carbapenem-hydrolysing nonmetallo-beta-lacta-
mases, such as NmcA beta-lactamase and in strains producing
IMI-1 beta-lactamase. Recently a class B metallo-beta-lactamase
(MBL) has been reported in an imipenem-resistant E. cloacae
strain, isolated in Korea, which carried a blaVIM-2-containing in-
tegron. In 2003, an E. cloacae strain with an imipenem MIC of
1 mg/L was isolated in a tertiary care hospital in Athens (Greece),
from the blood culture of a hospitalised patient. The strain dem-
onstrated a positive EDTA-disc synergy test and it was studied
for carbapenemase production.
Methods: E. cloacae was isolated from the blood culture of a
patient suffering from Fournier’s gangrene. Susceptibility testing
was performed by the disk diffusion technique and MICs were
determined by the broth microdilution method (Sensititre Ltd,
West Sussex, UK), according to NCCLS guidelines. EDTA-disc
synergy test, was used to screen for MBL production. Beta-lacta-
mases were detected by isoelectric focusing (IEF) and the presence
of a MBL gene was determined by PCR with the following set of
primers: VIM-F (50-ATGGTGTTTGGTCGCATATC-30) and VIM-B
(50-TGGGCCATTCAGCCAGATC-30). Sequencing of cloned PCR
products was performed by MWG- THE Genomic Company.
Results: The isolate was resistant to aminopenicillins, cephalospo-
rins and monobactams and had reduced susceptibility to imipe-
nem but not to meropenem (MICs; 1 and 0.25 mg/L, respectively).
It demonstrated a positive EDTA-disc synergy test. IEF identiﬁed a
beta-lactamase with pI of 9 probably corresponding to the chromo-
somal AmpC cephalosporinase of E. cloacae. No band of pI 5.3 was
visible. Sequencing of the cloned PCR product identiﬁed blaVIM-1.
Conclusions: To the best of our knowledge, this is the ﬁrst report of
the presence of blaVIM-1 MBL in E. cloacae. The spread of MBLs in
Enterobacteriaceae is becoming a grate concern in Greece as VIM-1
has also been reported in E. coli, and K. pneumoniae isolates. The
spread of blaVIM-1 could compromise the future usefulness of
carbapenems for the treatment of serious infections caused by
Gram-negative bacilli and requires more attention than ever before.
P1869 Prevalence of extended-spectrum beta-lactamases
and metallo-beta-lactamases in clinical isolates of Enterobacter
cloacae from Northern Italy
F. Luzzaro, A. Endimiani, M. Perilli, C. Colinon, G. Celenza,
G. Amicosante, G.M. Rossolini, A. Toniolo
Varese, L’Aquila, Siena, I
Objectives: Resistance to broad-spectrum cephalosporins in
Enterobacter cloacae may be a consequence of the selection of sta-
bly derepressed mutants producing a chromosomal group-1
beta-lactamase. This species can also acquire and express genes
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encoding extended-spectrum beta-lactamases (ESBL). So far, iso-
lates that produce metallo-beta-lactamases (MBL) have been
reported from Taiwan, Korea, and recently from Italy. This study
was initiated to investigate the prevalence of ESBL and MBL in
clinical isolates of E. cloacae collected at our Institution (Varese,
Italy) in the year 2002.
Methods: All consecutive E. cloacae isolates showing reduced sus-
ceptibility to broad-spectrum cephalosporins (MIC > 1 mg/L)
were collected. The double-disk synergy test was used to evaluate
ESBL production. The Etest method (AB Biodisk, Solna, Sweden)
was used to assess MIC values of several beta-lactams, including
last-generation cephalosporins, carbapenems, and aztreonam.
DNA probes speciﬁc for TEM, SHV, CTX-M and PER-1/2 genes
were used to assess the presence of these resistance determinants.
ESBL-positive isolates and those showing MIC for carbapenems
>1 mg/L were also investigated for MBL production with molecu-
lar methods (RFLP-multiplex PCR) and enzymatic assays. The
plasmid location of ESBL and MBL determinants was investigated
through conjugation experiments and Southern blot hybridisation.
Results: We studied 384 consecutive nonduplicate E. cloacae iso-
lates (252 from inpatients, 132 from outpatients). Overall, 86 iso-
lates (22.4%) were resistant to broad-spectrum cephalosporins
(27.9% in inpatients, 7.6% in outpatients). On the basis of the
double-disk synergy test, 28/384 (7.3%) isolates were found to
produce ESBL. Molecular analysis showed that six isolates carried
a CTX-M-type gene, whereas most of the remaining 22 carried the
SHV gene. Notably, two isolates were suspected to produce MBL
since they had EDTA-inhibitable carbapenemase activity. In the
latter strains, RFLP-multiplex PCR indicated that a VIM-1-like
gene was present. CTX-M and VIM determinants were carried on
plasmids that were transferred to E. coli recipients by conjugation.
Conclusions: In addition to classical TEM-type and SHV-type
ESBL, CTX-M-type enzymes and MBL appear to emerge among
clinical isolates of E. cloacae. Monitoring ESBL prevalence in this
species may be of value to control the spread of these worrisome
resistance determinants.
P1870 Drug resistance and molecular epidemiology of
beta-lactamase-producing Enterobacter cloacae strains isolated
from hospital and aquatic environments
R. Cernat, V. Lazar, C. Balotescu, M. Nicolae, O. Banu
Bucharest, RO
Introduction: Clinical and environmental E. cloacae isolates exhibit
high resistance to third generation cephems.
Objective: To compare antibiotic resistance patterns and to delin-
eate the clonal diversity and transmission patterns by plasmid
proﬁle, rep-PCR, PFGE and RAPD analysis between Enterobacter
cloacae strains isolated from different environments.
Methods: Sixteen E. cloacae strains from cardiovascular devices
inserted patients and seven E. cloacae strains from fresh and pol-
luted waters were studied for: antimicrobial susceptibility
(NCCLS) by disc diffusion method; double-disc and inductibility
disc diffusion tests, plasmid DNA proﬁles; Rep-PCR ﬁngerprint-
ing; DNA macrorestriction with XbaI endonuclease; RAPD using
primers HLWL74, AP4 and R108. PFGE and RAPD patterns were
visually compared into clonal groups and variants using UPGMA
algorithms and computational NTSYS program.
Results: A 62% of hospital isolates are ESBLs producers, with 7%
susceptibility to inhibitors; 20% intermediate susceptible to third
generation cephalosporins; 62% susceptible to quinolones, 40% to
aminoglicosides and 100% to imipenem. All aquatic strains
expressed inducible beta-lactamase phenotypes, with 100% resist-
ance to ampicillin, amoxicillin/clavulanic acid, chloramphenicol
and tetracycline, 80% to cephalosporins, 60% to aminoglycosides,
21% to quinolones. Plasmid DNA proﬁle analysis showed vari-
able number of plasmids (ranging from 2.5 to 30 kpb) for both
clinical and aquatic isolates. Chromosomal DNA digested with
XbaI produced an average of 20 fragments ranging between 40
and 700 kb. Nine of epidemiologically related strains were classi-
ﬁed in one cluster by rep-PCR and RAPD. Most informative
proﬁles were obtained with PFGE, six of these nine strains were
classiﬁed in one cluster whereas the remaining three strains were
not related to clonal strains and differed from each other. We
detected two clusters for aquatic strains: cluster B (ﬁve subtypes)
and cluster C (two subtypes), according to UPGMA criteria and
rep-PCR, RAPD and PFGE proﬁles.
Conclusions: Most of ESBL strains isolated from hospitalised
patients belong to the same clone. All inducible beta-lactamase
producing strains isolated from different aquatic sources belong
to two clones. Concluding, we found three spatial clusters and 10
unrelated isolates with possible clonal relatedness among them.
Both RAPD and PFGE are suitable for molecular typing E. cloacae
isolates with intra- and extra-hospital origins.
P1871 Spread of OXA-23-producing Acinetobacter
baumannii clones in England
J.M. Coelho, N. Woodford, M. Warner, J.F. Turton,
M.E. Kaufmann, T.L. Pitt, D.M. Livermore
London, UK
Introduction: Acinetobacter baumannii is an important nosocomial
pathogen, causing infections in immunocompromised patients
and those under artiﬁcial ventilation. Treatment is often complica-
ted by multi-resistance. Carbapenems have become the drugs of
choice, but reports of resistance are increasing. Target modiﬁca-
tion and/or porin loss can cause this resistance, but carbapene-
mases of molecular classes B (IMP and VIM) and D (OXA-23 and
-24-related) seem more frequent. We report here the spread of
two clones of OXA-23-producing A. baumannii across southern
England.
Methods: Carbapenem-resistant Acinetobacter were received for
MIC conﬁrmation and typing by the reference laboratories during
2002/2003. They were identiﬁed by standard methods, and typed
by PFGE. MICs were determined by Etest or agar dilution. Genes
encoding carbapenemases were sought by PCR with primers for
blaIMP, blaVIM, blaOXA-23-like and blaOXA-24-like; PCR prod-
ucts were sequenced on both strands. Chromosomal DNA was
digested with EcoRI and EcoRV restriction endonucleases, and an
OXA-23 probe was used in DNA-DNA hybridisations.
Results: blaOXA-23-like genes were detected by PCR in representa-
tives of the two clones (1 and 2), and sequencing indicated that the
enzyme was classical OXA-23. DNA–DNA hybridisation indicated
that the OXA-23 enzyme was chromosomally encoded in both
clones. Clones 1 and 2 had distinct PFGE proﬁles, with both con-
taining several PFGE variants. Both clones differed from the ori-
ginal OXA-23-producing A. baumannii reported in Scotland in 1985.
Eleven hospitals submitted samples from clone 1 only; three sub-
mitted samples from clone 2 only; and one submitted isolates
belonging to both clones. All affected hospitals were in southern
England. All isolates were carbapenem-resistant and were also
multi-resistant to ciproﬂoxacin, aminoglycosides and other beta-
lactams including sulbactam, and consistently sensitive only to pol-
ymyxins (MICs  0.5 mg/L) and minocycline (MICs 1–8 mg/L).
Conclusions: Two A. baumannii clones producing OXA-23 beta-lac-
tamase have spread in multiple hospitals in southern England.
This simultaneous spread of unrelated, but similarly resistant,
clones is disturbing.
P1872 The emergence of VIM-2 in Latin American
hospitals: report from the SENTRY Antimicrobial Surveillance
Programme
R. Mendes, M. Guzman, P. Garcia, R. Jones, M. Toleman,
T. Walsh, H. Sader
Sao Paulo, BR; Caracas, VE; Santiago, CL; North Liberty, USA; Bristol,
UK
Background: The VIM metallo-b-lactamases (MBL) are emerging
mobile resistance determinants recently described and reported in
various European countries and in the Far East. We report the
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detection and characterisation of Pseudomonas isolates producing
VIM-2 causing infections in Latin American (LA) hospitals.
Methods: As part of the SENTRY Programme, MBL production
was screened by Etest (AB BIODISK) MBL strip, then conﬁrmed
by hydrolyses assays and PCR for blaIMP, blaVIM and blaSPM
followed by gene sequencing. Integrons were detected with pri-
mer sets speciﬁc to the 50CS and 30CS of class 1 integrons. The
PCR products were sequenced bidirectionally using DuPont Auto-
mated systems and the sequences analysed by DNAstar.
Results: Two isolates were selected for characterisation. Strain 43-
14926A was a P. ﬂuorescens-putida isolated in Chile from blood-
stream infection in a 19-year-old female who was underwent bone
marrow transplantation. Strain 49.4597C was a P. aeruginosa isola-
ted in Venezuela from a 52-year-old male who developed sepsis
and nosocomial pneumonia as a complication from a surgical
abdominal infection. Both patients received imipenem (IMP) ther-
apy and other b-lactams previous to the isolation of the carbape-
nem-resistant (R) strains. Both isolates were R to IMP,
meropenem and ceftazidime. Sequence analysis revealed a MBL
gene blaVIM-2 in both isolates. Upstream from the MBL
(43-14926A) blaVIM-2, lies a class 1 integron. Downstream of bla-
VIM-2 was found a gene cassette aacA4 followed by aadA1 and
aadA2.
Conclusions: We documented the emergence of VIM-2 in two LA
hospitals. Global surveillance programmes, such as SENTRY, play
an important role in detecting the regional emergence and dissem-
ination of novel MBL mechanisms.
P1873 Endemic and epidemic occurrences of
metallo-beta-lactamases in Japanese medical centres (1998–2002):
report from the SENTRY Antimicrobial Surveillance Programme
R. Jones, G. Deshpande, J. Bell, J. Turnidge
North Liberty, USA; Alelaide, AUS
Background: Metallo-beta-lactamases (MBL) were initially charac-
terised in Japan, usually of the IMP-type and found in P. aerugi-
nosa (PSA), Acinetobacter spp. (ACB) or S. marcescens (SM). The
number of MBL types has increased worldwide, but geographical
dissemination in Japan has appeared limited. This study compares
baseline levels of MBL-resistance (R) from two, 22 centre studies
(1996–97) to the longitudinal sample (three sites) of Japanese iso-
lates from the SENTRY Programme (1998–2002).
Methods: All MICs were determined by reference NCCLS meth-
ods. 84 of 456 (18.4%) PSA, three of 88 (3.4%) ACB, and six of
258 (2.3%) Enterobacteriaceae (enterobacters and SM) with R to
both monitored carbapenems (CARB; MIC  8 mg/L) were
screened for MBL by disk approximation (EDTA and 2MPA
inhibitors), CARB hydrolysis by enzyme extracts and selected
PCR primers for all known MBLs. All MBL-positive strains (10)
were sequenced to determine type. Clonality in each centre was
determined by automated ribotyping and PFGE, where needed.
Results: The CARB-R rates in PSA (15.5–28.0%) appear to be
increasing over the monitored interval (1998–2002), but varied by
medical centre location. Among CARB-R isolates, 2.2% were
attributed to MBL strains (1.1% of all PSA tested). MBL identiﬁca-
tion showed: 5 PSA (3 IMP-1; 2 IMP-2), 4 SM (1 IMP-1; 2 IMP-
1 + OXA-1, and 1 novel MBL being characterised). The sequence
of the new MBL most closely resembles IMP-8 and has a complex
integron (integrase-MBL-aacA4-ORF1-QAC/SUL). Also a single
ACB had an IMP-1. Eight of 10 MBLs occurred between 2000 and
2002; four in 2002 (ACB, PSA, 2 SM). BRL42715, an AMP-C inhib-
itor conﬁrmed AMP-C-mediated R in 87.3% of PSA and OMP
changes were also discovered by membrane preparations. Prior
1997–98 (22 sites) results showed CARB-R at 22.4–25.6% and 0.5–
0.9% MBLs (IMP-1) overall.
Conclusions: MBL-producing strains from several species persist in
Japan, but represent a minority of all CARB-R isolates (1998–2002).
Epidemic (SM 196-3 ribotype in 2002) or endemic dissemination
was observed; and some novel beta-lactamase combinations and
MBL-types were discovered. MBL rates appear generally stable in
Japan. Continued global surveillance for these R mechanisms
appears to be a prudent practice due to the mobility of the genetic
determinants (plasmids or integrons) and the emergence of novel
enzyme types, especially in SM and other non-PSA species.
P1874 Resistance to imipenem and detection of class 1
integrons on Ps. aeruginosa and A. baumannii clinical isolates
M.J. Canduela, E. Sevillano, F.E. Calvo, A. Umaran, L. Gallego
Bilbao, E
Objectives: The aim of this study was to analyse the epidemiologi-
cal relationships among imipenem resistant (IR) clinical isolates of
Ps. aeruginosa and A. baumannii and to detect the presence of class
1 integrons in these isolates.
Methods: The study included all isolates obtained at a Hospital
from Bilbao (Northern Spain) during 2002 (226 and 88 isolates of
Ps. aeruginosa and A. baumannii, respectively). Susceptibility to
antimicrobial agents was determined by the agar dilution method
following the NCCLS recomendations. The antibiotics tested were
imipenem, meropenem, cefotaxime, ceftazidime, amikacin and
gentamicin. Total DNA was used as target for PCR-ﬁngerprinting
experiments with primers M13 and ERIC2. To detect class 1 integ-
rons, primers 30CS and 50CS were used in ampliﬁcation experi-
ments.
Results: Fifty-nine isolates (67.4%) of A. baumannii and 33 (14.6%)
of Ps. aeruginosa were resistant to imipenem. All imipenem resist-
ant A. baumannii isolates (IR-Ab) were also resistant to merope-
nem, 98.3% to gentamicin and 91.5% to cefotaxime, ceftazidime
and amikacin. A 72% of the imipenem resistant Ps. aeruginosa iso-
lates (IR-Ps) were resistant to gentamicin, 57.5% to cefotaxime,
54.5% to ceftazidime, 30% to meropenem, and 9% to amikacin.
Using the RAPD technique, four distinct genotypes were identi-
ﬁed among IR-Ab isolates. Clone I accounting for 69.5% (41 iso-
lates), clone II 23.7% (14 isolates) and Clone III 5,1% (three
isolates). Among IR-Ps isolates 22 distinct genotypes were recog-
nised; one of them (named 1) accounting for 27.3% (nine isolates)
and two of them (named 2 and 3) accounting for 6.1% (two iso-
lates respectively). All the isolates of IR-Ab bored integrons ran-
ging in size from 550 to 1600 bp. Integron named a (760 bp) was
the predominant accounting for 52 isolates (88%). Most of the iso-
lates bored combinations of three bands. Class 1 integrons were
present in most of the IR-Ps isolates, ranging in size from 600 to
1700 pb.
Conclusions: Resistance to imipenem in A. baumannii isolates was:
(a) higher than the one showed by Ps. Aeruginosa, (b) always com-
bined with meropenem resistance and (c) most of the isolates
were also resistant to all antibiotics tested. PCR-typing showed
that the majority of A. baumannii isolates belonged to few clones
but in Ps. aeruginosa several clones were identiﬁcated. All isolates
bored several class 1 integrons which means a rapid spread of the
resistant genes in nosocomial envirorment.
P1875 Metallo-beta-lactamase-mediated carbapenem
resistance in Pseudomonas aeruginosa in an Indian intensive
care unit
U. Sekar, H. Latha, V. Kamat
Chennai, IND
Objectives: Metallo beta lactamase mediated resistance is being
increasingly reported in Pseudomonas aeruginosa especially in the
far east Asian countries.The use of carbapenems has increased
over the last 2 years in our Intensive care unit (ICU) due to
increased prevalence of ESBL producing strains. This study was
performed in 2003 to determine the prevalence of metallo betalac-
tamase medited (MBL) carbapenem resistance in P. areuginosa in
ICU patients.
Methods: One hundred clinically signiﬁcant isolates of P. aerugi-
nosa from ICU patients were taken for the study. Susceptibility to
all anti pseudomonal drugs including imipenem and aztronam
was performed by disc diffusion technique and minimal inhibi-
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tory concentratrion (MIC) of imipenem and imipenem/EDTA
combination by agar dilution. For the detection of MBL two discs
method of imipenem 10 micrograms, imipenem EDTA 750 micro-
grams and ceftazidime 30 micrograms, ceftazidime EDTA
750 micrograms were used.
Results: Fourteen of the hundred strains were MBL producers.
Their MIC to imipenem was 16–128 micrograms. They exhibited
eight–128-fold decrease in MIC with imipenem EDTA combina-
tion. There was signiﬁcant difference in the inhibitory zone diam-
eters with EDTA as compared with MBL nonproducers. Two
strains exhibited this difference only with ceftazidime EDTA and
another only with imipenem EDTA. One isolate had high MIC
values to imipenem but was not an MBL producer reﬂecting other
mechanisms of resistance. All MBL producers had coresistance to
aminoglycosides and quinolones.
Conclusions: MBL mediated carbapenem resistance is present in
14% of pseudomonas strains in our ICU. With increased use of
carbapenems in the critically ill patients this is bound to increase.
This is to be addressed with judicious use of carbapenems and a
continuous monitoring programme. Use of both ceftazidime and
imipenem with EDTA will increase the sensitivity of MBL detec-
tion by the two discs method.
P1876 Outbreak of multiresistant Pseudomonas aeruginosa
producing the metallo beta-lactamase IMP-13 in a general
intensive care unit in southern Italy
R. Migliavacca, C. Colinon, J.-D. Docquier, M. Spalla, E. Nucleo,
M. Li Bergoli, M. Labonia, G.M. Rossolini, L. Pagani
Pavia, Siena, S.Giovanni Rotondo, I
Background and Objectives: Metallo-beta-lactamases (MBLs) of the
IMP and VIM type are emerging resistance determinants in
Gram-negative nosocomial pathogens. Their spreading is of con-
siderable concern for antimicrobial chemotherapy, due to their
carbapenemase activity and resistance to conventional beta-lacta-
mase inhibitors. Although epidemiology of these enzymes
remains largely unknown, in Europe IMP-type producers have
been reported less frequently than VIM-type producers, and only
in sporadic cases. In this work we describe an outbreak due to
P. aeruginosa producing an IMP-type MBL (IMP-13) in an Inten-
sive Care Unit of an Italian Hospital.
Methods: Twenty-seven nonreplicate carbapenem-resistant isolates
of P. aeruginosa were collected from 27 inpatients at the Intensive
Care Unit of the S. Giovanni Rotondo Hospital (southern Italy)
during the period October 2002 to June 2003. Most isolates (25
to 27) were from the lower respiratory tract. In vitro susceptibil-
ity tests were carried out by a microdilution method as recom-
mended by the NCCLS. The Etest and a broth microdilution
method (EPI test) were used for phenotypic detection of MBL
producers. PCR and sequencing were carried out to identify the
MBL determinants. Pulsed Field Gel Electrophoresis (PFGE),
using the SpeI restriction enzyme, was performed to evaluate
the clonal relationships between the imipenem-resistant clinical
isolates.
Results: Six carbapenem-resistant P. aeruginosa isolates were
shown to produce an MBL activity by the EPI test, while none of
them resulted positive with Etest. In all cases the MBL was identi-
ﬁed as IMP-13 by molecular methods. The IMP-13 producers were
resistant to imipenem, meropenem and ceftazidime, while 50%
retained susceptibility to piperacillin/tazobactam and 83% inter-
mediate susceptibility to aztreonam. PFGE analysis showed that
all the MBL producers were clonally related suggesting a clonal
spread within the ward. In the remaining isolates, which belonged
in clonal lineages different from that of the IMP-13 producers,
carbapenem resistance was due to mechanisms other than MBL
production.
Conclusions: To our best knowledge this is the ﬁrst report of a no-
socomial outbreak caused by P. aeruginosa producing the IMP-13
MBL. Concerning phenotypic detection, the EPI test could cor-
rectly detect all the IMP-13 producers, while the Etest failed in
revealing them.
P1877 Characterisation of integrons carrying blaVIM type
metallo-beta-lactamase genes from carbapenem-resistant
Pseudomonas aeruginosa clinical isolates in Hungary
B. Libisch, K. Csisza´r, L. Ro´kusz, G. Terna´k, M. Gacs, M. Fu¨zi
Budapest, HUN
Objectives: The aim of this study was to investigate the presence
and frequency of occurrence for acquired metallo-beta-lactamase
(MBL) producing Pseudomonas aeruginosa clinical isolates in
Hungary.
Methods: We screened the isolates by EDTA-inhibition based
phenotypic tests together with PCR using integron, blaVIM and
blaIMP speciﬁc primers to identify acquired MBL-producers.
Results: We recently isolated the ﬁrst integron-borne MBL gene in
Hungary from the urine sample of a Greek citizen treated in
August 2002 in Budapest. DNA sequencing revealed the presence
of a Class 1 integron carrying three gene casettes: an OXA-type
lactamase, an aminoglycoside 60-N-acetyltransferase and a bla-
VIM-4 type MBL gene cassette. VIM-4 has been reported for the
ﬁrst time from Greece in 2002. These observations raise the possi-
bility that this P. aeruginosa strain originates in Greece, and has
been imported to Hungary by a human carrier. In October 2003
another VIM-producing P. aeruginosa strain has been isolated in
Southern Hungary. PCR mapping experiments suggest that this
strain carries a class 1 integron with only two resistance gene cas-
settes in its variable region. The blaVIM type MBL gene cassette
is right upstream of the 30 conserved sequence. The structural dia-
gram of the two integrons is presented with implications for their
possible phylogenetic relationship.
Conclusions: With the isolation of a second VIM-producing strain
from an apparently independent case the repeated appearance of
MBL producing clinical isolates can be anticipated in Hungary. A
regular screening/monitoring system should be set up to prevent
the wider spread of these resistance determinants.
P1878 Metallo-beta-lactamase-producing Gram-negative
bacilli in KONSAR group hospitals: continued prevalence of
VIM-2-producing Pseudomonas spp. and increase of IMP-1-
producing Acinetobacter spp. in 2002
K. Lee, G. Ha, B. Shin, J. Kim, J. Kang, S. Jang, D. Yong
Seoul, Gyeong Ju, Inchon, Kuri, Kwangju, KOR
Objectives: Signiﬁcant proportion of carbapenem-resistant isolates
of P. aeruginosa and Acinetobacter spp. is due to acquired MBL pro-
duction, which renders all beta-lactams inactive. Since the ﬁrst
report of acquired MBLs, IMP-1 and VIM-1, MBL-producing
Gram-negative bacilli have been increasingly reported in many
countries. Previous study showed high prevalence of VIM-2-pro-
ducing Pseudomonas spp. and emergence of IMP-1-producing Aci-
netobacter spp. in KONSAR hospitals. The aim of this study was
to determine any change of prevalence of VIM-2-producing Pseu-
domonas spp. and IMP-1-poducing Acinetobacter spp. among iso-
lates collected from KONSAR hospitals in 2002.
Methods: Nonduplicate, imipenem nonsusceptible isolates of Pseu-
domonas spp. and Acinetobacter spp. were collected in 2002, from
27 KONSAR group hospitals. MBL production was screened by
the Hodge test and imipenem-EDTA + SMA double disk synergy
test. blaIMP-1 and blaVIM-2 alleles were detected by PCR using
heat-extracted DNA template. Xba I- and Sma I-digested genomic
DNAs of P. aeruginosa and Acinetobacter isolates, respectively, were
separated by PFGE and the patterns were compared.
Results: MBL-producing isolates of Pseudomonas spp. and Acinetob-
acter spp. were detected in 19 of 27 (70.3%) and 10 of 20 (50.0%)
hospitals, respectively, which are located in ﬁve of seven city/
province in Korea. Among the imipenem-nonsusceptible isolates,
53 of 459 (11.5%) Pseudomonas spp. and 31 of 212 (14.6%) Acine-
tobacter spp. were MBL producers. The proportions were similar
to those in 2000–2001, 11.4 and 14.2%, respectively. The species of
MBL-producing isolates were: 46 P. aeruginosa, seven P. putida, 30
saccharolytic Acinetobacter spp., and one A. lwofﬁi. Among the
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MBL-producing isolates, all isolates of Pseudomonas spp. had bla-
VIM-2 alleles, while 13 (41.9%) and 18 (58.1%) of Acinetobacter
spp., respectively, had blaVIM-2 and blaIMP-1 alleles. The propor-
tion of blaIMP-1-positive isolates was 28.9% in 2000–2001. The
source of isolation of MBL-producing strains were: 32.9% from
ICU patients and 64.7% from other inpatients; 36.9% from spu-
tum and 38.1% from urine.
Conclusions: High prevalence of blaVIM-2 allele-positive P. aerugi-
nosa remained similar. The proportion of blaIMP-1 allele-positive
Acinetobacter spp. became higher. This study suggests clonal
spread is a more important factor than horizontal transfer in dis-
semination of the resistance.
P1879 Characteristics of ESBL-producing Proteus mirabilis
isolates in Korea
D. Yong, Y. Lim, J. Yum, K. Lee, Y. Chong
Seoul, KOR
Objectives: Proteus mirabilis strains were usually susceptible to
ampicillin and other beta-lactams. However, a progressive
increase of beta-lactam resistance has been reported in this spe-
cies. Recently, P. mirabilis is the one of the common extended-
spectrum beta-lactamase producing organisms in Europe. How-
ever, ESBL-producing P. mirabilis has not been reported in Korea.
In this study, we performed the screening and conﬁrmation test
to detect ESBL-producers in P. mirabilis isolates in a Korean teach-
ing hospital, and characterised the ESBL types.
Methods: Consecutive 105 isolates of P. mirabilis were collected
from December 2002 to September 2003. The susceptibility was
tested by the NCCLS disk diffusion test. Double-disk synergy test
(DDST) with amoxicillin–clavulanate, cefotaxime, and ceftazidime
disks at a distance of 15 mm (edge to edge) was performed to
detect the ESBL-producers. Conjugations were carried out in some
of the representative isolates. blaTEM, blaSHV, and blaCTX-M
were detected by PCR. PCR-products of blaCTX-M were se-
quenced by dideoxynucleotide-chain termination method.
Results: Disk diffusion test showed 46 (43.8%) and 10 (9.5%) iso-
lates were resistant to ampicillin and to cefotaxime, respectively.
None of the isolates were resistant to ceftazidime, cefepime, and
cefoxitin. Twenty-one isolates suspected to have ESBLs according
to NCCLS criteria were tested by DDST. Among them, 10 isolates
with cefotaxime-resistance were positive in DDST with amoxicil-
lin–clavulanate and cefotaxime only. All of the 10 isolates had
blaCTX-M alleles. Sequencing showed that nine had blaCTX-M-14
and one had blaCTX-M-2 type. Among the 36 ampicillin-resistant,
cefotaxime-susceptible isolates, 31 strains were blaTEM positive,
one strain was both blaTEM and blaSHV positive, and four strains
were both blaTEM and blaSHV negative. Conjugations were not
successful in blaCTX-M alleles-positive strains.
Conclusions: This is the ﬁrst report on the presence of ESBL-pro-
ducing P. mirabilis isolates in Korea. It is very interesting that the
ESBLs detected in all P. mirabilis isolates were only CTX-M type.
The prevalence of CTX-M in P. mirabilis was very high, almost
10%. Further study on the transferability of CTX-M gene in
P. mirabilis isolates will be needed.
P1880 Clonal diversity and carbapenemase production in
carbapenem-resistant Acinetobacter baumannii isolated in a
Portuguese hospital, during a 3-year period
S.M. Quinteira, H. Ramos, J. Amorim, J.C. Sousa, L. Peixe
VN Famalico, Porto, P
Objectives: Carbapenemase production has been observed in Por-
tuguese clinical isolates of imipenem-resistant Acinetobacter bau-
mannii (IMRAb), associated to IMP-5 and OXA-40 enzymes. In
this work, we investigated the clonal relatedness of carbapenem-
resistant A. baumannii isolated from a University Hospital with a
high rate of imipenem resistance, together with the relative contri-
bution of carbapenemase production.
Methods: Carbapenem-resistant A. baumannii (n ¼ 108) were isola-
ted between March 2001 and March 2003, from patients attending
the Hospital de Santo Anto´nio, Porto. Genomic macrorestriction
analysis was obtained after digestion with ApaI restriction enzyme.
MICs were determined by Etest. Susceptibility to non-beta-lactam
antibiotics was performed by the disk diffusion method. Carbapen-
emase producing strains were detected by a bioassay. Genes were
sought by PCR with primers speciﬁc for blaIMP, blaVIM and bla-
OXA-24-like. Obtained products were sequenced on both strands.
Results: Imipenem resistance in A. baumannii increased from 32%
(n ¼ 47) in 2001 to 53% (n ¼ 31) in 2002, and all isolates (n ¼ 30)
obtained during the ﬁrst 3 months of 2003 showed imipenem resist-
ance. IMRAb were isolated from different hospital units, mainly
from intensive care units. No PCR evidence suggested the presence
of blaIMP or blaVIM type genes in all the isolates. A total of 44 carb-
apenem-resistant isolates yielded a PCR product with primers spe-
ciﬁc for blaOXA-24-like. Sequencing showed the presence of an
OXA-40 enzyme and analysis of PFGE revealed that these isolates
belong to a single clone. Resistance to all beta-lactams and variable
susceptibility to amikacin and tobramycin was a common feature of
this clone. Macrorestriction analysis of other 57 imipenem-resistant
isolates demonstrated the simultaneous dissemination of another
clonal type, which differs also in the susceptibility patterns. Apart
from the resistance to almost beta-lactams, isolates from this second
clone were susceptible to minocicline and presented variable beha-
viour to ceftazidime and to aminoglycosides.
Conclusions: The high rate of imipenem-resistant A. baumannii in
this hospital is associated to the presence of two major clones.
Also, the results suggest that the spreading of OXA-40 enzyme, in
Portugal, was mainly because of the progressive dissemination of
a single clone that persists until 2003.
P1881 Communitiy-acquired urinary tract infections by
extended-spectrum beta-lactamase-producing Escherichia coli in
children: clinical and molecular characteristics
M.A. Lee, H.W. Moon, S.J. Lee
Seoul, KOR
Objectives: Recently our institution noted a marked increase in the
number of ESBL (extended-spectrum beta-lactamase)-producing
E. coli isolated from children with urinary tract infections (UTI).
The children were ambulatory patients or had been seen in the
emergency department. The purpose of this study was to investi-
gate clinical and molecular characteristics of ESBL-producing
E. coli from community-acquired UTI in children.
Methods: We analysed 36 children with UTI due to ESBL-produ-
cing E. coli (cases) and 58 children with UTI due to non-ESBL-pro-
ducing E. coli (controls) in Ewha Womans University Hospital
from July 2001 to June 2002.
Results: Of the total 1136 E. coli isolates from urine, 119 (10.5%)
produced ESBL and the prevalence of UTI due to ESBL-producing
E. coli was higher in children (19.3%) than in adults (4.6%). Case
patients had signiﬁcantly higher resistance to aztreonam, ceftriax-
one, cefotaxime, cefepime, and ceftazidime than control patients
(P < 0.05). Case patients were younger (4  1 months) than con-
trol patients (24  76 months) and were more frequently male
(30of 36) than control patients (39 of 58). No signiﬁcant differences
were noted in prior UTI, prior antibiotic use, genitourinary abnor-
mality, vesicoureteral reﬂux, urinary catheter, pyelonephritis or
underlying diseases between cases and controls (P < 0.05). No sig-
niﬁcant difference in cure rate was noted between both groups,
but case patients had a signiﬁcantly higher relapse rate (41.7%)
than control patients (2.1%, P < 0.05). Of the 27 strains analysed
by PCR, 23 strains produced TEM, three produced TEM and
SHV, and one produced SHV. Pulsed-ﬁeld gel electrophoresis of
24 ESBL-producing organisms showed 18 distinct genotypes
including ﬁve clusters.
Conclusions: ESBL-producing E. coli may be a causative agent
of community-acquired UTI in children without any speciﬁc risk
factors. Most strains were genetically unrelated and these ﬁndings
suggested as community-acquired infection through dissemination
of plasmids rather than the clonal spread.
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Susceptibility to miscellaneous antimicrobial agents
P1882 Comparison of in vitro activity of gatiﬂoxacin,
moxiﬂoxacin, trovaﬂoxacin and clindamycin against clinically
signiﬁcant anaerobes
K. Aldridge, C. Manders, S. Broyles
New Orleans, USA
Objectives: Newer ﬂuoroquinolone antimicrobials have increas-
ingly broad-spectrum potency and activity against aerobic Gram-
positive and Gram-negative bacteria while their anaerobic cover-
age varies widely. This study was performed to provide contem-
porary in vitro data on the anti-anaerobe spectrum of three
quinolone agents: two respiratory ﬂuoroquinolones gatiﬂoxacin
(GAT) and moxiﬂoxacin (MXF); and trovaﬂoxacin (TRV), a previ-
ously FDA-approved ﬂuoroquinolone with good anti-anaerobe
activity, but limited use due to toxicity, and clindamycin (CLI), a
long-time used anti-anaerobic lincosamide.
Methods: Test isolates composed the B. fragilis group (no. 457);
Clostridium (no. 80); Fusobacterium (no. 22); Prevotella (no. 38); and
Peptostreptococcus (no. 89) isolated from wounds, abscesses, body
ﬂuids, blood, and Ob-Gyn specimens. The agents were tested in
twofold dilutions (0.06–64 mg/L) using the NCCLS-recommended
broth microdilution method with MIC determinations performed
at 48 h postinoculation.
Results: The table below compares the in vitro activity of each ﬂuor-
oquinolone agent indicating the mode MIC (M) and percentage of
isolates inhibited at 1, 2 and 4 mg/L which brackets the approved
NCCLS breakpoint of 2 mg/L for TRV. CLI activity was deter-
mined at the following NCCLS breakpoints: 2 (S), 4 (I), 8 (R).
Conclusions: Based on the present results, TRV was the most act-
ive ﬂuoroquinolone tested while GAT and MXF had comparable
with CLI overall and superior activity against gram-positive
anaerobes. Both MOX and GAT have no established breakpoints
for anaerobes and their spectrum of anti-anaerobic activity awaits
appropriate pharmacokinetic and clinical studies.
P1883 Antibiotic susceptibility of bacterial strains
isolated from community-acquired respiratory tract infections
in Austria 2002
S. Forsthuber, A. Buxbaum, W. Graninger, A. Georgopoulos
Vienna, A
Objective: The aim of this study was to determine the susceptibil-
ity of the most common bacterial pathogens in respiratory tract
infections.
Material and Methods: Between January 2002 and December 2002 a
total of 658 strains were collected from 361 adults and 297 chil-
dren with community acquired respiratory tract infections from
different Austrian regions. A total of 282 Staphylococcus aureus, 150
Streptococcus pyogenes, 120 Haemophilus inﬂuenzae and 106 S. pneu-
moniae were identiﬁed according to standard laboratory tech-
niques. Antimicrobial susceptibility testing was performed by
broth microdilution method according to NCCLS guidelines. The
following antibiotics were tested: erythromycin (ERY), clarithro-
mycin (CLA), azithromycin (AZI), telithromycin (TEL), penicillin
(PEN), amoxicillin–clavulanic acid (AUG), ampicillin (AMP), cefo-
taxime (CTX), cefpodoxime (CPD), ciproﬂoxacin (CIP), levoﬂoxa-
cin (LEV), moxiﬂoxacin (MXF), gatiﬂoxacin (GAT), tetracyclin
(TET), quinupristin–dalfopristin (SYN), linezolid (LNZ), vancomy-
cin (VAN), gentamicin (GEN) and fusidic acid (FUS).
Results: A 72% (n ¼ 475) of the strains were isolated from upper
respiratory tract and 28% (n ¼ 183) from lower respiratory tract.
Against S. aureus the most active agents were LNZ (100%), VAN
(100%), LEV (99%), MXF (99%), and FUS (99%). PEN, LNZ,
MXF, GAT, LEV, CTX and CPD showed the best activity against
S. pyogenes (from 100 to 99%). The most active agents against S.
pneumoniae were AUG, LNZ, MXF, TEL, CTX (100% susceptible).
Among H. inﬂuenzae 100% were susceptible among CIP, LEV,
MXF, GAT, TEL, CTX and CPD.
Conclusions: The results demonstrate that the resistance rates of
the respiratory tract pathogens among most antibiotics were less
than 10%.
P1884 A comparison of the bactericidal activities of
penems, a penam, a cephem and a ﬂuoroquinolone against
common respiratory tract pathogens
U. Ullman, S. Schubert, A. Dalhoff
Kiel, D
Objective: Evaluation of the concentration dependent or independ-
ent bactericidal effects of penems (imipenem, meropenem and er-
tapenem) as compared with a representative penam (amoxicillin),
a cephem (ceﬁxime) and a ﬂuoroquinolone (moxiﬂoxacin).
Methods: Time-kill studies were performed by exposing Staphylo-
coccus aureus, Streptococcus pneumoniae, Moraxella catarrhalis, Haemo-
philus inﬂuenzae, Escherichia coli and Klebsiella pneumoniae to
constant drug concentrations ranging from 1 to 32x their respect-
ive MICs. Samples were taken at 0.5, 1, 2, 4, 6, 8, and 24 h and
subcultured quantitatively.
Results: In general the penems exhibited the most pronounced
effects against all the bacterial species. In contrast to amoxicillin
and ceﬁxime, all the penems exhibited a concentration-dependent
bactericidal effect at all concentrations tested. Amongst the pen-
ems, imipenem tended to be the most bactericidal agent, followed
by ertapenem and meropenem; however, the differences were not
signiﬁcant. The bactericidal effect of amoxicillin and ceﬁxime could
not be enhanced beyond the concentration producing a maximal
effect. Moxiﬂoxacin was also bactericidal throughout the concen-
tration range studied. The bactericidal activity of moxiﬂoxacin was
similar to that of imipenem. However, moxiﬂoxacin was more act-
ive against H. inﬂuenzae compared with all the penems.
Conclusions: The penems and moxiﬂoxacin exhibit concentration
dependent killing against the major RTI pathogens, whereas the
penams and cephems do not. Unlike the penems, moxiﬂoxacin
has the advantage of being available as both an oral or parenteral
therapy. Thus, moxiﬂoxacin combines pronounced bactericidal
activity with the convenience of sequential therapy.
P1885 Antibiotic susceptibility of isolates in the intensive
care unit in Greece: 3 years of the Meronem Yearly
Susceptibility Test Information Collection (MYSTIC)
programme
A. Gikas, J.A. Papadakis, H. Triantafyllopoulou, A. Christidou,
A. Katsandri, D. Toffas, G. Petrikkos
Heraklion, Athens, GR
Objective: To determine the in vitro activity of meronem (MEM)
and seven other antimicrobial agents against isolates from inten-
GAT MXF TRV CLI
M 1 2 4 M 1 2 4 M 1 2 4 M s (2) I (4) R (8)
B.f.g 1 44 56 63 .5 32 44 61 .25 64 77 94 64 62 69 100
Clos. .5 66 90 94 .5 66 84 89 .25 85 93 96 .06 66 74 100
Fuso .25 68 82 91 .2 64 82 91 .5 82 91 96 .06 91 91 100
Prevo. 4 45 45 66 .5 45 48 69 .5 58 79 92 .06 76 0 24
Peptostr. 42 82 80 90 25 83 89 90 .25 88 80 96 .06 81 84 100
All .5 53 65 72 .5 53 67 74 .25 70 81 95 64 67 73 100
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sive care units (ICUs) in two Greek university hospitals the last
3 years. This is part of the MYSTIC (Meronem Yearly Susceptibil-
ity Test Information Collection) program.
Methods: Minimum inhibitory concentrations (MICs) for MEM,
imipenem (IPM), ceftazidime (CAZ), ceftazidime plus clavulanic
acid, piperacillin plus tazobactam (TAZ), ciproﬂoxacin (CIP), gen-
tamicin (GM) and tobramycin (TOB) were determined for 861 iso-
lates using NCCLS agar dilution method.
Results: During the period 2000–2002, a total of 538 Gram-negat-
ive strains and 323 methicillin-susceptible staphylococci were
collected and tested at the ICUs of two Greek university hospi-
tals. The most common Gram-negative species tested were
Escherichia coli (25.8%), Pseudomonas aeruginosa (23.1%), and Kle-
bsiella pneumoniae (15.2%), followed by Proteus mirabilis (11.3%),
Enterobacter cloacae (10.4%), Acinetobacter baumannii (7.1%), Serra-
tia marcescens (3.9%) and Klebsiella oxytoca (3.2%). The percent-
ages of susceptibility to MEM were the same as or higher than
IPM against every organism tested. The carbapenems were
highly active against the Enterobacteriaceae (>98%). All the
other tested agents also showed a high potency against Entero-
bacteriaceae (80.9–92.8% susceptibility). Especially K. pneumoniae
demonstrated relatively lower susceptibility to CAZ (70.7%),
TAZ (73.2%) and CIP (75.6%) when compared with MEM
(96.3%) and IPM (91.5%). Against P. aeruginosa, a higher pro-
portion of isolates were susceptible to TAZ (85.5%) and to
CAZ (80.6%) than to the carbapenemes (76.6 and 72.3% for
MEM and IPM, respectively). MEM and IPM were the most
active agents against A. baumannii (86.8 and 71.1% susceptibil-
ity, respectively), when compared with CAZ (13.2%), TAZ
(52.6%), CIP (5.3%) and aminoglycosides (25.8%). All the tes-
ted agents showed a high potency against methicillin-S-staphy-
lococci (88.9–93.5% susceptibility) with the exception of CAZ
and CIP (59.1 and 78.3%, respectively).
Conclusions: Carbapenems (MEM > IPM) were the most active of
the antimicrobials tested overall against the commonly isolated ICU
organisms in two Greek university hospitals, over the last 3 years.
P1886 Comparative in vitro activity of ertapenem against
respiratory pathogens circulating in Italy
L. Gualco, G. Schito, A. Marchese
Genoa, I
Objective: To evaluate the in vitro activity of ertapenem, a new
parenteral carbapenem, against recently isolated community-
acquired typical respiratory pathogens.
Methods: A total of 550 respiratory pathogens displaying different
resistance phenotypes have been studied. Minimal inhibitory con-
centrations of ertapenem and of 15 other comparative drugs have
been determined by the broth microdilution method (NCCLS,
M7-A5) and results interpreted according to NCCLS (2003)
approved breakpoints.
Results: Percentages of susceptible strains are depicted in the
Table.
Conclusions: Ertapenem, because of its in vitro activity encompas-
sing the most important respiratory pathogens, and its ability to
overcome different antibiotic resistance traits can be considered a
useful therapeutic option in the treatment of community-acquired
respiratory infections.
P1887 In vitro activity of ertapenem in comparison with
penicillin, piperacillin/tazobactam, clindamycin, and
metronidazole against clinical isolates of anaerobic bacteria
W. Pﬁster, J. Roedel, E. Straube
Jena, D
Objectives: Ertapenem is a new carbapenem with high activity
especially against enterobacteria. This antibiotic has no or only
weak effect on P. aeruginosa, other nonfermenters, enterococci, and
methicillin-resistant staphylococci. There are only a few reports
about activity of ertapenem to anaerobes.The aim of the study
was therefore to evaluate the in vitro activities of ertapenem
(ERT) in comparison with penicillin (PEN), piperacillin/tazobac-
tam (PIT), clindamycin (CLI), and metronidazole (MET) against
anaerobic bacteria.
Methods: A total of 370 clinical isolates of anaerobic bacteria from
patients of an university hospital were investigated in a prospect-
ive study over a time period of 6 months. They included 90 Prevo-
tella spp., 80 Bacteroides spp. including 38 B. fragilis and 18.
B. thetaiotaomicron, 55 Peptostreptococcus spp., 55 Veillonella spp., 46
Fusobacterium spp., 25 Porphyromonas spp., and 19 Clostridium spp.
(16 C. perfringens, three C. fallax). The MIC-values were deter-
mined by use of Etest on Brucella-Blood-Agar (AB Biodisk, Solna,
Sweden).
Results: The ranges of the MIC-values (mg/L) of ERT against the
anaerobic strains tested were: B. fragilis 0.032–0.5; B. thetaiotaomi-
cron 0.064–2; Bacteroides spp. 0.016–0.5; Prevotella spp. 0.008–0.125;
Porphyromonas spp. 0.008–0,016; Fusobacterium spp. 0.008–16; Veillo-
nella spp. 0.016–0.5; Peptostreptococcus spp. 0.016–1; Clostridium
spp. 0.016–1. With the exception of one strain of Fusobacterium var-
ium (MIC 16 mg/L) all other anaerobic strains were sensitive to
ertapenem. The number of resistant strains to the other antibiotics
tested was: B. fragilis (38) PEN 38 PIT 21 CLI 12 MET 1 B. theta-
iota (18) PEN 18 PIT 9 CLI 7 MET – Bacteroides sp.(24) PEN 18
PIT 8 CLI 2 MET 1 Prevotella sp. (90) PEN 23 PIT 1 CLI 5 MET
4 Fusobact. sp. (46) PEN 11 PIT 11 CLI 1 MET 2 Porphyrom.
sp. (25) PEN - PIT - CLI - MET 1 Veillonella sp.(55) PEN 19 PIT
19 CLI 3 MET 11 Peptostr. sp. (55) PEN 2 PIT - CLI 2 MET
55 Clostridium sp.(19) PEN 3 PIT 1 CLI 3 MET 1.
Conclusions: Ertapenem was in vitro the most active antibiotic
against the tested anaerobic clinical isolates. Only one strain of
370 exhibited resistance in this in vitro study.
Antibiotic/
(no of strains)
S. pneumoniae S. pyogenes S. aureus
Pen-S (100) Pen-I (50) Pen-R (30) Ery-S (40) Ery-R (60) Met-S (100)
Ertapenem 100 100 96.7 100 100 100
Ampicillin – – – – – 18
Amoxicillin/
clavulanate
100 100 63.3 100 100 100
Cefuroxime 100 42 0 – – 100
Cefotaxime 100 100 83.4 100 100 100
Imipenem 100 94 20 100 100 100
Clarithromycin 78 36 40 100 0 69
Chloramphenicol 94 54 53.3 100 100 98
Clindamycin 78 36 43 100 66.6 61
Tetracyclin 74 32 23.3 87.5 51.6 97
Ciproﬂoxacin – – – – – 99
Levoﬂoxacin 100 100 100 100 100 100
Gentamicin – – – – – 91
Amikacin – – – – – 98
Vancomycin 100 100 100 100 100 100
Antibiotic/
(no of strains)
H. inﬂuenzae M. catarrhalis* K. pnenumoniae
bla+ (20) bla+ (50) bla+ (50) bla (20) ESBL+ (10) ESBL (20)
Ertapenem 100 100 100 100 100 100
Ampicillin 0 100 0 100 0 0
Amoxicillin/
clavulanate
100 100 100 100 100 100
Cefuroxime 100 100 100 100 0 100
Cefotaxime 100 100 100 100 0 100
Ceftriaxone 100 100 100 100 0 100
Imipenem 100 100 100 100 100 100
Clarithromycin 100 88 100 100 – –
Chloramphenicol 100 86 100 100 10 80
Tetracycline 80 96 100 100 80 95
Ciproﬂoxacin 100 100 100 100 30 100
Levoﬂoxacin 100 100 100 100 – –
Gentamicin – – – – 0 100
Amikacin – – – – 100 100
*For interpretation of M. catarrhalis results, H. inﬂuenzae breakpoints have been adopted
–: not tested; Pen-S, Pen-I, Pen-R: penicillin-susceptible, -intermediate, -resistant; Ery-S
and Ery-R erythromycin - suscptible and resistent; Met-S: methicillin-susceptible; bla+ and
bla: beta-lactamase-positive and -negative; ESBL+ and ESBL: extended spectrum beta-
lactamase positive and negative.
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P1888 Is antibiotic combination more effective than single
drug therapy in anthrax?
A. Athamna, M. Athamna, N. Abu Rashed, E. Shlyakov, D. Bast,
E. Rubinstein
Kfar Qaraa, Tel Aviv, IL; Toronto, CAN
Objectives: Antibiotic combinations are used to enhance the anti-
bacterial effect and to prevent the development of bacterial resist-
ance. We have tested possible synergistic effect of several
antibacterial combinations in Bacillus anthracis.
Methods: The in vitro activity of antibiotic combinations against
two strains of B. anthracis, the Sterne strain and the Russian
anthrax Vaccine strain ST-1 were tested by calculating the frac-
tional inhibitory concentration derived from the MIC’s of the dif-
ferent agents and by measuring the rate of bacterial kill by
antibiotic combinations.
Results: The FIC calculations rendered the results shown in the
table:
The results of the bacterial time-kill demonstrated the same
trend, i.e combinations that exhibited antagonism had slower kill
rate than any of the members of the pair.
Conclusions: These in vitro results demonstrate the difﬁculties in
obtaining synergistic combinations of antibiotics against B. anthra-
cis and suggest that the recommendations for therapy with antibi-
otic combinations are unfounded.
P1889 Combination effect of ertapenem (MK 826) with
aminoglycosides against Gram-positive and Gram-negative
community-acquired pathogens
U. Frank, C. Wilson, E. Baumgarten, I. Engels, M. Dettenkofer,
F. Daschner
Freiburg, D
Introduction: Combination of beta-lactam and aminoglycoside anti-
biotics broadens the spectrum of bacterial coverage and often
achieves synergistic inhibition of the infecting pathogen. Ertape-
nem is a new carbapenem, which exhibits activity against gram-
negative and gram-positive aerobes and anaerobes.
Objectives: To provide insight into the optimal synergistic combi-
nation of ertapenem and an aminoglycoside.
Materials and Methods: During a 12-month period, bacterial strains
were prospectively isolated from patients with community-
acquired infections. The in vitro activity of ertapenem was evalu-
ated in combination with amikacin, netilmicin and tobramycin
against 100 isolates including E. coli, K. pneumoniae, P. mirabilis,
E. cloacae, methicillin susceptible and resistant coagulase-negative
staphylococci and S. aureus (MSSA, MRSA), E. faecalis and E. fae-
cium. Susceptibility testing was carried out according to NCCLS-
Guidelines. The combination effect was determined using the
checkerboard technique.
Results: Ertapenem exhibited a synergistic effect in 17% of all the
strains tested when combined with amikacin, but only in 3%
when combined with gentamicin. There were noticeable variations
between the different species tested. In combination with amika-
cin (MIC 4–16 lg/mL), ertapenem (MIC 2–32 lg/mL) was found
to be synergistic against enterococci (45%). The same combination
(ertapenem MIC 0.125–0.5 lg/mL; amikacin (MIC 2 lg/mL) was
also synergistic against one-third of methicillin-resistant CNS iso-
lates (33%) There was hardly any synergism against the other
species tested.
Conclusions: Ertapenem in combination with aminoglycoside anti-
biotics exhibited a marked synergistic effect against certain patho-
gens, including E. faecalis, E. faecium, and coagulase-negative
staphylococci. Based on these ﬁndings a combination therapy
could be beneﬁcial for the treatment of infectious diseases caused
by these organisms.
P1890 QC study evaluating the performance of
daptomycin and combination daptomycin/calcium disks and
Etest
L. Koeth, J. DiFranco
Westlake, USA
Background: In vitro susceptibility testing of daptomycin, a cyclic
lipopeptide antibiotic with good antimicrobial activity against
most Gram-positive bacteria, requires the presence of calcium
ions. Previous studies have shown that agar calcium levels as low
as 25 mcg/mL have been adequate for disk diffusion testing. This
study was performed to evaluate ﬁve commercial agars and to
determine the efﬁcacy of both disks and Etest strips containing a
combination of daptomycin and calcium.
Methods: We tested each of the QC strains, S. aureus ATCC 25923,
S. aureus ATCC 29213 and E. faecalis ATCC 29212, on multiple
days using Mueller–Hinton agar (MHA) from both BD and
Hardy, Mast Isotonic agar supplemented with 50 mcg/mL of cal-
cium (ISTA), and Oxoid IsoSensitest agar (ISOA). We studied each
of the strains on multiple days using a different lot of MHA from
BD and Remel. Thirty-microgram daptomycin disks/tablets from
each of the four different manufacturers, BBL (BD), Oxoid (Re-
mel), Mast (Hardy) and Rosco were tested. In addition, Mast disks
with 20, 40, 60, 80 and 100 mcg calcium and Etest strips with dap-
tomycin, daptomycin + 40 mcg/mL calcium and daptomy-
cin + 50 mcg/mL calcium were evaluated. Calcium testing of
each media was performed using an ion selective electrode.
Results: Mean zone diameters (mms) for S. aureus 25923 and mean
Etest MICs (mcg/mL) for S. aureus 29213 were:
Conclusions: Disks containing daptomycin alone from BBL, Rosco,
and Mast resulted in QC values in range for all media except ISOA.
With the exception of ISTA, the addition of 100 mcg of calcium to
daptomycin Mast disks and Rosco tablets provides for QC results
within range for all media including ISOA. The two different lots of
BBL affected the MICs and zone diameters. E-test containing dapto-
mycin and 40 mcg of calcium provided optimal QC results.
Antibiotic combination ST-1 strain Sterne strain
Ciproﬂoxacin+tetracycline Indifference Indifference
Ciproﬂoxacin+penicillin Indifference Indifference
Ciproﬂoxacin+clarithromycin Antagonism Antagonism
Ciproﬂoxacin+clindamycin Antagonism Indifference
Penicillin+quinup/dalfop Antagonism Antagonism
Penicillin+tetracycline Antagonism Antagonism
Penicillin+clindamycin Antagonism Indifference
Penicillin+vancomycin Antagonism Antagonism
Penicillin+rifampicin Antagonism Indifference
Penicillin+linezolid Antagonism Antagonism
Penicillin+telithromycin Antagonism Indifference
Rifampicin+clindamycin Synergism Synergism
Study 2 Study 1
BBL
MHA
Remel
MHA
BBL
MHA
Hardy
MHA
Oxoid
ISOA
Mast
ISTA
Disk - S. aureus 25923 (expected¼18–23 mm)
Oxoid 18.6 20.75 – – – –
BBL 18.75 21.05 20.19 21.09 15.28 22.17
Rosco 17.75 19.5 19.84 21.5 12.91 25
Mast 17.5 19.4 19.25 20.06 12.38 21.33
Mast+100 19.5 20.75 21.19 21.03 19.56 25.53
Rosco+ 20 20.8 22.06 22.44 20.94 27.42
Etest-S. aureus 29213 (expected ¼0.25–1 mcg/mL)
Dap 1.68 0.84 1.46 0.88 8.95 0.18
Dap+40 0.74 0.47 – – – –
Dap+50 0.35 0.23 0.35 0.19 0.4 0.08
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P1891 Impedimetry – test for determination of bactericidal
activity of antiseptics
T. Zarba, E. Bocian, S. Tyski
Warsaw, PL
Objectives: All products for chemical disinfection and antisepsis
should meet European Standards requirements. Normative docu-
ments describe a suspension test method for establishing bacteri-
cidal activity under the speciﬁc laboratory conditions. According
to those methods suspension of bacterial cells is added to portion
of the diluted product followed by collection of samples at speci-
ﬁed contact time and ﬁnally mixed with agar medium and incu-
bated up to 48 h. New alternative technique based on
impedimetric procedure (Bactometer BioMerieux, Vitek System,
USA), provide possibilities to reduce this time to several hours.
The procedure utilises the capability of an instrument to detect
bacterial growth in sample by measurement of media conductivity
changes. The impedance detection time is inversely proportional
to the number of micro-organisms present at initial inoculum and
it correlates with the original bacteria count in the sample as
determined by standard plate count method. The aim of the study
was to adapt the impedimetric method to microbiological control
of antiseptics used for skin treatment.
Methods: Eight different products were analysed throughout the
study as following: Kodan Tinktur Forte, Sagrosept and Octeni-
derm produced by Schulke & Mayer, Manorapid and Dermorapid
produced by Antiseptica GmbH, Hospidermin from Lysoform,
Frekasept 80 and Frekaderm produced by Fresenius Kabi
Deutschland GmbH. The bactericidal activities were evaluated
using four strains recommended by standards EN 1040 and EN
12054. Activity was measured by dilution–neutralisation method
described in normative documents and impedimetric method. The
samples for both methods were prepared in the same way. For
impedimetric assay curve was prepared for each strain. The con-
tact time of bacterial strains with antiseptics varied from 30 s to
1 min. The samples were neutralised and mixed with media. In
standard plate method the colonies were counted after incubation
whereas in Bactometer system the number of bacterial cells was
calculated automatically during incubation.
Results: The high correlation was observed between results
obtained by normative method and impedimetric measurement.
The neutralisation solution was effective and all tested products
meet standard requirements. The procedure utilising the Bactome-
ter, provided a rapid and accurate system for bacteria count in
bactericidal test.
P1892 In vitro synergism between linezolid and UV
radiation against bioﬁlms of Staphylococcus aureus
M. El-Azizi, N. Khardori
Springﬁeld, USA
Objective: Linezolid (LNZ) is an effective antibiotic against gram-
positive bacteria including those that are resistant to vancomycin.
However, the bacteriostatic activity of the antibiotic may limit its
usefulness. A good example is infections related to indwelling
medical devices where the micro-organisms exist within the bio-
ﬁlms and bactericidal antibiotics may be more effective. Our
objective was to study the effect of combination of linezolid
(LNZ) and UV radiation on viability of S. aureus (SA) within the
bioﬁlms.
Methods: We tested LNZ against 10 clinical isolates of S. aureus.
The MICs of the antibiotic were determined by using the broth
microdilution technique (NCCLS M7-A5). To form bioﬁlms,
100 ml portions of TSB medium containing 1  106 CFU/mL of
the micro-organism were delivered to ﬂat bottom 96 micro plates.
After 24 h incubation at 37C, the supernatants were aspirated
and the remaining bioﬁlms were washed twice with distilled
water. Plates used to study the effects of UV radiation alone or in
combination were then exposed for short UV radiation for 5 min.
TSB containing the antibiotics at MIC90 value was added to the
wells and plates were incubated again for 24 h. Plates were then
aspirated followed by addition of 100 microliter Lactate Ringer
solution containing XTT (0.5 gm/L) and menadione (1 micromol).
Plates were placed in plate shaker for 5 min followed by incuba-
tion for 1 h at 37C and then measured in microplate reader at
490 nm.
Results: When used alone LNZ, percentage viability range 74.33–
100, median 93.66 and mean 91.79, or UV radiation, percentage
viability range 85.40–100, median 95.52, and mean 94.33, showed
very low activity against the bioﬁlms. However in combination,
percent viability range 57.38–100, median 80.52 and mean 79, the
activity of LNZ was promoted. The killing effect when combined
the two agents was signiﬁcantly increased compared with LNZ
alone (P < 0.05) or UV radiation alone (P < 0.01).
Conclusions: Short time exposure of the bioﬁlms of SA to short
wave UV radiation promoted the killing effect of LNZ. This
approach to improving the activity of LNZ against bioﬁlm associ-
ated bacteria needs to be studied further.
P1893 Antimicrobial activity of amniotic membrane
soaked in antibiotics
R. Dei, R. Mencucci
Florence, I
Objectives: Amniotic membrane transplantation (AMT) is carried
out to accelerate or improve re-epithelisation and reduce inﬂam-
mation. It has been suggested that AM could be used to deliver
anti-infective drugs similar to collagen shields and a variety of
prosthetic devices. The aim of our study was therefore to evaluate
such hypothesis. We report an in vitro study to assess the antibac-
terial activity of amniotic-treated AM.
Methods: Aminoglycosides (netilmicin and gentamicin) and quino-
lones (oﬂoxacin and ciproﬂoxacin) were used. The AM fragments
were washed in saline, drained and immersed into the antibiotic
solution; after incubation at various times at 37C on a shaker, the
washed and drained AM fragments were either tested for antibac-
terial activity or further incubated in antibiotic-free medium, to
evaluate then the activity of both AM and elution media. Antibac-
terial activity was carried out by the Kirby–Bauer method,
measuring the inhibition zone after overnight incubation on
S. epidermidis.
Results: The AM fragments soaked in antibiotics inhibited bacter-
ial growth: Antibiotic uptake was dose-dependent, and occurred
rapidly. Most of the drug was released from the membrane, and
the antibacterial effect was present in the elution media at least
three days after treatment.
Conclusions: Our preliminary in vitro data show that AM might
be used to deliver antibiotics, as reported for collagen shields and
other medical prosthetic devices like heart valves.
References
1. Darouche RO et al. (2002) Antimicrobial activity of prosthetic heart valves
seweing cuffs coated with minocycline and rifampin. AAC 46: 543–545.
2. Kim JS et al. (2001) Amniotic membrane trasplantation in infectious
corneal ulcers. Cornea 20: 720–726.
3. Willoughby CE et al. (2002) Collagen corneal shields. Survey Ophthalmol 47:
174–182.
P1894 Mechanism of the inoculum effect of Providencia
stuartii with beta-lactam antibiotics
N. Khalaf, I. Wiegand, B. Wiedemann
Cairo, EGY; Bonn, D
Objectives: The inoculum effect (IE) is an increase in the MIC of
an antibiotic when the inoculum is increased. Most Enterobacteri-
aceae possess a chromosomally encoded AmpC beta-lactamase
that is expressed at low level in the absence of an inducer. Muta-
tions in regulatory genes result in high-level production. An IE
could be due to selection of derepressed mutants or cells with
decreased outer membrane permeability. IE might be regulated by
a quorum sensing mechanism via an extracellular signal accumu-
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lating with increasing cell count. Many studies referred to the IE
in relation to the quantity of beta-lactamase, but this was not
quantitatively proven for AmpC enzymes. The aim of this work is
to evidence that the IE of P. stuartii with beta-lactams is due to
the quantity of AmpC.
Methods: The MICs of beta-lactams against four P. stuartii strains
using different initial inocula (104–107 CFU/mL) were determined
by a microdilution procedure. Cefotiam MICs were determined
using 38 different inocula. To test for the presence of an extracel-
lular signal MIC determination was performed in a conditioned
medium according to Rather et al. [J Bac (1999) 181, 7185–7191).
Spontaneous cefotiam-resistant mutants of strain 34-33 were selec-
ted on MH agar plates. Hydrolysis of cefotiam in broth cultures
of P. stuartii 34-33 with initial inocula of 105–108 CFU/mL was
bioassayed using K. pneumoniae as indicator organism. Cefotiam
degradation by serially diluted crude beta-lactamase extracts from
P. stuartii 34-33 was tested similarly and the results were com-
pared using a computer program (GraFit, Erithacus software)
based on a linear equation.
Results: A strong inoculum effect was seen with all tested P. stu-
artii strains. Cefotiam MICs increased 2048-fold (from 0.125 to
256 microg/mL) with a 10-fold increase in the inoculum of P. stu-
artii 34-33 from 1.2  105 to 1.2  106 CFU/mL. Quorum sensing
was excluded as MICs were not inﬂuenced by the use of a condi-
tioned medium. Cefotiam selected resistant mutants at a fre-
quency of 10–7. Hydrolysis of cefotiam with increasing cell counts
was parallel to the breakdown of the antibiotic by the crude
enzyme extract and correlated with the MIC values.
Conclusions: A small increase in inoculum size converts P. stuartii
from a beta-lactam sensitive bacterium to a resistant one. This is
solely due to the cumulative beta-lactamase production as the cell
count increases. Selection of mutants and quorum sensing were
excluded to be the basis of the inoculum effect.
P1895 Evaluation of the antimicrobial activity of
chlorhexidine gluconate adjunctive zinc polycarboxylate cement
in ﬁxed prosthodontics
B. Orug, M. Baysallar, A. Kucukkaraaslan, D. Cetiner, L. Doganci,
B. Bal
Ankara, TR
Objectives: Dental cement is used as an adhesive material that
protects, seals, and insulates the tooth in ﬁxed prosthodontics.
The purpose of this study is to examine the feasibility of adding
antimicrobial activity to zinc polycarboxylate cement (DURELON
aˆ) by the addition of the antiseptic chlorhexidine gluconate (CHx).
Methods: A total of 36 teeth with 84 sites and samples were evalu-
ated. Sites were randomly assigned to either the test group (CHx
and zinc polycarboxylate cement) or the control group (conven-
tional zinc polycarboxylate cement). In the test group, CHx was
used instead of water. The bacteriological evaluations were done
at the begining and in 5th and 13th weeks after the restorations
were cemented. Subgingival microbiological samples were
obtained by inserting a sterile paper point for 30 s into the gingi-
val sulcus subjacent to the restoration. Standardised paper strips
were placed at six locations of each restored individual tooth after
isolating the quadrant from salivary contamination. All bridges
were made in porcelain and cemented with zinc-poly carboxylate
phosphate following standard procedures. The samples were cul-
tured both aerobically and anaerobically by conventional meth-
ods. Isolated bacteria were identiﬁed by using API Automated
System (BioMerieux, France).
Results: The restorations with only zinc polycarboxylate cement
resulted in changes in the associated microﬂora. The altered ﬂora
resembled in some ways that which has been observed in adult
chronic periodontitis. Increased proportions of Gram-negative
anaerobic rods especially Provotella intermedia and Fusobacterium
nucleatum were observed. The restorations with CHx and zinc pol-
ycarboxylate cement resulted in only relatively few changes in the
associated subgingival microﬂora relative to pre-experimental
ﬁndings.
Conclusions: The addition of CHx subscantially increased the anti-
microbial action of zinc-polycarboxylate luting agent without
interfering with its physical properties.
P1896 Reproducibility of mycobacterial QC strains in the
Sensititre rapid growing and slowly growing nontuberculosis
mycobacteria broth microdilution susceptibility procedure
M. Brimecombe, P. Stagg, G. Hammerton, S. Killian, C. Knapp,
R. Grist
East Grinstead, UK; Cleveland, USA
Objective: Presently there are no NCCLS QC ranges for M. avium
and only a few for rapid growing mycobacteria. The purpose of
this study was to measure reproducibility with M. peregrinum
ATCC 700686, M. smegmatis ATCC 19420 and M. avium ATCC
700898 on commercial Sensititre dried susceptibility panels. For
rapid growers, the effect of incubation time and the addition of
saline/0.2% Tween with or without glass beads was also investi-
gated. The antimicrobials evaluated were: amikacin, oﬂoxacin,
ansamycin, streptomycin, clofazimine, kanamycin, capreomycin,
rifampicin, ethambutol and isoniazid.
Method: Rapid growers: A 0.5 McFarland standard was prepared
from colonies on a 48-h-old TSA/blood plate. Suspensions were
vortexed for 5 min allowing large clumps to settle. 50 lL was
transferred to 10 mL Sensititre Mueller–Hinton broth. Hundred
microlitres were dosed into each well in the plate. Plates were
sealed and incubated at 30 degrees. Plates were examined for
growth after 72, 96 and 120 h. Two sites tested 25 and 50 repli-
cates MICs for each isolate. An additional 10 results were collec-
ted for each of the three suspending media.
Slow growers: The set up procedure was the same except that 7H9
or Sensititre Mueller Hinton broth were supplemented with
OADC. Plates were sealed and incubated at 35 degrees and read
at 10–14 days depending upon the extent of growth. A total of 50
replicates MICs were collected
Rapid growers: All onscale MICs fell within one doubling dilution
of the mode. The maximum shift in MIC over time was one dilu-
tion. The presence of saline/Tween resulted in a one well shift in
MIC for ansamycin and clofazimine with ATCC 19420 and clofazi-
mine with ATCC 700686
Slow growers: All MICs fell within four dilutions with the excep-
tion of Oﬂoxacin. Weak growth requiring 14 days incubation ten-
ded to give lower MICs but fell with four well range.
Conclusions: MICs were highly reproducible allowing tentative QC
ranges to be set for testing Sensititre plates. MICs were little affec-
ted by the length of incubation. Saline/Tween showed notable
effects on the MICs with two of the drugs with rapid growers.
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